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INTRODUCTION

In western countries, aortic stenosis is Ͳ together with mitral regurgitation Ͳ a
commonvalvularheartproblemofwhich itsprevalence increaseswithage1.The latter is
explained by the pathogenesis or aetiology of aortic stenosis. At variancewith the past,
valvular aortic stenosis is the result of a degenerative process that is similar to arterial
atherosclerosisinmostifnotallpatientsthatarecurrentlyseeninourpractice.Itconcernsa
processthatischaracterizedbyinfiltrationofsmallparticlestherebyinducinginflammation
andultimatelycalcificationofthevascularstructure.Itis,therefore,notsurprisingthatdue
to the ageing of our society, the absolute number of patients with aortic stenosis will
increase2.
Prognosis inpatientswith severeaortic stenosis (i.e. survivalandqualityof life) is
dismal,inparticularincaseofsymptomsorimpairedleftventricularfunctionirrespectiveof
symptoms3Ͳ5.Yet,advancedageandtheprevalenceofassociatedcardioͲvascularandnonͲ
cardiovascularantecedentsandcoͲmorbiditiesoftenrenderthesepatientslessamenableto
surgical aortic valve replacement (AVR)becauseof eitherhighoperative risk and/or long
postoperativerecovery.Itisestimatedthatapproximately30to50%ofpatientswithaortic
stenosisarenotreferredforfurtherevaluationortreatmentbecauseoftheperceivedriskof
AVR6,7.
In thequestofdevelopmentof less invasiveprocedures, transcatheteraorticvalve
implantation (TAVI) emerged as a novel treatment modality to treat patients who are
considered too high a risk for AVR8. TAVI consists of a catheterͲbased beating heart
procedureduringwhichatrileafletbioprosthesisisimplantedintothebaseoftheaorticroot
withouttheneedofsternotomy,cardioͲpulmonarybypassandcardiacarrest.
RandomisedcomparisonshaveshownTAVItobeanevidenceͲbasedalternative for
AVRinpatientswithincreasedriskforAVR9Ͳ12.Fuelledbytheseresultsandexpectations,the
numberofTAVIprocedureshas increasedexponentiallyacrosstheglobewithspeculations
of itsextensionto lowerriskpatientgroups13.StudiesassessingtheroleofTAVIrelativeto
AVRinpatientswithintermediateriskarecurrentlyperformed.
Similar toeveryother surgicalor interventionalprocedure, TAVI is also associated
withanumberadverseeventssuchasdeath,stroke,bleedingͲandvascularcomplications,
rhythm and conduction abnormalities in addition to paravalvar aortic regurgitation and
acutekidneyinjury.Obviously,outcomedependsonanumberoffactorsincludingpatientͲ,
procedureͲ,anddevicerelatedfactors.Insightintothesefactorsisimportanttoimprovethe
resultsofTAVI inpatientswhocurrentlyundergothisprocedureandbefore implementing
TAVI in lowerriskpatients.This issubjectofthepresentthesis inwhichthefrequencybut
alsopotentialpathophysiologicalmechanismsofperioperative complicationsare reported
andstudied.

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
AIMANDOUTLINEOFTHETHESIS

The outline of the thesis is as follows. In Part I (Chapters 2, 3 and 4), the clinical
decision making and factors influencing the outcome of patients referred for TAVI are
presentedanddiscussed.Chapter2addressestreatmentdecision, inͲhospitaloutcomeand
determinants of survivalwhile Chapter 3 provides an overview of common perioperative
complications. In Chapter 4, the effects of operator experience and improvements in
techniqueandtechnologyonoutcomeafterTAVIareevaluated.
Part II (Chapters5,6and7) focuseson the frequencyandpathophysiologyofnew
conduction abnormalitiesduring and after TAVI. The timing andpotentialmechanismsof
newintraventricularconductionabnormalitiesduringvariouspredefinedphasesofTAVIare
reported in Chapter 5. The persistency of these new conduction abnormalities between
hospitaldischargeuntil6monthsafterTAVI isevaluated inChapter6.Theeffectsofnew
conductionabnormalitiesonleftventricularsystolicfunctionarediscussedinChapter7.
PartIII(Chapters8and9)dealswiththeoccurrenceofperiͲoperativestroke,whichis
considered one of themost if not themost dreadful complication after any surgical or
interventionalprocedure includingTAVIbecauseof itseffectson survivaland,evenmore
important,qualityof life. InChapter8, the frequency, timingofoccurrence and causeof
stroke isdeterminedusing–amongothers–computed tomography toassess the typeof
strokeanditspotentialmechanisms.Chapter9concernssimilarworkbutinalargecohortof
patients (>1000) treated in various centersand inwhichdistinction ismadebetween the
potentialcausesofstrokeintheacute,subͲacuteandlatephasesfollowingTAVI.
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Part IV (Chapters10and11)provides informationonacutekidney injury (AKI).AKI
concernsaclinicallysilentbutpotentialharmfulcomplicationthatdevelopsduringthefirst
daysafterTAVI.InChapter10,thefrequency,pathophsyiologyandprognosticeffectofAKI
arediscussedfollowedbyaninͲdepthanalysisoftherelationbetweenperiͲoperativeblood
transfusionandtheriskofAKIinChapter11.
PartV(Chapter12)discussestheprevalenceofpreͲoperativeanemia inadditionto
the effects of the various levels of preͲoperative hemoglobin on shortͲ and longͲterm
mortalityinpatientsundergoingTAVIusinga10Ͳcenterstudyapproachencompassingclose
to1600patients.Theobjectiveofthisstudystemsfromthefactthatanemia isfrequently
seen inelderlypatientswhile–atthesametime Ͳanemia isknowntobean independent
riskfactorofmortality,inparticularincardiacpatients.
Chapter13concernsastudyassessingtheclinicalresultsofTAVI inapopulationof
differentorigin(LatinAmerica)whereTAVIwasintroducedin2008.


PART 1
CLINICAL DECISION-MAKING, 
COMPLICATIONS AND 
EFFECT OF EXPERIENCE
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Abstract
Aims To assess treatment decision and outcome in patients
referred for transcatheter aortic valve implantation (TAVI)
in addition to predictive factors of mortality after TAVI.
Methods Three-centre prospective observational study in-
cluding 358 patients. Endpoints were defined according to
the Valve Academic Research Consortium.
Results Of the 358 patients referred for TAVI, TAVI was
performed in 235 patients (65%), surgical aortic valve
replacement (AVR) in 24 (7%) and medical therapy (MT)
in 99 (28%). Reasons to decline TAVI in favour of AVR/MT
were patient preference (29%), peripheral vascular disease
(15%) and non-severe aortic stenosis (11%). The logistic
EuroSCORE was significantly higher in patients who under-
went TAVI and MT in comparison with those undergoing
AVR (19 vs. 10%, p=0.007). At 30 days, all-cause mortality
and the combined safety endpoint were 9 and 24% after
TAVI and 8 and 25% after AVR, respectively. All-cause
mortality was significantly lower in the TAVI group compared
with the MT group at 6 months, 1 year and 2 years (12% vs.
22%, 21% vs. 33% and 31% vs. 55%, respectively,
p<0.001). Multivariable analysis revealed that blood trans-
fusion (HR: 1.19; 95% CI: 1.05–1.33), pre-existing renal
failure (HR: 1.18; 95% CI: 1.06–1.33) and STS score (HR:
1.06; 95% CI: 1.02–1.10) were independent predictors of
mortality at a median of 10 (IQR: 3–23) months after TAVI.
Conclusions Approximately two-thirds of the patients
referred for TAVI receive this treatment with gratifying
short- and long-term survival. Another 7% underwent AVR.
Prognosis is poor in patients who do not receive valve
replacement therapy.
Keywords Aortic stenosis . Transcatheter aortic valve
implantation . Surgical aortic valve replacement . Treatment
decision . Complications . Prognosis
Introduction
Transcatheter aortic valve implantation (TAVI) is a catheter-
based treatment for patients with aortic stenosis (AS) who
are considered poor candidates for surgical aortic valve
replacement (AVR). Although it is increasingly being
considered the standard of care in such patients [1], not
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all patients receive TAVI but instead continue medical
therapy (MT). This may bear important consequences in
terms of prognosis and quality of life.
Historically, the treatment decision heavily depended upon
the assessment of risk of valve replacement by using the
Logistic EuroSCORE (LES) or Society of Thoracic Surgeons
(STS) score [2, 3]. These scores were developed to assess the
operative risk of patients undergoing open-heart surgery but
not for the subset of patients who are referred for TAVI.
Therefore, careful patient-to-patient case evaluation by Heart
Team meetings are strongly encouraged and play a crucial
role in the design of randomised clinical trials [1, 4–7]. In
this study, we sought to explore the reasons for the treatment
decision, the treatment-specific complications and survival in
patients referred for TAVI in addition to the predictive factors
of mortality in those undergoing TAVI.
Methods
Patients and eligibility
The population consists of all 358 patients who were referred
for TAVI at the Department of Cardiology of the Erasmus
Medical Centre, Rotterdam, the Netherlands and the Depart-
ments of Cardiology and Cardio-Thoracic Surgery of Angiog-
rafia de Occidente S.A., Cali, Colombia and Fundacion Clinica
Cardio Infantil, Bogota, Colombia between November 2005
and January 2011. In the three institutions, a similar database
and structure of data collection and follow-up was set up at the
initiation of TAVI as previously described [8].
Treatment decision (TAVI, AVR, MT) was taken by
consensus during the Heart Team meeting. Details of
eligibility for Medtronic Corevalve System (MCS) implan-
tation, the bioprosthesis and technique of implantation have
previously been described [8–10]. All patients underwent
transfemoral (n=228) or trans-subclavian TAVI (n=7) with
the 18 Fr third-generation MCS except for the first five
patients treated in 2005 and 2006, in whom a 21 Fr second-
generation MCS was implanted.
AVR was performed through mid-sternotomy using
standard surgical techniques. In all patients a biological
prosthesis was used.
Patients not undergoing valve intervention continued
MT. Balloon aortic valvuloplasty (BAV) was performed in
patients with AS and worsening symptoms as a bridge to
TAVI or as a palliative approach in patients who could not
undergo TAVI/AVR.
Data collection
All data were prospectively collected and entered in a
dedicated database. Source verification of the baseline data
and clinical events was performed by the first author at
each participating centre (within a Master of Science
Programme of the Netherlands Institute for Health
Sciences, Erasmus University Rotterdam, supported by
the Erasmus-Columbus Latin-European Exchange Grant -
www.erasmus-columbus.eu).
All endpoints were selected and defined according to the
Valve Academic Research Consortium (VARC) [11].
Cerebrovascular events were evaluated and adjudicated
by a vascular neurologist. A full blood and chemistry
sample was taken before and up to 3 days after the
procedure to assess the occurrence and severity of peri-
procedural vascular, bleeding and kidney complications.
Data on red blood cell (RBC) transfusions were recorded
by the institution’s blood bank. The occurrence and timing
of new atrial fibrillation and postprocedural 3rd degree
atrioventricular block was assessed by continuous telemetry
recording.
The VARC combined safety endpoint at 30 days con-
sisted of all-cause death, major stroke, major vascular
complication, life-threatening bleeding, acute kidney injury
(AKI) stage III and any in-hospital re-intervention due to
prosthesis dysfunction (interventional/surgical).
Follow-up
Follow-up information of patients treated at the Erasmus
Medical Centre (TAVI, AVR, MT) was collected by first
checking the vital status via the civil registries every
6 months. In case of survival, a questionnaire was sent to
the patient for the assessment of symptoms, (cardiac) events
and readmission(s). Also surviving patients were contacted
by telephone to confirm hospital readmission and reason
after which events were verified with the treating hospital.
All medical records were revised and general practitioners
were contacted when necessary. Follow-up was complete
for all patients.
Follow-up information of patients treated in Colombia
was obtained by the regular office visit and/or telephone
contact (dedicated local research nurse or doctor) with the
treating physician and/or general practitioner and/or patient
or family followed by verification of the event with the
treating hospital. Follow-up was complete for all except for
3 patients.
Statistical analysis
Categorical variables are presented as frequencies and
percentages and were compared with the Chi-square test
or Fisher’s exact test. Normal and skewed continuous
variables are presented as means ± SD and medians (IQR),
respectively. To compare the three treatment groups,
analysis of variance was used for continuous variables and
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the Chi-square test for categorical variables. Kaplan-Meier
survival methods were used to calculate the cumulative
survival at different time intervals and the log-rank test was
used to assess differences in survival. A stepwise Cox
regression analysis including all variables with p<0.10 in
the univariable analysis was used to determine independent
predictors of late mortality in patients undergoing TAVI. A
two-sided p<0.05 was considered to indicate significance
and all analyses were performed with SPSS software
(version 17.0).
Results
Of the 421 patients, 60 (14%) died on the waiting list at a
median (IQR) of 48 (14–110) days after first medical contact
and 3 (1%) were lost to follow-up. Therefore, the total study
population consists of 358 patients of whom 235 (65%)
underwent TAVI at a median (IQR) interval of 71 (30–119)
days and 24 (7%) AVR at an interval of 63 (33–122) days. The
remaining 99 patients (28%) continued MT. The reasons why
AVR orMTwas chosen instead of TAVI are depicted in Fig. 1.
The main reason to reject TAVI in favour of AVR or MT
were patient preference (29%), peripheral vascular disease
(PVD, 13%) and non-severe AS (11%). The baseline
characteristics of the three treatment groups are summarised
in Table 1. Not unexpectedly, patients who underwent TAVI
or continued MT had a significantly higher LES.
Thirty-day clinical outcome
Thirty-day all-cause and cardiovascular mortality was 9 and
6% in the TAVI group and 8 and 8% in the AVR group,
respectively (Table 2). In the TAVI group, six patients
died during the procedure. The cause of death was
hypotension during induction of anaesthesia (n=1), elec-
tromechanical dissociation (n=2), coronary obstruction
(n=1), left ventricular outflow tract rupture (n=1) and
retroperitoneal haemorrhage (n=1). Another 14 patients
died at a median of 7 (IQR: 3–13) days after TAVI due to
stroke (n=3), heart failure (n=2), sudden death (n=2:
unrecognised alternating left and right bundle branch
block leading to asystole at day 8 and sudden death
1 day after discharge on day 29), sepsis (n=2), pneumonia
(n=2), retroperitoneal haemorrhage (n=2) and cardiac
tamponade (n=1). In the surgical group, the cause of
death was ventricular fibrillation (n=1) and severe para-
valvular aortic regurgitation (n=1).
Cardiac re-intervention after the index procedure was
required in 3 patients in the TAVI group: immediate
conversion to AVR (n=1), closure of a paravalvar leak
14 days after TAVI (n=1) and post-implantation dilatation
of the MCS 21 days after TAVI (n=1). In the AVR group,
two patients underwent re-thoracotomy for severe aortic
regurgitation (n=1) and cardiac tamponade (n=1) 1 day
after AVR.
Although the total rate of vascular and bleeding
complications was higher in the TAVI group in comparison
with the AVR group, the combined 30-day safety endpoint
did not differ between the two groups (24 vs. 25%, p=1.0).
Follow-up
The median follow-up was 298 (IQR: 107–688) days in the
TAVI group, 836 (IQR: 327–1269) days in the surgical
group and 456 (IQR: 187–869) days in the medical group.
patient refusal
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Fig. 1 Reasons to decline TAVI
in favour of AVR and MT.
*Four patients had another
reason: severe left ventricular
dysfunction (LVEF <20%);
bleeding diathesis; abusive
alcohol use; unknown. AS =
aortic stenosis; CAD = coronary
artery disease; COPD = chronic
obstructive pulmonary disease;
PVD = peripheral vascular
disease
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Kaplan-Meier estimates of survival are shown in Fig. 2.
Estimated survival at 2 years was 80% in the AVR group,
69% in the TAVI group and 45% in patients who continued
MT (p<0.001). The median time between treatment (AVR
or TAVI) or first medical contact (MT) and death was 96
(IQR: 11–679) days in the surgical group, 171 (IQR: 24–
365) days in the TAVI group and 300 (IQR: 98–578) days
in the MT group.
Details of adverse events beyond 30 days are summar-
ised in Table 3. By univariable analysis, PVD, baseline
creatinine, STS score, RBC transfusion and AKI were
identified as potential determinants of mortality after TAVI.
Multivariable analysis retained RBC transfusion (HR: 1.19;
95% CI: 1.05–1.33), pre-existing renal failure (HR: 1.18;
95% CI: 1.06–1.33) and STS score (HR: 1.06; 95% CI:
1.02–1.10) as independent predictors of mortality after
TAVI
Discussion
We found that the majority of patients referred for TAVI
(72%) undergo valve implantation/replacement (TAVI 65%,
AVR 7%) but that nearly 30% continue MT mainly because
of comorbidity and patient preference not to receive TAVI/
AVR. Patients who underwent TAVI had a higher LES than
those who underwent AVR, were more symptomatic with a
higher prevalence of antecedent CABG and impaired renal
function but less PVD. The most frequent complications
after TAVI consisted of bleeding and vascular complications.
With respect to treatment allocation, the present findings
most likely reflect the current ‘real world’ practice. The
two-thirds acceptance and one-third rejection rate contrasts
with randomised studies such as the Placement of AoRTic
TraNscathetER valve (PARTNER) Cohort-B trial in which
only 12% of the referred patients were accepted for
Table 1 Baseline characteristics of patients undergoing TAVI, AVR and medical therapy
TAVI AVR Medical p-value
n=235 N=24 n=99
Age (years), mean ± SD 80±7 78±9 80±8 0.26
Male, n (%) 116 (49) 13 (54) 42 (42) 0.32
Height (cm), mean ± SD 166±11 169±8 166±8 0.50
Weight (kg), mean ± SD 71±13 75±11 69±16 0.14
BMI, mean ± SD 26.7±4 26.4±4 24.9 5 0.34
BSA, mean ± SD 1.81±0.19 1.87±0.15 1.77±0.24 0.14
NYHA class ≥III, n (%) 177 (75) 12 (50) 53 (53) 0.091
Previous MI, n (%) 45 (19) 5 (21) 16 (16) 0.78
Previous CABG, n (%) 54 (23) 0 21 (21) 0.032
Previous PCI, n (%) 60 (26) 5 (21) 26 (26) 0.92
PVD, n (%) 30 (13) 6 (25) 28 (28) 0.002
Diabetes mellitus, n (%) 57 (24) 5 (21) 28 (28) 0.64
Hypertension, n (%) 132 (56) 12 (50) 34 (34) 0.029
Creatinine, mean ± SD 123±131 104±56 129±68 0.75
Chronic haemodialysis, n (%) 11 (5) 1 (5) 0 0.20
COPD, n (%) 78 (33) 5 (21) 31 (31) 0.59
Permanent pacemaker, n (%) 26 (11) 3 (13) 10 (10) 0.96
Atrial fibrillation, n (%) 49 (21) 8 (33) 25 (25) 0.23
Aortic valve area (cm2), mean ± SD 0.67±0.21 0.81±0.39 0.77±0.27 0.001
LV, n (%)
- Poor (EF <30%) 34 (14) 2 (8) 10 (10) 0.89
- Moderate (EF 30–59%) 82 (35) 6 (25) 24 (24) 0.66
Mitral regurgitation grade ≥III, n (%) 28 (12) 2 (8) 5 (5) 0.29
Aortic regurgitation grade ≥III, n (%) 45 (19) 0 3 (3) 0.001
Logistic Euroscore, mean ± SD 19.1±13.7 10.1±4.3 18.9±12.1 0.007
STS score, mean ± SD 6.1±5.5 4.1±2.4 5.8±3.8 0.17
BMI body mass index, BSA body surface area, CABG coronary artery bypass graft, COPD chronic obstructive pulmonary disease, EF ejection
fraction, NYHA New York Heart Association, LV left ventricular, MI myocardial infarction, PCI percutaneous coronary intervention, PVD
peripheral vascular disease, STS Society of Thoracic Surgeons
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randomised treatment allocation. Of note, we observed a
significant increase in acceptance for TAVI from 2006 until
2010; it was 20% in 2006, 33% in 2007, 50% in 2008, 57%
in 2009 and 81% in 2010. This is not explained by
accepting less sick patients since the LES did not change
over time but is most likely explained by increased
experience and familiarity with the procedure in combination
with an increased public awareness resulting in less patients
who refuse therapy. This may also explain that – over time -
less patients were redirected to surgery (29% of the surgical
patients were treated in 2006; 29% in 2007; 25% in 2008;
13% in 2009 and 4% in 2010).
Initially the LES was a critical factor in patient acceptance
but a present consensus on treatment allocation by the Heart
Team has become the dominant factor. This is not surprising
since this score was neither designed nor validated for TAVI
and does not capture the spectrum of clinical details allowing a
balanced treatment decision [12, 13]. Also the LES is out of
synchrony with the STS score [12, 14]. The shortcomings of
the risk score models and the value of multidisciplinary
patient discussion are illustrated by the web-based confer-
ence call system used in the United States to review and
Table 2 Thirty-day clinical
outcome in patients undergoing
TAVI and AVR
AV atrioventricular, AVR aortic
valve replacement, BAV balloon
aortic valvuloplasty
Mutually non-exclusive analysis
(≥1 event/patient possible)
1Including TIA
2Closure of severe paravalvar
aortic regurgitation with
Amplatzer closure device
(n=1) in TAVI group and
resternotomy for severe
aortic regurgitation (n=1) and
bleeding (n=1) in AVR group
3For symptoms of valve-related
dysfunction or cardiac
decompensation
4Composite all-cause mortality,
major stroke, major vascular
complication, life-threatening
bleeding, acute kidney injury -
stage 3, peri-procedural myocar-
dial infarction, repeat procedure
for valve-related dysfunction
(surgical or interventional)
TAVI AVR p-value
n=235 n=24
Mortality, n (%)
- All-cause 20 (9) 2 (8) 1.0
- Cardiovascular cause 13 (6) 2 (8) 0.64
Myocardial infarction, n (%)
- All 3 (1) 1 (4) 0.32
- Periprocedural (<72 h) 2 (1) 0 1.0
Cerebrovascular complication, n (%)
- All1 20 (9) 2 (8) 1.0
- Major stroke 11 (5) 1 (4) 1.0
Vascular complication, n (%)
- All 42 (18) 0 0.036
- Major 24 (10) 0 0.14
Bleeding complication, n (%)
- All 67 (29) 2 (8) 0.049
- Life-threatening or disabling 21 (9) 2 (8) 1.0
Acute kidney injury, n (%)
- All 40 (17) 8 (33) 0.058
- Stage III 5 (2) 2 (8) 0.13
Cardiac re-intervention, n (%)
- AVR 1 (1) 0 1.0
- BAV 1 (1) 0 1.0
- Other2 1 (1) 2 (8) 0.023
New pacemaker implantation
- All 48 (21) 1 (4) 0.056
- For 3rd degree AV block 40 (17) 0 0.032
New atrial fibrillation 9 (5) 2 (11) 0.60
Repeat hospitalisation, n (%)3 3 (1) 0 1.0
Combined 30-day safety endpoint, n (%)4 55 (24) 6 (25) 1.0
Fig. 2 Kaplan-Meier survival curve for patients undergoing TAVI,
AVR and MT
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approve patients for TAVI, which is subsequently used in the
PARTNER trial [1]. Moreover, randomisation to TAVI or
AVR in the SURgery and Transcatheter Aortic Valve
Implantation (SURTAVI) trial will be based upon clinical
judgement by the Heart Team but not a risk score. The latter
will only be used as criterion for entry into the Heart Team
discussion [6].
The outcome in the TAVI group in the present study is
consistent with the findings of the multi-centre observa-
tional registries [14–18]. The worst complications are death
and stroke. Conceptually safety will increase when less sick
patients receive TAVI. It remains to be elucidated whether
stroke can be reduced by the use of embolic protection
devices during the procedure. As mentioned, the most
frequent complications are bleeding and vascular compli-
cations. Patient-related factors may play a role but are not
the only ones. At present there is no fully proven percutaneous
closure technique. Since bleeding and vascular complications
are inherently associated with a series of ensuing events
(e.g. transfusion) and complications (e.g. anaemia, renal
dysfunction) which in turn affect short- and long-term
outcome, surgical access and closure of the arterial entry site
should be considered [19–23]. The need for pacemaker
insertion is predominantly a device-related phenomenon. A
consistently higher frequency of new pacemaker implanta-
tion after MCS implantation (up to 49%) than after Edwards
implantation (up to 27%) is reported [24, 25]. This is not
without clinical importance since abnormal conduction
may impair left ventricular ejection fraction recovery after
TAVI [26].
Follow-up was characterised by a high incidence of cardiac
and non-cardiovascular events. As for immediate outcome, it
is conceivable that long-term outcome will be better in less
sick patients. This is the subject of investigation in an ongoing
Danish study in which age ≥70 is the main selection criterion
for random allocation to TAVI or AVR. (ClinicalTrials.gov,
Identifier: NCT01057173).
In the present study, outcome was poor in patients who
continued MT. MT was continued mainly because of Heart
Team rejection for TAVI because of comorbidity. Yet, a
substantial number of patients refused valve implantation/
replacement. Patient preference intrinsically is bi-directional
and will play an increasing role in treatment decisions due to
increased public awareness. This puts the medical community
Table 3 Adverse events beyond 30 days after TAVI, AVR and medical treatment
TAVIa AVRa Medicala
All (n=106) Fatal (n=40) All (n=10) Fatal (n=5) Fatal (n=59)
Cardiac 46 (43) 19 (48) 5 (50) 1 (20) 31 (53)
Heart failure 13 (12) 4 (10) 4 (40) 1 (20) 19 (32)
Sudden death 8 (8) 8 (20) 0 0 9 (15)
Myocardial infarction 2 (2) 2 (5) 1 (20) 0 1 (2)
Cardiac re-intervention 3 (3)1 0 0 0 0
Stroke or TIA 11 (10)2 4 (10) 0 0 2 (3)
Pacemaker implantation 9 (9) 1 (3)3 0 0 0
Non-cardiac 56 (53) 21 (52) 5 (50) 4 (80) 9 (15)
Infection 17 (16) 8 (20) 1 (10) 1 (20) 5 (8)
Renal failure 7 (7) 4 (10) 2 (20) 2 (40) 0
Vascular 3 (3) 0 0 0 0
Bleeding (non-cranial) 3 (3) 1 (3) 1 (10) 0 0
Neoplasm 9 (8) 4 (10) 0 0 1 (2)
Metabolic disease 2 (2) 2 (5) 0 0 0
Other 15 (14) 2 (5)4 1 (10) 1 (20)5 3 (5)6
Unknown 4 (4) 0 0 0 19 (32)
aMedian follow-up was 298 (IQR: 107–688) days in the TAVI group, 836 (IQR: 327–1269) days in the AVR group and 456 (IQR: 187–869) days
in the medical group
1 Re-interventions before discharge included AVR (n=1) and post-implantation balloon aortic valvuloplasty (n=2)
2 Including TIA (n=4); of the 11 events, 9 were ischaemic of which 2 fatal and 2 were haemorrhagic, both of which fatal
3 Pneumothorax following pacemaker implantation (n=1)
4 Blood transfusion reaction (n=1), euthanasia (n=1)
5 Delirium (n=1)
6 Obstructive pulmonary disease (n=2), lung emboli (n=1)
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under pressure since the position statement paper on
TAVI advocates not to include patient preference in the
treatment decision [4]. It also raises an ethical issue since
one may question whether one has the right to refuse a
treatment modality if a patient who is adequately informed
about treatment options, outcomes and the presence or
absence of future treatment possibilities in case of failure
of the index treatment persists in his/her treatment
preference.
Conclusion
Up to 65 and 7% of the patients with aortic stenosis who
are referred for TAVI undergo TAVI and AVR with
promising results. Patients who are rejected or refuse valve
replacement have a dismal prognosis.
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In-Hospital Complications After Transcatheter Aortic
Valve Implantation Revisited According to the Valve
Academic Research Consortium Definitions
Rutger-Jan Nuis,1 MSc, Nicolo Piazza,1 MD, Nicolas M. Van Mieghem,1 MD,
Amber M. Otten,1 MSc, Apostolos Tzikas,1 MD, Carl J. Schultz,1 MD, PhD,
Robert van der Boon,1 MSc, Robert-Jan van Geuns,1 MD, PhD, Ron T. van Domburg,1 PhD,
Peter J. Koudstaal,2 MD, PhD, Arie Pieter Kappetein,3 MD, PhD,
Patrick W. Serruys,1 MD, PhD, and Peter P.T. de Jaegere,1* MD, PhD
Objectives: To determine the occurrence of in-hospital complications after transcathe-
ter aortic valve implantation (TAVI) according to the Valve Academic Research Consor-
tium (VARC) criteria in addition to the length of stay (LOS). Background: The absence
of uniformity in endpoint definitions challenges the comparison between previously
reported major adverse cerebro- and cardiovascular event rates after TAVI. To address
this, in 2009, the VARC was established aiming to provide standardized endpoint defi-
nitions for TAVI clinical trials. Methods: Between November 2005 and September 2010,
we prospectively enrolled 150 consecutive patients who underwent TAVI with the Med-
tronic CoreValve System in our institution. Complications, prosthetic valve associated
endpoints, and therapy-specific endpoints were defined according to the definitions
provided by the VARC. Results: The mean age (6SD) was 81 (67) years and 55% were
female. Thirty-day or in-hospital mortality was 11%, and the 30-day combined safety
endpoint was 22%. Seventy-six patients (51%) had 1 cardiovascular and/or noncar-
diovascular complication of whom 16 also underwent a new permanent pacemaker
implantation (PPI). In the 74 patients with uneventful TAVI, 12 patients (8%) underwent
PPI. TAVI was truly uneventful in 62 patients (41%). Bleeding complications were
observed most frequently (31%), followed by acute kidney injury (18%), vascular com-
plications (16%), and stroke/TIA (11%). The median LOS in patients with a complicated
and a truly uncomplicated TAVI was 14.0 (8.0–20.5) and 8.0 (7.0–10.8) days, respectively
(P < 0.001). Conclusion: TAVI was associated with 1 cardiovascular and/or noncardio-
vascular event in 51% of the patients; new PPI was needed in another 8%, and TAVI
was truly uncomplicated in 41%. Complications and need for new PPI significantly
prolonged LOS. VC 2011 Wiley-Liss, Inc.
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INTRODUCTION
Transcatheter aortic valve implantation (TAVI) is a
new treatment modality for patients with aortic stenosis
who are considered poor surgical candidates because of
age and/or severe comorbidities. Given the lesser inva-
sive nature of TAVI in comparison with surgical aortic
valve replacement (AVR), TAVI is increasingly being
used to treat high-risk patients albeit in the absence of
sound data of safety and efficacy [1–4]. Safety is gen-
erally defined by the occurrence of major adverse car-
dio- and cerebrovascular events (MACCE) during or
immediately after the procedure up to 30 days and
includes death, stroke, myocardial infarction, bleeding,
and vascular complications. The current information on
safety of TAVI stems from predominantly single-center
observations with differences in data collection and,
above all, definitions [5–15]. Increasing awareness
among the growing heterogeneity of endpoint defini-
tions for reporting the results of TAVI [16–18] lead to
the development of an international multidisciplinary
expert group (Valve Academic Research Consortium—
VARC), which was established in 2009 with the spe-
cific goal of defining clinical trial endpoint definitions
for TAVI [19]. In line with this consortium, we sought
to determine the in-hospital events that occur during
and/or immediately after TAVI in a series of 150 con-
secutive patients. Because it may be difficult to collect
all complications that occur, we also determined the
length of stay (LOS), which is a nonspecific outcome
measure that can be used as a composite indicator of
adverse events.
MATERIALS AND METHODS
Study Population and Procedure
In this single center study, a total of 150 consecutive
patients underwent TAVI with the Medtronic Core-
Valve System (MCS) between November 2005 and
September 2010. Eligibility for TAVI has been
described in detail elsewhere as well as the prosthesis
and procedure [8,10].
In brief, patients with valvular aortic stenosis
(AVA < 1.0 cm2 or 0.6 cm2/m2) who were consid-
ered poor surgical candidates were eligible for TAVI.
The latter was initially defined by age  80 years or a
logistic EuroSCORE of 20 (November 2005–October
2006) and subsequently by age  75 or a logistic
EuroSCORE  15 (October 2006–present). Patients 
65 were also eligible irrespective of EuroSCORE in
case of severe comorbidity such as respiratory failure,
pulmonary hypertension, liver cirrhosis, cachexia, pre-
vious cardiac surgery, thoracic wall deformities, or a
porcelain aorta. Patients were not eligible in case of a
recent vascular event (stroke, myocardial infarction,
and percutaneous intervention), a planned intervention
within 30 days, infection, GFR < 20 ml/min, life ex-
pectancy less than 1 year, hypersensitivity, or contrain-
dication to aspirin or clopidogrel. Some patients with
GFR < 20 ml/min, however, were proposed TAVI af-
ter Heart Team consensus. Following this selection
process, every patient gave written informed consent
for the treatment, and all clinical data were collected
in the context of a structured follow-up to which every
patient treated in our department is subjected in ac-
cordance with IRB approval.
In the beginning of our series, TAVI was performed
under a regimen of dissociated anesthesia (sedation and
analgesia but no intubation and ventilation), later on
replaced by a strategy of general anesthesia for the
purpose of both patient and operator comfort. The
transarterial femoral approach was the default access
route, and surgical cut down was only performed in
patients who were treated with the second generation
21 F MCS (the initial five patients) or those treated by
the subclavian approach due to severe peripheral vas-
cular disease (four patients of which one with the 21 F
device). This resulted in a total of 142 patients in
whom a truly percutaneous transfemoral approach was
attempted.
Premedication regimen started 3 days before the pro-
cedure and consisted of aspirin 80 mg once daily and
clopidogrel 75 mg once daily or a loading dose of clo-
pidogrel of 300 mg one day of the procedure. During
the postprocedural course, a dual antiplatelet strategy
of aspirin 80 mg and plavix 75 mg was prescribed,
each daily, for 6 months, followed by aspirin 80 mg
lifelong.
Collection of Data and Outcome Measures
All predefined patient- and procedure-related varia-
bles were entered into a dedicated database [10]. Both
the logistic EuroSCORE and the STS score were calcu-
lated.
All cardiovascular and noncardiovascular complica-
tions, prosthetic valve associated endpoints, and ther-
apy-specific endpoints were defined according to the
definitions provided by the VARC [19]. Death, myo-
cardial infarction, stroke, vascular and bleeding com-
plications, and new-onset conduction abnormalities
were collected during or immediately after TAVI. All
cerebrovascular events were evaluated and adjudicated
by a vascular neurologist who reassessed patients with
the event daily. Serum creatinine results up to 72 hr af-
ter the procedure was collected to identify patients
with acute kidney injury (AKI), and data on red blood
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cell (RBC) transfusions were recorded by our institu-
tion’s blood bank laboratory.
Echo-Doppler cardiography was performed the day
before TAVI and within 7 days after TAVI. Details of
the methods of echocardiographical data collection and
analysis have previously been described [20]. Twelve-
lead electrocardiography was obtained at a median of 1
day (IQR: 1-1) before and 1 day (IQR: 1-1) after treat-
ment and examined by an independent core laboratory
(Cardialysis, Rotterdam, The Netherlands) for the
occurrence of new-onset left bundle branch block. In-
formation on additional treatment including antibiotic
drugs and the implantation of a new permanent pace-
maker were collected before hospital discharge.
LOS was analyzed for all patients excluding patients
who died during TAVI (i.e., before leaving the cathe-
terization room). Cardiac care unit (CCU) stay and
total LOS were defined by the time period from the
day of the procedure until the day of Medium Care
transfer and hospital discharge, respectively. In patients
who were discharged after TAVI to the referring insti-
tution, total LOS was defined by total time spent in the
treating and the referring hospital. In patients who died
after TAVI but before planned discharge, LOS was
defined by the time period from the day of the proce-
dure until the day of death. In addition, the location to
which the patient was discharged was determined and
defined as follows: 1] home, 2] nursing home, and 3]
rehabilitation center.
Statistical Management
LOS was expressed both as median (IQR) and mean
(SD). Normally distributed continuous variables were
expressed as mean (SD) and analyzed using the Stu-
dent’s t-test. Skewed distributed continuous variables
were expressed as medians (IQR) and analyzed by the
Mann–Whitney U test. Categorical variables were
expressed as percentages and analyzed by the Pearson
chi-square test or, when indicated, by the Fisher’s
exact test. Kaplan–Meier survival methods were used
to present a 30-day survival curve. Two-sided P-values
< 0.05 were considered to indicate statistical
significance. All statistical analyses were performed
with SPSS software version 17.0 (SPSS Institute,
Chicago, IL).
RESULTS
The baseline characteristics of the population are
summarized in Table I. In-hospital cardiovascular and
noncardiovascular complications, prosthetic valve asso-
ciated endpoints, and therapy-specific endpoints are
summarized in Table II. Details on in-hospital or 30-
day mortality, cerebrovascular complications, bleeding
and vascular complications, and pacemaker implanta-
tions are presented in Tables III–VI, respectively. All
cause and cardiovascular cause in-hospital or 30-day
mortality was 11% (n ¼ 16) and 7% (n ¼ 11), respec-
tively. The overall combined safety endpoint at 30
days was 22% (n ¼ 33, Table II), but decreased to
16% in the second half of the cohort (P ¼ 0.076)
and tended to be higher among patients with more
extensive risk profiles (EuroSCORE  20% or STS
score  10%) compared to those at lower risk (27 vs.
19%, P ¼ 0.28).
Seventy-six patients (51%) had 1 cardiovascular
and/or noncardiovascular complication. Bleeding
TABLE I. Baseline Characteristics and Medication Use in
Patients Undergoing TAVI
n ¼ 150
Baseline patient characteristics
Age, years; median (IQR) 81  7
Male, n (%) 68 (45)
Height (cm), mean  SD 167  9
Weight (kg), mean  SD 73  13
Body mass index, mean  SD 25.9  4.0
Body surface area, mean  SD 1.82  0.20
NYHA class III or IV, n (%) 118 (79)
Previous cerebrovascular event, n (%) 34 (23)
Previous myocardial infarction, n (%) 39 (26)
Previous coronary artery bypass graft surgery,
n (%)
36 (24)
Previous percutaneous coronary
intervention, n (%)
41 (27)
Diabetes mellitus, n (%) 33 (22)
Hypertension, n (%) 70 (47)
Glomerular filtration rate < 60 ml/min, n (%) 84 (56)
Chronic haemodialysis, n (%) 8 (5)
Chronic obstructive pulmonary disease, n (%) 41 (27)
Permanent pacemaker, n (%) 13 (9)
Atrial fibrillation, n (%) 38 (25)
Aortic valve annulus (mm), mean  SD 22.6  2.2
Left ventricular ejection fraction £35%, n (%) 16 (11)
Aortic valve area (cm2), mean  SD 0.64  0.20
Mean gradient (mm Hg), mean  SD 46  17
Mitral regurgitation grade  III, n (%) 23 (15)
Aortic regurgitation grade  III, n (%) 44 (29)
Logistic Euroscore, median (IQR) 12.3 (9.1–18.4)
STS score, median (IQR) 6.1 (3.7–12.5)
Baseline medication use
Antiplatelets 104 (69)
Diuretics 88 (59)
ACE inhibitors 42 (28)
Angiotensin II antagonists 28 (19)
Betablockers 78 (52)
Calcium antagonists 34 (23)
Antiarrythmics 9 (6)
Statins 68 (45)
Abbreviations: ACE, angiotensin converting enzyme; NYHA, New York
Heart Association.
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complications were the most frequent (31%), followed
by AKI (18%), vascular complications (16%), and
stroke or TIA (11%). In these 76 patients, 16 patients
underwent permanent pacemaker implantation (PPI).
Among the 74 patients without a cardiovascular and/or
noncardiovascular complication, 12 patients (8%)
underwent PPI. TAVI was uncomplicated and without
PPI in 62 patients (41%).
Infectious complications were seen in 35 patients
(23%) of which urinary tract infection was the most
frequent (10%), followed by pulmonary and access site
infection (5% and 3%, respectively).
In total, 14 patients died before hospital discharge
(9%) of whom three died during the procedure. As a
result, 147 patients (98%) were eligible for the analysis
of LOS. The median and mean CCU stay in the entire
cohort was 1.0 (IQR, 1.0–2.0) day and 2.0 (2.7)
days, respectively. The total LOS showed to be 10
(IQR, 7.0–17.0) days and 13.4 (9.4) days. The LOS
was significantly shorter in the 62 patients with a truly
uneventful procedure in comparison with the 85 of the
147 patients (58%) who suffered a cardiovascular and/
or noncardiovascular complication and/or underwent a
new PPI [8.0 (7.0–10.8) vs. 14.0 (8.0–20.5) days, P <
0.001]. Also, the LOS of patients with an uneventful
procedure showed an almost normal distribution (me-
dian 8.0, mean 9.2) and was associated with a narrow
IQR of 7.0–10.8. LOS in patients with an eventful pro-
cedure was skewed (median 14.0, mean 16.4) and
variable (IQR 8.0–20.5). A total of 136 patients were
discharged from the hospital, of whom the majority
(108 patients or 79%) was discharged home. Eleven
other patients (8%) were discharged to the referring
center, 14 (10%) to a nursing home, and 3 patients
(2%) to a rehabilitation center.
DISCUSSION
We found that 51% of the patients who underwent
TAVI suffered 1 cardiovascular and/or noncardiovas-
cular complication and that another 8% of the patients
underwent PPI after TAVI. TAVI was uncomplicated
and without additional treatment in 41%. As expected,
in-hospital LOS in patients with an uneventful proce-
dure was significantly shorter (median: 8 days) than in
patients with complicated TAVI (median: 14 days).
Cerebrovascular Complications
Overall, we found a similar frequency of the so-
called major adverse cardiovascular and cerebrovascu-
lar complications in comparison with previously
reported data [5–15]. By and large, the mortality after
TAVI is 10% (Fig. 1), which may not be surprising
TABLE II. In-Hospital Cardiovascular and Noncardiovascular
Complications, Prosthetic-Valve Associated, Therapy-Specific,
and Echocardiographic Results Following TAVI
n (%)
Cardiovascular and noncardiovascular complications
Cardiovascular complications
Mortality (30-day or in hospital)
All cause 16 (11)a
Cardiovascular cause 11 (7)a
Myocardial infarction, n (%)
Periprocedural (<72 hr) 1 (1)
Spontaneous (>72 hr) 0
Stroke, n (%)
Major 10 (7)
Minor 1 (1)
TIA 5 (3)
Vascular
Major 9 (6)
Minor 15 (10)
Bleeding
<24 hr
Life-threatening or disabling 11 (7)
Major 21 (14)
Minor 7 (5)
>24 hr
Life-threatening or disabling 4 (3)
Major 3 (2)
Minor 1 (1)
Noncardiovascular complications
Acute kidney injuryb
Stage I 20 (14)
Stage II 3 (2)
Stage III 3 (2)
Combined safety endpoint (at 30 days)c 33 (22)
Prosthetic valve-associated endpoints
Conduction disturbances
New left bundle branch block 69 (46)
New third-degree atrioventricular block 22 (15)
New permanent pacemaker implantation 28 (19)
Worsening mitral valve regurgitation 7 (5)
Worsening mitral valve stenosis 0
Left ventricular outflow tract rupture 1 (1)
New ventricular septal defect 1 (1)
Therapy-specific endpoints
Valve-in-valve implantation 8 (5)d
Postimplantation balloon dilatation 22 (15)
Unplanned cardiopulmonary bypass use 0
In-hospital reintervention 2 (1)
Echocardiography
Aortic valve area (cm2), mean  SD 1.7  0.5
Mean aortic gradient (mean  SD) 9  4
Mitral regurgitation grade  III [n (%)] 26 (17)
Aortic regurgitation grade  III [n (%)] 20 (13)
Mutually nonexclusive analysis (1 event/patient possible) except for
combined safety endpoint.
aIncluding three intraprocedural deaths.
bEight patients with preprocedural haemodialysis and three patients who
died during TAVI were excluded from the analysis of AKI.
cComposite all-cause mortality, major stroke, life-threatening bleeding,
acute kidney injury-stage III, myocardial infarction, and repeat procedure
for valve related dysfunction.
dIndications: ‘‘too deep’’ prosthesis positioning within left ventricular
outflow tract in six patients and valve embolization in two patients.
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given the nature of the patients that are currently
selected to undergo TAVI and the treatment itself. At
variance with previous data, however, we found a
higher incidence of stroke and TIA (11%). Grube et al.
[8] reported an incidence of 10% while in other stud-
ies, it varied between 3 and 6% [9,14]. This large
variation is most likely attributable to differences in
observation and definitions used to report outcomes, in
general, and stroke in particular [21]. In this study, a
vascular neurologist was consulted in case a neurologic
deficit was observed during the daily rounds after
TAVI, and this may explain the higher incidence of
stroke/TIA in comparison with previous reports. Next
to death, stroke is the most devastating periprocedural
complication. Moreover, none of the patients who sus-
tained a major stroke was discharged to home after the
procedure. The aetiology and determinants of stroke
need to be established so to be able to improve patient
selection, and, potentially, the procedure itself. Kahlert
et al. [22] and Ghanem et al. [23] sought to investigate
the underlying cause and found that clinically silent
foci of restricted diffusion on cerebral magnetic reso-
nance imaging were detected in the majority of patients
undergoing TAVI (84% and 73%, respectively), which
may reflect the pathophysiological associations
between periprocedural cerebral embolization and the
occurrence of stroke. Although the latter is a plausible
explanation, it should be recognized that stroke is not
always caused by atherosclerotic debris. The present
study identified two patients with a watershed infarc-
tion, which in itself is reported to be associated with
haemodynamic changes during cardiac surgery [24,25].
TABLE III. In-Hospital or 30-Day Mortality Following TAVI
Event number n in cohort Time of death (days) Timing Mortality cause Cardiovascular cause
1 10 6 Predischarge Cardiac tamponade Yes
2 41 29 Predischarge Sepsis No
3 49 0 Intraprocedural Induction of anaesthesia No
4 53 24 Postdischarge Major stroke Yes
5 55 11 Predischarge Sepsis No
6 59 8 Predischarge Asystole Yes
7 64 9 Predischarge Major stroke Yes
8 70 30 Predischarge Heart failure Yes
9 72 29 postdischarge Sudden death Yes
10 87 0 Intraprocedural Left ventricular outflow tract rupture Yes
11 89 14 Predischarge Paravalvular regurgitation grade IV Yes
12 90 0 Intraprocedural Elektromechanical dissociation Yes
13 104 28 Predischarge Pneumonia No
14 121 32 Predischarge Pneumothorax after pacemaker implantation Yes
15 132 28 Predischarge Pneumonia No
16 145 3 Predischarge Major stroke Yes
TABLE IV. In-Hospital Cerebrovascular Complications Following TAVI
Event
number n in cohort
Time of CT
(days)
Clinical symptoms
lasting 24 hr CT result
Rankin score 2
and NIHSS score 3a
Stroke
classification Discharge
1 7 1 No Negative imaging No TIA Home
2 16 3 Yes Ischemic lesion Yes Major stroke Stroke unit
3 17 2 Yes Ischemic lesion Yes Major stroke Stroke unit
4 18 7 No Negative imaging No TIA Home
5 19 1 No Negative imaging No TIA Home
6 22 6 No Negative imaging No TIA Home
7 26 6 Yes Ischemic lesion Yes Major stroke Rehabilitation center
8 44 0 Yes Negative imaging Yes Major stroke Rehabilitation center
9 53 0 Yes Ischemic lesion Yes Major stroke Death
10 54 2 Yes Negative imaging No Minor stroke Home
11 64 6 Yes Ischemic lesion Yes Major stroke Death
12 85 3 No Negative imaging No TIA Home
13 105 7 Yes Ischemic lesion Yes Major strokeb Nursing home
14 119 2 Yes Ischemic lesion Yes Major stroke Rehabilitation center
15 138 6 Yes Ischemic lesion Yes Major stroke Nursing home
16 145 1 Yes Ischemic lesion Yes Major stroke Death
Abbreviations: CT, computed tomography; NIHSS, National Institutes of Health Stroke Scale; TIA, transient ischaemic attack.
aAt 7 days or at discharge.bFollowed by a second stroke 2 days later.
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TABLE V. In-Hospital Bleeding and Vascular Complications Occurring <24 hr and >24 hr After the Initiation of TAVI
Event
number
n in
cohort
Source
of event
Event
specification
Additional
intervention
HB drop
(g/dl)
n RBC
transfusions
Bleeding
classification
VC
classification
<24 hr after start TAVI
1 1 Access site 2.4 5 Life threatening Major
2 2 Access site þ
thoracic aorta
Thoracic aortic
dissection
Balloon dilation 2.7 4 Life threatening Major
3 7 Access site Retroperitoneal
hemorrhage
5.2 3 Life threatening Minor
4 10 Myocardium Cardiac tamponade Pericardiocentesis þ
thoractomy
5.8 13 Life threatening No
5 21 Access site Retroperitoneal
hemorrhage
Surgical repair 7.4 9 Life threatening Major
6 22 Access site
(radial artery)
2.6 2 Major Minor
7 24 Access site 3.4 3 Major Minor
8 31 Access site 3.9 0 Major No
9 34 Access site Femoral perforation 4.7 0 Major No
10 36 Access site
(radial artery)
2.3 2 Major Minor
11 40 Access site Prostar failure Surgical exploration 4.0 0 Major Minor
12 41 Access site Prostar failure Surgical explorationa 1.6 0 Minor Major
13 44 Access site 2.7 2 Major Minor
14 50 Access site 2.1 2 Major Minor
15 51 Access site Prostar failure Surgical exploration 3.4 4 Life threatening Major
16 52 Access site 2.9 1 Minor No
17 56 Myocardium Cardiac tamponade Pericardiocentesis 4.2 4 Life threatening No
18 60 Access site Prostar failure Surgical exploration 4.4 2 Major Minor
19 81 Access site Prostar failure Stenting 0.3 2 Major Major
20 82 Access site 3.7 0 Major No
21 83 Access site 1.9 1 Minor No
22 84 Access site 1.1 1 Minor No
23 86 Access site Prostar failure Stentingb,
surgical repair
Unknown 7 Life threatening Major
24 87 Myocardium Fatal LVOT rupture na na Life threatening No
25 97 Access site 2.4 1 Minor No
26 98 Access site
(radial artery)
1.3 0 Minor No
27 99 Access site Prostar failure Stenting 0.6 2 Major Minor
28 103 Access site 2.1 1 Minor No
29 105 Access site 2.3 2 Major Minor
30 109 Access site Prostar failure Surgical exploration 0.3 3 Major Minor
31 111 Access site Prostar failure Surgical repair 0.6 9 Life threatening Major
32 112 Access site 2.9 3 Major Minor
33 113 Access site
(radial artery)
2.6 2 Major Minor
34 117 Access site Prostar failure Stenting 2.9 2 Major Minor
35 120 Access site 1.0 2 Major No
36 121 Access site Prostar failure Stenting 1.9 1 No Major
37 122 Access site 2.4 2 Major No
38 134 Access site 3.9 0 Major No
39 141 Pleural cavity Hematothorax Pleural drainage 4.2 2 Life threatening No
40 146 Access site 1.3 2 Major Minor
>24 hr after start TAVI
41 24 Myocardium Cardiac tamponade Pericardiocentesis 2.9 5 Life threatening No
42 26 Genitourinary Hematuria 1.3 1 Minor No
43 86 Gastrointestinal Melaena 2.1 10 Life threatening No
44 92 Gastrointestinal Melaena 0.8 5 Life threatening No
45 100 Genitourinary Hematuria 1.6 2 Major No
46 123 Gastrointestinal Angiodysplasia Coagulation 2.6 4 Life threatening No
47 130 Genitourinary Hematuria 3.7 0 Major No
All access site bleeding sources occurred at femoral artery unless specified otherwise.
Abbreviations: HB, hemoglobin; LVOT, left ventricular outflow tract; RBC, red blood cell; VC, vascular complication.
aLeading to infection, sepsis, and subsequent death.
bLeading to leg ischemia.
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Therefore, it remains to be seen to what extent filters,
which are positioned in the aortic arch and which are
capable of capturing small atherosclerotic emboli, will
reduce the incidence of stroke after TAVI. Proper ho-
meostasis may be equally important and highlights the
fact that TAVI is a multidisciplinary treatment includ-
ing a cardiovascular anesthesiologist [4].
Vascular and Bleeding Complications
Depending on the definition used, vascular complica-
tions during TAVI may occur in up to 34% of patients
and are associated with a two- or threefold higher 30-
day mortality [18,26–28]. The present study showed a
6% and 10% occurrence of major and minor vascular
complications, respectively. Essential elements that
TABLE VI. In-Hospital Permanent Pacemaker Requirements After TAVI
Event
number n in cohort
Baseline
ECG
Temporary
PM
Time of
PPI (days)
Reason for
time of PPI
Indication
for PPI Timing
<7 days after TAVI
1 14 SR, LAFB No 4 Postprocedural new-onset Third degree AVB Postprocedural
2 24 SR, LBBB No 6 Uncertainty of indication Third degree AVB Intraprocedural
3 30 SR, RBBB Yes 6 Logistical issue Third degree AVB Intraprocedural
4 33 SR, NC Yes 6 Logistical issue Third degree AVB Intraprocedural
5 47 SR, RBBB Yes 6 Temporary fever or
infection
Third degree AVB Intraprocedural
6 69 SR, RBBB Yes 2 None Third degree AVB Intraprocedural
7 73 SR, RBBB Yes 6 Temporary fever
or infection
Third degree AVB Intraprocedural
8 75 SR, NC Yes 1 None Third-degree AVB Intraprocedural
9 97 SR, AV1B, LBBB Yes 6 Logistical issue Third-degree AVB Intraprocedural
10 103 AF,RBBB Yes 4 Logistical issue Third-degree AVB Intraprocedural
11 106 SR Yes 6 Postprocedural
new-onset
slow ventricular
response with AF
Postprocedural
12 136 SR, LBBB Yes 6 Postprocedural
new-onset
Third-degree AVB Postprocedural
7–30 days after TAVI
13 8 SR, NC No 18 Postprocedural
new-onset
Second-degree AVB Postprocedural
14 54 AF, NC Yes 7 Logistical issue Third-degree AVB Postprocedural
15 66 AF, NC Yes 9 Uncertainty of
indication
Third-degree AVB Intraprocedural
16 71 SR, NC Yes 7 Logistical issue Third-degree AVB Intraprocedural
17 81 AF, LBBB Yes 14 Temporary fever
or infection
Third-degree AVB Intraprocedural
18 91 SR, NC Yes 18 Temporary fever
or infection
Third-degree AVB Intraprocedural
19 92 AF, LAFB Yes 8 Uncertainty
of indication
slow ventricular
response with AF
Intraprocedural
20 95 ST Yes 26 Postprocedural
new-onset
Third-degree AVB Postprocedural
21 117 AF Yes 20 Postprocedural
new-onset
Third-degree AVB Postprocedural
22 121 SR, incomplete LBBB Yes 12 Neurocognitive
dysfunction
Third-degree AVB Postprocedurala
23 123 SR, LBBB Yes 12 Logistical issue Third-degree AVB Postprocedural
24 131 AF Yes 10 Postprocedural
new-onset
slow ventricular
response with AF
Postprocedural
25 141 SR, NC Yes 14 Uncertainty of indication Third-degree AVB Intraprocedural
26 146 SR, NC Yes 11 Logistical issue Third-degree AVB Intraprocedural
>30 days after TAVI and before discharge
27 9 SR, NC No 46 Postprocedural
new-onset
NSVT Postprocedural
28 105 SR, NC No 41 Postprocedural
new-onset
Brady–tachy syndrome Postprocedural
Abbreviations: AF, atrial fibrillation; AV1B, 1st degree atrioventricular block; ECG, electrocardiogram; incl, incomplete; LAFB, left anterior fascicu-
lar block; LBBB, left bundle branch block; NC, normal conduction; NSVT, nonsustained ventricular tachycardia; PPI, permanent pacemaker implan-
tation; RBBB, right bundle branch block; SR, sinus rhythm.
aPPI leading to pneumothorax and subsequent death at day 32.
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should be addressed to minimize the occurrence and
potential deleterious consequences of vascular compli-
cations include careful patient selection with standard
diagnostic catheterization and multislice computed to-
mography to assess access site vessel diameter, severe
tortuosity, and circumferential calcification. In addition,
the use of fluoroscopy or echo-Doppler techniques dur-
ing femoral puncturing when using a Seldinger tech-
nique may help to avoid femoral perforations, whereas
a control angiogram at the end of the procedure may
detect unsuccessful hemostasis when a percutaneous
technique is used for vascular closure. Given the fre-
quency and the clinical and economic effects of these
complications, one may consider the use of a limited
surgical vascular access and closure that consists of the
exposure of the common femoral artery without its dis-
section free of its surrounding supporting structures.
With the exception of one event, all observed vascu-
lar complications in the present study were found to be
associated with overt bleeding events. In total, there
were 11 life-threatening or disabling, 21 major, and 7
minor overt bleeding events during or within 24 hr;
another eight bleeding events (four life-threatening,
three major, and one minor) were diagnosed beyond 24
hr after TAVI. An important marker that distinguishes
between the degree of severity of bleeding and vascu-
lar complications proposed by the VARC is the associ-
ated number of required RBC transfusions. Irrespective
of indication, our study reveals that 70% of all
patients underwent 1 RBC transfusion during the
index-hospitalization period of whom only 33% were
associated with an overt bleeding event (Fig. 2).
Acute Kidney Injury
The observed frequency of acute kidney injury
(AKI) of 18% with the need of initiation of hemodialy-
sis in 2% is in line with previous studies reporting a
frequency that ranges from 12 to 28% [29,30]. Both
studies found periprocedural RBC transfusion to be an
important predictor of AKI, which in itself—according
to the results of Bagur et al.—was independently asso-
ciated with 30-day mortality. The pathophysiological
interaction between periprocedural RBC transfusions
and AKI following TAVI remains uncertain. Neverthe-
less, patients with any of these risk factors require
close monitoring during the early postprocedural days
and potentially thereafter.
Permanent Pacemaker Implantation
In 28 patients, a new permanent pacemaker was
implanted after TAVI. The reported frequency of new
Fig. 2. Percentage of patients who underwent at least 1 RBC transfusion with or without
associated overt bleeding. Abbreviations: RBC, red blood cell.
Fig. 1. Kaplan–Meier survival up to 30 days after TAVI.
37Complications after TAVI according to VARC
PPI after TAVI varies between 4 and 47% [12,31].
This wide variation is not surprising given the differen-
ces in threshold for PPI between physicians and institu-
tions. TAVI is a relatively new and still experimental
treatment applied in elderly patients with or without
severe comorbidity and/or antecedent disease. The cur-
rent guidelines of pacemaker implantation may not suf-
fice in this population and specific treatment. As for
stroke, the clarification of the etiology of atrioventricu-
lar conduction abnormalities during TAVI may help.
Clinical observations in small series of patients who
underwent TAVI indicate that both patient (e.g., thick-
ness of interventricular septum and noncoronary cusp,
preexisting right bundle branch block, narrow left ven-
tricular outflow tract diameters, and severe mitral annu-
lus calcification) [32–34] and procedure-related (depth
of implantation of the CoreValve System as well its
induced mechanical stress on the aortic valvar com-
plex) factors play a role [33,34]. If true, these findings
may lead to improved patient and procedure planning
and, more importantly, to changes in implantation tech-
nique and guidance in addition to novel delivery cathe-
ters and valve technology.
In case of a new PPI, the LOS (median) was 18
days. In this population, 12 patients received a pace-
maker within 7 days after TAVI, another 14 patients
between 7 and 30 days, and 2 patients received a pace-
maker beyond 30 days after TAVI and before hospital
discharge. The reason of PPI beyond 7 days after
TAVI was postprocedural new-onset conduction distur-
bances (six patients), logistical issues (four patients),
uncertainty and discussion on the indication of PPI
(three patients), temporary fever or infection (two
patients), and neurocognitive dysfunctional behavior
(one patient).
Infections
A high proportion of patients had an infectious com-
plication after TAVI of which urinary tract infection
was the most frequent (10%), followed by pulmonary
and access site infection (5 and 3%, respectively).
Webb et al. [12] found a similar frequency of pulmo-
nary and local infections (4 and 3%, respectively).
Measures to avoid urinary tract infection include the
early removal of the urinary bladder catheter after
TAVI. This is often not possible, because—in our
observations—most patients need more time to become
fully ambulant as a result of which the urinary catheter
remains in situ for a longer period than strictly needed.
For patient and staff comfort, we perform TAVI under
general anesthesia. Despite the fact that patients are
extubated in the catheterization room immediately after
the procedure, it is conceivable that anesthesia and
ventilation have contributed to the occurrence of pul-
monary infection in addition to patient-related factors
such as chronic obstructive pulmonary disease. It
remains to be seen whether deep sedation and a laryn-
geal mask reduce pulmonary infections after TAVI.
Length of Stay
There is scant information on length of stay (LOS)
after TAVI. The LOS (median) thus far reported in
studies that focused on MACCE varies between 5 and
13 days [9,12]. In the absence of a uniform definition
of LOS (i.e., in- or excluding time spent in referring
hospital after discharge from treating center) and pre-
defined criteria of hospital discharge, it is difficult to
compare and interpret these data. Despite this, it is
clear that TAVI differs from other catheter-based treat-
ments and that the observed LOS is longer than the
one we may have assumed at the initiation of TAVI.
This is not surprising given the baseline characteristics
of the patients and the nature of TAVI itself and may
explain the high frequency of cardiovascular and of the
non-cardiovascular complications in this study.
The LOS in octogenarians who underwent surgical
AVR with or without combined bypass grafting varies
between 7 and 10 days (median) and between 9 and 20
days if expressed as mean [35–38]. Despite the differ-
ences in the patients who are selected for surgical
AVR and TAVI, the LOS after surgery is noteworthy
considering the surgical trauma and the use of cardio-
pulmonary support during the operation.
Limitation
We concentrated on clinical complications during
or after TAVI. Because of limitations in clinical ob-
servation, some complications may have remained
undetected. The sample size precluded a comprehen-
sive analysis of the independent determinants of com-
plications and LOS, which is needed to improve
patient selection and procedure planning. Also, this
analysis only reports on the results following treat-
ment with the MCS without a comparison with
patients undergoing TAVI with the Edwards–Sapien
prosthesis.
CONCLUSIONS
TAVI is associated with a 30-day combined safety
endpoint of 22%. At least 1 major adverse event
occurred in 51% of the patients; additional PPI was
needed in another 8%, and TAVI was truly uncompli-
cated in 41%. Complications and additional treatment
significantly prolonged LOS.
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Effect of Experience on Results of Transcatheter Aortic Valve
Implantation Using a Medtronic CoreValve System
Rutger-Jan Nuis, MSca, Nicolas M. van Mieghem, MDa, Robert M. van der Boon, MSca,
Robert-Jan van Geuns, MD, PhDa, Carl J. Schultz, MD, PhDa, Frans B. Oei, MDb,
Tjebbe W. Galema, MD, PhDa, Goris Bol Raap, MD, PhDb, Peter J. Koudstaal, MD, PhDc,
Marcel L. Geleijnse, MD, PhDa, Arie Pieter Kappetein, MD, PhDb, Patrick W. Serruys, MD, PhDa,
and Peter P. de Jaegere, MD, PhDa,*
Outcome after transcatheter aortic valve implantation (TAVI) depends on the patient risk
profile, operator experience, progress in technology, and technique. We sought to compare
the results of TAVI during the initiation phase and after certification to perform TAVI with
the Medtronic CoreValve System without proctoring. A total of 165 consecutive patients
was categorized into a first cohort of 33 patients treated before certification (November
2005 to December 2007) and a second cohort of 132 patients treated after certification
(January 2008 to October 2010). The study end points were selected and defined according
to the Valve Academic Research Consortium recommendations. Compared to cohort 2, the
patients in cohort 1 more frequently had New York Heart Association class III–IV (100%
vs 71%, p <0.001), hypertension (67% vs 39%, p  0.004), and aortic regurgitation grade
III–IV (46% vs 22%, p  0.006) before TAVI. Over time, the patients in cohort 2 more
frequently underwent a truly percutaneous approach (98% vs 82%, p  0.002) without
circulatory support (96% vs 67%, p <0.001) but with more concomitant percutaneous
coronary intervention (11% vs 0%, p 0.042) than the patients in cohort 1. They also more
often received a 29-mm prosthesis (72% vs 24%, p <0.001), required less postimplantation
balloon dilation (10% vs 27%, p  0.008), and had less aortic regurgitation grade III–IV
after TAVI (12% vs 30%, p  0.010). The clinical outcome showed a nonsignificant
reduction in the combined safety end point (30% to 17%) but a significant reduction in
cerebrovascular events (21% to 7%, p  0.020) and life-threatening bleeding (15% to 5%,
p  0.044) in cohort 2. However, the reduction in overall bleeding and vascular
complications (25% and 14%, respectively) was not significant. In conclusion, TAVI
became significantly less complex and was associated with better results over time but
remained associated with a high frequency of periprocedural major cardiovascular
complications. Crown Copyright © 2011 Published by Elsevier Inc. All rights reserved.
(Am J Cardiol 2011;107:1824–1829)
Compared to patients who underwent transcatheter aortic
valve implantation (TAVI) in the early days, patients treated
later have been reported to benefit from improved proce-
dural success rates, with subsequent improved survival.1
The developments of smaller delivery catheters, improve-
ments in frame technology, and increased operator experi-
ence, in addition to changes in the baseline risk of patients,
have played a role. In the present study, we describe the
effect of our experience, in addition to changes in patient
demographics, procedure, and outcome of TAVI with the
Medtronic CoreValve System (MCS), in a cohort treated
before (2005 to 2007) and after (January 2008) certification
to perform TAVI as a solo center.
Methods
From November 2005 to October 2010, 165 consecutive
patients with severe aortic stenosis underwent TAVI with
the MCS. All patients were accepted for TAVI by Heart
Team consensus by a cardiologist and cardiac surgeon who
agreed that surgical aortic valve replacement was associated
with a too high or prohibitive risk, using previously reported
criteria.2 The treatment decision was made on the basis of a
comprehensive analysis of symptoms, physical examination
findings, laboratory assessment, 12-lead electrocardiographic fi-
ndings, 2-dimensional transthoracic echocardiography, in-
cluding continuous pulsed wave Doppler examination of the
aortic valve for calculation of the aortic valve area and mean
gradient according to the recommendations of the American
Society of Echocardiography, and assessment of the coro-
nary and peripheral arteries by angiography or MSCT.3,4
Departments of aCardiology, bCardio-Thoracic Surgery, and cNeurol-
ogy, Erasmus Medical Center, Rotterdam, The Netherlands. Manuscript
received December 13, 2010; manuscript received and accepted February
12, 2011.
*Corresponding author: Tel: (00) 311-0703-1763; fax: (00) 311-0703-
4320.
E-mail address: p.dejaegere@erasmusmc.nl (P.P. de Jaegere).
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During the study period, 322 patients were screened, for
whom the acceptance rate for TAVI increased from 23% in
2006 to 76% in 2009. The patients agreed to TAVI in
writing.
The details of the device and the procedure have been
previously reported.5,6 The first 5 patients underwent TAVI
with the second-generation MCS, which is implanted using
a 21Fr delivery catheter inserted into the common femoral
(n  4) or the subclavian (n  1) artery using surgical
exposure without the use of an arterial sheath. All other
patients underwent TAVI with the third-generation MCS,
which is delivered using an 18Fr arterial sheath inserted into
the femoral artery using an echocardiographic-guided
Seldinger technique and closure with a 10Fr Prostar7 (Pro-
star XL, Abbott Vascular, Illinois); except for 4 who un-
derwent the subclavian approach. All patients underwent
general anesthesia, and valve implantation was done using
cine and fluoroscopic guidance.
The preprocedural demographic, clinical, laboratory, and
technical (electrocardiographic and echocardiographic) data
were prospectively collected and entered in a dedicated
database. Transthoracic echocardiography was performed 1
day before the procedure and within 7 days after TAVI. The
details of the analysis have been previously reported.7 The
Valve Academic Research Consortium recommendations
were used for all separate and composite end points in the
present study.8 The following separate clinical end points
were collected during or immediately after TAVI: death,
myocardial infarction, cerebrovascular complications, vas-
cular and bleeding complications, and acute kidney injury
(AKI). The following prosthetic valve associated end points
were recorded: new left bundle branch block, new third-
degree atrioventricular block, new permanent pacemaker
implantation, and coronary obstruction. Finally, the thera-
py-specific end points were recorded, including ventricular
perforation at any point resulting in cardiac tamponade,
postimplantation balloon dilation, valve-in-valve implanta-
tion, and unplanned cardiopulmonary bypass with or with-
out conversion to open surgical aortic valve replacement.
All cerebrovascular events were evaluated and adjudicated
by a vascular neurologist who reassessed such patients
daily. The serum creatinine results 72 hours after the
procedure were collected to identify the patients with AKI,
and data on the red blood cell transfusions were recorded by
our institution’s blood bank laboratory. Twelve-lead elec-
trocardiographic recordings were obtained 1 day before
treatment and 1 day after treatment, after which the elec-
trocardiograms were examined by an independent cardiol-
ogist for the occurrence of new left bundle branch block.
To assess the effect of the experience on clinical out-
come, the study population was divided into 2 patient co-
horts. Cohort 1 (C-1) included the initial 33 patients treated
from November 2005 to December 2007. Cohort 2 (C-2)
included the subsequent 132 patients who were treated from
January 2008 to October 2010. This distinction in time was
made by receipt of certification in January 2008, attesting
that our institution and team were qualified to perform
TAVI without any additional assistance or the presence of a
Table 1
Baseline patient characteristics stratified by cohort
Variable Entire Cohort
(n  165)
Cohort 1*
(n  33)
Cohort 2*
(n  132)
p Value
Age (years) 81  8 82  7 80 8 0.39
Men 75 (46%) 15 (46%) 60 (46%) 1.0
Height (cm) 167  9 167  8 167  9 0.86
Weight (kg) 73  13 73  13 72  13 0.77
Body mass index (kg/m2) 26.0 4.0 26.2  4.6 26.0  3.8 0.77
Body surface area (m2) 1.83  0.19 1.84  0.19 1.83  0.20 0.83
New York Heart Association class III 127 (77%) 33 (100%) 94 (71%) 0.001
Previous cerebrovascular event 35 (21%) 8 (24%) 27 (21%) 0.63
Previous myocardial infarction 43 (26%) 7 (21%) 36 (27%) 0.48
Previous coronary artery bypass graft surgery 42 (26%) 10 (30%) 32 (24%) 0.48
Previous percutaneous coronary intervention 46 (28%) 8 (24%) 38 (29%) 0.60
Diabetes mellitus 38 (23%) 8 (24%) 30 (23%) 0.85
Hypertension 73 (44%) 22 (67%) 51 (39%) 0.004
Glomerular filtration rate 60 ml/min 90 (55%) 20 (61%) 70 (53%) 0.43
Chronic hemodialysis 8 (5%) 2 (6%) 6 (5%) 1.0
Chronic obstructive pulmonary disease 45 (27%) 7 (21%) 38 (29%) 0.89
Permanent pacemaker 26 (16%) 5 (15%) 21 (16%) 0.89
Atrial fibrillation 40 (25%) 7 (21%) 33 (25%) 0.62
Aortic valve annulus (mm) 22.6 2.2 22.7  2.3 22.6  2.2 0.97
Aortic valve area (cm2) 0.64  0.21 0.67  0.17 0.63  0.22 0.34
Mean aortic gradient 45 17 48  19 45  16 0.38
Aortic regurgitation grade III or greater 44 (27%) 15 (46%) 29 (22%) 0.006
Mitral regurgitation grade III or greater 23 (14%) 7 (21%) 16 (21%) 0.18
Logistic European System for Cardiac Operative Risk Evaluation 13.1 (9.8–19.4) 14.2 (10.5–18.7) 12.6 (9.6–21.2) 0.53
Society of Thoracic Surgeons’ score 4.6 (3.3–6.7) 5.3 (3.0–8.0) 4.6 (3.3–6.3) 0.28
Data are expressed as mean  SD, median (interquartile range), or number of patients (%).
* Cohort 1 and 2 included patients treated before (n 33) and after (n 132) institutional qualification and certification in January 2008 to perform TAVI
as a solo center without additional assistance of a proctor, respectively.
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proctor. Also, 2005 to 2007 constituted the period during
which TAVI evolved from a hybrid surgical approach with
cardiopulmonary support to a truly percutaneous procedure
(October 2006), with the gradual omission of circulatory
support (December 2006).
The preprocedural, procedural, and in-hospital results
were compared between the 2 groups. The categorical vari-
ables are presented as frequencies and percentages and were
compared using the chi-square test or Fisher’s exact test.
The normal and skewed continuous variables are presented
as the mean  SD and median (interquartile range), respec-
tively. A comparison of the continuous variables was done
using the Student t test or Wilcoxon rank sum test. Two-
sided p values 0.05 were considered to indicate signifi-
cance. All statistical analyses were performed using the
Statistical Package for Social Sciences software, version
17.0 (SPSS, Chicago, Illinois).
Results
The baseline patient characteristics and procedural de-
tails of the entire population and the 2 cohorts are listed in
Tables 1 and 2, respectively. Compared to the C-2 patients,
the C-1 patients were more symptomatic (New York Heart
Association class III or IV, 100% vs 71%, p 0.001), more
frequently had a history of hypertension (67% vs 39%, p 
0.004), and more often presented with aortic regurgitation
grade III or greater (46% vs 22%, p  0.006).
The C-2 patients more frequently underwent a truly per-
Table 2
Procedural details and results stratified by cohort
Variable Cohort 1
(n  33)
Cohort 2
(n  132)
p Value
Vascular access
Surgical—femoral artery 4 (12%) 0 0.001
Surgical—subclavian artery 2 (6%) 3 (2%) 0.59
Percutaneous—femoral artery 27 (82%) 128 (98%) 0.002
Circulatory support*
Extracorporeal membrane
oxygenation
2 (6%) 1 (1%) 0.10
Left ventricular assist device 9 (27%) 4 (3%) 0.001
None 22 (67%) 126 (96%) 0.001
Additional interventions during
procedure
Percutaneous transluminal
angioplasty iliac artery
3 (9%) 2 (2%) 0.055
Percutaneous coronary intervention 0 15 (11%) 0.042
Prosthesis size† (mm)
26 25 (76%) 36 (28%) 0.001
29 8 (24%) 94 (72%) 0.001
Therapy-specific results
Ventricular perforation resulting in
cardiac tamponade
1 (3%) 0 1.0
Postimplantation balloon dilation 9 (27%) 13 (10%) 0.008
Valve-in-valve implantation 3 (9%) 5 (4%) 0.36
Unplanned cardiopulmonary
bypass use
0 0 1.0
Conversion to open surgical aortic
valve replacement
0 0 1.0
Contrast volume (ml) 211  71 176  83 0.041
Duration of procedure (min) 230 74 257  80 0.099
Data are expressed as mean  SD or number of patients (%).
* One patient died during induction of anesthesia.
† Two patients did not receive a valve (1 death during induction of
anesthesia and 1 death after balloon valvuloplasty).
Table 3
In-hospital clinical outcome, prosthetic-valve associated outcome, and
echocardiographic findings stratified by cohort*
Variable Cohort 1
(n  33)
Cohort 2
(n  132)
p Value
In-hospital clinical outcome
Thirty day or in-hospital death
All-cause 1 (3%) 15 (11%) 0.20
Cardiovascular cause 1 (3%) 10 (8%) 0.47
Periprocedural myocardial
infarction (72 hours)
1 (3%) 0 0.20
Spontaneous myocardial
infarction (72 hours)
0 0 1.0
Cerebrovascular complication 7 (21%) 9 (7%) 0.020
Major stroke 3 (9%) 7 (5%) 0.69
Minor stroke 0 1 (1%) 1.0
Transient ischemic attack 4 (12%) 1 (1%) 0.006
Vascular complication 6 (18%) 19 (14%) 0.59
Major 3 (9%) 7 (5%) 0.69
Minor 3 (9%) 12 (9%) 1.0
Bleeding complication 24
hours
8 (24%) 33 (25%) 0.95
Life-threatening or disabling 5 (15%) 6 (5%) 0.044
Major 3 (9%) 18 (14%) 0.48
Minor 0 9 (7%) 0.12
Bleeding complication 24
hours
2 (6%) 6 (5%) 1.0
Life-threatening or disabling 1 (3%) 3 (2%) 1.0
Major 0 3 (2%) 0.61
Minor 1 (3%) 0 0.20
Acute kidney injury 9 (27%) 18 (14%) 0.056
Stage 1 6 (18%) 15 (11%) 0.38
Stage 2 1 (3%) 2 (2%) 1.0
Stage 3 2 (6%) 1 (1%) 0.10
In-hospital reintervention 0 2 (2%) 1.0
Combined safety end point at
30 days†
10 (30%) 22 (17%) 0.076
Prosthetic-valve associated
outcome
Conduction disturbances
Left bundle branch block 14 (42%) 61 (46%) 0.70
Pacemaker for third-degree
atrioventricular block
4 (12%) 18 (14%) 0.58
Pacemaker for other than
third-degree
atrioventricular block
2 (6%) 5 (4%) 0.63
Coronary obstruction 1 (3%) 0 0.20
Echocardiography results
Aortic valve area (cm2) 1.69  0.53 1.76  0.55 0.60
Mean aortic gradient 11 6 9 3 0.013
Aortic regurgitation grade III
or greater
10 (30%) 16 (12%) 0.010
Mitral regurgitation grade III
or greater
6 (18%) 14 (10%) 0.24
Data are expressed as mean  SD or number of patients (%).
* Mutually nonexclusive analysis (1 event/patient possible).
† Composite all-cause mortality, major stroke, life-threatening bleeding,
acute kidney injury (stage 3), periprocedural myocardial infarction, repeat
procedure for valve-related dysfunction (surgical or interventional).
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cutaneous transfemoral approach (98% vs 82%, p  0.002)
without circulatory support (96% vs 67%, p 0.001) but
more often underwent concomitant percutaneous coronary
intervention during the TAVI procedure (11% vs 0%, p 
0.042). Because the 29-mm inflow valve became available
in October 2007, a smaller proportion of C-1 patients re-
ceived a 29-mm inflow valve (24% vs 72%, p 0.001).
Thus, additional balloon dilation immediately after valve
implantation was used less often in the C-2 patients (10% vs
27%, p  0.008). The TAVI procedures in C-2 were also
characterized by a reduced use of contrast media (176 vs
211 ml, p  0.041).
A trend was seen toward an increase in all-cause mor-
tality over time (3% to 11%). The time and cause of death
in the 15 patients in C-2 were as follows; 3 intraprocedural
(induction of anesthesia, left ventricular outflow tract rup-
ture, and electromechanical dissociation in 1 each), 11 in-
hospital (major stroke in 3, heart failure in 2, sepsis in 2,
pneumonia in 2, asystole in 1, and pneumothorax during
permanent pacemaker implantation in 1), and 1 sudden
death immediately after discharge. Despite this, a trend was
seen toward a reduction of the combined safety end point at
30 days from 30% to 17% (Table 3). The latter was pre-
dominantly caused by a reduction in life-threatening bleed-
ing events occurring during or immediately after TAVI
(15% to 5%, p  0.044). However, a significant reduction
occurred in cerebrovascular complications (21% to 7%, p
0.020), mainly because of a reduction in transient ischemic
attacks (12% to 1%, p  0.006). Computed tomography of
the brain was performed in all patients who experienced a
major or minor stroke and revealed that the cause of the
insult was ischemic in origin (embolus) in 81% and due to
hemodynamic changes during the procedure (watershed) in
19% of the patients.
To address the limitations of a breakdown of the popu-
lation into 2 unequally sized groups, the population of 165
patients was also categorized in 5 succeeding subgroups of
33 patients (Figure 1). A clear reduction in clinical compli-
cation rates over time was observed.
From a technical viewpoint, the C-2 patients had a
lower mean aortic valve gradient (9 vs 11 mm Hg, p 
0.013) and less frequently had aortic regurgitation grade
III or greater (12% vs 30%, p  0.010) at the predis-
charge echocardiographic Doppler analysis comparison
to the C-1 patients.
Discussion
We found that in the function of time, the patients treated
later were at a somewhat lower risk than those treated
during the initiation period and that the procedure became
less invasive and complex by avoiding circulatory support,
although TAVI was more often combined with percutane-
ous coronary intervention in the later series. In terms of
outcome, we observed an important improvement in safety
according to the Valve Academic Research Consortium
safety end point, mainly because of a reduction in life-
threatening periprocedural bleeding complications. Also a
significant reduction in transient ischemic attacks occurred.
From a procedural perspective, postimplantation balloon
dilation was less often performed in the C-2 patients and
they also had a lower incidence of aortic regurgitation grade
III or greater after TAVI.
This summary of findings was based on an analysis of
165 consecutive patients with a breakdown of these patients
into 2 groups; those treated during the initiation and devel-
opment period (November 2005 to December 2007) and
those treated after January 2008 when the TAVI certifica-
tion was obtained. The number of patients obviously affects
the robustness of these findings because 1 event more or less
in 1 group—in particular in C-1—could result in different
findings. However, when we analyzed the combined safety
end point at 30 days using 5 consecutive groups of 33
patients each, a substantial, and almost linear, reduction
in the complication rates was seen as a function of time
(Figure 1).
With respect to the patient characteristics, the change in
profile can be explained by the natural evolution of an
initially experimental clinical program and treatment. At
variance with percutaneous coronary intervention, TAVI
was initiated in patients who were rejected for surgery or
who were poor surgical candidates. The tendency of select-
ing less sick patients over time might not, therefore, be
surprising. To keep pace with the reality of clinical practice,
it is worth mentioning that planned randomized studies such
as the SURgery and transcatheter Aortic Valve Implantation
(SURTAVI) trial will enroll patients with a risk profile less
than the current criteria of eligibility for TAVI.9 The base-
line risk is currently most often expressed by the logistic
European System for Cardiac Operative Risk Evaluation
(EuroSCORE) or Society of Thoracic Surgeons’ score.
Given the skewed distribution of the individual character-
istics of the patients who undergo TAVI, we used the
median and interquartile range and not the mean values of
these scores. This explains why our reported values of
14.2% (interquartile range 10.5% to 18.7%) and 5.3% (in-
terquartile range 3.0% to 8.0%) were somewhat lower than
those reported in other studies.1,5,10,11 Also, differences in
the interpretation of the definitions of the variables that must
be entered in the risk model could play a role. When ex-
amining the individual patient characteristics between this
population and those of the published observational studies
reported, few differences were seen.1,5,10,11 Because the
limitations of risk models are widely recognized,12 the
Figure 1. Frequencies of combined safety end point at 30 days stratified by
fatal and nonfatal complications according to 5 subsequent patient cohorts
of 33 patients each. Safety end point at 30 days included composite
all-cause mortality, major stroke, life-threatening bleeding, acute kidney
injury (stage 3), periprocedural myocardial infarction, repeat procedure for
valve-related dysfunction (surgical or interventional).
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Heart Team discussion and consensus in treatment decision
and allocation has been gaining weight and importance in
clinical practice and studies.9
Not unexpectedly, the procedure substantially changed
as a function of time. The first patient was treated in No-
vember 2005, barely 1 year after the first transfemoral TAVI
in April 2004. At that time, all TAVI procedures with the
MCS were performed with the 25Fr or 21Fr sheathless
delivery catheter and implied surgical cutdown of the fem-
oral artery. Also, at that stage, it was believed that circula-
tory support was required during TAVI. As the experience
and insights into the procedure increased, it became clear
that this was not the case. Also, a reduction in the delivery
catheter size allowed a true percutaneous approach (October
2007) followed by the advent of a 29-mm inflow MCS that,
similar to the 26-mm inflow MCS, can be delivered with an
18Fr delivery catheter. Regarding the arterial access, only a
few subclavian procedures were performed. A more direct
access to the heart by way of the subclavian artery or direct
aortic access can be advantageous, given the superiority of
surgical hemostasis in comparison to the percutaneous tech-
niques and better valve positioning owing to the improved
catheter response while positioning, which, in turn, can lead
to fewer conduction abnormalities.13–15
This series does not allow a precise definition of the
factors that most contributed to the improvement in clinical
outcome as a function of time. The changes in the baseline
risk of the patients, improvements in the technology and
procedure (18Fr instead of 21Fr delivery catheter), omission
of circulatory support, increased experience of the opera-
tors, and improvements in postoperative care (e.g., lower
threshold for radiologic examination in the case of oozing
at the access site) could have played a role. When excluding
the first 5 patients who were treated with the 21Fr delivery
catheter, we found that the combined safety end point in C-1
decreased by only 2%. In addition, we believe that the
continuous improvement can more likely be explained by
the increasing operator/institutional experience, and not the
reduction in the size of the delivery catheter, although the
latter was invariably associated with an increased risk of
bleeding and vascular complications. Regarding the use of
circulatory support systems, it should be acknowledged that
in addition to their potential risks (e.g., bleeding-vascular
complications, AKI), these systems can have had a protec-
tive role, as well, especially in the early phase, or in patients
with poor left ventricular function.
We found no differences in the total frequency of bleed-
ing and vascular complications in our series. Depending on
the accuracy of observation and the definition used, the
reported incidence of these complications in the published
data has varied from 4% to 32%.16–18 According to the
Valve Academic Research Consortium consensus that pro-
poses the number of red blood cell transfusion as a measure
of bleeding severity, bleeding complications were less se-
vere in patients treated later because fewer transfusions (1.1
vs 2.1 U, p 0.007) were needed. All patients who required
additional surgical or interventional treatment because of
bleeding or vascular complications were related to incom-
plete femoral artery closure with the Prostar device. This
high rate of failure of hemostasis should not be surprising,
because the Prostar closure device is proposed for vascular
puncture holes 10Fr only.19 It is, therefore, logical that
some centers prefer a limited surgical cutdown of the fem-
oral artery, instead of “off label” use of a closure device.20
We did not observe a reduction in all-cause and cardio-
vascular mortality. The cardiovascular mortality rate varied
from 3% to 8% in the present study and was comparable to
the mortality reported in observational studies and in the
Placement of AoRTic TraNscathetER Valve Trial (PART-
NER) trial (5%).10,11,21 The most striking improvement was
the reduction in transient ischemic attacks. Whether this can
be attributed to improved operator skills of catheter han-
dling and valve positioning is unknown. A major stroke
occurred in 9% of the C-1 patients and in 5% of the C-2
patients. The latter, also, is in accordance with the data from
observational studies and the PARTNER trial (5%). Al-
though most of these accidents were of presumed cardio-
embolic origin, some were lacunar and resulted from cere-
bral small vessel disease and not embolism. A better
understanding of the etiology is needed to improve patient
selection and procedure planning and execution. For in-
stance, the prevalence of hypertension, an established pre-
dictor of stroke after cardiac surgery, was significantly less
in C-2 than in C-1.22
AKI is recognized to be associated with poor survival
after cardiac interventions, including percutaneous coronary
intervention, cardiac surgery, and TAVI and, thus, high-
lights the importance of its avoidance or prevention.23–26
This is particularly true for patients who undergo TAVI,
given the high prevalence of pre-existing impaired renal
function.25,26 In the present series, we found a reduction of
almost 50%, which can in part be explained by patient
variables such as a greater prevalence of antecedent hyper-
tension in the C-1 patients. Compared to the C-2 patients,
the C-1 patients had a greater risk of AKI, owing to the
more frequent use of circulatory support, more severe bleed-
ing, potentially inducing renal ischemia, more frequent ad-
ministration of red blood cell transfusions24 hours (2.1 vs
1.1 U, p  0.007), and, last, but not least, the greater
volumes of contrast administration (211 vs 176 ml, p 
0.041).
We did not observe a reduction in the occurrence of left
bundle branch block or third-degree atrioventricular block
after TAVI. The pathophysiology of these new conduction
abnormalities is complex. A number of studies have indi-
cated that both patient- and procedure-related variables,
such as the septal wall thickness, the noncoronary cusp
thickness, pre-existing right bundle branch block, the depth
of implantation within the left ventricular outflow tract, and
postimplant prosthesis expansion, in addition to the type of
prosthesis, are associated with new left bundle branch block
or permanent pacemaker implantation.27–29 From a proce-
dural viewpoint, it is conceivable that better valve size
selection and positioning will lead to fewer conduction
abnormalities.
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Aims New-onset left bundle branch block (LBBB) and complete atrioventricular block (AV3B) frequently occur following
transcatheter aortic valve implantation (TAVI). We sought to determine the timing and potential mechanisms of new
conduction abnormalities (CAs) during TAVI, using the Medtronic CoreValve System (MCS).
Methods
and results
Sixty-five consecutive patients underwent TAVI with continuous 12-lead ECG analysis. New CAs were defined by the
occurrence of LBBB, RBBB, and/or AV3B after the following pre-defined time points: (i) crossing of valve with stiff
wire, (ii) positioning of balloon catheter in the aortic annulus, (iii) balloon valvuloplasty, (iv) positioning of MCS in
the left ventricular outflow tract (LVOT), (v) expansion of MCS, (vi) removal of all catheters. A new CA occurred
during TAVI in 48 patients (74%) and after TAVI in 5 (8%). Of the 48 patients with procedural CAs, a single new CA
occurred in 43 patients (90%) and two types of CAs in 5 (10%). A new LBBB was seen in 40 patients (83%), AV3B in 9
(19%), and RBBB in 4 (8%). The new CA first occurred—in descending order of frequency—after balloon valvulo-
plasty in 22 patients (46%), MCS expansion in 14 (29%), MCS positioning in 6 (12%), positioning of balloon catheter in
3 (6%), wire-crossing of aortic valve in 2 (4%), and after catheter removal in 1 patient (2%). Patients who developed a
new CA during balloon valvuloplasty had a significantly higher balloon/annulus ratio than those who did not
(1.10+ 0.10 vs. 1.03+ 0.11, P ¼ 0.030). No such relationship was found with the valve/annulus ratio.
Conclusion Transcatheter aortic valve implantation with the MCS was associated with new CAs in 82% of which more than half
occurred before the actual valve implantation. It remains to be elucidated by dedicated studies whether new CAs can
be reduced by appropriate balloon sizing—a precept that also holds for valve size given the observed directional
signal of the valve size/aortic annulus ratio.
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Introduction
New-onset left bundle branch block (LBBB), third-degree atrioven-
tricular block (AV3B), and the need for new permanent pacemaker
implantation (PPI) constitute an important clinical problem during
transcatheter aortic valve implantation (TAVI). This is in particular
true after the implantation of the self-expanding Medtronic Core-
Valve System (MCS). Following the latter, new LBBB, AV3B, and
PPI have been reported to vary between 29 and 65%, 15 and
44%, and 9 and 49%, respectively1–5 and to vary between 6 and
18%, 0 and 27%, and 0 and 27%, respectively, after the implantation
of the EDWARDS Sapien valve.6–9
54 Chapter 5
The pathophysiology of new conduction abnormalities (CAs)
has not yet been elucidated. A number of studies indicate that
both patient- and procedure-related factors such as septal wall
thickness, non-coronary cusp thickness, pre-existing right bundle
branch block (RBBB), depth of valve implantation within the left
ventricular outflow tract (LVOT), post-implant prosthesis expan-
sion, and the type of prosthesis play a role.1–4,8,10–12
Transcatheter aortic valve implantation constitutes a complex
and multi-step procedure including crossing of the aortic valve
and exchange and manipulation of various guide wires and bulky
catheter systems in the LVOT, which may inflict temporary or per-
manent injury to the conduction system. Hence, procedure-related
causes of CAs during TAVI may not necessarily relate to the pros-
thesis itself but to many other actions inherently associated with
TAVI. Therefore, we sought to examine the timing of the occur-
rence of new CAs in a series of 65 consecutive patients who
underwent TAVI with the MCS during six pre-defined time
points of the procedure while using continuous ECG analysis and
sought to explore potential mechanisms of new CAs. In particular,
the relationship between new CAs and the balloon and valve/
annulus ratio in addition to markers of inflammation was studied.
The latter stems from propositions that the implantation of a bio-
prosthesis may induce an inflammatory reaction due to trauma
inflicted on the LVOT.2,4,8,11,13,14
Methods
Patients
The study population consisted of 65 consecutive patients with severe
symptomatic aortic stenosis who underwent TAVI with the MCS
between March 2009 and August 2010. Details of the prosthesis and
procedure have been previously published.5 Briefly, all patients were
accepted for TAVI by Heart Team consensus between a cardiologist
and a cardiac surgeon who agreed that conventional open-heart
surgery was associated with either too high or prohibitive risk. The
prosthesis consists of a self-expanding nitinol tri-level frame to which
is secured a trileaflet bioprosthetic porcine pericardial tissue valve.
Currently, the prosthesis is available in sizes of 26 and 29 mm. In
case a 26 mm MCS was chosen, pre-dilatation of the aortic valve
was performed with a 22 mm nucleus balloon (NuMed, Hopkington,
NY, USA). In case of a 29 mm MCS, a 23 mm Z-Med-II balloon was
used (NuMed). The procedure was performed with the patient
under general anaesthesia, with a temporary pacemaker wire posi-
tioned in the right ventricle and with default femoral arterial access
through an 18F sheath. Patients were extubated before leaving the
catheterization laboratory or within 2 h after arrival in the cardiac
care unit. Per TAVI protocol, the temporary pacemaker was main-
tained for at least 48 h after the procedure or longer if indicated.
This study complies with the Declaration of Helsinki.
Data collection
Patient demographics and procedural and post-procedural data were
prospectively collected and entered in a dedicated database. Endpoints
regarding in-hospital outcome were selected and defined according to
the Valve Academic Research Consortium (VARC) recommendations,
including the 30-day safety endpoint, defined as composite all-cause
death, major stroke, major vascular complication, life-threatening
bleeding, acute kidney injury—stage 3, peri-procedural myocardial
infarction, repeat procedure for valve-related dysfunction.15
All 12-lead surface ECGs immediately before and after the pro-
cedure and at discharge were analysed by two senior cardiologists
who are not involved in the TAVI procedure and who were blinded
to the results of the continuous rhythm analysis during the procedure.
These surface ECGs were used to record the heart rate and rhythm,
PR interval, and the presence of first-, second-, or third-degree AV
block. Left and right fascicular hemiblocks and left and right bundle
branch blocks were defined according to the guidelines of World
Health Organization and International Society and Federation for Car-
diology Task Force.16
During TAVI, an electronic 12-lead ECG was continuously recorded
and digitally collected in the catheterization laboratory database for
invasive cardiac procedures. These strips were analysed by two inde-
pendent researchers (postgraduate research fellows, interventional
cardiology) for the assessment of new CAs after the following six pre-
defined phases of TAVI. Phase 1: crossing of the stenotic valve with a
straight wire and exchange for a stiff support wire; phase 2: positioning
of a balloon catheter (typical size 22 or 23 mm × 4 cm) within the
aortic annulus used for pre-dilatation; phase 3: full inflation of the
balloon catheter under rapid ventricular pacing at a rate of 180 or
220 b.p.m.; phase 4: positioning of the MCS delivery catheter into
the LVOT with the ventricular edge of the frame approximately
within 6–8 mm of the lower edge of the non-coronary cusp as ident-
ified by contrast aortography; phase 5: complete expansion of the MCS
prosthesis; phase 6: retrieval of all catheters and wires.
For this study, the following new CAs were collected during the
procedure: LBBB, RBBB, and AV3B. For confirmation purposes, all
electronic rhythm strips were printed after each individual phase.
New CAs were considered (i) persistent if present during all sub-
sequent phases of the procedure; (ii) intermittent in case of spon-
taneous appearance and disappearance during the procedure; and
(iii) permanent if still present on the ECG at hospital discharge.
To explore the mechanisms of new CAs, a univariate analysis was
performed assessing the relationship between the balloon/aortic
annulus ratio and new CAs during phase 3 (balloon valvuloplasty)
and the valve size/aortic annulus ratio and new CAs during phase 5
(valve expansion). Also, the relationship was studied between
markers of inflammation [C-reactive protein and white blood cell
count (WBC) at 24 and 72 h after TAVI] and new CAs. The balloon
and valve sizes were defined by the nominal size provided by the man-
ufacturer. The aortic annulus was defined and quantified using multi-
sliced computed tomography according to the protocol previously
described.17 The mean of the minimum and maximum diameter in,
respectively, the sagital and coronoral view was used to define the
diameter of the aortic annulus.17
Categorical variables are presented as frequencies and percentages,
and normal and skewed continuous variables are presented as means
(+SD) and medians (IQR), respectively. The normality distribution for
continuous data was examined with the Shapiro–Wilk test. Compari-
son of categorical variables was performed using the two-sided
Student’s t-test or Wilcoxon rank-sum test, and the x2 or Fischer’s
exact tests were used to compare categorical variables, with a two-
sided P, 0.05 indicating statistical significance. All analyses were per-
formed with the SPSS software (version 17).
Results
A total of 65 consecutive patients underwent TAVI with the MCS
(transfemoral 64, subclavian 1) of which the baseline characteristics
and in-hospital clinical results are listed in Tables 1 and 2, respectively.
The 30-day event rate was 17% both in patients with (n ¼ 9) and
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without (n ¼ 2) a new CA (P ¼ 1.0). The in-hospital or 30-day mor-
tality, however, was 11% in patients with a new CA and 0% in those
without a newCA(P ¼ 0.35). Twopatients diedduringTAVI (electro-
mechanical dissociation during phase 1 in one patient and LVOT
rupture after phase 3 in another), and four deaths occurred during
hospital stay [severe paravalvular aortic regurgitation (AR) at day 14
in one patient, pneumonia at day 28 in two patients, and pneu-
mothorax following PPI at day 32 in another patient]. In these four
patients, the ECG just before in-hospital death was used to determine
the persistence of the CAs eventually seen during TAVI.
Details of the type and timing of new CAs are listed in Sup-
plement A. Of the 65 patients, 12 patients (18%) had a pre-existing
CA. In 3 out of these 12 patients, the pre-existing LBBB/RBBB pro-
gressed to AV3B during TAVI. In another 45 patients, a new CA
was seen during TAVI. In five other patients, a new CA occurred
after TAVI (as identified on ECG at discharge) but not during
the procedure. In all five patients, the new CA consisted of an
LBBB except in one who had a pre-existing LBBB and developed
an AV3B after the procedure. Therefore, a total of 53 patients
(82%) had new peri-procedural CAs: during TAVI in 48 patients
(74%) and after TAVI in another 5 patients (8%). Details are sum-
marized in Table 3.
In the 48 patients with a new CA during TAVI, a single new CA
was seen in 43 (90%) and two types of CAs in 5 (10%). A new
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Table 1 Baseline patient characteristics and medication use according to patients who developed a new conduction
abnormality during or after transcatheter aortic valve implantation
Entire cohort (n 5 65) New CAs (n 5 53) No new CAs (n 5 12) P-value
Baseline patient characteristics
Age (years), mean+ SD 80+8 80+8 83+5 0.22
Male, n (%) 32 (49) 24 (45) 8 (67) 0.18
Height (cm), mean+ SD 167+10 166+10 171+9 0.11
Weight (kg), mean+ SD 73+14 72+14 78+14 0.17
Body mass index, mean+ SD 26.1+3.9 26.0+4.0 26.6+3.6 0.65
Body surface area, mean+ SD 1.84+0.21 1.82+0.21 1.92+0.20 0.11
NYHA class III or IV, n (%) 44 (68) 34 (64) 10 (83) 0.31
Previous cerebrovascular event, n (%) 15 (23) 14 (26) 1 (8) 0.27
Previous myocardial infarction, n (%) 18 (28) 14 (26) 4 (33) 0.72
Previous coronary artery bypass graft surgery, n (%) 12 (19) 9 (17) 3 (25) 0.68
Previous percutaneous coronary intervention, n (%) 21 (32) 16 (30) 5 (42) 0.50
Diabetes mellitus, n (%) 14 (22) 11 (21) 3 (25) 1.00
Hypertension, n (%) 24 (37) 19 (36) 5 (42) 0.75
Glomerular filtration rate ,60 mL/min, n (%) 32 (49) 26 (49) 6 (50) 1.00
Creatinine, mean+ SD 107+73 105 67 113+95 0.75
Chronic obstructive pulmonary disease, n (%) 21 (32) 17 (32) 4 (33) 1.00
Permanent pacemaker, n (%) 6 (9) 2 (4) 4 (33) 0.009
Atrial fibrillation, n (%) 16 (25) 13 (25) 3 (27) 1.00
Aortic valve area (cm2), mean+ SD 0.65+0.23 0.65+0.20 0.66+0.35 0.89
Aortic valve annulus (mm), mean+ SD 22.7+2.20 22.4+2.35 23.0+1.91 0.37
Left ventricular ejection fraction ≤35%, n (%) 5 (8) 4 (8) 1 (8) 1.00
Mitral regurgitation grade ≥III, n (%) 9 (14) 7 (13) 2 (17) 1.00
Aortic regurgitation grade ≥III, n (%) 7 (11) 5 (9) 2 (17) 0.60
Logistic Euroscore, median (IQR) 11.0 (8.9–18.6) 11.1 (8.7–19.3) 11.0 (10.0–16.6) 0.67
STS score, median (IQR) 3.8 (3.3–5.6) 3.8 (3.0–5.8) 4.1 (3.3–5.1) 0.90
Baseline medication use, n (%)
Anti-platelets 47 (72) 40 (76) 7 (58) 0.29
Diuretics 37 (57) 29 (55) 8 (67) 0.45
ACE-inhibitors 19 (29) 15 (29) 4 (33) 1.00
Angiotensin II antagonists 15 (23) 12 (23) 3 (27) 1.00
Betablockers 39 (60) 31 (58) 8 (67) 0.75
Calcium antagonists 20 (31) 19 (36) 1 (8) 0.09
Anti-arrhythmics 7 (11) 6 (11) 1 (9) 1.00
Statins 31 (48) 24 (54) 7 (58) 0.41
ACE, angiotensin-converting enzyme; CAs, conduction abnormalities; NYHA, New York Heart Association.
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LBBB was seen the most (40 patients or 83%), followed by AV3B in
9 (19%) and RBBB in 4 patients (8%). In three patients, the new
CAs that occurred during TAVI changed from RBBB to LBBB at dis-
charge in one patient (No. 5) and progressed from LBBB to AV3B
in two patients (Nos 16 and 39).
In these 48 patients, the new CAs first occurred—in descending
order of frequency—during phase 3 (balloon valvuloplasty) in 22
patients (46%), phase 5 (complete MCS expansion) in 14 patients
(29%), phase 4 (positioning of MCS in the LVOT) in 6 patients
(12%), phase 2 (positioning of balloon catheter in the LVOT) in
3 patients (6%), phase 1 (crossing of aortic valve with wire) in 2
patients (4%), and phase 6 (removal of catheters from the
body—most likely caused by the touching of the cone of the
LVOT when removing the delivery catheter out of the left ventri-
cle) in 1 patient (2%) (Figure 1). Hence, 56% of the new CAs
occurred during the preparatory phases (phases 1–3) and 44%
during and after valve delivery and implantation (phases 4–6).
In 70% of the patients in whom the new CA first occurred before
the actual valve implantation (phases 1–3), the CAwas still present
on the discharge ECG. It was 62% in the patients in whom the new
CA first occurred during the actual valve implantation (phases 4–
6). Overall, the new CAs were intermittent in 12 (25%) and persist-
ent in 36 patients (75%) out of the total of 48 patients in whom a new
CAwas observed during TAVI. In 31 (65%) out of these 48 patients,
the new CAwas permanent (still present on the ECG at discharge).
In 14 out of the 65 patients (22%), a new permanent pacemaker
after TAVI was implanted because of new-onset AV3B in 10
patients, persisting bradycardia in 3, and brachy-tachy-syndrome
in 1 patient (Supplement B). Among those with AV3B, the diagno-
sis was made during the procedure in seven patients and after the
procedure in three patients (two at day 2 and one at day 5).
Table 4 summarizes potential determinants of new CAs during
balloon valvuloplasty (phase 3) and during valve implantation
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 In-hospital peri-procedural complications,
therapy-specific and echocardiographic results in
patients undergoing transcatheter aortic valve
implantation (n 5 65)
Peri-procedural complications
Mortality (30-day or in-hospital), n (%)
All cause 6 (9)a
Cardiovascular cause 4 (6)a
Myocardial infarction, n (%)
Peri-procedural (,72 h) 0
Spontaneous (.72 h) 0
Cerebrovascular, n (%)
Major stroke 3 (5)
Minor stroke 0
Transient ischaemic attack 1 (2)
Vascular, n (%)
Major 4 (6)
Minor 6 (9)
Bleeding, n (%)
,24 h
Life-threatening or disabling 4 (6)
Major 11 (17)
Minor 5 (8)
.24 h
Life-threatening or disabling 4 (6)
Major 3 (5)
Minor 0
Acute kidney injury, n (%)b
Stage I 7 (12)
Stage II 2 (3)
Stage III 1 (2)
Combined safety endpoint (at 30 days), n (%)c 11 (17)
Therapy-specific results
Valve-in-valve implantation, n (%) 2 (3)
Post-implantation balloon dilatation, n (%) 8 (12)
Unplanned cardiopulmonary bypass use, n (%) 0
In-hospital re-intervention, n (%) 2 (3)
Echocardiography
Aortic valve area (cm2), mean+ SD 1.8+0.8
Left ventricular ejection fraction ≤35%, n (%) 6 (9)
Aortic regurgitation grade ≥III, n (%) 8 (12)
Mitral regurgitation grade ≥III, n (%) 6 (9)
Mutually non-exclusive analysis (one or more events/patient possible).
aIncluding two intraprocedural deaths.
bFour patients with pre-procedural haemodialysis and two patients who died
during TAVI were excluded from the analysis of acute kidney injury.
cComposite all-cause mortality, major stroke, major vascular
complication, life-threatening bleeding, acute kidney injury—stage III,
peri-procedural, myocardial infarction, repeat procedure for valve-related
dysfunction.
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Table 3 Summary of 53 patients with new conduction
abnormalities during and after transcatheter aortic
valve implantation
Type of CAs During TAVI, n (%) After TAVI, n (%)
Single type
LBBB 36 (68)a 4 (8)
RBBB 2 (4)b 0
AV3B 5 (9) 1 (2)
Two types
RBBB, LBBB 1 (2) 0
RBBB, AV3B 1 (2) 0
LBBB, AV3B 3 (6) 0
Total 48 (91) 5 (9)
AV3B, third-degree atrioventricular block; CAs, conduction abnormalities; LBBB,
left bundle branch block; RBBB, right bundle branch block.
aNew LBBB during TAVI changed to AV3B after TAVI in two patients.
bNew RBBB during TAVI changed to LBBB after TAVI in one patient.
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(phase 5). Patients who developed a newCAduring balloon valvulo-
plasty had a significantly higher balloon/annulus ratio than thosewho
did not (1.10+0.10 vs. 1.03+0.11, P ¼ 0.030). No such relation-
ship was found with the valve size/annulus ratio. Patients who devel-
oped new CAs during valve expansion (phase 5) had a higher WBC
at 24 and 72 h after TAVI than those who did not develop a newCA.
Discussion
In this study in which 65 consecutive patients underwent TAVI
using the MCS, we found that peri-procedural new CAs occurred
in 82% of the patients. The majority of these new CAs occurred
during the procedure (91%) of which 56% occurred before the
actual valve implantation and most often consisted of a new
LBBB (83%). A higher balloon/annulus ratio was associated with
a new CA during balloon valvuloplasty. We did not find a relation-
ship between the valve size/annulus ratio and new CAs.
The close anatomical relationship between the aortic valvar
complex and the conduction tissue explains the high frequency
of new CAs during TAVI with the MCS.18 The herein reported inci-
dence of new CAs is in accordance with the observations made by
others with both the MCS and the EDWARDS valve although that
the incidence of new LBBB and AV3B is higher after the self
expanding MCS (29–65% and 15–44%, respectively) than after
Figure 1 Distribution of first occurrence of new CAs (LBBB, RBBB, and AV3B) per phase of TAVI and associations with permanent change as
identified on discharge ECG among a total of 48 patients with new CAs during TAVI. The frequencies of first appearance of new CAs (¼LBBB,
RBBB, and/or AV3B) on the continuous ECG analysis are presented per phase of the TAVI procedure as well as the association with a perma-
nent change as identified on the discharge ECG among 48 patients who developed a new CA during TAVI. AV3B, third-degree atrioventricular
block; CAs, conduction abnormalities; LBBB, left bundle branch block; RBBB, right bundle branch block; TAVI, transcatheter aortic valve
implantation.
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Table 4 Technical and inflammatory associations with new conduction abnormality occurrences during phases 3 and 5
in patients undergoing transcatheter aortic valve implantation
Phase 3 new
CAs
Phase 3 no
CAs
P-value Phase 5 new
CAs
Phase 5 no
CAs
P-value
Balloon size—minimal annulus diameter ratio,
mean+ SD
1.10+0.10 1.03+0.11 0.030 1.06+0.12 1.06+0.11 0.83
Balloon size—maximal annulus diameter ratio,
mean+ SD
0.85+0.07 0.84+0.08 0.89 0.84+0.07 0.85+0.08 0.48
Valve size—minimal annulus diameter ratio,
mean+ SD
1.36+0.11 1.30+0.12 0.069 1.30+0.17 1.33+0.10 0.35
Valve size—maximal annulus diameter ratio,
mean+ SD
1.04+0.07 1.06+0.07 0.43 1.04+0.09 1.05+0.07 0.60
Depth of implantation from non-coronary cusp,
mean+ SD
9.01+3.64 8.01+3.15 0.25 7.76+3.05 8.66+3.47 0.35
Depth of implantation from left coronary cusp,
mean+ SD
9.68+4.06 8.50+3.51 0.22 8.30+3.87 9.22+3.73 0.39
Leucocyte count ,24 h (× 109/L), mean+ SD 11.25+3.48 11.43+4.24 0.87 14.07+ 5.24 10.39+2.80 0.001
Leucocyte count ,72 h (× 109/L), mean+ SD 12.71+4.42 11.78+4.18 0.41 14.97+5.26 11.09+3.32 0.001
C-reactive protein ,24 h, mean+ SD 64+90 64+55 0.98 71+64 62+73 0.64
C-reactive protein ,72 h, mean+ SD 84+113 75+61 0.70 85+66 76+92 0.74
CAs, conduction abnormalities.
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the balloon expandable EDWARDS valve (6–18% and 0–27%,
respectively).1–4,7–9 Moreover, transapical aortic valve implan-
tation may be associated with few CAs and new PPI most likely
as a result of less manipulations and trauma to the LVOT during
the procedure. The rate of AV3B and new PPI following transapical
TAVI are both reported to vary between 0 and 20%.2,8,19
Of note, we found that a new CA may occur not only during but
also at some time after the procedure, which was the case in five
patients in our study who were free of new CAs during the pro-
cedure. In all patients, it concerned a new LBBB except one in
whom a pre-existing LBBB progressed to a complete heart
block. In addition, a progression of procedural new CAs to com-
plete heart block after TAVI was seen in three other patients.
Whether the late new CAs are caused by injury or oedema of
the conduction tissue by the continuous radial expansive force
of the self-expanding nitinol frame of the MCS needs to be eluci-
dated. This clinical observation underscores the importance of
careful monitoring of patients who undergo TAVI by means of con-
tinuous telemonitoring similar to the surgical practice.
More than half of the new CAs in our series occurred before the
actual valve implantation. A minority of previous studies reported
new CAs following balloon valvuloplasty prior to the valve implan-
tation, which may be explained by the fact that in these studies no
continuous ECG recordings were used to determine the occur-
rence of CAs during the procedure.1–4,7,8,10–12,14,20–22 Our find-
ings are, moreover, in accordance with the incidence of new
CAs reported after isolated aortic balloon valvuloplasty.23–25
In terms of mechanisms of new CAs, Bleiziffer et al.12 recently
reported an association between balloon size and the occurrence
of new-onset AV3B requiring PPI after TAVI. In the present study,
we found a significantly higher balloon/annulus ratio in patients
who developed a new CA during balloon valvuloplasty in compari-
son with those who did not (1.10+ 0.10 vs. 1.03+ 0.11,
P ¼ 0.030).
Given the preponderance of new CAs during balloon valvulo-
plasty and its relationship with the balloon/annulus ratio, the find-
ings of this study suggest that new CAs (and potentially new PPI)
may be reduced by using a balloon/annulus ratio close to 1.0.
This is independent of the valve technology itself and the access
to the aortic valve (transfemoral, transapical, subclavian, direct
access via the ascending aorta) since pre-dilatation of the stenotic
aortic valve is a standard step in all procedures. Yet, the observa-
tional nature of this study does not allow to draw firm conclusions.
This needs to be demonstrated by appropriately designed studies
in which one should also acknowledge that differences in the phys-
ical properties of the frame between a self-expanding and a balloon
expandable prosthesis (i.e. continuous radial force vs. plastic defor-
mation without continuous radial force) and the technique of
implantation in addition to shape and height of the frame may
result in a difference in the incidence of new CAs during the
actual valve implantation, which in turn may explain a disparity in
the overall incidence of new CAs during TAVI between these
two technologies.
We acknowledge that the overlap in balloon/aortic annulus
between the two groups in this series is considerable. Therefore,
the proposal of balloon sizing needs to be examined in larger
series allowing a more precise cutoff value and needs to be
validated in prospective clinical research projects. One should
also bear in mind that the use of smaller balloons may result in sub-
optimal pre-dilatation of the native valve, leading to a higher inci-
dence of paravalvular AR after TAVI which in turn may induce
CAs due to increased wall tension and stretch of the conduction
tissue.26,27
At variance with Gutie´rrez et al.,8 who studied 33 patients who
underwent transapical TAVI, we found no relationship between the
valve size/aortic annulus ratio and new CAs. Yet, the data of this
study nevertheless indicate a higher risk of new CAs in case of a
higher ratio. We most likely would have found such a relationship
in case of a more disperse distribution of the data, thereby allowing
a proposal of sizing. The present data indicate, however, that a
ratio of approximately 1.30 (when using the minimal annulus
dimension) and a ratio of approximately 1.05 (when using the
maximum annulus dimension) are safe and may be recommended
to avoid new CAs. Similar to the proposal of balloon size selection,
proposals of valve size selection need to be confirmed by more
in-depth analysis in larger cohorts of patients allowing multivariate
analysis and need subsequently to be validated in prospective
research projects. At present, only two sizes of valves are available.
The issue will be even more pertinent when four sizes become
available.
We also found that the new CA occurrence during valve implan-
tation (phase 5) was associated with increased levels of leucocyte
count after TAVI (14.07 vs. 10.39 × 109/L, P ¼ 0.001). It is unclear
whether this concerns a causal relationship (e.g. more trauma and/
or oedema of the conduction tissue during TAVI) or whether the
increased leucocyte count is caused by post-TAVI conditions (e.g.
more frequent pacing). In case of the former, all measures should
be taken to limit injury and, thus, inflammation. In this respect,
more direct access to the aortic valve that is achieved by transapi-
cal, subclavian, and direct access of the ascending aorta may play a
role as they may be associated with less contact and injury of the
LVOT.28–30 The information currently available on PPI rates after
transfemoral and transapical implantation of the EDWARDS
valve, however, does not reveal a difference. It varies between
2–27% and 0–20%, respectively.8,9,19,31 Also, better control of
the positioning and release of the valve may help to reduce
injury to the tissue of the LVOT during the procedure. This may
be achieved by software allowing online definition of annulus and
base of frame during implantation and/or by novel delivery
systems with improved ergonomics and enhanced control of cath-
eter stability during release and the eventual retrieval of the
valve.32
Limitations
Although it concerns a prospective study in which two indepen-
dent researchers continuously monitored the electrocardiographic
recordings during the procedure, some electrocardiographic
changes may have remained undetected, leading to an underesti-
mation of the reported frequency of new CAs during TAVI. In
addition, post-procedural onset of CAs as identified on continuous
telemetry recordings was less intensively monitored and was most
likely only detected in the case of more evident CAs. Also, the dur-
ation of analysis was limited to the hospital stay, and, therefore, the
occurrence of late new CAs as well as late disappearance of
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TAVI-induced CAs remains uncertain although they are unlikely to
occur.4 Considering the observational nature of the current study,
further research is needed to elucidate whether the association
between balloon/annulus ratio and new CAs represents a causal
relationship and if modification of the sizing will reduce the fre-
quency of new CAs. In addition, the study lacks the power to
provide a comprehensive analysis of the mechanisms or determi-
nants of new CAs. Many potential determinants may have
remained undetected.
Conclusions
Transcatheter aortic valve implantation with the MCS was associ-
ated with peri-procedural new CAs in 82% of the patients. More
than half of these new CAs occurred before the actual valve
implantation, and two-thirds of the new CAs were still present
on the ECG at discharge. It remains to be elucidated by dedicated
studies whether appropriate balloon and valve sizing will reduce
new CAs.
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online.
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Abstract
Aims: Early conduction abnormalities and need for pacemaking after transcatheter aortic valve implantation
(TAVI) is well recognised. It is still unknown, however, if these conduction abnormalities are persistent, and
what is the need for permanent pacemaking after 1-month follow-up. In this prospective study, we
examined the incidence of post-procedural and 6-month conduction abnormalities and need for
permanent pacemaking after TAVI. 
Methods and results: We examined the 12-lead electrocardiogram (ECG) of 91 consecutive patients in whom
a Medtronic CoreValve ReValving System was implanted between November 2005 and April 2009. We evaluated
the ECGs before treatment, after treatment, at 1-month and 6-month follow-up. The requirement and timing of
permanent pacemaking was documented. The mean age of patients was 81±7 years and the mean logistic
EuroSCORE was 16±9%. Median duration of follow-up was 213 days (IQR 64, 519). There was a 39% increase
in the frequency of LBBB after TAVI (15% before treatment vs. 54% after treatment, p<0.001). Importantly,
there was no significant change in the frequency of LBBB from after treatment to 1- or 6-month follow-up (54%
after treatment vs. 42% at 1-month follow-up, p=0.45, and 54% after treatment vs. 45% at 6-month follow-up,
p=0.39). Permanent pacemaking was required in 17/91 (19%) of patients. A permanent pacemaker was
implanted in 8/17 patients (47%) within seven days of TAVI, in 6/17 (35%) at 7-30 days, and in 3/17 (18%) after
30 days. Male gender, previous myocardial infarction, pre-existing right bundle branch block, actual diameter
(mm) of the inflow portion of the CoreValve frame post-implantation and depth of implantation were predictors for
new LBBB; pre-treatment QRS duration (msec) and septal wall thickness were predictors for permanent
pacemaking.
Conclusions: These results suggest that early conduction abnormalities occurring after TAVI persist at 6-months
follow-up. Patient-related, anatomical-related, and procedure-related factors need to be considered in the
pathogenesis of conduction abnormalities after TAVI.
KEYWORDS
TAVI, conduction
abnormalities,
pacemaking
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Introduction
Early conduction abnormalities and need for pacemaking is well
recognised after transcatheter aortic valve implantation (TAVI)1-4.
The occurrence of conduction abnormalities is not surprising when
one considers the anatomical proximity of the aortic valvar complex
to the conduction system5. Furthermore, pre-existing conduction
abnormalities are common in patients with aortic valvar stenosis6,7.
In our previous work, we demonstrated a 40% increase in the
occurrence of LBBB after TAVI1. Although there was a non-
significant decrease in the frequency of LBBB from the time after
implantation to 1-month follow-up, there was a significant decrease
in QRS duration suggesting an improvement in intraventricular
conduction. Furthermore, a correlation was found between the
depth of implantation of the prosthesis within the left ventricular
outflow tract and the occurrence left bundle branch block. Although
the clinical implications of new LBBB acquired after TAVI are yet
unknown, it is apparent from the surgical literature that new and
persistent bundle branch block acquired after aortic valve
replacement is associated with an increased risk of subsequent
arrhythmic events, such as syncope, AV dissociation, and sudden
death8. Furthermore, left bundle branch block can be associated
with left ventricular mechanical dyssynchrony, left ventricular
remodelling and impaired systolic and diastolic heart function9.
It is still unknown, however, if conduction abnormalities occurring
after TAVI are persistent, and what is the need for permanent
pacemaking after 1-month follow-up. In this prospective study, we
examined the incidence of conduction abnormalities up to 6-month
follow-up and need for permanent pacemaking. Furthermore, we
sought to identify predictors of left bundle branch block and need
for permanent pacemaking acquired after TAVI.
Methods
Patients
We prospectively enrolled consecutive patients with severe aortic
stenosis in whom a CoreValve ReValving System (Medtronic,
Minneapolis, MN, USA) was implanted between November 2005
and April 2009. For a patient to undergo TAVI, a Heart Team
(specifically an interventional cardiologist and cardiac surgeon) had
to agree that surgical aortic valve replacement would be associated
with either high or prohibitive risk.
Inclusion and exclusion criteria for implantation of the CoreValve
ReValving System are in accordance with the 18 Fr Expanded
Evaluation Registry study criteria and have been described elsewhere10.
Description of the device and procedure
The CoreValve bioprosthesis consists of a self-expanding nitinol tri-
level frame to which is sewn a trileaflet porcine pericardial heart
valve. The non-cylindrical frame design exhibits three different
diameters associated with three different degrees of radial stiffness.
In particular, the (lower) inflow level of the frame exerts high radial
stiffness for secure intra-annular anchoring. This inflow portion of
the frame has been implicated in the development of conduction
abnormalities depending on its depth of implantation1.
The prosthesis is currently available in two sizes based on the
diameter of its inflow portion (or ventricular end): 26 or 29 mm.
Selection of the prosthesis size is dependent on measurements of
the aortic root and ascending aorta5.
Technical details of the procedure have been previously
published11. Briefly, a temporary pacemaker was implanted via the
femoral vein and positioned in the right ventricle at the beginning of
the procedure. Balloon aortic valvuloplasty was performed in all
patients before valve implantation. Positioning and deployment of
the device was guided by fluoroscopic and angiographic imaging.
During our initial experience, it was recommended to position the
ventricular edge of the prosthesis 10-12 mm below the lower edge
of the non-coronary leaflet. As a result of our previous work relating
depth of implantation to the development of conduction
abnormalities, we now intend to position the ventricular edge of the
prosthesis approximately 6-7 mm below the lower edge of the non-
coronary leaflet1.
Following valve implantation, the temporary pacemaker was left in
place for 24-72 hours and subsequently removed in the absence of
high-degree atrioventricular block. Patients were further monitored
by telemetry until discharge.
Collection of ECG and pacemaking data
Twelve-lead electrocardiographic recordings were obtained before
treatment, after treatment, at 1-month and 6-month follow-up and
examined by a core laboratory (Cardialysis, Rotterdam, The
Netherlands). More specifically, the ECGs were analysed for
rhythm, heart rate (beats/min), PR, QRS, and corrected QT intervals
(all in milliseconds), and the presence of atrioventricular block (first,
second, and third degree).
In addition, the diagnostic criteria endorsed by the World Health
Organisation and International Society and Federation for
Cardiology Task Force were used to code for right and left fascicular
hemi block and right and left bundle branch block12.
A continuous 3-lead rhythm strip was continuously recorded and stored
electronically. We subsequently analysed the rhythm strips for new
widening of the QRS duration (i.e., ≥120 msec) and further categorised
the event as occurring either before or after valve implantation.
We documented the need for temporary or permanent pacemaking.
Furthermore, the indication and timing of permanent pacemaker
implantation from valve implantation (days) was recorded.
Quantitative angiographic measurements (depth of implantation of
the frame, percent expansion of the inflow portion of the frame,
aortic root angle)
Quantitative angiographic analysis was performed using CAAS 5.4
software (Pie Medical, Maastricht, The Netherlands). Calibration
was achieved using a graduated pigtail with radiopaque markers
separated 10 mm apart.
We measured the depth of implantation of the frame defined as the
distance from the lower edge of the non-coronary and left coronary
leaflet to the ventricular edge of the frame. We sought to correlate
the depth of implantation of the frame to the occurrence of left
bundle branch block acquired specifically after valve implantation
(as opposed to new-onset left bundle branch block occurring before
valve implantation) (Figure 1). As a result of our previous work
65persistence of conduction abnormalities after TAVI
relating depth of implantation to the development of conduction
abnormalities, we now aim to position the ventricular edge of the
prosthesis approximately 6-7 mm below the lower edge of the non-
coronary leaflet. In an effort to assess the clinical impact of our
previous findings1, we also compared the first half and second half
of patients with respect to the depth of implantation from the non-
coronary sinus.
The percent expansion of the inflow portion of the frame was
defined as the diameter of the inflow portion of the frame measured
by quantitative techniques divided by the nominal diameter of the
inflow portion of the frame (either 26 or 29 mm depending on the
size of the valve implanted). This was calculated in two orthogonal
views using biplane imaging. We wanted to investigate the
association between the actual expansion of the inflow portion of the
frame and newly acquired conduction abnormalities.
Statistical analysis
Continuous variables are presented as means (±SD) or median
(interquartile range, IQR) depending if the data is normally or non-
normally distributed, respectively. Categorical variables are
presented as frequencies. The Wilcoxon signed-rank test (for
continuous variable) and the McNemar test conducted by exact
methods (for binomial variables) were used to perform paired
comparisons between pre-treatment vs. after treatment, pre-
treatment vs. 1-month follow-up, pre-treatment vs. 6-month follow-
up, after treatment vs. 1-month follow-up, after treatment vs.
6-month follow-up, and 1-month vs. 6-month follow-up. The
analysis was performed upon the entire cohort that included 89
available ECGs before treatment, 85 after treatment, 47 at 1-month
follow-up, and 45 at 6-month follow-up. To verify the consistency of
the results, the analysis was repeated upon a cohort of 44 patients
who had complete serial ECG follow-up.
We used a univariable logistic regression model to examine for
separate predictors of new-onset left bundle branch block acquired
after valve implantation (as opposed to new-onset left bundle
branch block acquired before the valve was implanted) or new
permanent pacemaking. Patients with pre-existing LBBB or pre-
existing permanent pacemakers were excluded from the respective
analyses. The following variables were included in the univariable
analysis: baseline characteristics listed in Table 1, conduction
abnormalities identified on the baseline ECG interpreted from
Table 2, septal wall thickness (mm), the size of implanted valve (26
or 29 mm), ratio of the size of implanted valve to the diameter of the
aortic valve annulus, diameter of the inflow portion of the frame (in
AP and lateral projections), depth of implantation of the frame (from
the non-coronary and left coronary view) and post-implant
dilatation.
Statistical tests were two-sided with a p-value of < 0.05 indicating
statistical significance. All statistical analyses were performed with
SPSS software version 12 (SPSS Institute, Chicago, IL, USA).
Results
We prospectively enrolled 91 consecutive patients in whom a
CoreValve ReValving System was implanted between November
2005 and April 2009. Baseline characteristics are listed in Table 1.
As a result of three intra-procedural deaths, procedural success
was achieved in 88/91 patients (97%). Median duration of follow-up
was 213 days (IQR 64, 519). Cumulative survival at 30 days and six
months was 87% and 83%, respectively. Survival data was 100%
complete at 1- and 6-month follow-up.
Figure 1. Measurement of depth of implantation from the base of the non-coronary and left coronary sinus to the ventricular end of the
bioprosthesis. (A) Contrast aortography performed after CoreValve implantation. (B) Same figure as in A but includes measurements of the depth
of implantation. (C) Pictorial diagram demonstrating depth of implantation (double-headed arrows).
Table 1. Baseline characteristics
n=91
Age, yrs. (mean±SD) 81±7
Male, n (%) 39 (43)
Coronary artery disease, n (%) 48 (53)
History of myocardial infarction 20 (23)
History of percutaneous coronary intervention, n (%) 20 (22)
History of coronary artery bypass, n (%) 26 (29)
Left ventricular ejection fraction, % (mean ± SD) 52±14.7
Permanent pacemaker, n (%) 8 (9)
Diabetes, n (%) 18 (20)
Hypertension, n (%) 46 (51)
Chronic renal failure, n (%) 82 (93)
Aortic valve area (cm2), mean±SD 0.62±0.19
LVOT diameter (mm), mean±SD 19.3±2.63
Mitral annular calcification, n (%) 27 (31)
Prosthesis inflow size, n (%)
26-mm 42 (47)
29-mm 47 (53)
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At 6-month follow-up, 28/91 patients (31%) had died. Sudden
cardiac death (SCD) was responsible for 5/28 deaths (18%); these
occurred on day 8, 244, 282, 400 and 887. In these patients, the
latest electrocardiographic findings demonstrated normal sinus
rhythm in one, incomplete left bundle branch block in one, left
bundle branch in two, and a paced rhythm in one patient.
Twelve-lead ECG evaluation
The number of 12-lead ECGs analysed at each follow-up interval is
shown in Figure 2. Results of the ECG interpretation are shown in
Table 2 for the total cohort.
RHYTHM
The percent of patients in sinus rhythm decreased significantly from
70% before treatment to 55% after treatment (p=0.002). This
decrease remained significant at 1- and 6-month follow-up (70 vs.
44%, p < 0.001 and 70 vs. 58%, p=0.021, respectively).
There was a significant increase in the frequency of paced rhythm
after device insertion (2% before vs. 16% after treatment,
p <0.001) that was maintained at 1- and 6-month follow-up (2%
before vs. 21% at 1-month follow-up, p=0.004, and 2% before vs.
18% at 6-month follow-up, p=0.031).
QRS DURATION
After device insertion, there was a significant increase in QRS
duration (110±26 before treatment vs. 141±31 msec after
treatment, p <0.001). Although the QRS duration decreased
significantly from after treatment to 1- and 6-month follow-up
(141±31 after treatment vs. 131±29 msec at 1-month follow-up,
p <0.001 and 141±31 after treatment vs. 134±30 msec at 6-month
follow-up, p < 0.001, respectively), there was no significant change
between 1 and 6-month follow-up (131±29 at 1-month follow-up
vs. 134±30 msec at 6-month follow-up, p=0.79).
Analysis of individual patient data from 1- to 6-month follow-up
demonstrated that 45% had a decrease in QRS width, 19% had no
change, and 36% had an increase. The range for the differences in
QRS width from 1- to 6-month follow-up was –52 to 58 msec.
BUNDLE BRANCH BLOCK
New-onset left bundle branch block (LBBB) occurred in 38% of
patients after device insertion (15% before treatment vs. 53% after
treatment, p <0.001). The number of patients with new-onset LBBB
remained significantly higher at 1- and 6-month follow-up than at
baseline (15% before treatment vs. 44% at 1-month follow-up,
p=0.004, and 15% before treatment vs. 43% at 6-month follow-up,
p=0.001, respectively). Furthermore, there was no significant
change in the frequency of LBBB from after treatment to 1- or 6-
Table 2. Interpretation of electrocardiograms before treatment after treatment 1-month follow-up and 6-month follow-up (overall cohort).
Before After 1 month 6 month p Value before p Value before p Value before p Value after p Value after
treatement treatment treatment vs. treatment vs. treatment vs. treatment vs. treatment vs.
(n=89) (n=85) (n=59) (n=57) after treatment 1-month 6-month 1-month 6-month 
follow-up follow-up follow-up follow-up
Rhythm, n (%)
Sinus 62(70) 48(55) 27(46) 33(58) 0.002 <0.001 0.021 0.289 1.000
Atrial fibrillation 25(28) 23(26) 20(34) 14(25) 1.000 0.687 1.000 0.453 1.000
Pacemaker 2(2) 14(16) 12(20) 10(18) <0.001 0.001 0.008 0.625 0.727
Junctional 0(0) 2(2) 0(0) 0(0) 0.500 0.500 0.500 1.000
Heart rate (bpm) 73±13 77±19 78±13 76±17 0.029 0.102 0.077 0.570 0.960
PR interval (msec) 186±33 184±36 180±32 181±50 0.744 0.976 0.656 0.715 0.280
QRS width (msec) 110±26 141±31 133±35 135±31 <0.001 <0.001 <0.001 <0.001 <0.001
QT interval (msec) 427±39 469±45 437±38 436±34 <0.001 0.015 0.001 <0.001 <0.001
Hemiblock, n (%)
None 74(83) 82(99) 54(95) 53(93) 0.002 0.109 0.180 0.500 0.375
Anterior 13(15) 1(1) 3(5) 4(7) 0.006 0.289 0.219 0.500 0.375
Posterior 2(2) 0(0) 0(0) 0(0) 1.000 0.500 1.000 1.000 1.000
Bundle branch block, n (%)
None 66(74) 26(31) 27(47) 25(45) <0.001 0.027 0.210 0.006 0.003
Left 13(15) 45(54) 24(42) 25(45) <0.001 0.001 <0.001 0.453 0.388
Right 5(6) 4(5) 2(4) 1(2) 1.000 1.000 0.500 0.500 0.375
Incomplete left 4(5) 8(10) 4(7) 4(7) 0.344 1.000 1.000 0.625 1.000
Incomplete right 1(1) 0(0) 0(0) 1(2) 1.000 1.000 1.000 1.000 1.000
Figure 2. Patient flow diagram showing number of 12-lead electrocar-
diograms (ECGs) available for interpretation.
Before treatment ECG (n=89/91)
After treatment ECG (n=85/88)
1-month follow-up ECG (n=59/79)
6-month follow-up ECG (n=57/74)
(2 missing ECGs)
(3 patients died, 3 missing ECGs)
(9 additional patients died,
20 missing ECGs)
(5 additional patients died,
17 missing ECGs)
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month follow-up (53% after treatment vs. 44% at 1-month follow-
up, p=1.0, and 53% after treatment vs. 43% at 1-month follow-up,
p=0.45).
SERIAL ECG FOLLOW-UP IN 44 PATIENTS
Similar results to those of the entire cohort (Table 2) were observed
in 44 patients with complete serial ECG follow-up (Table 3).
TIMING OF QRS WIDENING
Examination of the intra-procedural 3-lead rhythm strip revealed
that QRS widening occurred before and after valve implantation in
48% and 52% of patients, respectively. In those cases occurring
before valve implantation, there was a temporal relation with either
wire crossing of the native aortic valve or pre-implantation balloon
aortic valvuloplasty.
NEED FOR PACEMAKING
Approximately one-tenth of patients had a history permanent
pacemaker implantation before valve insertion (Table 1). During the
procedure, the need for temporary pacemaking was documented in
19/91 patients (21%). Of those with a requirement for temporary
pacemaking, 13/19 patients (68%) ultimately received a permanent
pacemaker.
There were 17 patients who ultimately received a new permanent
pacemaker. Considering the fact that there were three intra-
procedural deaths and eight patients with a prior history of
permanent pacemaker, 17/80 patients (21%) had a requirement
for new permanent pacemaking. Thus, 13/17 patients (76%)
implanted with a permanent pacemaker had a documentation of
temporary pacemaking during the procedure. Third degree
atrioventricular block was the indication for permanent pacemaker
implantation in 14/17 patients (82%). The permanent pacemaker
was implanted within seven days of the index procedure in 8/17
patients (47%), within 7-30 days in 6/17 patients (35%), and after
30 days in 3/17 (18%) (Table 4). More precisely, the median time
from valve to permanent pacemaker implantation was seven days
(IQR 6, 18 days). Furthermore, the vast majority of patients (88%)
had the permanent pacemaker implanted during their
hospitalisation. The median length of hospital stay was significantly
longer in patients implanted with a new permanent pacemaker than
in those not implanted with a permanent pacemaker (17 IQR 9,
21 days vs. 9 IQR 7, 12 days, p=0.015).
All five patients with a pre-existing right bundle branch block
developed complete heart block after device insertion.
QUANTITATIVE ANGIOGRAPHIC MEASUREMENTS
Measurements of the depth of implantation of the frame (mm) and
diameter of the inflow portion of the frame (percent expansion and
difference between nominal (26 or 29 mm inflow) and actual
measurements) are shown in Table 5. The depth of implantation
measured from the non-coronary sinus was significantly greater in
patients who developed LBBB after the valve was implanted than in
those who did not develop LBBB or did develop LBBB but before
the valve was implanted (7.3±2.7 vs. 10.2±2.6 mm, p<0.001);
there was no difference in depth of implantation relative to the left
coronary sinus (8.6±3.8 vs. 10.4±4.0 mm, p=0.106). Figure 3
shows the positive correlation between the depth of implantation
and percent expansion of the inflow portion of the frame and its
relationship to the development of LBBB after valve implantation.
Despite our intention to implant the valve at a target depth of 6-
7 mm, we did not find a significant difference in the depth of
implantation between the first- and second-half of the study
patients (8.2±2.9 mm vs. 7.8±2.9 mm, respectively, p=0.56).
Table 3. Interpretation of electrocardiograms before treatment after treatment at 1-month follow-up and 6-month follow-up (serial cohort
of 44 patients).
Before After 1 month 6 month p Value before p Value before p Value before p Value after p Value after
treatement treatment treatment vs. treatment vs. treatment vs. treatment vs. treatment vs.
(n=44) (n=44) (n=44) (n=44) after treatment 1-month 6-month 1-month 6-month 
follow-up follow-up follow-up follow-up
Rhythm, n (%)
Sinus 30(70) 24(55) 23(52) 24(55) 0.039 0.008 0.070 1.000 1.000
Atrial fibrillation 12(28) 12(37) 14(32) 13(30) 1.000 0.625 1.000 0.625 1.000
Pacemaker 1(2) 6(14) 7(16) 7(16) 0.063 0.031 0.063 1.000 1.000
Junctional 0(0) 2(5) 0(0) 0(0) 0.500 0.500 1.000 0.500 0.500
Heart rate (bpm) 74±12 76±16 77±13 78±18 0.041 0.005 0.088 0.259 0.500
PR Interval (msec) 180±26 176±36 179±33 170±45 0.887 0.798 0.343 0.826 0.793
QRS width (msec) 110±26 14229 133±29 132±32 <0.001 0.001 <0.001 0.002 0.889
QT interval (msec) 422±32 461±42 437±34 435±31 <0.001 0.003 0.011 0.014 0.025
Hemiblock, n(%)
None 36(84) 42(96) 41(93) 41(93) 0.070 0.289 0.289 0.500 0.625
Anterior 6(14) 1(2) 3(7) 3(7) 0.125 0.453 0.375 0.500 0.625
Posterior 1(2) 1(2) 0(0) 0(0) 1.000 1.000 1.000 1.000 1.000
Bundle branch block, n(%)
None 29(67) 13(30) 18(41) 20(47) 0.001 0.031 0.648 0.070 0.001
Left 7(16) 21(48) 21(48) 19(44) 0.002 0.001 0.001 1.000 1.000
Right 2(5) 4(9) 2(5) 0(0) 0.625 1.000 0.500 0.500 0.125
Incomplete left 4(9) 6(14) 3(7) 3(7) 0.727 1.000 1.000 0.250 0.687
Incomplete right 1(2) 0(0) 0(0) 1(2) 1.000 1.000 1.000 1.000 1.000
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PREDICTORS OF NEW-ONSET LEFT BUNDLE BRANCH
BLOCK AND NEED FOR PERMANENT PACEMAKING
Tables 6 and 7 show the results of the univariable analysis for
predictors of new-onset LBBB and need for new permanent
pacemaking, respectively.
Discussion
In this study we found that early conduction abnormalities (LBBB)
occurring after CoreValve implantation persisted at 6-month follow-
up. In addition, one-fifth of patients had implantation of a new
permanent pacemaker –50% were implanted seven days after the
TAVI procedure. Predictors of new-onset LBBB were male gender,
previous history of myocardial infarction, pre-existing right bundle
branch block, actual diameter of the inflow portion of the frame after
Table 5. Quantitative angiographic measurements.
Mean±SD
Overall cohort (n=91)
Depth of implantation - left coronary leaflet, mm (±SD) 9.1 (±3.4)
Depth of implantation - noncoronary leaflet, mm (±SD) 8.0 (±2.5)
New-onset LBBB acquired during or after valve implantation
Depth of implantation - left coronary leaflet, mm (±SD) 10.4 (±4.0)
Depth of implantation - noncoronary leaflet, mm (±SD) 10.2 (±2.6)
No new-onset LBBB or new-onset LBBB acquired during 
procedure but before valve implantation
Depth of implantation - left coronary leaflet, mm (±SD) 8.6 (±3.8)
Depth of implantation - noncoronary leaflet, mm (±SD) 7.3 (±2.7)
Percent expansion of inflow portion of frame - AP view, % (±SD) 83 (±10)
Percent expansion of inflow portion of frame - Lateral view, % (±SD) 78 (±10)
Table 4. Permanent pacemaking requirements after TAVI.
Permanent pacemaker 
Patient Baseline Temporary Permanent implanted  during index Days after TAVI Indication for Timing when AVB 
number ECG PM PM hospitalisation or Permanent PM implanted Permanent PM noticed
post-discharge
<7 Days, n=8
14 SR. LAFB No VVI Index hospitalisation 4 3rd degree AVB Post procedural
24 SR. LBBB Yes DDDR Index hospitalisation 6 3rd deqree AVB Intra procedural
30 SR. RBBB Yes DDDICD Index hospitalisation 6 3rd deqree AVB Intra procedural
33 SR. NC Yes DDDR Index hospitalisation 6 3rd degree AVB Infra procedural
47 SR. RBBB Yes DDDR Index hospitalisation 6 3rd degree AVB Intra procedural
69 SR. RBBB Yes DDDR Index hospitalisation 2 3rd degree AVB Intra procedural
73 SR. RBBB Yes DDDR Index hospitalisation 6 3rd degree AVB Intra procedural
75 SR. NC Yes DDDR Index hospitalisation 1 3rd degree AVB Intra procecural
7-30 Days, n=6
8 SR. NC No VVI Index hospitalisation 18 2nd degree AVB* Post procedural
54 AF. NC Yes VVI Index hospitalisation 7 3rd degree AVB Post procedural
66 AF. NC Yes VVI Index hospitalisation 9 3rd degree AVB Intra procedural
71 SR. NC Yes DDDR Index hospitalisation 7 3rd degree AVB Intra procedural
81 AF. LBBB Yes VVI Index hospitalisation 14 3rd deqree AVB Intra procedural
91 SR. NC Yes DDDR Index hospitalisation 18 3rd degree AVB Intra procedural
>30 Days, n=3
4 SR. NC Yes DDDICD Post-discharqe 41 3rd degree AVB Post procedural
9 SR. NC No DDDICD Index hospitalisation 46 Bradyarrhythmia/NSVT Post procedural
18 SR. NC No DDDR Post-discharge 423 Syncope Post procedural
AF: atrial fibrillation; AVB: atrioventricular block; LAFB: left anterior fascicular block; LBBB: left bundle branch block; NC: normal conduction; NSVT: non-
sustained ventricular tachycardia; PM: pacemaker; RBBB: right bundle branch; *Type II
Figure 3. Correlation between depth of implantation (from the non-
coronary sinus) and percent expansion of inflow level of the CoreValve
(relative to valve size 26- or 29-mm). Pearson Correlation Coefficient 0.51,
p<0.001.
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implantation and depth of implantation. Predictors for new
permanent pacemaking were pre-treatment QRS duration (msec)
and septal wall thickness. Finally, we propose a framework to
understand the potential mechanisms implicated in the
development of conduction abnormalities after TAVI.
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We have previously demonstrated that new-onset LBBB is the most
common conduction abnormality after implantation of the
CoreValve device and is persistent at 1-month follow-up1. These
findings have been confirmed by subsequent studies3,4. In our
previous study, however, the observed decrease in QRS duration at
1-month follow-up (150±32 msec after treatment vs. 134±29 msec
at 1-month follow-up, p<0.001) would seem to imply an improvement
in conduction1. This led us to question whether conduction
abnormalities occurring after CoreValve implantation were transient
or persistent? Possible explanations include inflammation, oedema,
Table 6. Univariable analysis for predictors of new-onset LBBB
after valve implantation.
OR (95% CI) P value
Baseline patient characteristics
Age (years) 1.04 (0.92 to 1.10) 0.93
Gender 3.96 (1.12 to 14.06) 0.033
Logistic EuroSCORE (%) 1.00 (0.94 to 1.07) 1.00
New York Heart Association (I-IV)
II Reference 0.41
III 0 1.00
IV 4.33 (0.51 to 36.70) 0.18
Hypertension 3.24 (0.92 to 11.47) 0.068
Diabetes mellitus 1.67 (0.45 to 6.24) 0.45
Coronary artery disease 1.33 (0.41 to 4.30) 0.63
Myocardial infarction 3.48 (1.00 to 12.05) 0.049
Percutaneous coronary 
intervention 1.67 (0.45 to 6.24) 0.45
Coronary artery bypass graft 
surgery 0.96 (0.27 to 3.53) 0.97
History of atrial fibrillation 1.01 (0.24 to 4.15) 0.99
Stroke 1.37 (0.37 to 5.05) 0.64
Peripheral vascular disease 5.00 (0.64 to 39.06) 0.13
Chronic renal failure 1.45 (0.30 to 6.92) 0.64
Dialysis 0.67 (0.35 to 1.29) 0.23
Chronic obstructive pulmonary 
disease 1.06 (0.29 to 3.83) 0.93
Pulmonary hypertension 1.36 (0.42 to 4.44) 0.61
Baseline echocardiography
Left ventricular outflow tract (mm) 1.13 (0.89 to 1.43) 0.33
Aortic valve annulus (mm) 0.974 (0.71 to 1.23) 0.63
Septal wall thickness (mm) 0.83 (0.65 to 1.07) 0.16
Aortic valve area (cm2) 0.73 (0.03 to 17.52) 0.84
Ejection fraction (%) 0.98 (0.94 to 1.03) 0.40
Mitral annular calcification 0.48 (0.12 to 1.92) 0.30
Baseline electrocardiogram
Cardiac rhythm
Sinus Reference 0.64
Atrial fibrillation 1.83 (0.53 to 6.35) 0.34
PR interval (msec) 1.00 (0.98 to 1.02) 0.91
QRS duration (msec) 0.99 (0.96 to 1.02) 0.48
QT interval (msec) 1.00 (0.98 to 1.01) 0.78
Hemiblock
None Reference 0.92
Left anterior hemiblock 1.36 (0.32 to 5.79) 0.67
Left posterior hemiblock 0 1.00
Bundle branch block
No bundle branch block Reference 0.17
RBBB 15.00 (1.43 to 157.90) 0.024
Procedural-related factors
Valve size
26 mm inflow Reference 1.00
29 mm inflow 1.87 (0.58 to 6.05) 0.30
Measurement of inflow diameter 
(mm) - AP view 1.27 (1.01 to 1.61) 0.046
Measurement of inflow diameter 
(mm) - Lateral 1.26 (0.9 to 1.65) 0.083
Ratio of valve size (26- or  
29-mm) to AV annulus (mm) 9.63 (0.38 to 246.46) 0.17
Depth of implantation from 
non-coronary leaflet (mm) 1.20 (1.32 to 3.17) 0.001
Depth of implantation from left 
coronary leaflet (mm) 1.20 (1.01 to 1.43) 0.037
Post-implant dilatation 1.71 (0.35 to 8.37) 0.51
Table 7. Univariable analysis for predictors of new permanent
pacemaking.
OR (95% CI) P value
Baseline patient characteristics
Age (years) 1.02 (0.94 to 1.12) 0.59
Gender 1.58 (0.53 to 4.72) 0.42
Logistic EuroSCORE (%) 1.01 (0.96 to 1.07) 0.67
New York Head Association (I-IV)
II Reference 0.89
III 0.73 (0.17 to 3.12) 0.67
IV 0.91 (0.15 to 5.58) 0.92
Hypertension 1.25 (0.42 to 3.74) 0.69
Diabetes mellitus 1.53 (0.42 to 5.56) 0.52
Coronary artery disease 0.52 (0.17 to 1.58) 0.25
Myocardial infarction 0.50 (0.10 to 2.43) 0.39
Percutaneous coronary 
intervention 0.39 (0.08 to 1.88) 0.24
Coronary artery bypass graft 
surgery 1.45 (0.44 to 4.80) 0.54
History of atrial fibrillation 0.63 (0.16 to 2.46) 0.51
Stroke 0.42 (0.09 to 2.04) 0.28
Peripheral vascular disease 1.42 (0.14 to 14.65) 0.78
Chronic renal failure 3.54 (0.75 to 16.69) 0.11
Dialysis 1.05 (0.60 to 1.82) 0.88
Chronic obstructive pulmonary 
disease 0.36 (0.08 to 1.74) 0.20
Pulmonary hypertension 2.20 (0.72 to 6.63) 0.17
Baseline echocardiography
Left ventricular outflow tract (mm) 1.13 (0.89 to 1.43) 0.33
Aortic valve annulus (mm) 0.974 (0.71 to 1.23) 0.63
Septal wall thickness (mm) 1.28 (1.03 to 1.60) 0.026
Aortic valve area (cm2) 2.79 (0.13 to 59 13) 0.51
Ejection fraction (%) 1.00 (0.96 to 1.03) 0.70
Mitral annular calcification 0.72 (0.21 to 2.50) 0.60
Baseline electrocardiogram
Cardiac rhythm
Sinus Reference 1.00
Atrial fibrillation 2.45 (0.50 to 11.88) 0.21
PR interval (msec) 1.01 (0.99 to 1.03) 0.39
QRS duration (msec) 1.03 (1.00 to 1.05) 0.020
QT interval (msec) 1.01 (1.00 to 1.03) 0.070
Hemiblock
None Reference 0.55
Left anterior hemiblock 0.22 (0.01 to 3.81) 0.30
Left posterior hemiblock 0.18 (0.01 to 4.26) 0.29
Bundle branch block
No bundle branch block Reference 0.55
LBBB 0.82(0.16 to 4.18) 0.81
RBBB 4.50(026 to 77.14) 0.30
Procedural-related factors
Valve size
26 mm inflow Reference 1.0
29 mm inflow 1.50(0.50 to 4.51) 0.47
Measurement of inflow diameter 
(mm) - AP view 0.93 (0.76 to 1.13) 0.47
Measurement of inflow diameter 
(mm) - Lateral 0.95 (0.78 to 1.16) 0.61
Ratio of valve size (26- or  
29-mm) to AV annulus (mm) 0.57 (0.02 to 15.36) 0.74
Depth of implantation from 
non-coronary leaflet (mm) 0.93(0.76 to 1.13) 0.46
Depth of implantation from 
left coronary leaflet (mm) 1.05 (0.89 to 1.22) 0.58
Post-implant dilatation 1.88 (0.38 to 9.20) 0.44
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ischaemia and/or mechanical stress with recovery of conduction. In
the present study, we observed a significant decrease in QRS
duration from after treatment to 1-month follow-up (143±31 vs.
132±30 msec, p=0.002) but there was no significant change in
QRS duration or frequency of LBBB from 1-month to 6-month
follow-up. In contrast, Gutiérrez et al observed a significant
decrease in QRS duration (msec) and frequency of new-onset
LBBB from post-treatment to 1-month follow-up after implantation
of the balloon-expandable Edwards prosthesis (Edwards
Lifesciences, Irvine, CA, USA) such that there was no significant
difference between baseline and 1-month follow-up (LBBB pre-
treatment 9% vs. post-treatment 27% vs. 1-month follow-up 13%
and QRS duration pre-treatment 114 vs. post-treatment 129 vs. 1-
month follow-up 118 msec). We speculate that differences in QRS
duration and new-onset LBBB overtime between the self-
expandable and balloon-expandable transcatheter aortic valve
systems may be related to technical differences (e.g., depth of
implantation) and physical design properties of the frame and/or
stent (self-expanding nitinol vs. balloon expandable stainless steel).
The implications of persistent LBBB after TAVI are currently
unknown. What is known, however, is that acquirement of new
bundle branch block after surgical aortic valve replacement is
associated with increased risk of subsequent arrhythmic events
after 1-year follow-up (specifically, syncope, AV dissociation, and
sudden death)8,13. Our study was underpowered to pursue a similar
analysis. These surgical reports propose prophylactic pacemaker
insertion in patients who develop bundle branch block after aortic
valve replacement8,13.
In our centre, we do not implant “prophylactic” permanent
pacemakers (e.g., for new-onset LBBB). The concept of
“prophylactic” permanent pacemaker stems from the surgical
literature. In a study of 133 patients undergoing surgical aortic valve
replacement, Thomas et al observed that 32% of patients
developed new-onset LBBB. At 2.5 years mean follow-up, the
cumulative survival was 24% lower in those who developed new
onset LBBB than in those who did not develop LBBB (66% vs.
90%, p<0.001) (reference). In a similar study of 389 patients
undergoing surgical aortic valve replacement, El-Khally et al
observed that 16% of patients developed a new-onset bundle
branch block. At a mean follow-up of 4.5 years, the composite
endpoint of complete heart block, syncope, and sudden cardiac
death was 16% higher in those patients who developed bundle
branch block than in those who did not develop bundle branch
block. Both investigators concluded that “prophylactic permanent
pacemaker” should be considered in patients who develop bundle
branch block after surgical aortic valve replacement.
A new permanent pacemaker was inserted in approximately one-
fifth of our patients after CoreValve implantation. The higher rate of
permanent pacemaker implantation reported by other centres (up
to 33%) most likely reflects a combination of “prophylactic”
pacemaker implantation for concerns of patient safety and
administrative logistics4,14. In our study, 3rd AV block was present in
four-fifths of patients who received a new permanent pacemaker.
Although 15/17 patients (88%) underwent permanent pacemaker
implantation during hospitalisation, 9/17 (52%) patients underwent
implantation seven days after valve implantation. The duration of
hospitalisation was significantly longer in those patients who
required permanent pacemaking than in those who did not require
permanent pacemaking. Strategies to avoid unnecessary and
prolonged hospitalisation due to pacemaker implantation should be
the focus of future studies. Considering the fact that three-quarter of
patients requiring temporary pacemaking ultimately required
permanent pacemaking, immediate implantation of a permanent
pacemaker in these particular patients may promote earlier
mobilisation and discharge. In fact, anecdotal experiences seem to
suggest that “prophylactic” permanent pacemaker implantation
may conceivably lead to reduced hospital stay.
In the present study male gender, previous myocardial infarction,
pre-existing right bundle branch block, diameter (mm) of the inflow
portion of the frame after implantation, and depth of implantation
were predictors for new-onset left bundle branch block.
Recently, Osamu et al examined the distance (mm) from the base of
the non-coronary cusp to the lower edge of the membranous septum
where the left bundle branch originated invariably in 100 autopsied
hearts15. More specifically, the left bundle branch was located
6.3±2.4 mm from the base of the non-coronary cusp. Thus it is highly
plausible that a deep implantation of the CoreValve device might play
an important role in the occurrence of LBBB. The depth of the left
bundle branch as noted by Osamu et al appears to be consistent with
our suggestion to implant the CoreValve device <6-7 mm from the
basal attachment of the aortic valve leaflets.
Two recent studies support our findings about the correlation
between the depth of implantation and occurrence of LBBB after
transcatheter aortic valve implantation. Gutiérrez et al observed a
correlation between the depth of implantation of the Edwards
SAPIEN (Edwards Lifesciences) device and the occurrence of left
bundle branch block16. More specifically, 35% of patients in whom
the ventricular end of the prosthesis was located below the hinge
point of the anterior mitral leaflet developed left bundle branch
block compared with none of the patients in whom the ventricular
end was implanted above the hinge point (identified by
transesophageal echocardiography) (p=0.029). In another study,
Koektuerk et al found a correlation between the depth of
implantation (>8 mm) of the CoreValve device assessed by
fluoroscopy and the need for permanent pacemaking17.
Despite our intentions to implant the prosthesis at a target depth of
6-7 mm, we did not find a significant difference in the depth of
implantation between the first and second half of the study patients.
This observation may question the technical feasibility (whether
device- or operated-related) to precisely implant the CoreValve at a
particular location. It is possible the learning curve and iterations in
device design will improve the accuracy of device implantation.
In the present study, pre-treatment QRS duration and septal wall
thickness were univariate predictors for permanent pacemaking.
This would imply that patients with pre-existing conduction disease
would have a greater chance of receiving a permanent pacemaker
after CoreValve implantation. A single-centre study by Jilaihawi et al
also identified septal wall thickness, in addition to LBBB with left axis
deviation and non-coronary cusp thickness >8 mm as predictors for
permanent pacemaking after CoreValve implantation4. Independent
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predictors for permanent pacemaking after surgical aortic valve
replacement include age, pre-existing right and left bundle branch
block, aortic regurgitation at baseline, multivalvar surgery, left atrial
enlargement, left ventricular dysfunction, pulmonary hypertension,
previous myocardial infarction, and post-operative electrolyte
imbalances18-21.
As can be appreciated from Table 4, there was a discrepancy
between the timing “when the AV block was first noticed” and
“when the permanent pacemaker was implanted”. Retrospective
analysis of the patient dossiers revealed that the disparity between
recognising the AV block and implantation of the permanent
pacemaker was mainly due to administrative logistics and in some
patients, urinary tract infection or low-grade fever of unknown origin
that eventually resolved. Of the 15 patients who had a permanent
pacemaker implanted during the index hospitalisation, AV block
was recognised during the procedure in 11 patients (73%) and
post-procedure in four patients (27%).
We propose the following framework to better understand the
potential mechanisms involved in the development of conduction
abnormalities: (1) patient-related; (2) anatomical-related; and (3)
procedural-related (e.g., device or operator-related). Thus, gender,
previous myocardial infarction and pre-existing right bundle branch
block can be considered as patient-related factors; variations in the
location of the left bundle branch exit point as an anatomical-related
factor; self-expanding characteristics and high radial force of the
CoreValve frame as device-related; and control of the depth of
implantation as operator-related.
Study limitations
The following limitations need to be addressed. This report
represents a single centre experience and therefore the results may
not be generalisable. The results of this study relate to only one type
of prosthesis and the conclusions, therefore, may not be applicable
to other transcatheter aortic valve bioprostheses. Furthermore,
variables (e.g., degree of aortic valve calcification) potentially
associated with development of conduction abnormalities after
CoreValve implantation may have been omitted from the analysis.
The modest number of patients included in the analysis may have
been underpowered to identify additional predictors of new LBBB or
need for permanent pacemaking.
Currently, there is no gold standard to measure the depth of
implantation of transcatheter aortic valves. In this study, the depth
of implantation was measured by quantitative angiographic
measurements using the “working” gantry angle (i.e., implantation
viewing angle). The possibility exists that the depth of implantation
was systematically underestimated. The alternative of
overestimating the depth of implantation is not possible.
Nevertheless, it was in this “working” gantry angle that the
operators estimated the depth of implantation during the
procedure. Also of note is that there was minimal overlap in the
depth of implantation between those with new-onset LBBB vs. those
who did not develop LBBB (10±2 mm vs. 7±2 mm, respectively).
Alternative imaging modalities such as MSCT or echocardiography
were not used to assess the depth of implantation and may have
provided additional information.
This study was not designed to systematically interrogate newly
implanted pacemakers at 1- and/or 6-months. It is possible that
complete AV conduction disturbances may disappear as a sign of
healing after some days or weeks.
Practical clinical implications
Our results would suggest that implanting the CoreValve prosthesis
in a more superior location within the left ventricular outflow tract
(i.e., depth of implantation <6-7 mm) might mitigate the occurrence
of LBBB. It is likely that a number of inter-relating factors such as
patient characteristics, anatomic variations, operator technique,
and device characteristics are playing a role in the development of
conduction abnormalities after TAVI. The clinical consequences of
new-onset LBBB or new permanent pacemaking after CoreValve
implantation are currently unknown.
The significant inter-hospital variations in the frequency of new
permanent pacemaker reported in the literature likely reflects
variations in physician threshold, country-based healthcare norms,
and reimbursement strategies. There is currently a lack of
standardised guidelines for new permanent pacemaker
implantation, duration of temporary pacemaking, and duration of
monitoring (in-hospital or post-discharge) after TAVI. In our centre,
we use the AHA/ACC guidelines on when to implant a permanent
pacemaker after TAVI22. The temporary pacemaker wire is typically
removed on day 2-3 post-procedure. Subsequently, patients are
maintained on telemetry monitoring for the duration of
hospitalisation. An ECG is obtained at 1-month, 6-month, and 12-
month clinical follow-up.
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Frequency of Conduction Abnormalities After Transcatheter Aortic
Valve Implantation With the Medtronic-CoreValve and the Effect
on Left Ventricular Ejection Fraction
Apostolos Tzikas, MD*, Bas M. van Dalen, MD, PhD, Nicolas M. Van Mieghem, MD,
Juan-Luis Gutierrez-Chico, MD, PhD, Rutger-Jan Nuis, MS, Floris Kauer, MD,
Carl Schultz, MD, PhD, Patrick W. Serruys, MD, PhD, Peter P. T. de Jaegere, MD, PhD, and
Marcel L. Geleijnse, MD, PhD
New conduction abnormalities occur frequently after transcatheter aortic valve implanta-
tion (TAVI). The relation between new conduction disorders and left ventricular (LV)
systolic function after TAVI is unknown. The purpose of the present prospective, single-
center study was to investigate the effect of TAVI on LV systolic function in relation to
TAVI-induced conduction abnormalities. A total of 27 patients had undergone electrocar-
diography and transthoracic echocardiography the day before and 6 days after TAVI with
the Medtronic-CoreValve system. The LV ejection fraction (EF) was calculated using the
biplane Simpson method. The systolic mitral annular velocities and longitudinal strain
were measured using speckle tracking echocardiography. After TAVI, 18 patients (67%)
had new conduction abnormalities; 4 (15%) had a new paced rhythm and 14 patients (52%)
had new left bundle branch block. In the patients with new conduction abnormalities, the
EF decreased from 47  12% to 44  10%. In contrast, in those without new conduction
abnormalities, the EF increased from 49  12% to 54%  12%. The change in EF was
significantly different among those with and without new conduction abnormalities (p
<0.05). In patients without new conduction abnormalities, an improvement was found in
the systolic mitral annular velocities and longitudinal strain (p <0.05). In contrast, in
patients with new conduction abnormalities, the changes were not significant. In conclu-
sion, the induction of new conduction abnormalities after TAVI with the Medtronic-
CoreValve was associated with a lack of improvement in LV systolic function. © 2011
Elsevier Inc. All rights reserved. (Am J Cardiol 2011;107:285–289)
Transcatheter aortic valve implantation (TAVI) is a new
promising therapeutic option for high-risk patients with
severe aortic stenosis.1–5 The most experience has been
achieved with the Medtronic-CoreValve system (Medtronic-
CoreValve, Minneapolis, Minnesota) and the Edwards SAPIEN
(Edwards Lifesiences, Irvine, California) bioprosthetic valve.
Both devices have demonstrated favorable hemodynamic
results, with a significant decrease in transaortic gradients
and considerable clinical improvement. Despite this imme-
diate decrease in the transaortic gradient, the left ventricular
(LV) ejection fraction (EF) has been reported to remain
unchanged after TAVI with the Medtronic-CoreValve.6,7
More subtle measurements of LV systolic function have
included mitral annular velocities and longitudinal strain
(active deformation of the cardiac muscle). Speckle tracking
echocardiography (STE) can assess both parameters reli-
ably, independent of the angulation of the transducer and
with optimal reproducibility.8 After TAVI with the
Medtronic-CoreValve, a left bundle branch block (LBBB)
or an atrioventricular block requiring permanent pacemaker
implantation occur in 40% to 65% and 20% to 33% of
patients, respectively.9–12 To date, the relation between the
occurrence of conduction disorders and LV systolic func-
tion after TAVI is unknown. The purpose of the present
prospective, single-center study was to investigate the effect
of TAVI on LV systolic function in relation to TAVI-
induced conduction abnormalities.
Methods
The study population included 27 consecutive patients
who had undergone TAVI with the Medtronic-CoreValve
and had transthoracic echocardiograms of adequate quality
available before and after the procedure. The inclusion and
exclusion criteria for TAVI have been previously described
in detail.3 In brief, the patients were included if they had
severe native aortic valve stenosis with an aortic valve area
1 cm2 or 0.6 cm2/m2, with or without aortic regurgita-
tion, and were deemed high-risk surgical candidates. All
patients provided written informed consent (postmarketing
surveillance registry). The Medtronic-CoreValve System
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consisted of a trileaflet porcine pericardial tissue valve,
mounted in an hourglass-shaped, self-expanding nitinol
frame (50 to 51 mm high). Currently, the prosthesis is
available in sizes with a 26- and 29-mm inflow diameter for
patient annulus diameters of 20 to 27 mm.
We obtained 12-lead electrocardiographic tracings in all
patients before and after treatment and analyzed them for
rhythm, heart rate, PR interval duration, QRS duration and
morphology, and the presence of atrioventricular/fascicular
block, according to recent recommendations.13 In addition,
an electronic single-lead rhythm strip was continuously re-
corded during the echocardiographic studies. The patients
were considered to have new conduction abnormalities
when a new LBBB or a new paced rhythm was recorded
after the index procedure. The decision to implant a perma-
nent pacemaker was determined according to the latest
guidelines.14
Two-dimensional transthoracic echocardiography was
performed by an independent experienced echocardiogra-
pher the day before and 1 week after the procedure, using a
commercially available system (iE33, Philips, Best, The
Netherlands) with the patient in the left lateral decubitus
position, according to published recommendations.15 All
echocardiograms were saved as video loops or still frames
in a digital database and were analyzed by a second inde-
pendent investigator. The LVEF was calculated using the
biplane modified Simpson rule. The transaortic peak veloc-
ity, peak and mean gradient, and velocity-time integral were
measured using continuous-wave Doppler through the na-
tive or prosthetic aortic valve. The aortic valve area was
estimated using the continuity equation approach [aortic
valve area  LV outflow tract area  (velocity-time inte-
gral LV outflow tract/velocity-time integral valve)]. Aortic
regurgitation and mitral regurgitation were assessed semi-
quantitatively according to the current guidelines for the
evaluation of native valves.16
STE was performed using 2-dimensional grayscale har-
monic images at a frame rate of 70 to 80 frames/s. The data
sets were transferred to a QLAB workstation for analysis
using the QLAB Advanced Quantification Software, ver-
sion 6.0 (Philips, Best, The Netherlands). The details re-
garding speckle tracking analysis have been previously pub-
lished.8 For the purposes of the present study, systolic mitral
annular velocities and longitudinal wall strain were assessed
from the inferoseptal and anterolateral sides of the left
ventricle (from the base to the distal part of the particular
wall) in an apical 4-chamber view. The interobserver vari-
abilities were 3.7  3.3% and 4.8  5.2%.8
The continuous variables are presented as the mean 
SD, and the categorical variables are presented as frequen-
cies and percentages. For the comparisons between 2 time
points, a paired sample t test or Wilcoxon signed rank test
for 2 related samples was used for normally distributed or
skewed data, respectively. For ordinal variables (aortic re-
gurgitation and mitral regurgitation grade), a constant dif-
ference between values was assumed. A 2-sided p value of
0.05 was considered statistically significant. All statistical
analyses were performed using the Statistical Package for
Social Sciences, version 17.0, software (SPSS, Chicago,
Illinois).
Results
The baseline patient characteristics are summarized in
Table 1. The study population consisted of elderly patients
with a number of co-morbidities. Of the 27 patients, 4
(15%) had a baseline EF of 35%; 8 patients (30%) un-
derwent TAVI using a 26-mm and 19 (70%) using a 29-mm
inflow Medtronic-CoreValve. Postdeployment balloon dila-
tion was performed in 3 patients (11%). No patient required
a second bioprosthesis as a valve-in-valve bailout.
Before TAVI (1 day before), no patient had a paced
rhythm, 1 patient (4%) had a LBBB, and 4 patients (15%)
had a left anterior fascicular block. After TAVI (day 6), 4
patients (15%) had a paced rhythm, 15 patients (56%) had
a LBBB (14 patients [52%] with a new LBBB), and no
patient had a left anterior fascicular block. Therefore, 18
patients (67%) had new conduction abnormalities. With
respect to the baseline characteristics, a comparison be-
tween the patients with and without new conduction abnor-
malities did not reveal statistically significant differences.
The indication for permanent pacemaker implantation was
(in all 4 cases) complete heart block.
The echocardiographic changes after TAVI are listed in
Table 2. The mean transaortic gradient decreased from 44
14 to 9 3 mm Hg, and the aortic valve area increased from
0.62  0.20 to 1.65  0.38 cm2 (p 0.001). A small,
nonsignificant decrease in aortic regurgitation and mitral
regurgitation severity was observed. Overall, the EF and
longitudinal strain did not change significantly; however,
the systolic mitral annular velocities improved. The results
of a subgroup analysis of LV systolic parameters in relation
to new conduction abnormalities are listed in Table 3. In
patients with new conduction abnormalities, the EF de-
creased from 47 12% to 44% 10%. In contrast, in those
without new conduction abnormalities, the EF increased
from 49  12% to 54%  12% (Figure 1). The change in
Table 1
Baseline characteristics
Variable Study Population
(n  27)
Age (years) 81 (78–86)
Men 14 (52%)
Body mass index (kg/m2) 26  4
Body surface area (m2) 1.84 0.19
Antecedents
Cerebrovascular events 6 (22%)
Myocardial infarction 6 (22%)
Percutaneous coronary intervention 8 (30%)
Coronary artery bypass 7 (26%)
Co-morbidities
Chronic obstructive pulmonary disease 8 (30%)
Chronic renal disease 3 (11%)
Peripheral vascular disease 5 (19%)
Atrial fibrillation 6 (22%)
Diabetes mellitus 6 (22%)
Ejection fraction 35% 4 (15%)
New York Heart Association status
I-II 5 (19%)
III-IV 22 (81%)
Logistic EuroSCORE 11 (9–22)
Data are presented as mean SD, median (interquartile range), or n (%).
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the EF was significantly different among the patients with
and without new conduction abnormalities (p 0.05). In
addition, in patients without new conduction abnormali-
ties, an improvement was found in the systolic mitral
annular velocities and longitudinal strain (p 0.05). In
contrast, in patients with new conduction abnormalities,
the changes were not significant. In the 4 patients with an
EF of 35% at baseline, the EF increased from 29  6%
to 34%  8% (p  0.28)
Discussion
The main finding of the present study was that the in-
duction of new conduction abnormalities after TAVI with
the Medtronic-CoreValve was associated with a lack of
improvement in LV systolic function.
After surgical aortic valve replacement, the incidence of
a new LBBB has been reported to be 6%.17 In contrast, the
need for permanent pacing has been reported to be 3% to
6%.18 Conduction disorders have been associated with
longer hospital stays and more cardiac adverse events
within 1 year after surgical aortic valve replacement.17 To
date, no report has been published on the long-term effects
of TAVI-induced conduction abnormalities. However, it
should be noted that epidemiologic studies have shown
increased mortality in patients with a combination of com-
plete heart block or LBBB and structural heart disease.19
Conduction disorders occur frequently after TAVI. The
anatomic proximity of the aortic valve to the branching
atrioventricular bundle, degeneration and calcification of
the conduction system, direct trauma by guidewires and
catheters and preimplantation balloon valvuloplasty could
be possible explanations.9–12 TAVI using the Medtronic-
CoreValve has been associated with a greater incidence of
conduction disorders compared to the Edwards SAPIEN
valve.10 This could be explained by the differing sizes of the
bioprostheses (height 50 to 51 mm vs 15 to 16 mm) and the
different methods of deployment (self expandable vs bal-
loon expandable).20 The depth of implantation of the
Medtronic-CoreValve within the LV outflow track has been
reported to predict the occurrence of new conduction ab-
normalities. In addition, the self-expandable frame per se
might produce more permanent trauma to the adjacent tissue
by applying continuous pressure on it.10,20 Pre-existing con-
duction disorders such as right bundle branch block have
been found to predict the need for pacemaker implantation
after TAVI.10 In the present study, no patient had right
bundle branch block before or after TAVI. The single pa-
tient with LBBB at baseline continued to have LBBB after
TAVI. Two of 4 patients with left anterior fascicular block
at baseline developed LBBB and 2 developed complete
heart block and received a pacemaker.
Most studies investigating the echocardiographic out-
come after TAVI used the EF to assess the LV systolic
function (Table 4). Not all investigators have reported the
EF after TAVI with the Medtronic-CoreValve.3,4 It seems
reasonable to assume that the reason for not reporting the
EF after TAVI was the lack of significant changes. Never-
theless, in most studies in which EF was reported, the
changes were insignificant, with the exception of subgroup
analyses of patients with a low baseline EF in whom sig-
nificant immediate improvement was found.6,21 The lack of
improvement in the EF was also observed by our group in
a previous cohort of 74 patients who were not included in
the present study.7 In contrast, most of the studies on TAVI
using the Edwards SAPIEN valve have shown a significant
immediate increase in the EF, which was more prominent in
patients with a low EF.1,2,5,22–24 The results of the present
study have provided a possible explanation for this discrep-
ancy. Normally, the LV and right ventricular contraction is
synchronous. In the presence of LBBB or right apical pacing,
right ventricular activation/contraction will precede LV activa-
tion/contraction. Consequently, this interventricular asyn-
chrony results in paradoxical septal movement that has been
associated with a decrease in global EF, even in the absence of
heart failure.25 The lack of improvement in EF after TAVI
with the Medtronic-CoreValve might be because of the greater
incidence of new conduction abnormalities, which influence
the LV synchronous contraction and, thus, systolic perfor-
mance. However, although the EF and/or longitudinal strain
measurements are useful for the assessment of LV systolic
function, they are not synonymous with it. Therefore, the
results should be interpreted with caution.
LV systolic function after TAVI was evaluated using
Doppler tissue imaging in 2 studies. In the first, involving 8
patients, who had undergone TAVI with the Edwards SA-
PIEN valve, Bauer et al23 found a significant increase in the
EF, systolic mitral velocities, and longitudinal strain. In the
second, involving 39 patients, the EF showed no significant
change after TAVI with the Medtronic-CoreValve; how-
ever, a small improvement was found in the systolic mitral
velocities at 30 days of follow-up, similar to our findings.6
In our study, the systolic mitral velocities and longitudinal
strain increased significantly in the group of patients with-
out new conduction abnormalities. In contrast, in patients
with new conduction disorders, the changes were insignif-
icant, in line with the changes in EF. Systolic mitral veloc-
ities and longitudinal strain were assessed using STE, which
is more sensitive and reproducible than the EF measure-
ments obtained using conventional echocardiography.8 In
addition, the accuracy of STE is greater than that of Doppler
tissue imaging. STE directly tracks the speckles on an echo-
Table 2
Echocardiographic changes after transcatheter aortic valve implantation
(TAVI) (n  27)
Variable Pre-TAVI Post-TAVI p Value
Peak aortic gradient (mm Hg) 75 23 18  7 0.001
Mean aortic gradient (mm Hg) 44 14 9  3 0.001
Peak aortic velocity (cm/s) 422 58 210  40 0.001
Aortic valve area (cm2) 0.62  0.20 1.65  0.38 0.001
Aortic regurgitation grade
(1–4)
1.8  1.0 1.6  1.2 0.61
Mitral regurgitation grade
(1–4)
1.8  0.7 1.6  0.8 0.06
Ejection fraction (%) 47 11 48  12 0.94
Mitral annular velocity (cm/s)
Inferoseptal 4.0  1.2 5.1  1.7 0.05
Anterolateral 4.5  1.4 5.6  1.9 0.05
Longitudinal strain (%) 11 3 12 3 0.64
Data are presented as mean  SD.
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cardiogram and, thus, myocardial motion and deformation
and is, therefore, independent of the angle of insonation.8
The present study was a single-center, prospective study,
designed to investigate the immediate effects of TAVI on
LV function. Other studies are needed to conclude whether
TAVI-induced conduction disorders persist or recover dur-
ing follow-up. Another limitation was the relatively small
number of patients. However, all data (pre- and post-TAVI,
including speckle tracking measurements) were 100% com-
plete, allowing a robust paired statistical analysis. Never-
Table 3
Left ventricular (LV) systolic function in relation to new conduction abnormalities
Variable New Conduction Abnormalities
No
(n  9)
Yes
(n  18)
Pre-TAVI Post-TAVI Pre-TAVI Post-TAVI
Mitral annular velocity (cm/s)
Inferoseptal 4.3  1.4 6.5  2.2* 3.8  1.0 4.4  0.8
Anterolateral 4.8  1.3 6.6  2.5* 4.4  1.5 5.1  1.4
Longitudinal strain (%) 11  3 13 3* 11  4 11  2
Ejection fraction (%) 49  12 54  12 47  12 44  10†
* p 0.05 versus pre-TAVI in patients without new conduction abnormalities.
† p 0.05 versus post-TAVI in patients without new conduction abnormalities.
Figure 1. Changes in EF after TAVI. Overall, EF did not change significantly after TAVI (black line). In patients without new conduction abnormalities (blue
doted line), the EF increased but in those with new conduction abnormalities (green doted line), EF decreased. The change in EF was significantly different
among patients with and without new conduction abnormalities (paired sample t test, 2-sided, p 0.05).
Table 4
Reported immediate changes in left ventricular (LV) ejection fraction (EF) after transcatheter aortic valve implantation (TAVI)
Investigator Year Device Patients
(n)
Pre-TAVI EF
(%)
Post-TAVI EF
(%)
p Value
Bauer et al23 2004 Edwards 8 48  18 57  12 0.01
Cribier et al1 2006 Edwards 22 45  18 53  14 0.02
Webb et al2 2007 Edwards 43 53  15 57  13 0.0001
Clavel et al22 2009 Edwards 50 54  16 59  12 0.05
Ye et al5 2010 Edwards* 71 56  13 61  7 NS
Bauer et al24 2010 Edwards 88 48  17 57  15 0.01
Grube et al3 2007 CoreValve 86 54  16 NA NA
Jilaihawi et al21 2009 CoreValve 50 50  14 56  9 0.001
Tzikas et al7 2010 CoreValve 71 52  15 52  15 NS
Buellesfeld et al4 2010 CoreValve 168 51  16 NA NA
Gotzmann et al6 2010 CoreValve 39 57  10 59  10 NS
* Transapical.
NA  not available; NS, not significant.
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theless, the generalizability of our results should be tested in
larger scale studies.
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This editorial refers to ‘Electrocardiographic and further
predictors for permanent pacemaker requirement after
transcatheter aortic valve implantation’ by D. Erkapic
et al., on page 1188.
Erkapic et al.1 report on the frequency of atrioventricular (AV)
conduction abnormalities and new permanent pacemaker (PM)
implantation in a series of 50 patients undergoing either Medtronic
CoreValve implantation via the femoral artery or the Edwards
Sapien valve via a transapical approach. The clinical relevance of
this report is related to the fact that conduction abnormalities
and implantation of a new PM is currently subject of debate
whether this should be considered as a serious adverse event or
not. There is a point to do so, since the loss of appropriate con-
duction and electrical activation of the myocardium in these
elderly patients with age-related histological changes in addition
to histological changes induced by the increased afterload may
affect cardiac output and thus quality of life.
Following surgical aortic valve replacement (SAVR), a new onset
left bundle branch block (BBB) has been reported in 16–32% of
the patients and new PM implantations are performed in 3–
8%.2–5 The close anatomic relationship between the aortic valve
complex and the AV and intraventricular conduction tissue may
explain the occurrence of the conduction disturbances following
valve procedures.6 Following transcatheter aortic valve implan-
tation (TAVI), a new onset left BBB and PM implantation with
the Medtronic CoreValve Revalving System (CRS) have been
reported in up to 65 and 30%, respectively.7–11 Patients treated
with the Edwards–Sapien prosthesis are reported to have left
BBB and PM implantation in 20 and 10%, respectively.9,12
In a series of 50 patients, Erkapic et al. confirmed that a third-
degree AV block and subsequent new PM implantation were
more common in patients treated with the CRS (16/36, 44%) com-
pared with those who underwent transapical implantation of the
Edwards–Sapien bioprosthesis (1/14, 7%). They report that pre-
existing right BBB and CRS are predictors for new onset AV
block and PM implantation and, therefore, they conclude that
using the Edwards device might be more effective in reducing
the risk of PM implantation.
These findings and statements need to be interpreted with
caution, given the sample size and the complex and multifactorial
aetiology of conduction abnormalities during and after TAVI. The
only consistency with previous reports which also stem from small-
sized single-centre observations is the direction of outcome. This
and other studies lack the power and are of insufficient design to
adequately interpret the point estimate and the predictive factors
of conduction abnormalities. Among others, aetiological factors
such as depth of implantation and sizing could not be explored by
Erkapic et al. In addition, the authors do not report echo-Doppler
cardiographic findings. Aortic regurgitation is a well-established
predictor of conduction disturbances after surgical valve implan-
tation.2,4,8 This in turn may lead to a higher frequency of conduction
abnormalities during the follow-up period as a result of increased
stretch on the conduction tissue. In other words, some potential
aetiological factors are correctable (such as depth of implantation
and correct sizing) while others are not. Despite the consistency
of the direction of outcome, it is premature and fallacious to postu-
late on the basis of an observation in 50 patients that the occurrence
of conduction abnormalities is device related.
Finally, in the absence of criteria of PM implantation, the
reported frequency of PM implantation is difficult to interpret. It
is astonishing to see that in the presence of an ever increasing
number of TAVI procedures, there is a remarkable absence of
in-depth knowledge and understanding of the procedure.13
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Frequency and Causes of Stroke During or After Transcatheter
Aortic Valve Implantation
Rutger-Jan Nuis, MSca, Nicolas M. Van Mieghem, MDa, Carl J. Schultz, MD, PhDa,
Adriaan Moelker, MD, PhDb, Robert M. van der Boon, MSca, Robert Jan van Geuns, MD, PhDa,
Aad van der Lugt, MD, PhDb, Patrick W. Serruys, MD, PhDa, Josep Rodés-Cabau, MDc,
Ron T. van Domburg, PhDd, Peter J. Koudstaal, MD, PhDe, and Peter P. de Jaegere, MD, PhDa,*
Transcatheter aortic valve implantation (TAVI) is invariably associated with the risk of
clinically manifest transient or irreversible neurologic impairment. We sought to investi-
gate the incidence and causes of clinically manifest stroke during TAVI. A total of 214
consecutive patients underwent TAVI with the Medtronic-CoreValve System from Novem-
ber 2005 to September 2011 at our institution. Stroke was defined according to the Valve
Academic Research Consortium recommendations. Its cause was established by analyzing
the point of onset of symptoms, correlating the symptoms with the computed tomography-
detected defects in the brain, and analyzing the presence of potential coexisting causes of
stroke, in addition to a multivariate analysis to determine the independent predictors.
Stroke occurred in 19 patients (9%) and was major in 10 (5%), minor in 3 (1%), and
transient (transient ischemic attack) in 6 (3%). The onset of symptoms was early (<24
hours) in 8 patients (42%) and delayed (>24 hours) in 11 (58%). Brain computed tomog-
raphy showed a cortical infarct in 8 patients (42%), a lacunar infarct in 5 (26%), hemor-
rhage in 1 (5%), and no abnormalities in 5 (26%). Independent determinants of stroke were
new-onset atrial fibrillation after TAVI (odds ratio 4.4, 95% confidence interval 1.2 to 15.6),
and baseline aortic regurgitation grade III or greater (odds ratio 3.2, 95% confidence
interval 1.1 to 9.3). In conclusion, the incidence of stroke was 9%, of which >1/2 occurred
>24 hours after the procedure. New-onset atrial fibrillation was associated with a 4.4-fold
increased risk of stroke. In conclusion, these findings indicate that improvements in
postoperative care after TAVI are equally, if not more, important for the reduction of
periprocedural stroke than preventive measures during the procedure. © 2012 Elsevier
Inc. All rights reserved. (Am J Cardiol 2012;xx:xxx)
Transcatheter aortic valve implantation (TAVI) is in-
creasingly used to treat patients with aortic stenosis who are
considered too high a risk for surgical valve replacement
(aortic valve replacement).1 Despite its clinical benefits,
TAVI is invariably associated with the risk of clinically
manifest transient or irreversible neurologic impairment.2–5
This can be explained by the various catheter and wire
manipulations during TAVI that can result in a cerebral
embolus but also by cerebral hypoperfusion due to episodes
of hypotension during TAVI resulting from—for instance—
rapid right ventricular pacing during aortic balloon valvu-
loplasty. Also gaseous and atherosclerotic microemboli can
provoke ischemia and/or occlusion of deep penetrating ar-
teries of the brain, as recently demonstrated.5–10 A neuro-
logic deficit can also occur at some point after TAVI for
reasons not directly related to the procedure itself, such as is
seen in cardiac surgery.11–13 The understanding of the
pathophysiology or cause of stroke during TAVI could help
to determine which preventive strategies during and/or after
TAVI will most effectively reduce the stroke rates. We,
therefore, sought to elucidate the incidence and causes of
stroke in a series of 214 consecutive patients by analyzing
the time of symptom onset in relation to the procedure and
by correlating the symptoms with the computed tomo-
graphic (CT)-detected defects in the brain, in addition to the
assessment of independent predictors of stroke.
Methods
The study population consisted of all 214 patients (3
intraprocedural deaths excluded) who underwent transfemo-
ral or transsubclavian TAVI with the Medtronic CoreValve
System between November 2005 and September 2011 in the
Erasmus Thoraxcenter (Rotterdam, The Netherlands). The
patient selection criteria and the methods used for Doppler
echocardiography have been previously described in de-
tail.14,15 The treatment strategy (TAVI, aortic valve replace-
ment, or medical therapy) was discussed at a joint cardio-
thoracic surgical and medical conference.16
TAVI was performed with the patient under general
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anesthesia. The first 5 patients underwent TAVI with a 21F
delivery catheter that was inserted into the common femoral
(n  4) or subclavian (n  1) artery after a surgical cut
down. All other patients underwent TAVI with an 18F
compatible delivery catheter that was inserted into the com-
mon femoral artery using an ultrasound-guided Seldinger
technique, except for 5 patients who underwent TAVI by
way of the left subclavian artery (surgical exposure and
closure).14 Extracorporal support (extracorporeal membrane
oxygenation/TandemHeart, CardiacAssist, Pittsburgh, PA)
was used in patients with impaired left ventricular function
and a suspected increased risk of periprocedural hemody-
namic instability. The subsequent phases of the transfemo-
ral TAVI procedure have been described previously.17
Patients who were not taking aspirin and/or clopidogrel
received a dose of 80 and 600 mg, respectively, the day
before TAVI. Patients who were receiving oral anticoagu-
lant therapy were instructed to stop this treatment 3 days
before the procedure. Anticoagulant therapy was replaced
by enoxaprin until the day before TAVI in patients with a
strict indication for anticoagulant therapy. At admission, a
full blood examination was performed, including the pro-
thombin time and international normalized ratio (INR).
After insertion of the arterial sheath, a bolus of 70 U/kg
IU unfractionated heparin was administered, followed by
additional doses to maintain the activated clotting time at
250 to 350 seconds. The activated clotting time was checked
every 30 minutes. The activated partial thromboplastin time
was checked within 6 hours after the procedure.
After completion of the procedure (percutaneous or sur-
gical closure of the access site), sedation was stopped,
followed by extubation. All patients were transferred to the
intensive care unit/cardiac care unit for 12 to 24 hours, or
longer if clinically indicated. They were then transferred to
the medium care unit until hospital discharge. According to
the TAVI protocol, rhythm monitoring by telemetry was
Table 1
Baseline characteristics of patients with and without stroke after transcatheter aortic valve implantation (TAVI)
Variable Entire Cohort
(n  214)
No Stroke
(n  195)
Stroke
(n  19)
p Value
Age (years) 80  8 80  8 82  6 0.48
Men 107 (50%) 101 (52%) 6 (32%) 0.093
Height (cm) 167 11 167  12 166  8 0.75
Weight (kg) 74 13 74  13 76  12 0.50
Body mass index (kg/m2) 26.2  4.1 26.1 4.1 27.3  4.3 0.25
Body surface area (m2) 1.85  0.19 1.85 0.19 1.86  0.17 0.78
New York Heart Association class III or greater 175 (82%) 158 (81%) 17 (90%) 0.54
Previous cerebrovascular event 49 (23%) 47 (24%) 2 (11%) 0.26
Previous myocardial infarction 51 (24%) 49 (25%) 2 (11%) 0.26
Previous coronary artery bypass graft surgery 58 (27%) 55 (28%) 3 (16%) 0.25
Previous percutaneous coronary intervention 56 (26%) 51 (26%) 5 (26%) 1.0
Diabetes mellitus 50 (24%) 46 (24%) 4 (21%) 1.0
Hypertension 126 (59%) 116 (60%) 10 (53%) 0.56
Peripheral vascular disease 26 (21%) 24 (12%) 2 (11%) 1.0
Chronic obstructive pulmonary disease 60 (28%) 53 (27%) 7 (37%) 0.37
Creatinine 95 (76–123) 96 (77–123) 84 (66–112) 0.27
Glomerular filtration rate 57 20 57  20 58  18 0.86
Hemoglobin (g/dl) 12.3 1.7 12.3 1.7 12.1  1.2 0.62
Thrombocyte count 225 67 223  67 244  63 0.21
Prothrombin time (s) 14 8 14 8 14  3 0.89
International normalized ratio 1.21 1.01 1.22 1.05 1.16  0.28 0.83
Atrial fibrillation
All 64 (30%) 57 (29%) 7 (37%) 0.49
Chronic 44 (21%) 38 (20%) 6 (32%) 0.24
Paroxysmal 20 (9%) 19 (10%) 1 (5%) 1.0
Preprocedural rhythm
Atrial fibrillation 48 (23%) 44 (23%) 4 (21%) 1.0
Paced 10 (5%) 8 (4%) 2 (11%) 0.22
Porcelain aorta 45 (21%) 38 (20%) 7 (37%) 0.084
Aortic valve area (cm2) 0.66  0.21 0.66 0.22 0.61  0.16 0.33
Peak velocity 4.3  0.8 4.3  0.8 4.2  0.8 0.76
Mean aortic gradient 45 17 46  17 44  18 0.68
Left ventricular ejection fraction 35% 24 (14%) 23 (14%) 1 (6%) 0.70
Aortic regurgitation grade III or greater 42 (20%) 34 (17%) 8 (42%) 0.016
Mitral regurgitation grade III or greater 26 (12%) 23 (12%) 3 (16%) 0.71
Logistic European system for cardiac operative risk evaluation 13.8 (10.0–22.0) 13.8 (10.0–22.8) 12.0 (8.4–16.5) 0.14
Society of Thoracic Surgeon score 5.0 (3.4–7.5) 5.0 (3.4–7.3) 4.3 (3.5–7.5) 0.96
Antiplatelets 105 (49%) 96 (50%) 9 (47%) 1.0
Anticoagulants 67 (32%) 63 (33%) 4 (21%) 0.30
Data are expressed as mean  SD, median (IQR), or number of patients (%).
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performed during the hospital stay. All patients received
aspirin 80 mg and clopidogrel 75 mg for 6 months. Patients
with an indication for oral anticoagulant therapy only re-
ceived clopidogrel. In these patients, unfractionated heparin
was continued after TAVI until adequate INR levels were
obtained by acenocoumarol. In-hospital anticoagulant treat-
ment was guided by the prothombin time, INR and activated
partial thromboplastin time.
Stroke was defined according to the Valve Academic
Research Consortium end point definitions.18 This implies
the following: (1) exclusion of metabolic or toxic enceph-
alopathy or pharmacologic influences explaining the symp-
toms, in addition to a solely nonfocal neurologic syndrome,
(2) execution of a CT study to confirm the clinical diagno-
sis, (3) the distinction between stroke and transient ischemic
attack, and (4) classification of stroke as major or minor
according to the degree of disability (modified Rankin score
after the procedure and at 30 and 90 days). For patients in
whom a modified Rankin score was not documented during
the 3 intervals, a detailed chart review was performed to
estimate this and accurately classify strokes as major or
minor events.
The brain CT scan findings were analyzed using a
standard protocol.19 The cause of stroke was established
by (1) analyzing the time of symptom onset, (2) corre-
lating the symptoms with CT-detected defects in the
brain, and (3) analyzing the presence of potential coex-
isting causes of stroke, in addition to multivariate anal-
ysis to determine the independent predictors of stroke.
Infarcts were categorized as old or new, with the latter
Table 2
Procedural and postprocedural results of patients with and without stroke after transcatheter aortic valve implantation (TAVI)
Variable No Stroke
(n  195)
Stroke
(n  19)
p Value
Procedural results
Vascular access
Surgical—femoral artery 4 (2%) 0 1.0
Surgical—subclavian artery 6 (3%) 0 1.0
Percutaneous—femoral artery 185 (95%) 19 (100%) 0.25
Circulatory support 15 (8%) 3 (16%) 0.21
Additional interventions during TAVI
Percutaneous transluminal angioplasty iliac artery 6 (3%) 0 1.0
Percutaneous coronary intervention 15 (8%) 2 (11%) 0.65
Prosthesis size* (mm)
26 59 (30%) 9 (47%) 0.13
29 or 31 135 (69%) 10 (53%) 0.14
Valve/annulus ratio 1.15 0.08 1.16  0.08 0.73
Life-threatening arrhythmia 9 (5%) 0 1.0
Any complication leading to severe hypotension 4 (2%) 0 1.0
Highest activated clotting time (s) 284 87 283  64 0.97
Lowest activated clotting time (s) 221 72 231  73 0.65
Red blood cell transfusions 1.2 2.2 1.3  1.3 0.86
Hemoglobin decrease—uncorrected for red blood cell transfusion (g/dl) 2.0 1.3 2.1  1.0 0.82
Hemoglobin decrease—corrected for red blood cell transfusion (g/dl) 3.2 2.6 3.4  1.7 0.77
Thrombocyte decrease 60 45 60  36 0.98
Therapy-specific results
Postimplantion balloon dilation 34 (17%) 1 (5%) 0.33
Valve dislodgement† 19 (10%) 1 (5%) 1.0
Valve-in-valve implantation 10 (5%) 1 (5%) 1.0
Duration of procedure (min) 215 75 197  83 0.32
Postprocedural results
Activated partial thromboplastin time (s)‡ 128  92 133  92 0.85
Prosthetic-valve associated results
Permanent atrial fibrillation§ 40 (21%) 6 (33%) 0.23
New atrial fibrillation 17 (9%) 5 (26%) 0.032
New left bundle branch block 85 (46%) 6 (32%) 0.31
New permanent pacemaker 41 (21%) 2 (11%) 0.38
Echocardiography
Peak velocity 2.0  0.5 2.1  0.7 0.59
Mean aortic gradient 9 4 11 6 0.19
Aortic regurgitation grade III or greater 24 (12%) 3 (16%) 0.72
Mitral regurgitation grade III or greater 20 (10%) 3 (16%) 0.44
* One patient did not receive a valve because of aborted TAVI after failed introduction of 18F sheath.
† In all cases, the valve was recaptured and successfully implanted in a second attempt.
‡ Checked within 6 hours after the procedure.
§ Atrial fibrillation before, during, and after TAVI.
 Neither preprocedural nor a history of AF.
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further defined as cortical (territorial), cortical watershed,
or lacunar infarct.
With respect to the timing of stroke, a distinction was
made between stroke that occurred during versus after
TAVI. The first was considered directly related to the pro-
cedure itself (e.g., due to catheter manipulations or hemo-
dynamic changes) and the second was considered indirectly
related to the procedure but not to the procedure itself.
Stroke during TAVI was defined if the first sym-
ptoms and/or signs were detected 24 hours after termina-
tion of TAVI. Stroke after TAVI was defined when the first
symptoms and/or signs were detected 24 hours after ter-
mination of TAVI. The termination of TAVI was defined by
the time of vascular closure and hemostasis by either a
percutaneous closure device or surgically.
All pre-, intra-, and postprocedural and follow-up data
were prospectively collected and entered in a dedicated
database as previously described.17 Porcelain aorta was de-
fined as an extensive circumferential calcification of the
thoracic aorta, as assessed by computed tomography and/or
fluoroscopy.20 The blood coagulant status was assessed by
collecting the prothombin time, INR, and thrombocyte lev-
els before the procedure. The maximum and minimum ac-
tivated clotting time levels were documented during the
procedure, and the activated partial thromboplastin time
was checked within 6 hours after the procedure. Data on red
blood cell transfusions were recorded by the institution’s
blood bank laboratory and used to determine the corrected
hemoglobin decrease within 24 hours after TAVI according
to the modified Landefeld equation.21,22 In this equation, 1
U of packed red blood cells is considered to represent 1 g/dl
of hemoglobin; therefore, the net hemoglobin decrease cor-
responds to the addition of the number of packed red blood
cells to the baseline minus the measured nadir hemoglo-
bin level.
The occurrence and timing of new atrial fibrillation (AF)
after TAVI—defined as any episode of AF lasting 30
seconds in patients with no history of chronic/paroxysmal
AF—was determined by collecting the baseline and all
postoperative 12-lead ECGs and 24-hour telemetry rhythm
strips.23,24 Follow-up information was prospectively col-
lected during the structured outpatient clinic visits after
hospital discharge. In addition, the survival and cause of
death was obtained every 6 months by contacting the Dutch
Civil Register.
The categorical variables are presented as frequencies
and percentages and were compared using the chi-square
test or Fisher’s exact test. The normality of distributions was
assessed with the Shapiro-Wilk test. Normal and skewed
continuous variables are presented as the mean  SD and
median (interquartile range [IQR]), respectively. A compar-
ison of continuous variables was done using Student t tests
or Wilcoxon’s rank sum test, when appropriate. Univariate
analysis was performed to characterize the patients with
and without stroke. Multivariate logistic regression anal-
ysis was performed to determine the predictive factors for
stroke or transient ischemic attack, taking into account
the restricted number of events. Preprocedural AF rhythm
was included in the model. A 2-sided p value 0.05 was
considered to indicate significance, and all statistical
analyses were performed with SPSS software, version 17
(SPSS, Chicago, IL).
Results
The baseline characteristics and procedural details are
listed in Tables 1 and 2. The incidence of stroke was 9% (19
patients) and—in accordance with the Valve Academic Re-
search Consortium criteria—consisted of major stroke in 10
patients (5%), minor in 3 (1%), and transient ischemic
attack in 6 (3%).
In all patients, except 1, who experienced a subdural
hemorrhage (event number 18), the stroke was ischemic
(Table 3) and occurred early (24 hours after TAVI) in 8
patients (42%) and was delayed (24 hours, mean 3.5 days
after TAVI) in 11 (58%). CT scan analysis of the brain
revealed that stroke consisted of a cortical infarct in 8
patients (of which 4 were territorial and 2 were watershed)
and a lacunar infarct in 5. In descending order of odds, new
AF (odds ratio 4.4, 95% confidence interval 1.2 to 15.6) and
baseline aortic regurgitation grade III or greater (odds ratio
3.2, 95% confidence interval 1.1 to 9.3) were identified as
independent predictors. New AF occurred in 22 (14%) at a
median of 2 days (IQR 1 to 4.5) after TAVI and resolved
spontaneously within 12 hours in 8 patients (36%). Seven
patients (32%) received pharmacologic treatment (n 6) or
electric (n 1) conversion. Antithrombotic therapy (aspirin
and clopidogrel) without anticoagulant therapy was main-
tained in 7 patients (36%) in whom the risk of bleeding was
considered greater than the risk of thromboembolism. None
of the 5 patients with new AF who experienced a stroke had
received anticoagulant therapy.
The hospital or 30-day mortality rate in patients with a
stroke was 16% (n  3) and was 6% (n  15) in patients
without a stroke (p  0.14). The cause of death in these 3
patients was the neurologic event itself. Clinical follow-up
was complete for all patients (median 13 months, IQR 6 to
30). During follow-up, 3 patients developed a fatal stroke
(2 hemorrhagic, 1 uncertain) and 6, a nonfatal stroke (all
ischemic).
Discussion
The present study of 214 consecutive patients who un-
derwent TAVI has shown that a clinically manifest neuro-
logic impairment occurred in 19 patients (9%), with most
events (n  11; 58%) occurring 24 hours after TAVI at a
mean of 3.5 days. Furthermore, we found that new-onset
AF after TAVI was associated with a 4.4-fold greater risk
of stroke.
Our observation that most events occur after and not
during TAVI is consistent with the findings of the Canadian
multicenter TAVI registry (345 patients) in which proce-
dural stroke was reported in 0.6% of the patients and stroke
at 30 days in 2.3%.20 Supplementary information from the
Placement of AoRtic TraNscathetER Valves (PARTNER)
Cohort B study revealed that 5 of the 11 strokes occurred at
day 0 or 1 after TAVI (45%) and 6 (55%) at day 2 or later.2
Of note, in cardiac surgery, 65% of the neurologic events
are seen after the operation.11–13 In addition, patients un-
dergoing TAVI appear to be at a high risk of stroke, irre-
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spective of any intervention (cardiac or otherwise), as indi-
cated by the rather frequent occurrence of stroke during
follow-up, such as seen in this and other studies.2,25
That most strokes occurred after TAVI indicate that—in
a number of patients—there is no direct relation between the
intervention and the cerebral complication. These findings
suggest that clinical, rather than technical or procedural,
factors play a more important role in the occurrence of
stroke during TAVI and that, therefore, preventive measures
should, above all, be directed at improved postoperative
management. It also suggests that endovascular embolic
protection devices used during the procedure—if safe and
effective—might reduce the stroke rates in only about ½ of
the patients.26 This is further supported by the fact that 26%
of the strokes were lacunar, which is widely regarded as
caused by cerebral hypoperfusion in the presence of local
atherosclerosis. This implies that all efforts should be made
during TAVI to maintain adequate brain perfusion. In this
respect, TAVI without balloon valvuloplasty, such as pro-
posed by Grube et al,27 might be beneficial if this technique
does not induce the dislodgement of calcified atheroscle-
rotic emboli, while advancing the prosthesis in the aortic
annulus.27
The role of improved postoperative care is supported by
the finding that new AF after TAVI was the main determi-
nant of stroke. Because the present study lacks the power to
perform a comprehensive multivariate analysis, other fac-
tors might have remained undetected. The reason patients
with aortic regurgitation grade 3 before TAVI are at
increased risk of stroke remains to be elucidated. Although
this might be a finding by chance owing to the small sample
size and the absence of a pathophysiologic concept, these
patients possibly had a more impaired and/or dilated left
atrium, which is known to predict new AF after cardiac
surgery and also after TAVI.28,29 Scant information is avail-
able on new AF after TAVI. In the PARTNER cohort B
study, new AF was seen in 1 of the 151 patients with no
previous AF (0.7%), who underwent transfemoral TAVI.2
The incidence of new AF in the PARTNER Cohort A study
was 7.5% after transfemoral and 11.5% after transapical
TAVI.3 Similar to the results of Amat-Santos et al,29 who
found new AF in 16% of the patients undergoing transfemo-
ral TAVI, we found new AF in 22 (14%) of the 154 patients
with no previous AF.29 In accordance with the findings from
Amat-Santos et al,29 the data of our study also indicate that
suboptimal anticoagulant therapy in patients with new AF
plays a role in the occurrence of stroke because none of the
5 patients with new AF who experienced a stroke received
anticoagulant therapy. No clear guidelines are available on
anticoagulation therapy after short episodes of AF after
cardiac surgery.24 However, patients undergoing TAVI are
at high risk of thromboembolism when atrial fibrillation
occurs (median CHADS2 score 3 [IQR 2 to 4] in patients
with new AF). Therefore, immediate anticoagulant therapy
should probably be implemented in these patients on the
diagnosis of AF.
The results of the multivariate analysis must be inter-
preted in the context of the number of patients included in
the present study. In the control group, 17 of the 195
patients had new AF compared to 5 of the 19 in the stroke
group. One patient less or more in 1 group can significantly
affect the results of the analysis. However, it is quite con-
ceivable that new AF is an important cause of stroke in the
present reported patients, because new AF is known to be
associated with an increased risk of cardioembolism.29,30
New AF preceded the first signs of neurologic impairment
in all patients with an ischemic stroke (Table 3) and in 3 of
the 6 patients with a (territorial) cortical infarct—typically
of thrombotic origin—were preceded by new AF and no
patient with a lacunar infarct—typically not caused by a
large thrombus or embolus—had new AF after TAVI.
The main limitation of the present study was the number
of patients, thereby limiting the precision of the observed
point estimate of the incidence of stroke and the power and
robustness of the multivariate analysis. In particular, the
lack of statistical correction in the present study might have
influenced the significance of the predictors of stroke; there-
fore, these findings merit confirmation in larger series. Fur-
thermore, we lacked a standardized, complete diagnostic
workup for all patients with stroke. For instance, duplex or
angiography of the carotid and vertebral arteries was not
performed in the large majority of the present series of
patients.
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Luis Nombela-Franco, MD; John G. Webb, MD; Peter P. de Jaegere, MD, PhD;
Stefan Toggweiler, MD; Rutger-Jan Nuis, MSc; Antonio E. Dager, MD; Ignacio J. Amat-Santos, MD;
Anson Cheung, MD; Jian Ye, MD; Ronald K. Binder, MD; Robert M. van der Boon, MSc;
Nicolas Van Mieghem, MD; Luis M. Benitez, MD; Sergio Pe´rez, MD; Javier Lopez, MD, PhD;
Jose´ A. San Roman, MD, PhD; Daniel Doyle, MD; Robert DeLarochellie`re, MD; Marina Urena, MD;
Jonathon Leipsic, MD; Eric Dumont, MD; Josep Rode´s-Cabau, MD
Background—The objective of this study was to evaluate the timing, predictive factors, and prognostic value of
cerebrovascular events (CVEs) after transcatheter aortic valve implantation.
Methods and Results—The study included 1061 consecutive patients who underwent transcatheter aortic valve
implantation with a balloon-expandable (64%) or self-expandable (36%) valve. CVEs were classified as acute (24
hours), subacute (1–30 days), or late (30 days). CVEs occurred in 54 patients (5.1%; stroke, 4.2%) within 30 days after
transcatheter aortic valve implantation (acute in 54% of cases). The predictors of acute CVEs were balloon postdilation
of the valve prosthesis (odds ratio, 2.46; 95% confidence interval,1.07–5.67) and valve dislodgment/embolization (odds
ratio, 4.36; 95% CI, 1.21–15.69); new-onset atrial fibrillation (odds ratio, 2.76; 95% CI, 1.11–6.83) was a predictor of
subacute CVEs. Late CVEs occurred in 35 patients (3.3%; stroke, 2.1%) at a median follow-up of 12 months (3–23
months). The predictors of late CVEs were chronic atrial fibrillation (2.84; 95% CI, 1.46–5.53), peripheral vascular
disease (hazard ratio, 2.02; 95% CI, 1.02–3.97), and prior cerebrovascular disease (hazard ratio, 2.04; 95% CI,
1.01–4.15). Major stroke was associated with 30-day (odds ratio, 7.43; 95% CI, 2.45–22.53) and late (hazard ratio, 1.75;
95% CI, 1.01–3.04) mortality.
Conclusions—In a large cohort of patients undergoing transcatheter aortic valve implantation, the rates of acute and
subacute CVEs were 2.7% and 2.4%, respectively. While balloon postdilation and valve dislodgment/embolization were
the predictors of acute CVEs, new-onset atrial fibrillation determined a higher risk for subacute events. Late events were
determined mainly by a history of chronic atrial fibrillation and peripheral and cerebrovascular disease. The occurrence
of major stroke was associated with increased early and late mortality. These results provide important insights for the
implementation of preventive measures for CVEs after transcatheter aortic valve implantation. (Circulation. 2012;126:
3041-3053.)
Key Words: aortic valve stenosis  heart valve prosthesis implantation  heart valves  stroke
Transcatheter aortic valve implantation (TAVI) has re-cently emerged as the preferred therapy for inoperable
patients with severe aortic stenosis and as an alternative to
surgical aortic valve replacement in high-risk patients.1 Al-
though TAVI has been associated with a very high procedural
success rate, the occurrence of cerebrovascular events
(CVEs) has appeared to be one of the most worrisome
complications associated with these procedures. Several ce-
rebral magnetic resonance imaging studies have shown a very
high incidence (66%–86%) of new ischemic defects after
TAVI regardless of the transcatheter valve type (balloon-
expandable, self-expandable) and approach (transfemoral,
transapical).2 Although these new cerebral defects are silent
in most cases, the incidence of clinically apparent stroke after
TAVI has been3.5% (ranging from 1.2%–6.7%),3–11 one of
the highest ever reported in the field of interventional
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cardiology. In addition, the Placement of Aortic Transcathe-
ter Valve Trial (PARTNER) showed that TAVI was associ-
ated with a higher rate of CVEs compared with medical
treatment/balloon valvuloplasty or aortic valve replace-
ment.10,11 A better knowledge of the mechanisms determining
this high rate of CVEs after TAVI would therefore be crucial
for the implementation of appropriate preventive measures.
Transcranial Doppler studies have shown that cerebral emboli
can occur any time during the TAVI procedure but seem to be
more frequent during valve prosthesis positioning and im-
plantation.12–15 However, about half the periprocedural CVEs
occur 24 hours after the TAVI procedure,2 suggesting that
mechanisms other than those directly related to the catheter,
wire, and valve prosthesis manipulation are also involved in
the 30-day CVE rate. A few studies including a relatively
limited number of patients have suggested the presence of
smaller valve areas, balloon postdilation, multiple valve
implantation attempts, and atrial arrhythmias as factors de-
termining a higher rate of early CVEs after TAVI.16–20
However, the relatively low absolute number of events in
these studies might have precluded an accurate analysis of the
predictors of CVEs. In addition, no data exist on the baseline
and procedural variables associated with CVEs occurring in
the acute phase (24 hours) after TAVI compared with those
occurring later. Finally, it is well known that stroke signifi-
cantly affects survival and quality of life after aortic valve
replacement,21,22 but few data exist on the independent
prognostic value of this complication at short-term and
midterm follow-up in a large cohort of TAVI patients.7
Therefore, the objective of this study was to determine the
timing, predictive factors, and prognostic value of CVEs in a
large cohort of consecutive patients undergoing TAVI.
Editorial see p 2921
Clinical Perspective on p 3053
Methods
Study Population and TAVI Procedures
A total of 1061 consecutive patients with symptomatic severe aortic
stenosis who underwent TAVI with either balloon-expandable or
self-expandable valves in 5 centers were included (Figure 1).
Eligibility for TAVI was established at each center and based on the
consensus of a local multidisciplinary team composed of interven-
tional cardiologists and cardiac surgeons. Baseline clinical and
echocardiography data were prospectively gathered in each partici-
pating center. Comorbidities were defined according to the Society
of Thoracic Surgeons criteria. The degree of calcification of the
thoracic aorta was assessed by computed tomography and/or fluo-
roscopy, and the presence of severely calcified aorta was recorded in
all patients. The presence of complex atheroma aortic plaques was
determined by transesophageal echocardiography (data available in
689 patients) and defined as large plaques (4 mm in thickness),
plaques with ulceration, or mobile components.23 Selection of the
access route was based on the appropriateness of the iliofemoral axis.
The patients treated by transfemoral/subclavian approach received
dual antiplatelet therapy (aspirin plus clopidogrel) the day before
TAVI. The patients treated by transapical/transaortic approach re-
ceived single antiplatelet therapy (aspirin) before the procedure
except if the patient had a prior medical condition for which dual
antiplatelet therapy was required. Patients who were receiving oral
anticoagulation therapy were instructed to stop it 3 days before the
procedure, and single or dual antiplatelet therapy was administrated.
Intraprocedural anticoagulation was achieved by a dose of unfrac-
tionated heparin (70–100 U/kg) at the beginning of the procedure
and adjusted by activated clothing time (250 seconds) during the
procedure. Antithrombotic treatment after TAVI consisted of aspirin
(indefinitely) plus clopidogrel (3–6 months) unless contraindicated.
If anticoagulation was indicated for any other reason, oral anticoag-
ulant therapy was administered (with or without single or dual
Figure 1. Study flow diagram of patients who underwent transcatheter valve implantation of each participating center. IQR indicates
interquartile range.
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Table 1. Baseline Characteristics of the Study Population, Overall and According to the Occurrence of
30-Day Cerebrovascular Events After Transcatheter Aortic Valve Implantation
Variables All (n1061)
30-Day Cerebrovascular Event
PYes (n54) No (n1007)
Baseline variables
Age, y 818 826 818 0.155
Male sex, n (%) 538 (50.7) 22 (40.7) 516 (51.2) 0.133
BMI, kg/m2 26.05.0 26.74.7 26.05.0 0.337
Diabetes mellitus, n (%) 312 (29.4) 22 (40.7) 290 (28.8) 0.061
Previous heart failure, n (%) 721 (68.0) 32 (59.3) 689 (68.4) 0.160
Hypertension, n (%) 790 (74.5) 39 (72.2) 751 (74.6) 0.699
NYHA functional class III–IV, n (%) 886 (83.5) 49 (90.7) 837 (83.1) 0.141
Chronic atrial fibrillation, n (%) 276 (26.0) 15 (27.8) 261 (25.9) 0.765
Coronary artery disease, n (%) 686 (64.7) 32 (59.3) 654 (64.9) 0.394
Previous myocardial infarction, n (%) 377 (35.6) 16 (29.6) 361 (35.9) 0.347
Prior CABG, n (%) 320 (30.2) 14 (25.9) 306 (30.4) 0.486
Cerebrovascular disease, n (%) 191 (18.1) 9 (16.7) 182 (18.2) 0.778
Peripheral vascular disease, n (%) 278 (26.2) 9 (16.7) 269 (26.7) 0.116
COPD, n (%) 310 (29.2) 19 (35.2) 291 (28.9) 0.322
Severely calcified aorta, n (%) 193 (18.4) 14 (25.9) 179 (18.0) 0.142
eGFR, mg/min 60.127.8 58.843.3 60.226.7 0.726
STS-PROM score, % 6.5 (4.3–9.7) 6.4 (3.8–10.4) 6.5 (4.4–9.7) 0.578
CHADS2 score 2.91.2 3.01.3 2.91.2 0.711
Echocardiography data
Mean aortic gradient, mm Hg 4316 4618 4316 0.281
Aortic valve area, cm2 0.660.19 0.610.18 0.660.19 0.110
LVEF 40%, n (%) 235 (22.1) 8 (14.8) 227 (22.5) 0.193
Complex aortic plaques†, n (%) 119 (17.3) 6 (21.4) 113 (17.1) 0.608
Periprocedural data, n (%)
Learning curve* 0.098
First half 532 (50.1) 33 (6.2) 499 (93.8)
Second half 529 (49.9) 21 (4.0) 508 (96.0)
Approach 0.722
Transfemoral 726 (68.4) 40 (74.1) 686 (68.1)
Transapical 322 (30.3) 14 (25.9) 308 (30.6)
Subclavian 9 (0.8) 0 9 (0.9)
Transaortic 4 (0.4) 0 4 (0.4)
Prosthesis type 0.236
Cribier-Edwards 57 (5.4) 3 (5.6) 54 (5.4)
Edwards Sapien 388 (36.6) 20 (37.0) 368 (36.5)
Sapien XT 234 (22.1) 6 (11.1) 228 (22.6)
CoreValve (second generation) 5 (0.5) 0 5 (0.5)
CoreValve (third generation) 349 (32.9) 24 (44.4) 325 (32.3)
St. Jude Portico 7 (0.7) 1 (1.9) 6 (0.6)
Prosthesis size, mm 0.981
20 3 (0.3) 0 3 (0.3)
23 305 (29.3) 15 (27.8) 290 (29.4)
26 502 (48.3) 28 (51.9) 474 (48.1)
29 228 (21.9) 11 (20.4) 217 (22.0)
31 2 (0.2) 0 2 (0.2)
(Continued)
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antiplatelet therapy). Data on procedural success and periprocedural
complications defined according to the Valve Academic Research
Consortium (VARC) criteria were prospectively collected in each
participating center.24
Cerebrovascular Events
Cerebrovascular events were defined according to the VARC criteria
and categorized as transient ischemic attack or stroke.24 Transient
ischemic attack was defined as an episode of neurological dysfunc-
tion that lasted 24 hours without association of cerebral infarction
on imaging. Clinical stroke was defined as an acute neurological
dysfunction lasting 24 hours and/or with evidence of infarction on
imaging and further classified according to the modified Rankin
Scale as major stroke (modified Rankin Scale score 2 at 30 days)
or minor stroke (modified Rankin Scale score 2 at 30 days). The
modified Rankin Scale was calculated prospectively on the publica-
tion of the VARC definitions (January 2011; 21% of the study
population) and retrospectively in patients undergoing TAVI before
the publication of the VARC definitions.24 A detailed chart review
was done to calculate the modified Rankin Scale score and to classify
strokes as major or minor events. CVEs were also classified
according to the timing with respect to the TAVI procedure as acute
(24 hours), subacute (1–30 days), and late (30 days) events. The
diagnosis of CVE was always confirmed by a neurologist, and a
neuroimaging procedure was performed in all cases.
Follow-Up
Clinical follow-up and postdischarge events were carried out in
clinical visits and/or through phone contact. Referring cardiologists,
general practitioners, and patients’ families were contacted whenever
necessary for further information. Patients were followed up at 1 to
3 months, at 12 months, and yearly thereafter in all participating
centers. Mortality and the occurrence of CVEs at any time during the
follow-up period were prospectively recorded by each participating
center. All clinical events were defined according to the VARC
criteria.24
Table 1. Continued
Variables
All
(n1061)
30-Day Cerebrovascular Event
PYes (n54) No (n1007)
Ratio of prosthesis size to annulus size 1.130.08 1.130.07 1.130.08 0.909
Balloon postdilation 189 (17.8) 16 (29.6) 173 (17.2) 0.020
Valve dislodgment/embolization 44 (4.1) 4 (7.4) 40 (4.0) 0.217
Need for a second valve 33 (3.1) 2 (3.7) 31 (3.1) 0.797
Need for hemodynamic support or severe
maintained hypotension
54 (5.1) 4 (7.4) 50 (5.0) 0.431
Major vascular complication 100 (9.4) 3 (5.6) 97 (9.6) 0.318
New-onset atrial fibrillation 127 (12.0) 12 (22.2) 115 (11.4) 0.017
Antithrombotic treatment, n (%)
Baseline 0.135
None 156 (14.7) 13 (24.1) 143 (14.2)
Single antiplatelet therapy 431 (40.6) 22 (40.7) 409 (40.6)
Dual antiplatelet therapy 163 (15.4) 5 (9.3) 158 (15.7)
Anticoagulation therapy 187 (17.6) 7 (13.0) 180 (17.9)
Single antiplateletanticoagulation therapy 111 (10.5) 5 (9.3) 106 (10.5)
Triple therapy 13 (1.2) 2 (3.7) 11 (1.1)
Discharge 0.379
None 18 (1.8) 1 (2.1) 17 (1.8)
Single antiplatelet therapy 84 (8.5) 1 (2.1) 83 (8.9)
Dual antiplatelet therapy 539 (54.8) 26 (54.2) 513 (54.8)
Anticoagulation therapy 54 (5.5) 5 (10.4) 49 (5.2)
Single antiplateletanticoagulation therapy 249 (25.3) 12 (25.0) 237 (25.3)
Triple therapy 40 (4.1) 3 (6.3) 37 (4.0)
30-d Follow-up 0.160
None 11 (1.2) 1 (2.3) 10 (1.2)
Single antiplatelet therapy 75 (8.4) 1 (2.3) 74 (8.7)
Dual antiplatelet therapy 492 (55.0) 22 (50.0) 470 (55.2)
Anticoagulation therapy 56 (6.3) 6 (13.6) 50 (5.9)
Single antiplateletanticoagulation therapy 228 (25.5) 11 (25.0) 217 (25.5)
Triple therapy 33 (3.7) 3 (6.8) 30 (3.5)
BMI indicates body mass index; NYHA, New York Heart Association; CABG, coronary artery bypass graft; COPD, chronic obstructive
pulmonary disease; eGFR, estimated glomerular filtration rate; STS-PROM, Society of Thoracic Surgeons predicted risk of mortality;
and LVEF, left ventricular ejection fraction. Data are presented as meanSD or median (interquartile range) as appropriate.
*First versus second cohort of patients in each participating center.
†Data available in 689 patients.
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Statistical Analysis
Categorical variables were expressed as percentages and continuous
variables as mean (standard deviation) or median (25th–75 percen-
tile) when not normally distributed. The normality distribution for
continuous data was verified with the Shapiro-Wilk test. Comparison
of numeric variables was performed by use of the 2-sided Student t
test or Wilcoxon rank-sum test if necessary, and the 2 or Fischer
exact test was used to compare qualitative variables. Variables with
a value of P0.10 in the univariate analysis were entered into a
logistic regression analysis to determine the independent predictors
of 30-day, acute, and subacute CVEs. Patients with acute (24
hours) CVEs or death were excluded from the analysis of the
predictors of subacute CVEs. Univariate and multivariate
competing-risk (mortality not related to CVE) regression analyses
were done to determine the predictors of late CVEs (landmark
analysis starting at 31 days, excluding patients with 30-day CVE or
mortality) and cumulative CVEs (analysis starting at the time of the
procedure). The association between CVE and mortality was as-
sessed with the use of multivariate logistic regression (30-day
mortality) or Cox proportional hazards (cumulative mortality) anal-
yses including the variables with a value of P0.05 in the univariate
analysis. Freedom from CVE and mortality curves were calculated
with the Kaplan-Meier method, and comparison between groups was
obtained with the log-rank test. A value of P0.05 was considered
significant for all statistical tests. Analyses were done with the SAS
statistical package, version 9.2 (SAS Institute Inc, Cary, NC).
Results
Baseline and procedural characteristics of the study popula-
tion are shown in Table 1. Transfemoral approach was the
access route in 726 patients (68.4%); transapical approach, in
322 patients (30.3%). At least 1 valve was implanted in 1040
patients (98%). The reasons that a valve could not be
deployed are detailed in Table I in the online-only Data
Supplement.
A total of 54 patients (5.1%) had a CVE within 30 days
after the TAVI procedure, and the type of CVE was distrib-
uted as follows: stroke, 45 (4.2%); major stroke, 30 (2.8%);
minor stroke, 15 (1.4%); and transient ischemic attack, 9
(0.8%). The stroke was of ischemic origin in all but 2 patients
who experienced a hemorrhagic stroke confirmed by com-
puted tomography. There were no significant differences in
stroke rate between centers (P0.59). The temporal distribu-
tion of CVEs is shown in Figure 2. A total of 29 of the 54
CVEs (54%) were acute (within 24 hours after TAVI) and 25
CVEs were subacute (1–30 days after TAVI). Details on
antithrombotic treatment for all patients who suffered a CVE
within 30 days are provided in Table II in the online-only
Data Supplement.
Predictors of 30-Day (Acute and Subacute) CVEs
Baseline and procedural characteristics, grouped according to
the occurrence of a CVE at 30 days, at24 hours (acute), and
at 1 to 30 days (subacute), are shown in Tables 1, 2, and 3,
respectively. The results of univariate and multivariate anal-
yses to determine the predictors of acute, subacute, and
30-day CVEs are shown in Table 4. New-onset atrial fibril-
lation (NOAF; odds ratio [OR], 2.27; 95% confidence inter-
val [CI], 1.15–4.48; P0.018) and balloon postdilation (OR,
1.94; 95% CI, 1.05–3.60; P0.034) were the 2 independent
predictors of CVEs within 30 days after the procedure (Table
4). The type of valve and approach did not affect the rate of
CVE. Whereas balloon postdilation (OR, 2.46; 95% CI,
1.07–5.67; P0.034) and valve embolization/dislodgment
(OR, 4.36; 95% CI, 1.21–15.69; P0.024) were the predic-
tors of acute CVEs, NOAF was the only predictor of subacute
CVEs after TAVI (OR, 2.76; 95% CI, 1.11–6.83; P0.028).
Late (>30 Days) CVEs
The cumulative incidence of CVEs was 8.4% (n89) at a
median follow-up of 12 months (3–23 months). During the
follow-up period, CVEs occurred in a total of 35 patients
(3.3%; stroke, 2.1%), and 25 and 10 of them occurred at 1 to
12 and 12 months after TAVI, respectively. Stroke was
diagnosed in 22 patients (16 ischemic, 6 hemorrhagic) and
transient ischemic attack was diagnosed in 13 patients during
the follow-up period. There were no differences in the rates of
late stroke between participating centers (P0.92). Details on
antithrombotic treatment for all patients who suffered a late
CVE are provided in Table III in the online-only Data
Supplement. The Kaplan-Meier curves at the 1-year
follow-up showing freedom from CVE, stroke, and major
stroke are shown in Figure 3.
Baseline and procedural characteristics of the study popu-
lation, grouped according to the occurrence of late CVEs and
cumulative CVEs, are shown in Tables IV and V in the
online-only Data Supplement. Results of the univariate and
multivariate analyses to determine the predictors of late and
cumulative CVEs are shown in Table 5.
Prognostic Value of 30-day CVEs
A total of 92 patients (8.7%) died within 30 days after the
TAVI procedure, and 309 patients (29.1%) died during the
follow-up period. The Kaplan-Meier survival curves up to
the 1-year follow-up are shown in Figure 4. The occurrence
of CVEs (16.7% versus 8.2%; P0.044), stroke (20.0%
versus 8.2%; P0.012), and major stroke (30.0% versus
8.1%; P0.001) was associated with a higher mortality rate
at 30 days. The occurrence of 30-day stroke (33.1% versus
22.1%; P0.041) or major stroke (41.6% versus 22.1%;
P0.003), but not CVEs (29.7% versus 22.2%; P0.152),
was associated with a higher 1-year mortality. The Kaplan-
Meier survival curves at the 1-year follow-up according to the
Figure 2. Timing of cerebrovascular events (CVEs) within 30
days after transcatheter aortic valve implantation. TIA indicates
transient ischemic attack.
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occurrence of 30-day CVE, stroke, and major stroke are
shown in Figure 4. The predictors of 30-day and cumulative
mortality within the univariate and multivariate analyses are
shown in Tables 6 and 7. Major stroke at 30 days was an
independent predictor of mortality at 30 days (OR, 7.43; 95%
CI, 2.45–22.53; P0.001) and at follow-up (hazard ratio,
1.75; 95% CI, 1.01–3.04; P0.043).
Discussion
In a large cohort of patients who underwent TAVI, the overall
incidence of 30-day CVEs, regardless of valve type or access
route, was 5.1% (stroke, 4.2%), with about half of these
events occurring immediately or within the first few hours
after the procedure. The predictors of acute (24 hours)
events were mechanical factors such us balloon postdilation
of the valve prosthesis and the occurrence of valve dislodg-
ment/embolization, whereas atrial arrhythmias (NOAF) de-
termined mainly the events occurring in the subacute period
(days 1–30) after the procedure. Late (30 days) CVEs
occurred in 3.3% of the patients (stroke, 2.1%) after a median
follow-up of 12 months and were determined mainly by a
history of chronic atrial fibrillation, peripheral vascular dis-
ease, and prior cerebrovascular disease. Major stroke at 30
days was associated with a higher mortality rate at 30 days
and at follow-up.
Table 2. Baseline and Procedural Characteristics, According
to the Occurrence of Acute (<24 Hours) Cerebrovascular
Events After Transcatheter Aortic Valve Implantation
Variables
Acute Cerebrovascular Event
PYes (n29) No (n1032)
Baseline variables
Age, y 826 818 0.269
Male sex, n (%) 12 (41.4) 526 (51.0) 0.308
BMI, kg/m2 27.15.1 26.05.0 0.235
Diabetes mellitus, n (%) 10 (34.5) 302 (29.3) 0.543
Previous heart failure, n (%) 17 (58.6) 704 (68.2) 0.275
Hypertension, n (%) 21 (72.4) 769 (74.5) 0.798
NYHA functional class III–IV, n (%) 28 (96.6) 858 (83.1) 0.071
Chronic atrial fibrillation, n (%) 7 (24.1) 269 (26.1) 0.813
Coronary artery disease, n (%) 16 (55.2) 670 (64.9) 0.279
Previous myocardial infarction,
n (%)
7 (24.1) 370 (35.9) 0.191
Prior CABG, n (%) 7 (24.1) 313 (30.3) 0.474
Cerebrovascular disease, n (%) 5 (17.2) 186 (18.0) 0.903
Peripheral vascular disease,
n (%)
5 (17.2) 273 (26.5) 0.308
COPD, n (%) 11 (37.9) 299 (29.0) 0.295
Severely calcified aorta, n (%) 5 (17.2) 188 (18.2) 0.872
eGFR, mg/min 58.843.3 60.127.8 0.405
STS score, % 5.6 (3.9–9.3) 6.5 (4.3–9.7) 0.459
CHADS2 score 2.91.1 2.91.2 0.900
Echocardiography data
Mean aortic gradient, mm Hg 4920 4316 0.147
Aortic valve area, cm2 0.590.15 0.660.19 0.086
LVEF 40%, n (%) 3 (10.3) 232 (22.5) 0.134
Complex aortic plaques†, n (%) 4 (25.0) 115 (17.1) 0.498
Periprocedural data, n (%)
Learning curve* 0.354
First half 17 (3.2) 515 (96.8)
Second half 12 (2.3) 517 (97.7)
Approach 0.615
Transfemoral 23 (79.3) 703 (68.1)
Transapical 6 (20.7) 316 (30.6)
Subclavian 0 9 (0.9)
Transaortic 0 4 (0.4)
Prosthesis type 0.313
Cribier-Edwards 1 (3.4) 56 (5.4)
Edwards Sapien 13 (44.8) 375 (36.3)
Sapien XT 3 (10.3) 231 (22.4)
CoreValve (second generation) 0 5 (0.5)
CoreValve (third generation) 11 (37.9) 338 (32.8)
St. Jude Portico 1 (3.4) 6 (0.6)
Prosthesis size, mm 0.950
20 0 3 (0.3)
23 10 (34.5) 295 (29.2)
26 14 (48.3) 488 (48.3)
29 5 (17.2) 223 (22.1)
31 0 2 (0.2)
(Continued)
Table 2. Continued
Variables
Acute Cerebrovascular Event
PYes (n29) No (n1032)
Ratio of prosthesis size to
annulus size
1.120.07 1.130.08 0.534
Balloon postdilation 10 (34.5) 179 (17.3) 0.017
Valve
dislodgment/embolization
4 (13.8) 40 (3.9) 0.029
Need for a second valve 2 (6.9) 31 (3.0) 0.227
Need for hemodynamic
support or severe maintained
hypotension
3 (10.3) 51 (4.9) 0.181
Major vascular complication 3 (10.3) 97 (9.4) 0.749
New-onset atrial fibrillation 5 (17.2) 122 (11.8) 0.375
Antithrombotic treatment, n (%)
Baseline 0.209
None 8 (27.6) 148 (14.3)
Single antiplatelet therapy 10 (34.5) 421 (40.8)
Dual antiplatelet therapy 4 (13.8) 159 (15.4)
Anticoagulation therapy 2 (6.9) 185 (17.9)
Single antiplatelet
anticoagulation therapy
4 (13.8) 107 (10.4)
Triple therapy 1 (3.4) 12 (1.2)
BMI indicates body mass index; NYHA, New York Heart Association; CABG,
coronary artery bypass graft; COPD, chronic obstructive pulmonary disease;
eGFR, estimated glomerular filtration rate; STS, Society of Thoracic Surgeons;
and LVEF, left ventricular ejection fraction. Data are presented as meanSD or
median (interquartile range) as appropriate.
*First versus second cohort of patients in each participating center.
†Data available in 689 patients.
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CVEs at 30 Days
The 5.1% rate of CVEs at 30 days, with a 4.2% stroke rate,
is consistent with the rates reported in registries (stroke,
3.5%, ranging from 1.7%–4.1%),3–8 in a recent meta-anal-
ysis (3.31.8%),9 and in the PARTNER trial (cohort A:
5.5%; stroke, 4.7%; cohort B: 6.7%; stroke, 6.7%).10,11 In
addition, some preliminary data suggested that about half of the
CVEs occur during or very early after the procedure (24
Table 3. Baseline and Procedural Characteristics, According
to the Occurrence of Subacute (1–30 Days) Cerebrovascular
Events After Transcatheter Aortic Valve Implantation
Variables
Subacute
Cerebrovascular Event
PYes (n25) No (n992)
Baseline variables, n (%)
Age, y 826 818 0.377
Male sex, n (%) 10 (40.0) 513 (51.7) 0.247
BMI, kg/m2 26.24.3 26.05.0 0.882
Diabetes mellitus, n (%) 12 (48.0) 287 (28.9) 0.039
Previous heart failure, n (%) 15 (60.0) 680 (68.5) 0.364
Hypertension, n (%) 18 (72.0) 741 (74.7) 0.759
NYHA functional class III–IV, n (%) 21 (84.0) 826 (83.3) 0.923
Chronic atrial fibrillation, n (%) 8 (32.0) 257 (25.9) 0.495
Coronary artery disease, n (%) 16 (64.0) 650 (65.5) 0.874
Previous myocardial infarction,
n (%)
9 (36.0) 359 (36.2) 0.978
Prior CABG, n (%) 7 (28.0) 305 (30.7) 0.769
Cerebrovascular disease, n (%) 4 (16.0) 181 (18.2) 0.763
Peripheral vascular disease,
n (%)
4 (16.0) 264 (26.6) 0.234
COPD, n (%) 8 (32.0) 287 (28.9) 0.738
Severely calcified aorta, n (%) 9 (36.0) 175 (17.6) 0.032
eGFR, mg/min 62.240.1 60.326.7 0.737
STS score, % 6.5 (3.8–10.9) 6.5 (4.3–9.6) 0.986
CHADS2 score 3.001.58 2.911.22 0.707
Echocardiography data
Mean aortic gradient, mm Hg 4215 4317 0.734
Aortic valve area, cm2 0.640.21 0.660.19 0.560
LVEF 40%, n (%) 5 (20.0) 223 (22.5) 0.753
Complex aortic plaques†, n (%) 2 (16.7) 113 (17.3) 0.956
Periprocedural data, n (%)
Learning curve* 0.144
First half 16 (3.2) 488 (96.8)
Second half 9 (1.8) 504 (98.2)
Approach 0.957
Transfemoral 17 (68.0) 676 (68.1)
Transapical 8 (32.0) 304 (30.6)
Subclavian 0 8 (0.9)
Transaortic 0 4 (0.4)
Prosthesis type 0.447
Cribier-Edwards 2 (8.0) 54 (5.4)
Edwards Sapien 7 (28.0) 363 (36.6)
Sapien XT 3 (12.0) 228 (23.0)
CoreValve (second generation) 0 5 (0.5)
CoreValve (third generation) 13 (52.0) 318 (32.1)
St. Jude Portico 0 6 (0.6)
Prosthesis size, mm 0.879
20 0 3 (0.3)
23 5 (20.0) 285 (29.3)
26 14 (56.0) 470 (48.3)
29 6 (24.0) 214 (22.0)
31 0 2 (0.2)
(Continued)
Table 3. Continued
Variables
Subacute
Cerebrovascular Event
PYes (n25) No (n992)
Ratio of prosthesis size to
annulus size
1.150.06 1.130.08 0.406
Balloon postdilation 6 (24.0) 172 (17.3) 0.421
Valve dislodgment/
embolization
0 38 (3.8) 0.381
Need for a second valve 0 30 (3.0) 0.469
Need for hemodynamic
support or severe maintained
hypotension
1 (4.0) 44 (4.5) 1.000
Major vascular complications 0 93 (9.4) 0.158
New-onset atrial fibrillation 7 (28.0) 115 (11.6) 0.023
Antithrombotic treatment, n (%)
Baseline 0.309
None 5 (20.0) 139 (14.0)
Single antiplatelet therapy 12 (48.0) 402 (40.5)
Dual antiplatelet therapy 1 (4.0) 157 (15.8)
Anticoagulation therapy 5 (20.0) 177 (17.8)
Single antiplatelet
anticoagulation therapy
1 (4.0) 106 (10.7)
Triple therapy 1 (4.0) 11 (1.1)
Discharge 0.210
None 0 (0) 17 (1.8)
Single antiplatelet therapy 0 (0) 83 (8.9)
Dual antiplatelet therapy 9 (40.9) 513 (54.8)
Anticoagulation therapy 2 (9.1) 49 (5.2)
Single antiplatelet
anticoagulation therapy
9 (40.9) 237 (25.3)
Triple therapy 2 (9.1) 37 (4.0)
30-d Follow-up 0.162
None 0 (0) 10 (1.2)
Single antiplatelet therapy 0 (0) 74 (8.7)
Dual antiplatelet therapy 9 (40.9) 470 (55.2)
Anticoagulation therapy 3 (13.6) 50 (5.9)
Single antiplatelet
anticoagulation therapy
8 (36.4) 217 (25.5)
Triple therapy 2 (9.1) 30 (3.5)
BMI indicates body mass index; NYHA, New York Heart Association; CABG,
coronary artery bypass graft; COPD, chronic obstructive pulmonary disease;
eGFR, estimated glomerular filtration rate; STS, Society of Thoracic Surgeons;
and LVEF, left ventricular ejection fraction. Data are presented as meanSD or
median (interquartile range) as appropriate.
*First versus second cohort of patients in each participating center.
†Data available in 689 patients.
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hours),10,18,25 and our analysis of a large number of patients
including different valve types and approaches confirms this
high risk of CVEs in the very early period after TAVI.
The present study shows that both procedural mechanical
factors such as balloon postdilation and atrial arrhythmias
were the main predictors of CVEs within 30 days after the
TAVI procedure, but the temporal trends for the increased
embolic risk associated with these 2 factors were very
different. While balloon postdilation determined a higher risk
of acute (24 hours) events, the occurrence of atrial arrhyth-
mias was associated with a higher risk of subacute (days
1–30) events. Transcranial Doppler studies have shown that
most cerebral high-intensity transient signals occur during
valve positioning and implantation,12–15 suggesting that the
mechanical interaction between the transcatheter valve and
the calcified native aortic valve plays a major role in
periprocedural cerebral emboli. Miller et al16 showed that
patients with smaller valve areas had a higher risk of CVEs in
the early period after TAVI (up to 7 days after the procedure),
which indirectly supports the role of the calcified native valve
in postprocedural CVEs, especially in view of the good
correlation between the degree of valve calcification and
aortic stenosis severity.26 The presence of a smaller valve area
showed a clear tendency toward a higher rate of acute events
in our study, although this variable was not found to be an
independent predictor of CVEs in the multivariable analysis.
Balloon postdilation is used in about one fourth of the
patients after valve prosthesis implantation, with the objective
of reducing residual aortic regurgitation secondary to paraval-
vular leaks.27–29 Preliminary data suggested an increase in
CVEs with balloon postdilation,17 and the results of the
present study confirm that the further stretching of the
calcified native valve during balloon postdilation is indepen-
dently associated with a 2-fold risk of CVEs immediately
or within the first few hours after the procedure. Balloon
postdilation increases the interaction between the stent frame
of the valve prosthesis and the native aortic valve, which might
indeed favor the dislodgment of calcific particles from the native
valve. The results of our study suggest that balloon postdilation
should probably be limited to those patients with a more
significant paravalvular leak. The study also highlights the
importance of an appropriate sizing of the aortic annulus to
avoid the implantation of undersized valves requiring further
balloon postdilation and the development of valve prostheses
with antiparavalvular leak properties. Finally, the use of embolic
protection devices may be of particular importance in patients
requiring balloon postdilation.30–32
Valve dislodgment and/or embolization occurred in up to
4.1% of the patients in this study. Valve dislodgment has
been described mostly for the self-expandable CoreValve
system; it is usually managed by pulling back the partially
deployed valve through the aortic arch and descending aorta
up to the 18F iliofemoral sheath.33 Valve prosthesis emboli-
zation occurs mainly toward the ascending aorta; the valve
prosthesis is usually removed up to the aortic arch or
descending aorta with the use of an inflated balloon within
the valve or by snaring the prosthesis stent frame.34,35 All
these maneuvers are associated with significant mechanical
friction between the prosthesis frame and the aortic wall and
are potentially highly thromboembolic. This study shows, for
the first time, that this complication is associated with a high
risk of periprocedural acute CVEs and highlights the impor-
tance of accurate valve positioning and implantation to avoid
this complication. In addition, the development of valve
prostheses that can be fully recaptured in case of valve
malpositioning may contribute to reducing this complication.
NOAF is a well-known complication associated with
cardiac surgery, and its occurrence has been associated with
Table 4. Univariate and Multivariate Predictors of Cerebrovascular Events Within 30 Days After
Transcatheter Aortic Valve Implantation
Variable
Univariate Analysis Multivariate Analysis
OR (95% CI) P OR (95% CI) P
Predictors of 30-d cerebrovascular events
New-onset atrial fibrillation 2.21 (1.13–4.33) 0.017 2.27 (1.15–4.48) 0.018
Balloon postdilation 1.95 (1.06–3.58) 0.020 1.94 (1.05–3.60) 0.034
Diabetes mellitus 1.70 (0.97–2.97) 0.061 1.76 (0.97–3.10) 0.055
Learning curve (second half) 0.62 (0.36–1.09) 0.098 0.62 (0.35–1.10) 0.105
Predictors of acute (24 h)
cerebrovascular events
Balloon postdilation 2.51 (1.15–5.49) 0.017 2.46 (1.07–5.67) 0.034
Valve dislodgment/embolization 3.97 (1.32–11.94) 0.029 4.36 (1.21–15.69) 0.024
Aortic valve area (per 0.1-cm2 decrease) 1.21 (0.97–1.53) 0.086 1.22 (0.96–1.53) 0.097
NYHA functional class III–IV 5.68 (0.77–42.01) 0.071 5.06 (0.68–37.77) 0.114
Predictors of subacute (1-d–30-d)
cerebrovascular events
New-onset atrial fibrillation 2.96 (1.21–7.25) 0.023 2.76 (1.11–6.83) 0.028
Severely calcified aorta 2.59 (1.13–5.97) 0.032 2.28 (0.98–5.30) 0.056
Diabetes mellitus 2.27 (1.02–5.03) 0.039 2.17 (0.97–4.84) 0.060
OR indicates odds ratio; CI, confidence interval; and NYHA, New York Heart Association.
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a higher rate of periprocedural CVEs and cardiac mortality.36
NOAF occurred in 12% of the patients in the present study
(18% after exclusion of those patients with prior chronic
atrial fibrillation), which is similar to the 15% rate observed
in the PARTNER trial among those patients with no prior
history of AF.11 Two recent studies in the TAVI field
including a relatively low number of patients suggested an
increased risk of CVEs when NOAF occurs as a complication
of the TAVI procedure.19,20 The results of the present study
confirm these preliminary findings in a large cohort of
patients and using an appropriate multivariate model for
determining predictive factors for CVEs. Of note, this com-
plication was found to be the one mainly responsible for those
CVEs occurring in the subacute phase (1–30 days) of the
postprocedural period, suggesting that improvements in both
the prevention of atrial arrhythmias and antithrombotic treat-
ment after the procedures should play a role in the reduction
of the 30-day CVE rate associated with TAVI.
Previous studies with magnetic resonance imaging or
transcranial Doppler have shown a similar incidence of silent
new ischemic lesions or transient signals, respectively, be-
tween transfemoral or transapical approaches, and clinical
studies have failed to show any significant differences in
CVE rate between the 2 approaches.2–11 The results of our
study are consistent with these previous data and indirectly
support the interaction between valve prosthesis and the
native aortic valve as the main mechanism of CVE during
TAVI procedures. Also in accordance with previous stud-
ies,2–11 similar rates of CVEs were observed with the use of
balloon-expandable and self-expandable transcatheter valves.
Late CVEs
The incidence of late (30-day) CVEs, stroke, and major
stroke was 3.3%, 2.1%, and 1.7%, respectively. This is
similar to the late CVE and stroke rates reported in the
PARTNER trial.10,11 Miller et al16 showed that patients with
prior stroke and “nontransfemoral candidates” had a higher
rate of late CVEs after TAVI. The present study shows, for
the first time, that chronic atrial fibrillation was the main
predictor of late CVEs, in addition to both peripheral vascular
disease and prior cerebrovascular disease. Therefore, the
factors associated with these late events reflect the back-
ground risks of this population and make it highly unlikely
that late CVEs after TAVI could be related to the valve
prosthesis or the procedure per se. In accordance with these
results, TAVI was not found to be a significant risk factor for
late neurological events in the PARTNER trial.16 The popu-
lation undergoing TAVI nowadays consists of patients of
advanced age with several comorbidities, which increases the
risk for CVEs in the follow-up period. The stroke rate
increases with each decade of life, reaching a rate of1.9%/y
in patients 85 years of age, comparable to our late stroke
rate of 2.1%, in a population with a lower risk profile than
TAVI candidates.37 More than 25% of our study population
had chronic atrial fibrillation, which is a known risk factor for
future CVEs even with anticoagulant therapy, with an inci-
dence of 2.4%/y in patients on warfarin treatment.38 Indeed,
the median CHADS2 score of our study population was 3,
which emphasizes the importance of an appropriate antico-
agulation treatment in such patients. However, up to 6
patients with late CVEs presented with hemorrhagic stroke
(27% of late strokes), also highlighting the difficult equilib-
rium between ischemic and bleeding events in this very old
and high-risk population.
Prognosis of CVE
Several studies have demonstrated the poorer short- and
long-term outcomes of patients who suffer a stroke after
aortic valve replacement.22,39 Although data on CVEs and
outcomes in TAVI patients are very limited, in a substudy of
the PARTNER trial,16 mortality in TAVI and aortic valve
Figure 3. Kaplan-Meier survival curves up to 1 year of follow-up
showing the percentage of patients free of cerebrovascular
events (CVEs; A), stroke (B), and major stroke (C) after trans-
catheter aortic valve implantation.
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replacement patients was higher than expected after a CVE.
More recently, Stortecky et al18 found a higher risk of 30-day
mortality in patients who suffered a CVE. Tamburino et al7
found periprocedural stroke to be a predictor of increased
mortality in 663 patients treated with the CoreValve system.
In accordance with these data, our study also points to the
negative impact of this complication in 30-day and late
outcomes after TAVI. In a further step, the results of the
present study also show that the impact of CVEs on mortality
was determined mainly by the severity of the neurological
Figure 4. Kaplan-Meier survival curves up to 1 year of follow-up showing the percentage of patients free of death according to the
occurrence of early (30 days) cerebrovascular events (CVEs; A), stroke (B), major stroke (C), and severity of the CVE as assessed by
the Modified Rankin scale (D) after transcatheter aortic valve implantation.
Table 5. Univariate and Multivariate Predictors of Late (>30-Day) and Cumulative Cerebrovascular Events
After Transcatheter Aortic Valve Implantation
Variable
Univariate Analysis Multivariate Analysis
HR (95% CI) P HR (95% CI) P
Predictors of late (30-d) cerebrovascular events
Chronic atrial fibrillation 2.83 (1.45–5.50) 0.002 2.84 (1.46–5.53) 0.002
Peripheral vascular disease 2.19 (1.12–4.27) 0.022 2.02 (1.02–3.97) 0.043
Cerebrovascular disease 2.35 (1.17–4.73) 0.016 2.04 (1.01–4.15) 0.047
Antithrombotic treatment at hospital discharge* 2.57 (1.32–5.00) 0.005 1.73 (0.78–3.81) 0.172
Predictors of cumulative cerebrovascular events
Age, y (per 1-y increase) 1.03 (1.00–1.07) 0.032 1.03 (1.01–1.06) 0.043
Chronic atrial fibrillation 1.62 (1.05–2.51) 0.030 1.91 (1.19–3.06) 0.007
Balloon postdilation 1.74 (1.09–2.78) 0.020 1.88 (1.17–3.00) 0.008
New-onset atrial fibrillation 1.93 (1.15–3.24) 0.013 2.53 (1.45–4.43) 0.001
Antithrombotic treatment at hospital discharge* 1.70 (1.12–2.58) 0.013 1.22 (0.74–2.01) 0.429
HR indicates hazard ratio; CI, confidence interval.
*Anticoagulation therapy (with or without antiplatelet therapy).
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event, and only events leaving permanent deficits (major
stroke) were associated with a significantly increased risk of
early and late mortality after TAVI, even after adjustment for
other major procedural complications and baseline clinical
characteristics. Furthermore, this finding highlights the major
importance of understanding the mechanisms associated with
CVEs for implementing the appropriate measures to reduce
its occurrence.
Limitations
This study has several limitations. Although the data were
prospectively collected in each participating center, there was
no prespecified case report form or event adjudication com-
mittee for this study. No systematic neurological evaluation
of the patients by a neurology specialist was performed
before and after the procedure. However, although this might
have led to some minor events being missed, it seems
unlikely that this would have been associated with significant
changes in the rates of major stroke. The evaluation of
complex aortic atheroma plaques by transesophageal echo-
cardiography was available in about two thirds of the patients,
and this might have precluded an appropriate evaluation of
the role of this important factor in the occurrence of CVEs.
Conclusions
TAVI was associated with an increased risk of early CVEs
after the procedure, with the highest risk occurring immedi-
ately after or within the first few hours after TAVI and
extending throughout several days after the procedure, with
those events leaving permanent neurological defects (major
Table 6. Univariate and Multivariate Predictors of 30-Day Mortality After Transcatheter Aortic Valve
Implantation
Variable
Univariate Analysis Multivariate Analysis
OR 95% CI P OR 95% CI P
eGFR 60 mL/min 1.92 1.20–3.08 0.007 1.03 0.52–2.03 0.938
STS (each increase in 1%) 2.31 1.67–3.18 0.001 1.66 0.96–2.87 0.070
Mitral regurgitation (baseline) 3 2.03 1.28–3.22 0.002 1.76 0.89–3.47 0.103
Learning curve (second half) 0.43 0.27–0.68 0.001 0.72 0.36–1.45 0.361
Device success 0.34 0.21–0.56 0.001 0.51 0.23–1.12 0.093
Need hemodynamic support or severe
maintained hypotension
11.0 6.09–19.84 0.001 4.45 1.73–11.47 0.002
Life-threatening bleeding 7.87 4.65–13.34 0.001 7.15 3.37–15.20 0.001
Major stroke at 30 d 4.89 2.17–11.03 0.001 7.43 2.45–22.53 0.001
Aortic regurgitation (post-TAVI) 2 2.28 1.27–4.07 0.004 2.33 1.18–4.58 0.015
OR indicates odds ratio; CI, confidence interval; eGFR, estimated glomerular filtration rate; STS, Society of Thoracic Surgeons; and
TAVI, transcatheter aortic valve implantation.
Table 7. Univariate and Multivariate Predictors of Cumulative Mortality After Transcatheter Aortic
Valve Implantation
Variable
Univariable Multivariable
HR 95% CI P HR 95% CI P
Sex (male) 1.47 1.17–1.84 0.001 1.57 1.22–2.02 0.001
Chronic AF 1.72 1.36–2.17 0.001 1.62 1.27–2.08 0.001
Previous MI 1.28 1.02–1.61 0.031 1.08 0.85–1.39 0.519
Peripheral vascular disease 1.41 1.11–1.80 0.004 1.06 0.78–1.45 0.717
COPD 1.40 1.11–1.76 0.005 1.33 1.03–1.71 0.028
eGFR 60 mL/min 1.51 1.19–1.90 0.001 1.27 0.99–1.64 0.062
LVEF 40% 1.49 1.16–1.91 0.002 1.16 0.88–1.53 0.288
Pulmonary hypertension 1.69 1.25–2.28 0.001 1.34 0.98–1.84 0.067
STS (each increase in 1%) 1.95 1.66–2.30 0.001 1.76 1.44–2.16 0.001
Nontransfemoral approach 1.37 1.09–1.73 0.007 1.12 0.83–1.51 0.467
Need hemodynamic support or
severe maintained hypotension
3.52 2.44–5.09 0.001 2.66 1.72–4.10 0.001
Life-threatening bleeding 2.39 1.75–3.26 0.001 2.18 1.54–3.08 0.001
Major stroke at 30 d 2.07 1.23–3.48 0.006 1.75 1.01–3.04 0.043
HR indicates hazard ratio; CI, confidence interval; AF, atrial fibrillation; MI, myocardial infarction; COPD, chronic obstructive
pulmonary disease; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; and STS, Society of Thoracic
Surgeons.
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stroke) being associated with much poorer short-term and
midterm outcomes. Mechanical factors such as further
stretching of the valve prosthesis with balloon postdilation or
valve dislodgment/embolization determined a higher risk of
acute (24 hours) CVEs and highlight the importance of
further evaluating the potential usefulness of embolic protec-
tion devices during TAVI procedures. The occurrence of
atrial arrhythmias increased the risk of subacute (1–30 days)
CVEs and suggests that efforts to reduce these events should
probably focus on both determining the most appropriate
antithrombotic treatment after TAVI and establishing preven-
tive therapies to reduce the occurrence of new episodes of
AF. Finally, late (30 days) events were associated mainly
with an increased atherosclerotic burden and chronic atrial
arrhythmias, both well-known risk factors of CVEs. These
results providing important insight into the pathophysiology
and prognostic value of CVEs after TAVI procedures should
help to determine the most appropriate therapeutic measures
to reduce the high incidence of CVEs associated with TAVI.
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CLINICAL PERSPECTIVE
Transcatheter aortic valve implantation has been associated with a higher rate of cerebrovascular events (CVEs) compared
with medical treatment or surgical aortic valve replacement. This multicenter study evaluated in a large cohort of
consecutive patients (n1061) the timing, predictors, and clinical impact of CVEs after transcatheter aortic valve
implantation. The incidence of 30-day CVEs was 5.1% (stroke, 4.2%), with about half of these events occurring
immediately or within the first few hours after the procedure. The predictors of acute (24 hours) CVEs were mechanical
factors such as further stretching of the valve prosthesis with balloon postdilation (odds ratio, 2.46; P0.034) and valve
dislodgment/embolization (odds ratio, 4.36; P0.024), whereas subacute (1–30 days) CVEs were determined mainly by
the occurrence of atrial arrhythmias (new-onset atrial fibrillation; odds ratio, 2.76; P0.028). There were no differences
in 30-day CVE rate between different types of valves (balloon expandable, self-expandable) or access routes (transfemoral,
transapical). The rate of late (30 days) CVEs was 3.3% (stroke, 2.1%) at a median follow-up of 12 months (3–23 months).
The predictors of late CVEs were chronic atrial fibrillation (hazard ratio, 2.84; P0.002), peripheral vascular disease
(hazard ratio, 2.02; P0.043), and prior cerebrovascular disease (hazard ratio, 2.04; P0.047). The impact of CVEs on
mortality was determined mainly by the severity of the event, and only the occurrence of major stroke was independently
associated with an increased 30-day (hazard ratio, 7.43; P0.001) and late cumulative (hazard ratio, 1.75; P0.043)
mortality. These results providing important insight into the pathophysiology and prognosis value of CVEs after
transcatheter aortic valve implantation procedures should help to determine the most appropriate therapeutic measures to
reduce the high incidence of CVEs associated with transcatheter aortic valve implantation.
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Frequency, Determinants, and Prognostic Effects
of Acute Kidney Injury and Red Blood Cell
Transfusion in Patients Undergoing Transcatheter
Aortic Valve Implantation
Rutger-Jan M. Nuis,1 MSc, Nicolas M. Van Mieghem,1 MD, Apostolos Tzikas,1 MD,
Nicolo Piazza,1 MD, Amber M. Otten,1 MSc, Jin Cheng,1 MD, Ron T. van Domburg,1 PhD,
Michiel Betjes,2 MD, PhD, Patrick W. Serruys,1 MD, PhD,
and Peter P.T. de Jaegere,1* MD, PhD
Objectives: To determine the frequency and independent predictors of acute kidney
injury (AKI) in addition to the prognostic implications of both AKI and periprocedural red
blood cell (RBC) transfusions on 30 day and cumulative late mortality in patients under-
going transcatheter aortic valve implantation (TAVI). Background: RBC transfusions
have been reported to predict AKI following TAVI. Data on the prognostic implications of
both factors, however, are lacking. Methods: 126 consecutive patients underwent TAVI
with the Medtronic CoreValve Revalving System. AKI was defined according to the valve
academic research consortium definitions as an absolute increase in serum creatinine
0.3 mg dL21 (26.4 lmol L21) or a percentage increase 50% within 72 hr following
TAVI. Results: Five patients on chronic haemodialysis and three intraprocedural deaths
were excluded, leading to a final study population of 118 patients. AKI occurred in 19%
of the patients necessitating temporary haemodialysis in 2%. Independent predictors of
AKI included: previous myocardial infarction (OR: 5.72; 95% CI: 1.64–19.94), periproce-
dural (<24 hr) RBC transfusions (OR: 1.29; 95% CI: 1.01–1.70), postprocedural (<72 hr)
leucocyte count (OR: 1.18; 95% CI: 1.02–1.37), and logistic EuroSCORE (OR: 1.08; 95%
CI: 1.01–1.14). In patients with AKI, 30-day mortality was 23% and cumulative late mortal-
ity (median: 13 months) was 55%. AKI (OR: 5.47; 95% CI: 1.23–24.21) and postprocedural
leucocyte count (OR: 1.20; 95% CI: 1.03–1.38) were independent predictors of 30-day
mortality while AKI (HR: 2.79; 95% CI: 1.36–5.71) was the only independent predictor of
late mortality. Conclusions: AKI following TAVI occurred in 19% of the patients. RBC
transfusion was found to be an independent predictor of AKI, which in turn predicted
both 30-day and cumulative late mortality. VC 2011 Wiley-Liss, Inc.
Key words: aortic valve replacement; percutaneous heart valve; acute renal failure;
prognosis
INTRODUCTION
Surgical aortic valve replacement (AVR) with cardio-
pulmonary bypass is the standard treatment for patients
with severe aortic stenosis and is associated with a low
morbidity and mortality rate in selected patients [1].
Yet, acute kidney injury (AKI) following cardiac sur-
gery is reported to occur in 4–30% of the patients [2,3]
and is associated with an increased mortality that is pro-
portional to the severity of AKI [4,5]. In addition, a
number of studies found that small increments in serum
creatinine also adversely affect mortality [2,3,6,7].
Transcatheter aortic valve implantation (TAVI) is a
less invasive technique that is performed on the beating
heart without the need of extracorporeal support and
may, therefore, be associated with a lower incidence of
1Department of Cardiology, Erasmus Medical Center,
Rotterdam, The Netherlands
2Department of Nephrology, Erasmus Medical Center,
Rotterdam, The Netherlands
Conflict of interest: N. Piazza is a consultant to Medtronic; P. de
Jaegere is a proctor for Medtronic.
*Correspondence to: Peter P.T. de Jaegere, MD, PhD, Thoraxcenter,
‘s-Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands.
E-mail: p.dejaegere@erasmusmc.nl
Received 20 August 2010; Revision accepted 14 October 2010
DOI 10.1002/ccd.22874
Published online 16 March 2011 in Wiley Online Library
(wileyonlinelibrary.com)
VC 2011 Wiley-Liss, Inc.
116 Chapter 10
AKI. Yet, TAVI is currently performed in elderly patients
or patients deemed too high a risk for AVR because of
severe comorbidities. They often have impaired renal
function and are, therefore, at increased risk for AKI also
after TAVI due to the haemodynamic changes during the
procedure and the use of contrast agents. The risk of
AKI has been shown to be independently associated with
periprocedural red blood cell (RBC) transfusions during
cardiac surgery [8,9] and TAVI [10,11]. Both may syn-
ergistically affect mortality. The objectives of this study
were to determine the incidence and predictive factors of
AKI following TAVI in addition to the prognostic effects
of RBC transfusions and AKI on 30-day and cumulative
late mortality.
MATERIALS AND METHODS
Patients and Procedure
A total of 126 patients with aortic stenosis under-
went TAVI with the Medtronic CoreValve Revalving
System (CRS) between November 2005 and April
2010. Patients were accepted for TAVI on the basis of
an agreement between a cardiologist and a cardiac sur-
geon during the heartteam meeting. In accordance with
the institution policy, every patient gave written
informed consent for treatment and all clinical data
were collected in the context of a structured follow-up
to which every patient treated in our department is sub-
jected in accordance with IRB approval.
Criteria for the implantation of the Medtronic CRS
have been described elsewhere [12]. Details of the de-
vice and the procedure have been previously published
[13]. All patients underwent a standard preoperative
coronary angiography at a median (IQR) of 60 (38–96)
days before TAVI. In 83 patients (70%), multi-sliced
computed tomography was performed at a median
(IQR) of 58 (22–85) days before the procedure during
which a contrast bolus (50–60 mL VisipaqueVR 320 mg
mL1, GE Health Care, Eindhoven, The Netherlands)
was injected in an antecubital vein at a flow rate of 5.0
mL sec1 followed by a second contrast bolus of 30–
40 mL at 3.0 mL sec1 up to a total of 80 mL.
According to the in-hospital protocol, all patients with
a glomerular filtration rate (GFR) <45 mL min1 in
the absence of diabetes or GFR <60 mL min1 in the
presence of diabetes and/or two other risk factors for
impaired renal function after contrast agents (e.g. age
>75, heart failure) received prehydration (NaCl 0.9%,
12–16 mL kg1 4–6 hr before and after TAVI).
Definitions and Collection of Data
Predefined baseline characteristics, medication and
technical measurements (electrocardiography, echo-
Doppler) were prospectively collected during the out-
patient clinic visit prior to the procedure. Blood sam-
ples for haematology and chemistry were taken 1 day
before TAVI and daily up to 72-hr post-treatment.
Haematological variables included the nadir haemoglo-
bin concentration, nadir platelet count, maximal leuco-
cyte count and maximal serum creatinine (SCr). Creati-
nine-based equations for estimation of GFR were
applied to identify patients with impaired renal func-
tion and to classify them in chronic kidney disease
stage I, II, and III, defined as a preprocedural GFR of
>90, 60–89, and <60 mL/min/1.73m2, respectively.
The simplified modification of diet in renal disease for-
mula [14] was used to estimate GFR, which is normal-
ized to 1.73 m2 body surface area and adjusted for sex,
age, race, and SCr.
AKI was defined according to the valve academic
research consortium (VARC) [15] definitions as an
absolute (<72 hr) reduction in kidney function and
defined as: (1) an absolute increase in the highest value
of SCr  0.3 mg dL1 (26.4 lmol L1) or (2) a per-
centage increase in the highest value of SCr  50%
(1.5-fold from baseline). Patients who developed AKI
were classified according to the degree of the severity
of AKI in stage I (increase in SCr of 150–200% or
increase of 0.3 mg dL1 (26.4 lmol L1), stage II
(increase in SCr of 200–300%) or stage III (increase in
SCr of 300 or increase of 4.0 mg dL1 (354
lmol L1) with an acute increase of 0.5 mg dL1
(44 lmol L1).
Considering the possible association between proce-
dural hypotensive periods with renal hypoperfusion and
subsequent AKI, we documented procedural systolic
and diastolic aortic pressures immediately after valve
implantation as well as the occurrence of bleeding
events due to any vascular complication. The latter
was defined according to the VARC as (i) any aortic
dissection; (ii) access site injury leading to death, 2
RBC transfusions, with or without percutaneous or sur-
gical intervention, with or without irreversible end-
organ damage; (iii) distal embolization (non-cerebral)
from a vascular source leading or not leading to sur-
gery, amputation or irreversible end-organ damage.
Anemia was defined according to the American Col-
lege of Physicians and WHO criteria as a haemoglobin
level <13 g dL1 in men and <12 g dL1 in women
[16]. Thrombocytopenia was defined as a platelet count
<140  109/L. Data on RBC and platelet transfusions
were recorded by the institutions’ blood bank labora-
tory. All cause of death and cardiovascular death were
collected.
In addition, the length of hospital stay (LOS) was
recorded and defined as the period between the day of
the procedure until the day of discharge or in-hospital
Catheterization and Cardiovascular Interventions DOI 10.1002/ccd.
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death, excluding the patients who died during the pro-
cedure. In case a patient was transferred to the refer-
ring hospital, the LOS was defined as the total time
spent in the treating and the referring center. Through-
out this article, the terms ‘‘periprocedural’’ and ‘‘post-
procedural’’ correspond to a time-frame of 24 and 72
hr after the start of the procedure, respectively.
Statistical Analysis
Categorical variables are presented as frequencies
and percentages and were compared with the chi-
square test or Fisher’s exact test. The normality of dis-
tributions was assessed with the Shapiro-Wilk test; nor-
mal and skewed continuous variables are presented as
means  SD and medians (IQR), respectively. Com-
parison of continuous variables was done by using the
Student’s t tests or Wilcoxon’s rank-sum test.
Kaplan–Meier methods were used to estimate sur-
vival rate and the Log-Rank test was performed to
assess differences in survival among patients with and
without AKI. A stepwise logistic regression analysis
including all variables with P < 0.05 in the univariable
analysis was used to determine the predictive factors of
AKI and 30-day mortality. A stepwise Cox regression
analysis including all variables with P < 0.05 in the
Cox univariable analysis was used to determine the
predictive factors of cumulative late mortality. For the
purpose of the assessment of the prognostic value of
periprocedural RBC transfusions and the occurrence of
AKI, both variables were forced into the multivariable
analyses for 30-day and late mortality, irrespective of
the P-value obtained from the univariable analyses. A
two-sided P < 0.05 was considered to indicate signifi-
cance. All statistical analyses were performed with
SPSS software (version 15).
RESULTS
A total of 126 patients underwent TAVI with the
Medtronic CRS. Five patients who were on chronic
haemodialysis before TAVI and three patients who
died during the procedure were excluded from analysis
leading to a final study population of 118 patients. The
baseline characteristics and preprocedural clinical
results dichotomized according to the presence or ab-
sence of AKI are presented in Table I. A similar table
for periprocedural, postprocedural, and in-hospital
results is shown in Table II.
AKI occurred in 22 patients (19%) of whom 2
patients (2%) underwent haemodialysis during hospital
stay. The distribution of patients who developed AKI
stage I, II, or III after TAVI according to the baseline
GFR is shown in Fig. 1.
Predictive Factors of AKI
By univariable analysis, the patients with AKI had a
higher frequency of previous myocardial infarction
(55% vs. 19%, P ¼ 0.001), coronary bypass surgery
(46% vs. 21%, P ¼ 0.017), low-flow low-gradient aor-
tic stenosis (27% vs. 8%, P ¼ 0.023) and thrombocyto-
penia (18% vs. 4%, P ¼ 0.039), and showed a higher
mean SCr (119 vs. 95  109 lmol L1, P ¼ 0.017).
They also received more periprocedural RBC transfu-
sions (2.7 vs. 1.1 U, P ¼ 0.001) and had a higher post-
procedural leucocyte count (14.4 vs. 12.3  109/L, P
¼ 0.035). Compared to those without AKI, patients
with AKI received in total more RBC transfusions (4.4
vs. 1.8 U, P < 0.001) during their longer hospitaliza-
tion period (17 vs. 9 days, P < 0.001). The independ-
ent predictors of AKI included: previous myocardial
infarction (OR: 5.72; 95% CI: 1.64–19.94), periproce-
dural RBC transfusions (OR: 1.29; 95% CI: 1.01–
1.70), postprocedural leucocyte count (OR: 1.18; 95%
CI: 1.02–1.37) and logistic EuroSCORE (OR: 1.08;
95% CI: 1.01–1.14).
Predictive Factors of 30-Day Mortality
Overall, 30-day mortality was 8% (nine patients). It
was significantly higher in patients with AKI com-
pared to those patients without AKI (23% vs. 4%,
respectively, P ¼ 0.011). The causes of death in
patients with AKI were sepsis (in two), heart failure
necessitating intravenous diuretics (in two) and asystole
at day 8 (one patient) due to an unrecognized alternat-
ing right and left bundle branch block after TAVI. The
independent predictors of 30-day mortality were AKI
(OR: 5.47; 95% CI: 1.23–24.21) and postprocedural leu-
cocyte count (OR: 1.20; 95% CI: 1.03–1.38).
Predictive Factors of Cumulative
Late Mortality
Clinical follow-up was available in all patients and
ranged from 1 to 54 months, with a median (IQR) of
13 (5–24) months. A total of 33 patients (28%) died
during the follow-up period, at a median (IQR) of 188
(30–385) days after TAVI. The cause of death was car-
diovascular in 21 patients and non-cardiovascular in 12
patients. Among these, there was a borderline signifi-
cant lower frequency of noncardiovascular death in
patients without AKI in comparison to those with AKI
(5/21 or 24% vs. 7/12 or 58%, P ¼ 0.054). In the latter
group, the causes for noncardiovascular death were
sepsis (in two), terminal kidney failure, infection,
hypovolemic shock, euthanasia and hypoglycaemia.
For patients without AKI, noncardiovascular deaths
were pneumonia (in two), diarrhea with dehydration
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(in two), and cancer. Univariable comparison of the
patients who died during the follow-up in comparison
to those who did not is shown in Table III. Multivari-
able analysis revealed that AKI was the only independ-
ent predictor of late mortality (HR: 2.79; 95% CI:
1.36–5.71). Kaplan–Meier survival curves for patients
with and without AKI are presented in Fig. 2.
DISCUSSION
We found that AKI occurred in 19% of the patients
following TAVI of whom 2% needed temporary hae-
modialysis. Predictive factors of AKI included previous
myocardial infarction, periprocedural RBC transfusion,
postprocedural leucocyte count and logistic Euro-
SCORE. AKI was associated with a longer hospital
stay and was found to be an independent predictor of
both 30-day and cumulative late mortality.
The occurrence of AKI following TAVI in this study
is consistent with the observations of Aregger et al.
[10] and Bagur et al. [11] who found a frequency of
28 and 12% in a series of 58 and 213 patients, respec-
tively. Of note, the definitions of AKI in these studies
(RIFLE criteria) were almost similar to the herein
reported VARC criteria except for the time at which
AKI was defined; 72 hr in this study compared to 48 hr
TABLE I. Baseline Characteristics According to the Presence or Absence of AKI Following TAVI
Entire cohort (n ¼ 118) AKI (n ¼ 22) no AKI (n ¼ 96) P-value
Baseline patient characteristics
Age (years), median (IQR) 82 (78–86) 83 (76–85) 82 (79–86) 0.61
Male, n (%) 53 (45) 11 (50) 42 (44) 0.60
Height (cm), mean  SD 167  8 169  9 167  8 0.38
Weight (kg), mean  SD 73  13 76  13 72  12 0.20
Body mass index, mean  SD 26.0  4.0 26.7  3.8 25.9  4.0 0.38
Body surface area (m2), mean  SD 1.8  0.2 1.9  0.2 1.8  0.2 0.18
NYHA class II, n (%) 17 (14) 2 (9) 15 (16) 0.74
NYHA class III, n (%) 83 (70) 14 (64) 69 (72) 0.45
NYHA class IV, n (%) 17 (14) 6 (27) 11 (12) 0.087
Previous cerebrovascular event, n (%) 29 (25) 6 (27) 23 (24) 0.75
Previous myocardial infarction, n (%) 30 (25) 12 (55) 18 (19) 0.001
Previous coronary artery bypass graft surgery, n (%) 30 (25) 10 (46) 20 (21) 0.017
Previous percutaneous coronary intervention, n (%) 32 (27) 6 (27) 26 (27) 0.99
Diabetes mellitus, n (%) 27 (23) 8 (36) 19 (20) 0.095
Hypertension, n (%) 53 (44) 11 (50) 42 (44) 0.60
Chronic obstructive pulmonary disease, n (%) 34 (29) 4 (18) 30 (31) 0.22
Permanent pacemaker, n (%) 13 (11) 2 (9) 11 (12) 1.0
Atrial fibrillation, n (%) 32 (27) 7 (32) 25 (26) 0.60
Logistic EuroSCORE (%), median (IQR) 12.3 (9.0–18.4) 18.4 (8.7–30.5) 12.1 (9.0–16.5) 0.052
STS score (%), median (IQR) 6.1 (3.7–12.6) 9.3 (3.9–13.8) 5.4 (3.6–12.5) 0.20
Multi-sliced computed tomography, n (%) 83 (70) 13 (59) 70 (73) 0.20
Baseline echocardiography
Left ventricular ejection fraction (%), mean  SD 51  16 45  15 52  16 0.064
Aortic valve area (cm2), mean  SD 0.63  0.2 0.67  0.2 0.63  0.2 0.31
Mean gradient, mean  SD 47  17 42  17 48  16 0.17
Low-flow low-gradient aortic stenosis, n (%)a 14 (12) 6 (27) 8 (8) 0.023
Mitral regurgitation grade  III, n (%) 22 (19) 6 (27) 16 (17) 0.25
Aortic regurgitation grade  III, n (%) 38 (32) 8 (36) 30 (31) 0.64
Baseline laboratory results
Glomerular filtration rate (ml/min/1.73 m2), mean  SD 59  18 54  20 61  18 0.11
Serum creatinine (lmol l1), mean  SD 99  43 119  71 95  32 0.017
Thrombocytopenia, n (%) 8 (7) 4 (18) 4 (4) 0.039
Leucocyte count ( 109/l), mean  SD 7.4  2.0 7.5  2.0 7.4  2.0 0.88
Anemia, n (%) 57 (48) 8 (36) 49 (51) 0.21
Baseline medication use
Anti-platelets, n (%) 85 (76) 12 (67) 73 (79) 0.72
Diuretics, n (%) 71 (64) 14 (78) 57 (61) 0.40
ACE-inhibitors, n (%) 33 (30) 7 (39) 26 (28) 0.35
Angiotensin II antagonists, n (%) 25 (23) 3 (17) 22 (24) 0.80
Betablockers, n (%) 61 (55) 12 (67) 49 (53) 0.28
Calcium antagonists, n (%) 27 (24) 3 (17) 24 (26) 0.63
Abbreviations: ACE ¼ angiotensin converting enzym; AKI ¼ acute kidney injury; NYHA ¼ New York Heart Association; RBC ¼ red blood cell.
aDefined as a mean gradient <30 mm Hg in the presence of an aortic valve area <1cm2.
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in the other studies. The variation in the point estimates
is also explained by the differences in the number of
patients in whom AKI was determined and type of
patient. Aregger et al. [10] for instance also included
two patients who were on chronic haemodialysis.
We found a number of patient- (antecedent myocar-
dial infarction, EuroSCORE) and procedure-related
(RBC transfusion) predictors of AKI in addition to leu-
cocyte count after TAVI. The EuroSCORE, which is a
conglomerate of a number of patient-related variables,
was entered into the model. This may have precluded
the identification of individual patient-related variables
such as pre-existing renal impairment. Indeed, prepro-
cedural SCr was found to be an independent predictor
of AKI when the EuroSCORE was left out of the
model (OR: 1.01; 95% CI: 1.00–1.03).
A previous myocardial infarction was found to be
the most powerful predictor of AKI. In addition, those
with a history of myocardial infarction as well as the
patients that developed AKI more frequently showed
worse left ventricular ejection fractions (45% vs. 52%,
P ¼ 0.064 and 45% vs. 53%, P ¼ 0.032, respectively)
and were more likely to have low-flow, low-gradient
aortic stenosis (17% vs. 10%, P ¼ 0.34 and 27% vs.
8%, P ¼ 0.023) compared to patients without myocar-
dial infarction and AKI. From a pathophysiologic point
of view, this may reflect that these patients have an
impaired cardio-circulatory homeostasis and, therefore,
TABLE II. Periprocedural, Postprocedural, and In-Hospital Outcomes According to the Presence or Absence of AKI Following
TAVI
Entire cohort (n ¼ 118) AKI (n ¼ 22) no AKI (n ¼ 96) P-value
Periprocedural (<24 hr after start procedure)
Aortic systolic pressure (mm Hg), mean  SD 139  34 133  27 140  36 0.47
Aortic diastolic pressure (mm Hg), mean  SD 54  13 53  19 52  12 0.90
Any vascular complication, n (%) 22 (19) 7 (32) 15 (16) 0.079
Contrast volume (ml), mean  SD 199  81 213  56 196  86 0.42
RBC transfusions, mean  SD 1.4  2.0 2.7  3.6 1.1  1.3 0.001
Platelet transfusions  1, n (%) 6 (5) 2 (9) 4 (4) 0.34
Duration of procedure (min), mean  SD 247  79 271  82 241  78 0.12
Postprocedural (<72 hrs after start procedure)
Glomerular filtration rate (ml/min/1.73 m2), mean  SD
Preprocedural 59  18 54  19 61  18 0.11
Postprocedural 57  21 34  16 62  19 <0.001
Serum creatinine (lmol l1), mean  SD
Preprocedural 99  43 119  71 95  32 0.017
Postprocedural 111  59 182  87 95  33 <0.001
Leucocyte count ( 109/l), mean  SD
Preprocedural 7.4  2.0 7.5  2.0 7.4  2.0 0.88
Postprocedural 12.7  4.1 14.4  4.2 12.3  4.0 0.035
Anemia, n (%)
Preprocedural 57 (48) 8 (36) 49 (51) 0.21
Postprocedural 115 (98) 22 (100) 93 (97) 1.0
Thrombocytopenia, n (%)
Preprocedural 8 (7) 4 (18) 4 (4) 0.039
Postprocedural 56 (48) 14 (64) 42 (44) 0.092
In-hospital
RBC transfusions, mean  SD 2.3  2.7 4.4  4.3 1.8  1.8 <0.001
LOS (days), median (IQR) 10 (8–18) 17 (11–30) 9 (7–14) <0.001
Mortality
30-day, n (%) 9 (8) 5 (23) 4 (4) 0.011
Cumulative late, n (%) 33 (28) 12 (55) 21 (22) 0.002
Abbreviations: AKI ¼ acute kidney injury; LOS ¼ length of stay; RBC ¼ red blood cell.
Fig. 1. Distribution of patients who developed AKI stage I, II,
or III according to the baseline GFR category. [Color figure
can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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more difficulties in maintaining adequate renal perfu-
sion during TAVI which is known to be associated
with episodes of haemodynamic alterations. Although
we could not confirm the latter with blood pressure
data that were obtained after complete prosthesis
release, it is likely that other phases of the procedure
TABLE III. Baseline Characteristics and Periprocedural, Postprocedural, and In-Hospital Results According to the Occurrence
of Cumulative Late Mortality Following TAVI
Cumulative late mortality (n ¼ 33) Cumulative late survival (n ¼ 85) P-value
Baseline patient characteristics
Age (years), median (IQR) 82 (76–86) 83 (79–86) 0.50
Male, n (%) 20 (61) 33 (39) 0.033
Height (cm), mean  SD 169  8 167  8 0.23
Weight (kg), mean  SD 74  12 73  13 0.79
Body mass index, mean  SD 25.8  3.7 26.1  4.1 0.69
Body surface area (m2), mean  SD 1.85  0.2 1.82  0.2 0.56
NYHA class II, n (%) 3 (9) 14 (17) 0.39
NYHA class III, n (%) 21 (64) 62 (73) 0.32
NYHA class IV, n (%) 9 (27) 8 (9) 0.020
Previous cerebrovascular event, n (%) 9 (27) 20 (24) 0.67
Previous myocardial infarction, n (%) 11 (33) 19 (22) 0.22
Previous coronary artery bypass graft surgery, n (%) 10 (30) 20 (24) 0.45
Previous percutaneous coronary intervention, n (%) 6 (18) 26 (31) 0.17
Diabetes mellitus, n (%) 9 (27) 18 (21) 0.48
Hypertension, n (%) 16 (49) 37 (44) 0.63
Chronic obstructive pulmonary disease, n (%) 11 (33) 23 (27) 0.50
Permanent pacemaker, n (%) 5 (15) 8 (10) 0.51
Atrial fibrillation, n (%) 9 (28) 23 (27) 0.91
Logistic EuroSCORE (%), median (IQR) 14.3 (9.5–21.7) 12.1 (8.9–16.6) 0.19
STS score (%), median (IQR) 5.1 (3.3–7.5) 7.0 (3.9–14.4) 0.044
Baseline echocardiography
Left ventricular ejection fraction (%), mean  SD 46  15 53  16 0.042
Aortic valve area (cm2), mean  SD 0.66  0.21 0.62  0.18 0.36
Mean gradient, mean  SD 50  15 45  17 0.22
Low-flow low-gradient aortic stenosis, n (%)a 3 (9) 11 (13) 0.78
Mitral regurgitation grade  III, n (%) 8 (24) 14 (17) 0.33
Aortic regurgitation grade  III, n (%) 13 (39) 25 (29) 0.30
Periprocedural (<24 hrs after start procedure)
Any vascular complication, n (%) 5 (15) 17 (20) 0.49
Contrast volume (ml), mean  SD 205  73 196  85 0.60
RBC transfusions, mean  SD 2.0  2.8 1.2  1.6 0.074
Platelet transfusions  1, n (%) 1 (3) 5 (6) 1.0
Duration of procedure (min), mean  SD 254  76 243  81 0.54
Postprocedural (<72 hrs after start procedure)
Glomerular filtration rate (ml/min/1.73 m2), mean  SD
Preprocedural 58  18 60  18 0.75
Postprocedural 50  22 60  20 0.022
Serum creatinine (lmol l1), mean  SD
Preprocedural 106  41 97  43 0.31
Postprocedural 134  64 103  55 0.009
Leucocyte count (109/l), mean  SD
Preprocedural 7.7  2.0 7.3  1.9 0.35
Postprocedural 13.8  5.1 12.2  3.6 0.064
Anemia, n (%)
Preprocedural 20 (61) 37 (44) 0.096
Postprocedural 33 (100) 82 (97) 0.56
Thrombocytopenia, n (%)
Preprocedural 4 (12) 4 (5) 0.22
Postprocedural 15 (46) 41 (48) 0.79
In-hospital
RBC transfusions, mean  SD 3.1  3.6 2.0  2.2 0.042
Acute kidney injury, n (%) 12 (36) 10 (12) 0.002
LOS (days), median (IQR) 14 (8–25) 10 (8–14) 0.19
Abbreviations: AKI ¼ acute kidney injury; LOS ¼ length of stay; NYHA ¼ New York Heart Association; RBC ¼ red blood cell.
aDefined as a mean gradient <30 mm Hg in the presence of an aortic valve area <1cm2.
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such as rapid right ventricular pacing during predilata-
tion of the native aortic valve may have induced such
kidney affecting hypotensive periods. For these rea-
sons, close monitoring of procedural blood pressures
with adequate treatment in the case of sudden pressure
decline may be necessary in these patients.
In accordance with Aregger et al. [10] and Bagur
et al. [11], we found that RBC transfusion independ-
ently predicted AKI following TAVI. Whether there is
a relationship between the number of RBC transfusions
and the severity of AKI, as observed in the univariable
analysis remains to be elucidated. This study may have
lacked the power to exclude confounders. Of note, a
relation between the number of RBC transfusions and
multi organ failure has been reported in trauma patients
[19]. Since RBC transfusion is associated with the
coadministration of a number of other molecular and
cellular substances [17] such as interleukin-8 which
typically accumulates in stored packed red cells caus-
ing transient leucocytosis [18], the observed association
between increased leucocyte count and AKI is most
likely a direct result of the transfusion rather than
being a cause of AKI.
Although the mean volume of contrast media used
in the present study was twice as high compared to the
results from Bagur et al. [11] (199 vs. 97 mL), we
were unable to find an association with the occurrence
of AKI. This is even more noteworthy since we meas-
ured AKI at 72 hr as outlined by the VARC instead of
48 hr. It is known that the increase in SCr reaches its
peak at about 3–5 days after contrast exposure [20].
Despite the longer window of analysis in this study,
we still failed to observe a relationship. A reason for
this may be associated with the fact that patients
suffering from pre-existing renal failure (who were
found to be at risk for AKI as identified from the mul-
tivariable analysis when EuroSCORE was excluded)
tended to receive less amounts of contrast volumes
compared to patients without pre-existing renal failure
(187 vs. 212 mL, P ¼ 0.14). Importantly, the deleteri-
ous implications of contrast-induced nephropathy after
percutaneous coronary intervention (PCI) are well
known and, therefore, minimization of the use of these
agents is warranted [21–23].
Similar to many reports on patients who underwent
cardiac surgery and PCI, we found AKI to be an inde-
pendent predictor of both 30-day and cumulative late
mortality [2,4,7,22–28]. Bagur et al. [11] is the only
study that determined the impact of AKI following
TAVI on mortality and found AKI to be an independ-
ent predictor of 30-day mortality. The present study
shows that relative to patients without AKI, non-cardi-
ovascular causes of death were more common in those
with AKI and included sepsis (in 2) at Day 11 and 29;
terminal kidney failure at Day 450; and infection,
hypovolemic shock, euthanasia and hypoglycaemia at
Days 172, 567, 694, and 873, respectively. The first
three deaths were possibly related with postprocedural
AKI whereas non-cardiovascular deaths in patients
without AKI were less likely to be associated with re-
nal dysfunction (pneumonia in two, diarrhea with dehy-
dration in two, and cancer in one). These findings may
reflect important consequences of AKI following TAVI
that require close monitoring in the early postproce-
dural days and even after hospital discharge.
Considering the prognostic effects of AKI and the
role of RBC transfusion in the development of AKI as
observed in both this study and, perhaps more impor-
tantly the one of Bagur et al. [11] given the observed
odds ratio and 95% CI (this study: 1.4 [1.0–1.8], Bagur
et al.: 3.5 [1.3–9.3]), it emphasizes the importance of a
strict surgical discipline in the execution of TAVI by—
among others—strict control of haemostasis. Vascular
access site complications, which are the most common
cause of bleeding, are reported to occur in up to 34%
of the patients [29–32]. Despite our meticulous effort
to ensure proper entry of the common femoral artery
by echo-guided puncture and closure with the Prostar
system, 19% of our patients suffered from a vascular
complication. These patients in particular are at
increased risk for both renal hypoperfusion and RBC
transfusion. Both these factors were associated with
AKI by univariable analysis, but only transfusion was
found to be an independent predictor of AKI. Although
this may suggest a causative mechanism of transfusion
rather than of hypotension-related vascular complica-
tions, we sought to evaluate the potential confounding
effects of vascular complication by including this
Fig. 2. Kaplan–Meier survival rates stratified for the presence
and absence of AKI in patients undergoing TAVI (The Log-
Rank was used for comparison of survival rates). [Color figure
can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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factor in the multivariable analysis for AKI predictors.
This, however, did not change the model. The high fre-
quency of vascular complications nevertheless
expresses the need of improvement of this part of the
procedure. It is the reason why some advocate a lim-
ited surgical cut-down of the femoral artery that con-
sists of the exposure of the ventral side of the femoral
artery without a complete dissection of the artery free
of its surrounding supportive structures.
Improvement can also be obtained by changes in the
patient selection, pre- and perioperative management.
Bagur et al. [11] found chronic obstructive disease and
hypertension to be independently associated with AKI
while we found previous myocardial infarction.
Patients with a history of myocardial infarction and/or
impaired ejection fractions may benefit from close
blood pressure monitoring during the procedure with
adequate treatment in the case of sudden instability of
pressures. Regarding RBC transfusions, we changed
our practice to a more restrictive strategy which seems
beneficial but challenging given the high prevalence of
anemia at presentation (48%) in these patients. Despite
this, we found that the first half of our patient cohort
received on average 2.1 RBC transfusions whereas
later treated patients received on average 1.3 units,
while our vascular complication rates only showed a
small reduction from 20% to 16%. Also, more aware-
ness among the potential impact of contrast on the
occurrence of AKI in these multimorbid patients who
often present with pre-existing renal failure is war-
ranted and should be addressed with a dedicated prehy-
dration protocol. Finally, patients diagnosed with AKI
after TAVI require close monitoring during the early
postprocedural days and thereafter since they are at
increased risk of worse survival.
Limitations
The data used for this study were prospectively col-
lected and analyses were performed on a relatively
small sample size with a small number of outcome
events. As a result, potential model overfitting and
overparamterization may have affected the results
which therefore constitutes an important limitation of
this study. However, this may have had a minor impact
since the direction of outcome is consistent with previ-
ous reports of Aregger et al. and Bagur et al.
CONCLUSION
AKI following TAVI occurred in 19% of the
patients. In addition to patient-related variables and
leucocyte count after TAVI, RBC transfusion was
found to be an independent predictor of AKI, which in
turn predicted both 30-day and cumulative late mortal-
ity. It remains to be elucidated whether improvement
in patient selection, pre- and perioperative management
reduce AKI.
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 CHAPTER 11
Blood tranfusion and the risk of acute 
kidney injury following transcatheter 
aortic valve implantation

127Blood transfusion and AKI after TAVI
Transcatheter aortic valve implantation (TAVI) is increasingly used to treat patients with aortic stenosis, 
who are considered at high risk for surgical aortic valve 
replacement.1 Despite its minimally invasive nature, TAVI 
is invariably associated with a number of complications 
that may affect outcome. Some of these complications are 
clinically manifest during the procedure for which imme-
diate actions are taken, whereas others such as acute kid-
ney injury (AKI) are detected later and may have silent, but 
harmful, prognostic effects. AKI is reported in 12% to 57% 
of the patients who undergo TAVI and is associated with a 
2- to 6-fold increased risk of death during short- and long-
term follow-up.2–10
At present, the pathophysiologic mechanisms of AKI after 
TAVI are unclear. Some studies suggest a direct relation 
between perioperative blood transfusion and AKI.5,6,10 This 
may be explained by the fact that in association with the 
transfusion of red blood cells (RBC) a number of other cellular 
and molecular substances are administrated that either directly 
or indirectly (eg, inflammation) induce kidney damage,11 yet 
one may question whether the triggers for blood transfusion, 
such as perioperative blood loss because of bleeding-vascular 
Background—Blood transfusion is associated with acute kidney injury (AKI) after transcatheter aortic valve implantation 
(TAVI). We sought to elucidate in more detail the relation between blood transfusion and AKI and its effects on short- and 
long-term mortality.
Methods and Results—Nine hundred ninety-five patients with aortic stenosis underwent TAVI with the Medtronic 
CoreValve or the Edwards Valve in 7 centers. AKI was defined by the Valve Academic Research Consortium (absolute 
increase in serum creatinine ≥0.3 mg/dL [≥26.4 μmol/L] or ≥50% increase ≤72 hours). Logistic and Cox regression 
was used for predictor and survival analysis. AKI occurred in 20.7% (n=206). The number of units of blood transfusion 
≤24 hours was the strongest predictor of AKI (≥5 units, OR, 4.81 [1.45–15.95], 3–4 units, OR, 3.05 [1.24–7.53], 
1–2 units, OR, 1.47 [0.98–2.22]) followed by peripheral vascular disease (OR, 1.48 [1.05–2.10]), history of heart failure 
(OR, 1.43 [1.01–2.03]), leucocyte count ≤72 hours after TAVI (OR, 1.05 [1.02–1.09]) and European System for Cardiac 
Operative Risk Evaluation (EuroSCORE; OR, 1.02 [1.00–1.03]). Potential triggers of blood transfusion such as baseline 
anemia, bleeding-vascular complications, and perioperative blood loss were not identified as predictors. AKI and life-
threatening bleeding were independent predictors of 30-day mortality (OR, 3.15 [1.56–6.38], OR, 6.65 [2.28–19.44], 
respectively), whereas transfusion (≥3 units), baseline anemia, and AKI predicted mortality beyond 30 days.
Conclusions—AKI occurred in 21% of the patients after TAVI. The number of blood transfusions but not the indication 
of transfusion predicted AKI. AKI was a predictor of both short- and long-term mortality, whereas blood transfusion 
predicted long-term mortality. These findings indicate that outcome of TAVI may be improved by more restrictive use of 
blood transfusions. (Circ Cardiovasc Interv. 2012;5:680-688.)
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complications may also play a role. This also holds for the 
presence of baseline anemia, impaired kidney function, and 
other procedural factors such as changes in cardiovascular 
hemodynamics during TAVI.7,12 We, therefore, sought to 
explore in more detail the relation between blood transfusion 
and AKI after TAVI relative to a number of baseline and 
procedural variables in a series of 995 patients in addition to 
the effects of blood transfusion and AKI on mortality.
Methods
Patients
Between November 2005 and January 2012, 1050 patients with aor-
tic stenosis underwent TAVI with the Medtronic CoreValve System 
(Medtronic Inc) or the Edwards SAPIEN Valve (Edwards Life 
 Sciences) in the Erasmus Thoraxcenter, Rotterdam, The Netherlands 
(n=220); Quebec Heart and Lung Institute, Quebec City, Quebec, 
Canada (n=216); University Hospital Bonn, Bonn, Germany (n=182); 
University Hospital Maastricht, Maastricht, The Netherlands (n=145); 
University Hospital Saint-Luc, Brussels, Belgium (n=122); University 
Hospital Antwerp, Antwerp, Belgium (n=97); and Angiografia 
de Occidente, Cali, Colombia (n=68). Patients on chronic hemo-
dialysis (n=35) and those who died within 72 hours precluding 
creatinine measurements during the first 3 days after TAVI (n=23— 
including 3 patients on chronic hemodialysis [causes of death are 
listed in online-only Data Supplement]) were excluded from the 
study. The final study population consisted, therefore, of 995 patients.
In each institution, patients with symptomatic aortic stenosis were 
screened at the outpatient clinic during which a structured interview, 
physical examination, ECG, and blood sampling were performed. 
Invasive diagnostic workup included a left heart catheterization 
(performed by the referring institution in most patients) to determine 
the coronary anatomy and hemodynamic status; echo-(Doppler) car-
diography (transthoracic or transesophageal), contrast angiography, 
or contrast enhanced multisliced CT were performed >2 weeks before 
TAVI to assess the valvular and vascular anatomy and to define the 
vascular access strategy (transfemoral, transapical, transsubclavian, 
transaortic). Treatment eligibility was based on previously described 
patient-selection criteria, and final acceptance for TAVI was estab-
lished by Heart Team consensus.13
In accordance with the institutions policies, every patient gave 
written informed consent for TAVI and the use of anonymous 
clinical, procedural and follow-up data for research in accordance 
with Institutional Review Board approval. This study complies with 
the Declaration of Helsinki.
Procedure
TAVI was performed under general or local anesthesia using the 
Medtronic CoreValve System (26, 29, or 31 mm) or Edwards 
SAPIEN Valve (20, 23, or 26 mm) via a transfemoral, transapical, 
transsubclavian, or transaortic approach of which details have been 
described previously.14–18 Details of the prehydration protocol for the 
various institutions are summarized in online-only Data Supplement.
The amount of contrast and the occurrence of life-threatening ar-
rhythmias (any episode of ventricular tachycardia, ventricular fibril-
lation, asystole requiring vasopressive drugs, electric defibrillation, or 
cardiopulmonary resuscitation), any complication leading to severe 
sustained hypotension, postimplantation balloon dilation, and (Valve 
Academic Research Consortium-defined) bleeding and vascular com-
plications were recorded during or immediately after TAVI.19
After the procedure, patients were extubated in the catheteriza-
tion room or after transfer in the cardiac care unit shortly after the 
procedure or later if clinically indicated. Antiplatelet therapy after 
Medtronic CoreValve System and Edwards SAPIEN Valve im-
plantation consisted of clopidogrel 75 mg for 6 months and aspirin 
80 to 100 mg indefinitely. Patients on oral anticoagulant therapy 
 before TAVI received periprocedural therapeutic anticoagulation 
with unfractionated heparin or low-molecular-weight heparin in 
combination with either clopidogrel or aspirin to cover the time 
with subtherapeutic INR levels. Oral anticoagulation was resumed 
shortly after TAVI.
Laboratory Measurements and AKI Definition
Preoperative serum creatinine (SCr) values were used to calculate the 
baseline SCr clearance using the Cockcroft and Gault equation: SCr 
clearance (mL/min)=(140−age)×weight (kg)÷72×SCr (mg/dL) (×0.85 
for women).20 Chronic kidney disease (CKD) was defined as a calcu-
lated SCr clearance <60 mL/min.21,22 Patients with CKD were further 
classified in tertiles to examine the effect of mild (45.0–60.0 mL/min), 
moderate (35.0–44.9 mL/min), and severe CKD (<35 mL/min).
AKI was defined according to the Valve Academic Research 
Consortium recommendations as an absolute (≤72 hours) reduction in 
kidney function and defined as: (1) an absolute increase in the highest 
value of SCr ≥0.3 mg/dL (≥26.4 μmol/L) or (2) a percentage increase 
in the highest value of SCr ≥50% (1.5-fold from baseline). AKI sever-
ity was further classified as stage I (increase in SCr of 150%–200% 
or increase of ≥0.3 mg/dL ≥26.4 μmol/L]), stage II (increase in SCr 
of 200%–300%), or stage III (increase in SCr of ≥300% or increase 
of ≥4.0 mg/dL [≥354 μmol/L]) with an acute increase of ≥0.5 mg/dL 
(44 μmol/L). Patients receiving renal replacement therapy (hemody-
alysis, peritoneal dialysis, or hemofiltration) during hospitalization or 
within 30 days after the procedure were considered to be classified 
as stage III.19
Preoperative hemoglobin (Hb) values were used to define baseline 
anemia according to the American College of Physicians and WHO 
criteria as a Hb level <13 g/dL in men and <12 g/dL in women.23 
Patients with anemia were classified in tertiles to assess the effects of 
mild (12.0–12.99 g/dL in men; 11.30–11.99 g/dL in women), mod-
erate (10.80–11.99 g/dL in men; 10.23–11.29 g/dL in women), and 
severe anemia (<10.80 g/dL in men, <10.23 g/dL in women).
Data on RBC transfusions were recorded by the institution’s blood 
bank laboratory and used to determine the corrected Hb drop ≤24 
hours after TAVI according to the modified Landefeld equation.24,25 
In this equation 1 unit of packed RBCs is considered to represent 
1 g/dL of Hb and, therefore, the net Hb drop corresponds to the ad-
dition of the number of packed RBC to the baseline-minus-measured 
nadir Hb.12
Follow-Up
After hospital discharge, mortality data were collected by contacting 
the civil registries or the referring physician or general practitioner 
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and was complete in 98.4% of the 937 patients who survived the 
first 30 days (median [interquartile range] follow-up time; 12 [4–23] 
months). Death at any time during the follow-up period was classified 
as cardiac or noncardiac according to the Valve Academic Research 
Consortium criteria.19
Statistical Analysis
Details of data completeness and management are summarized in 
online-only Data Supplement. Categorical variables are presented as 
frequencies and percentages and were compared with the χ2 test or 
Fisher exact test. The normality of distributions was assessed with 
the Shapiro-Wilk test; comparison of continuous variables was 
done by using the Student t test or Wilcoxon rank-sum test when 
appropriate. A stepwise logistic regression analysis including all 
variables from Tables 1 and 2 exhibiting P<0.10 in the univariable 
analysis was used to determine the predictive factors of AKI and 
30-day mortality. Two interaction terms were tested to evaluate 
synergistic effects of (1) baseline anemia and Hb drop ≤24 hours 
and (2) baseline CKD and contrast load.10 A stepwise Cox regression 
analysis including all variables from Tables 1 and 2 exhibiting 
P<0.10 in the Cox univariable analysis was used to determine the 
predictive factors of long-term mortality in patients who survived the 
first 30 days after TAVI (landmark analysis). For the purpose of this 
Table 1. Baseline Characteristics of Patients With and Without AKI After TAVI
Entire Cohort
(n=995)
No AKI
(n=789)
AKI
(n=206) P  Value
Age, y, median (IQR) 82 (77–86) 82 (78–86) 82 (77–86) 0.42
Male sex, no (%) 497 (50) 393 (50) 104 (50) 0.86
 Height, cm, mean±SD 164±10 164±10 165±10 0.31
 Weight, kg, mean±SD 72±15 71±15 73±16 0.092
 Body mass index, mean±SD 26.4±5.0 26.3±4.8 26.9±5.5 0.14
 Body surface area, mean±SD 1.79±0.21 1.79±0.21 1.82±0.22 0.097
New York Heart Association class ≥III, no (%) 806 (81) 631 (80) 175 (85) 0.11
 Previous cerebrovascular event, no (%) 198 (20) 155 (20) 43 (21) 0.71
 Previous myocardial infarction, no (%) 262 (26) 201 (26) 61 (30) 0.23
 Previous coronary artery bypass graft surgery, no (%) 267 (27) 214 (27) 53 (26) 0.68
 Previous percutaneous coronary intervention, no (%) 303 (31) 239 (30) 64 (31) 0.83
Congestive heart failure, no (%) 577 (58) 442 (56) 135 (66) 0.010
Diabetes mellitus, no (%) 274 (28) 218 (28) 56 (27) 0.90
Hypertension, no (%) 772 (78) 603 (76) 169 (82) 0.085
Peripheral vascular disease, no (%) 301 (30) 222 (28) 79 (39) 0.004
Chronic obstructive pulmonary disease, no (%) 281 (28) 217 (28) 64 (31) 0.31
 Creatinine, median (IQR) 100 (81–129) 99 (81–126) 106 (80–139) 0.12
Chronic kidney disease, no (%)*
 Mild* 243 (24) 198 (25) 45 (22) 0.40
 Moderate* 250 (25) 203 (26) 47 (23)
 Severe* 242 (24) 184 (23) 58 (28)
Hemoglobin, mean±SD 12.2±3.8 12.2±4.2 12.0±1.7 0.42
Anemia, no (%)†
 Mild† 200 (20) 157 (20) 43 (21) 0.82
 Moderate† 192 (19) 150 (19) 42 (20)
 Severe† 175 (18) 136 (17) 39 (19)
Leucocyte count (×109 cells/L), mean±SD 7.3±2.0 7.3±2.2 7.2±2.1 0.55
Atrial fibrillation, no (%) 265 (27) 209 (27) 56 (27) 0.82
Permanent pacemaker, no (%) 133 (13) 100 (13) 33 (16) 0.21
 Left ventricular ejection fraction ≤35%, no (%) 157 (16) 116 (15) 41 (20) 0.068
 Aortic valve area, cm2, mean±SD 0.66±0.19 0.66±0.20 0.66±0.17 0.89
 Peak gradient, mean±SD 71±25 71±25 71±26 0.93
 Mitral regurgitation grade ≥III, no (%) 118 (12) 102 (13) 16 (8) 0.041
 Aortic regurgitation grade ≥III, no (%) 86 (9) 71 (9) 15 (7) 0.44
Logistic Euroscore, median (IQR) 17 (11–30) 15 (10–28) 22 (12–35) <0.001
AKI indicates acute kidney injury; TAVI, transcatheter aortic valve implantation; and IQR, interquartile range.
*Chronic kidney disease was defined as a calculated creatinine clearance <60 mL/min; mild 45.0 to 60.0 mL/min, moderate 35.0 to 44.9 mL/min and 
severe <35 mL/min.
†Anemia was defined as Hb <13 g/dL in men and <12 g/dL in women,23 mild anemia 12.0 to 12.99 g/dL in men and 11.30 to 11.99 g/dL in women, moderate anemia 
10.80 to 11.99 g/dL in men and 10.23 to 11.29 g/dL in women, and severe anemia <10.80 g/dL in men and <10.23 g/dL in women.
130 Chapter 11
study, RBC transfusion was forced into the multivariable analyses 
for predictors of AKI, whereas both RBC transfusion and AKI were 
forced into the multivariable analyses of 30-day and late mortality, 
irrespective of the P value obtained from the univariable analyses. 
Variables included in the multivariable model for the prediction of 
AKI, 30-day mortality, and long-term mortality are listed in online-
only Data Supplement. Results are reported as adjusted OR or 
hazard ratio (HR) with a 95% CI. Survival curves for time-to-event 
variables were constructed on the basis of all available follow-up 
data in patients who survived the first 30 days after TAVI (landmark 
analysis) with the use of Kaplan–Meier estimates and were 
compared with the log-rank test. Patients lost to follow-up (1.6%) 
were considered at risk until the date of last contact, at which point 
they were censored. A 2-sided P<0.05 was considered to indicate 
significance. All statistical analyses were performed with SPSS 
software (version 17).
Results
The baseline patient characteristics and perioperative details 
of the total population and of the patients with and without 
AKI are summarized in Tables 1 and 2, respectively. AKI 
occurred in 20.7% (n=206) of the patients of whom 3.1% 
(n=31) received renal replacement therapy. Details of AKI 
(stages I–III) and other changes in renal function are depicted 
in Figure 1. Patients with AKI had a significantly higher mor-
tality at 30 days and during follow-up (Table 2).
Predictors of AKI
By univariable analysis, patients with AKI had a higher preva-
lence of congestive heart failure (66 versus 56%, P=0.010) 
and peripheral vascular disease (39 versus 28%, P=0.004) 
explaining a higher operative risk (Logistic EuroSCORE 22 
Table 2. Perioperative Results for Patients With and Without 
AKI After TAVI
No AKI
(n=89)
AKI
(n=206) P  Value
Intraoperative or ≤24 h
 Access strategy, no (%)
  Transfemoral 561 (71) 130 (63) 0.002
  Transapical 210 (27) 67 (33)
  Transsubclavian 18 (2) 6 (3)
  Transaortic 0 3 (2)
 Circulatory support, no (%) 20 (3) 9 (4) 0.16
 Prosthesis size, mm, no (%)*
  20, 23, 26 517 (66) 146 (71) 0.12
  29, 31 272 (34) 59 (29) 0.12
  Any complication leading to severe 
sustained hypotension, no (%)
24 (3) 8 (4) 0.54
  Life-threatening arrhythmia, no (%) 29 (4) 10 (5) 0.44
  Postimplantation balloon dilation, 
no (%)
130 (16) 39 (19) 0.41
 Contrast volume, mL, mean±SD 142±97 158±96 0.052
  Duration of procedure, min, 
mean±SD
99 (70–156) 105 (70–173) 0.32
  Major vascular complication, 
no (%)
55 (7) 26 (13) 0.008
 Bleeding complication, no (%)
  Life threatening or major,  
  no (%)
104 (13) 37 (18) 0.080
  Life threatening 39 (5) 15 (7) 0.19
 RBC transfusion, no (%)
  None 632 (80) 133 (64) <0.001
  1–2 units 137 (17) 54 (26)
  3–4 units 14 (2) 11 (5)
  ≥5 units 6 (1) 8 (4)
  Hemoglobin drop—uncorrected 
for RBC TF, g/dL, mean±SD
2.3±4.1 2.3±1.7 0.94
  Hemoglobin drop—corrected for 
RBC TF, g/dL, mean±SD
2.7±4.3 3.2±2.7 0.12
Postoperative ≤72 h
  Serum creatinine (μmol/L),  median (IQR)
  Preprocedural 99 (81–126) 106 (80–139) 0.12
  Postprocedural 83 (67–106) 172 (122–229) <0.001
  Creatinine clearance (mL/min), mean±SD
  Preprocedural 48±20 50±27 0.49
  Postprocedural 63±37 33±29 <0.001
  Leucocyte count (×109 cells/L), mean±SD
  Preprocedural 7.3±2.2 7.2±2.1 0.55
  Postprocedural 11.7±4.8 13.0±4.9 0.001
 Hemoglobin (g/dL), mean±SD
  Preprocedural 12.2±4.2 12.0±1.7 0.42
  Postprocedural 9.4±1.5 9.1±1.5 0.011
 RBC transfusion, no (%)
  None 515 (65) 98 (48) <0.001
  1–2 units 209 (27) 63 (31)
(Continued)
Table 2. (Continued).
No AKI
(n=89)
AKI
(n=206) P  Value
  3–4 units 49 (6) 28 (14)
  ≥5 units 16 (2) 17 (8)
In-hospital
 Echocardiography
  Peak gradient, mean±SD 19±11 19±12 0.99
   Mitral regurgitation grade  
≥III, no (%)
62 (9) 10 (6) 0.21
   Aortic regurgitation grade  
≥III, no (%)
40 (6) 10 (5) 0.96
Length of stay (days), median (IQR) 10 (6–14) 13 (8–22) <0.001
Mortality
 ≤30 days 28 (4) 30 (15) <0.001
 ≤30 days cardiac 14 (2) 17 (8) <0.001
 >30 days† 140 (18) 59 (34) <0.001
 >30 days cardiac†‡ 61 (8) 26 (15) <0.001
AKI indicates acute kidney injury; TAVI, transcatheter aortic valve implantation; 
RBC, red blood cell; TF transfusion.
*One patient did not receive a valve due to aborted TAVI after failed 
introduction of 18F sheath.
†N=937 patients survived >30 days after TAVI of which 199 patients died at 
a median of 12 (IQR: 4–23) months after TAVI.
‡The cause of death was missing or unknown in 27 of the 199 deaths 
(14%; n=8 in AKI group, n=19 in no AKI group).
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versus 15%, P<0.001, Table 1). They also more often under-
went transapical TAVI (33 versus 27%, P=0.002) and suffered 
more major vascular complications (13 versus 7%, P=0.008, 
Table 2). Despite the latter, there was no difference in periop-
erative blood loss (corrected Hb drop) between patients with 
and without AKI, yet patients with AKI received significantly 
more blood transfusions within 24 and 72 hours after TAVI. 
Because baseline anemia might affect the decision to adminis-
ter blood transfusion, the mean Hb drop and number of blood 
transfusions for patients with no and with various degrees of 
baseline anemia was analyzed (Figure 2A–2B); patients with 
severe baseline anemia had 2.4 times less blood loss but on 
average received 2.3-fold more units of blood transfusions 
in comparison with patients without anemia before TAVI 
(P<0.001). Neither contrast use (P=0.052) nor any of the 
interaction terms (baseline anemia and Hb drop ≤24 hours, 
P=0.31; baseline CKD and contrast load, P=0.10) were sig-
nificantly associated with AKI.
Figure 1. Changes in creatinine 
≤72 hours after transcatheter 
aortic valve implantation.
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Figure 2. Mean percent Hb drop and mean 
number of blood transfusions ≤24 and  
≤72 hours after transcatheter aortic valve 
implantation (TAVI) grouped according to 
various degrees of baseline anemia. Baseline 
anemia was defined as Hb <13 g/dL in men 
and <12 g/dL in women23; mild anemia 12.0 
to 12.99 g/dL in men and 11.30 to 11.99 g/
dL in women, moderate anemia 10.80 to 
11.99 g/dL in men and 10.23 to 11.29 g/dL 
in women, and severe anemia <10.80 g/dL in 
men and <10.23 g/dL in women. Hb indicates 
hemoglobin. A, Mean percent Hb drop ≤24 
and ≤72 hours after TAVI. Percent Hb drop 
≤24 h=(baseline Hb−nadir Hb ≤24 h)/(base-
line Hb); Percent Hb drop ≤72 h=(baseline 
Hb−nadir Hb ≤72 hours)/(baseline Hb). B, 
Mean number of blood transfusions ≤24 and 
≤72 hours after TAVI. AKI indicates acute 
kidney injury.
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In a descending order of the magnitude of the OR, we 
found by multivariable analysis that the number of units of 
blood transfusion ≤24 hours was the strongest predictor of 
AKI (≥5 units, OR, 4.81 [1.45–15.95]; 3–4 units, OR, 3.05 
[1.24–7.53]; 1–2 units, OR, 1.47 [0.98–2.22]), followed by 
peripheral vascular disease (OR, 1.48 [1.05–2.10]), conges-
tive heart failure (OR, 1.43 [1.01–2.03]), leucocyte count 
≤72 hours after TAVI (OR, 1.05 [1.02–1.09]), and Logistic 
EuroSCORE (OR, 1.02 [1.00–1.03]). Potential triggers of 
blood transfusion such as baseline anemia, bleeding-vascu-
lar complications, and perioperative blood loss (corrected 
Hb drop) were not identified as independent predictors of 
AKI (Table 3).
Prognostic Implications
Independent predictors of 30-day mortality consisted of peri-
operative life-threatening bleeding (OR, 6.65 [2.28–19.44]), 
aortic regurgitation post-TAVI (OR, 4.80 [1.78–12.96]), AKI 
(OR, 3.15 [1.56–6.38]), leucocyte count ≤72 hours (OR, 1.13 
[1.06–1.20]), and Logistic EuroSCORE (OR, 1.04 [1.02–1.06], 
Table 4). Mortality during follow-up in patients who survived 
the first 30 days was determined by a mix of patient-related 
variables and by the administration of blood transfusion for 
≤72 hours (≥5 units, HR, 2.54 [1.34–4.81], 3–4 units, HR, 2.03 
[1.26–3.24], 1–2 units, HR, 1.32 [0.94–1.86]) in addition to 
AKI (HR, 1.57 [1.13–2.17], Table 5). Kaplan–Meier survival 
estimates for increasing severity of AKI, baseline anemia, and 
number of transfusions are shown in Figure 3.
Discussion
In this multicenter study including 995 patients who under-
went TAVI we found that AKI occurred in 21% of the patients 
and that the number of perioperative blood transfusions was 
the strongest predictor of AKI but not the clinical indications 
of transfusion (ie, baseline anemia, perioperative vascular-
bleeding complications, or blood loss). AKI was a predictor 
of both short- and long-term mortality, whereas blood transfu-
sion predicted long-term mortality.
The frequency of AKI after TAVI has been reported to 
vary between 12% and 57% in previous but smaller series 
of patients using various definitions of AKI.2–10 The herein 
reported point estimate of 21% most likely reflects the inci-
dence of AKI encountered in clinical practice, given the sam-
ple size and the multicenter nature of this study. Irrespective 
of the true value, AKI poses a clinical problem as it is associ-
ated with an increased mortality at 30 days and beyond. This 
has also been shown by others and suggests that the outcome 
of TAVI may be improved by—among others—implementing 
all measures to prevent AKI.5–10
For that purpose it is essential to understand the pathophysi-
ologic mechanism(s) of AKI after TAVI. Unfortunately, a clin-
ical study such as this one cannot do so, yet the analysis of the 
association between AKI and patient- and procedure-related 
variables that are readily available (eg, patient demographics) 
or subject to change or improvement (eg, execution of proce-
dure) may be helpful.
With respect to execution of the procedure, the findings 
of this study indicate that AKI and, therefore, outcome may 
be improved by a more careful use of blood transfusions. 
As mentioned, the number of blood transfusions was found 
Table 4. Independent Predictors of Mortality ≤30 Days After 
Transcatheter Aortic Valve Implantation
Variable OR (95% CI) P  Value
Life-threatening bleeding 6.65 (2.28–19.44) 0.001
Post operative aortic regurgitation 
grade ≥III
4.80 (1.78–12.96) 0.002
Acute kidney injury 3.15 (1.56–6.38) 0.001
Maximum leucocyte count ≤72 h  
(per 109 cells/L increase)
1.13 (1.06–1.20) <0.001
Logistic EuroSCORE (per % increase) 1.04 (1.02–1.06) <0.001
RBC transfusion ≤24 h
 None Reference 0.72
 1–2 units 0.76 (0.33–1.75) 0.51
 3–4 units 0.31 (0.03–3.06) 0.31
 ≥5 units 1.01 (0.15–6.73) 0.99
Table 5. Independent Predictors of Mortality >30 Days After 
Transcatheter Aortic Valve Implantation
Variable HR (95% CI) P  Value
RBC transfusion ≤72 h
 None Reference 0.004
 1–2 units 1.32 (0.94–1.86) 0.11
 3–4 units 2.03 (1.26–3.24) 0.003
 ≥5 units 2.54 (1.34–4.81) 0.004
Baseline anemia
 None Reference 0.005
 Mild 0.85 (0.54–1.34) 0.48
 Moderate 1.49 (1.01–2.20) 0.043
 Severe 1.75 (1.18–2.60) 0.005
Acute kidney injury 1.57 (1.13–2.17) 0.007
Peripheral vascular disease 1.69 (1.25–2.30) 0.001
Congestive heart failure 1.62 (1.16–2.26) 0.004
Male sex 1.53 (1.14–2.06) 0.005
Atrial fibrillation 1.46 (1.06–1.99) 0.019
RBC denotes red blood cell.
Table 3. Independent Predictors of AKI After TAVI
Variable OR (95% CI) P  Value
RBC transfusion ≤24 h
 None Reference 0.003
 1–2 units 1.47 (0.98–2.22) 0.064
 3–4 units 3.05 (1.24–7.53) 0.015
 ≥5 units 4.81 (1.45–15.95) 0.010
Peripheral vascular disease 1.48 (1.05–2.10) 0.026
Congestive heart failure 1.43 (1.01–2.03) 0.042
Maximum leucocyte count ≤72 h  
(per 109 cells/L increase)
1.05 (1.02–1.09) 0.001
Logistic EuroSCORE (per % increase) 1.02 (1.00–1.03) 0.006
AKI indicates acute kidney injury; TAVI, transcatheter aortic valve implantation; 
RBC, red blood cell.
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to be the strongest predictor of AKI with a distinct gradient 
of risk. The relation between AKI and transfusion is consis-
tent with other reports that studied patients who underwent 
TAVI or cardiac surgery,5,6,10,26,27 yet, such a strong relation-
ship between AKI and the number of transfusions has not 
been reported. Noteworthy, we also found that the clinical 
triggers upon which one may decide to administer blood 
during TAVI were not associated with AKI. If true, this sug-
gests that one should be more restrictive in the use of blood 
transfusions during TAVI and that the need of unequivocal 
criteria for the decision of blood transfusion is advocated. 
This is illustrated by the findings that patients without ane-
mia had a 2.4 times greater Hb drop in comparison with 
patients with severe baseline anemia. This may be explained 
by a different patient and procedure planning in addition to 
differences in the execution of TAVI (ie, control of hemo-
stasis) in patients with different baseline risks. Interventions 
that reduce perioperative transfusions may protect against 
AKI, especially in anemic patients.27
The absence of a relationship between AKI and the indications 
for transfusion in addition to the fact that we did not find a rela-
tionship between AKI and periprocedural complications leading 
to hypotension supports a direct harmful effect of transfusion on 
the kidneys. It is known that preserved RBCs suffer structural or 
functional changes including reduced deformability and increased 
aggregability, all of which—particularly in older patients with 
impaired renal function—might induce (further) renal dysfunc-
tion.28 Also the coadministration of proinflammatory molecules 
may play a role either directly or indirectly by inducing inflam-
mation.29 This may explain the relation found in this and other 
studies between postoperative leucocyte count and AKI.4,6,10,30
At variance with percutaneous coronary intervention (PCI),31 
we found a borderline association between contrast load and 
AKI in the univariable analysis, yet contrast load was not found 
to be an independent predictor. The absence of an association 
cannot be explained by a restrictive use of contrast in the pres-
ent population considering the mean values and standard devia-
tions (142±97 and 158±96 mL) although this may be an issue 
of sample size as a result of which a significant statistical differ-
ence was not detected. The current findings suggest that unlike 
PCI, contrast has only a minor effect on the development of 
AKI in patients who undergo TAVI.
With respect to the patient-related variables and, thus, 
patient selection, it is unlikely that we will exclude patients 
with peripheral vascular disease because TAVI was specifi-
cally developed for patients who are too high a risk for aortic 
Figure 3. Time-to-event curves for selected risk factors in patients who survived the first 30 days after transcatheter aortic valve 
 implantation (TAVI) (landmark analysis). Event rates were calculated with the use of Kaplan–Meier methods and compared with the use of 
the log-rank test. A, Time-to-event curves for patients without acute kidney injury (AKI), AKI-stage I and with AKI-stage II or III after TAVI. 
B, Time-to-event curves for patients without transfusions, 1–2 transfusions and with >2 transfusions ≤72 h after TAVI. C, Time-to-event 
curves for patients with no and various degrees of baseline anemia. Baseline anemia was defined as Hb <13 g/dL in men and <12 g/dL 
in women23; mild anemia 12.0 to 12.99 g/dL in men and 11.30 to 11.99 g/dL in women, moderate anemia 10.80 to 11.99 g/dL in men and 
10.23 to 11.29 g/dL in women, and severe anemia <10.80 g/dL in men and <10.23 g/dL in women. Hb indicates hemoglobin.
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valve replacement. These patients often have widespread ath-
erosclerosis including the peripheral circulation. It remains to 
be seen how additional pre- and postoperative care may avoid 
AKI such as optimal perioperative hydration.
Apart from perioperative blood transfusion and AKI, we 
found a number of other predictors of early and late mortality 
after TAVI. In accordance with previous series, we found severe 
bleeding and postoperative aortic regurgitation to be associated 
with a 5-fold increased risk of early death,32 whereas severe 
baseline anemia, peripheral vascular disease, heart failure, 
male sex, and atrial fibrillation were independent predictors 
of late death.12,33,34 These findings confirm the importance of 
appropriate patient selection to improve outcome after TAVI.
Limitations
This multicenter observational assessment in a large series 
of patients may estimate the frequency of AKI and its pre-
dictors but it cannot elucidate the precise pathophysiologic 
mechanism(s). This is needed to propose in greater detail 
improvements in patient and procedure planning and execu-
tion in addition to eventual changes in postoperative care. We 
also acknowledge the formulation of the research question 
during and after the data collection and the absence of a pre-
specified case report form. As a result, despite a high degree 
of completeness (online-only Data Supplement), the timing of 
the collection of the individual variables may not be consis-
tent, which may affect the precision of the current findings. In 
addition, there was no uniform protocol of blood transfusion, 
as a result of which we were are not able to unravel the true 
triggers of transfusion, thereby precluding specific proposi-
tions of improvement.
Conclusions
AKI occurred in 21% of the patients after TAVI. The num-
ber of blood transfusions, but not the indication of transfu-
sion, predicted AKI. AKI was a predictor of both short- and 
long-term mortality, whereas blood transfusion predicted 
long-term mortality. These findings indicate that the outcome 
of TAVI may be improved by a more restrictive use of blood 
transfusions.
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PART 5
EFFECTS OF PRE-OPERATIVE ANEMIA 
AND BLOOD TRANSFUSIONS

 CHAPTER 12
Prevalence and eff ects of pre-operative 
anemia on short- and long-term 
mortality in patients undergoing 
transcatheter aortic valve implantation
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ABSTRACT 
Background - There is scant information on the prevalence of pre-operative anemia in 
patients undergoing transcatheter aortic valve implantation (TAVI) and whether it is an 
independent predictor of mortality. This study sought to determine the prevalence of pre-
operative anemia and the effects of the various levels of pre-operative hemoglobin (Hb) on 
short- and long-term mortality in patients undergoing TAVI.  
Methods and Results - 10-center observational study encompassing 1599 patients with aortic 
stenosis who underwent TAVI. Pre-operative anemia was defined by the World Health 
Organization criteria (Hb <12.0 in women and <13.0 g/dL in men). Uni- and multivariable 
analyses were performed to assess the association between preoperative anemia and various 
Hb levels, and all-cause mortality (30 days, 1 year median follow-up).
The prevalence of preoperative anemia was 57% with a mean pre-operative Hb concentration 
of 12.1 ± 1.7 g/dL. Independent determinants of preoperative anemia were the following 
dichotomous patient-related variables (descending order of OR [95% CI]): pre-operative 
mitral regurgitation grade ,,,  > -2.52]), history of heart failure (1.74 [1.41-2.16]), 
diabetes (1.47 [1.14-1.88]), male gender (1.46 [1.16-1.85]) and peripheral vascular disease 
(1.36 [1.07-1.73]). Body mass index was inversely associated with preoperative anemia (0.29
[0.16-0.51]). Postoperative aortic regurgitation grade ,,, ZDV WKH PRVW GRPLQDQW 25
[95%CI]) independent predictor of 30-day mortality (4.64 [1.89-11.43]) while preoperative 
anemia was associated with an OR (95%CI) of 1.89 (1.04-3.46). Yet, the severity of 
preoperative anemia was the strongest independent predictor of mortality during follow-up; 
HR (95% CI) was 2.38 (1.37-4.13) in patients with Hb 10-11 g/dl and 2.92 (1.66-5.13) in 
patients with Hb <10 g/dl. Patients with anemia received 2 times more often  EORRG
transfusion in comparison to patients without anemia. Blood transfusion independently 
predicted mortality at 30 days and follow-up; per unit of transfusion the risk of death 
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increased by 20% (95% CI: 4-39%) at 30 days and with 13% (95% CI: 6-21%) during follow-
up.
Conclusions - Preoperative anemia is prevalent in more than half of patients undergoing 
TAVI. Notwithstanding differences in baseline characteristics, preoperative anemia 
independently predicted 30-day and late mortality. The need for blood transfusion was 
associated with worse outcome.  
Keywords: Transcatheter aortic valve implantation; anemia; hemoglobin; blood transfusion; 
predictors
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Introduction
Transcatheter aortic valve implantation (TAVI) is increasingly used to treat patients 
with aortic stenosis who are considered at high risk for surgical valve replacement (AVR)1-2.
These patients, therefore, often have pre-existing comorbid conditions that may affect 
outcome offsetting treatment effects.
Anemia is a common finding in (elderly) patients and has been shown to be an 
independent risk factor for early and/or late mortality in the general and elderly population3-4,
in patients with coronary artery disease including acute coronary syndrome5 and heart failure6
and in patients undergoing percutaneous and surgical cardiac interventions7-10.
In  a recent study including 118 patients who underwent TAVI, pre-operative anemia 
was seen in half of the patients and was associated with increased 1-year mortality11. Yet, the 
relationship between the degree of pre-operative anemia and the impact of confounders due to 
differences in baseline risk between patients with and without anemia on outcome need 
further elucidation. This information may be helpful since measures aimed at correcting or 
treating anemia and its cause may conceptually improve operative outcome12
The study population stems from a cohort of 1651 patients who underwent TAVI with 
the Medtronic CoreValve System (MCS, Medtronic Inc, MN), the Edwards SAPIEN or 
SAPIEN XT Valve (ESV, Edwards Lifesciences, Irvine, CA) or the Direct Flow Valve (DFV, 
Direct Flow Medical, Inc) from November 2005 to August 2012 in the following institutions:
.
We, therefore, sought to determine the prevalence of pre-operative anemia and the 
effects of the various levels of pre-operative hemoglobin (Hb) concentration on short- and 
long-term mortality in a series of 1599 patients undergoing TAVI. 
Methods
Study Population.
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1) Quebec Heart and Lung Institute, Canada (n=287); 2) Rotterdam Thoraxcenter,
Netherlands (n=267); 3) University Hospital Bonn, Germany (n=255); 4) Bergmannsheil,
Ruhr-University Bochum, Germany (n=202); 5) University Hospital Maastricht, Netherlands
(n=145); 6) University Hospital Saint-Luc, Belgium (n=122); 7) University Hospital Antwerp, 
Belgium (n=120); 8) Angiografia de Occidente, Colombia (n=93); 9) Royal Perth Hospital, 
Australia (n=90); 10) Hospital Clínico Universitario de Valladolid, Spain (n=70).
Patients with missing baseline Hb values (n=9), and patients on chronic hemodialysis (n=43)
were excluded from analyses because anemia in the latter group is most likely a marker of the 
severity of illness9. The final study population, therefore, consists of 1599 patients.
In accordance with the institutions policies, every patient gave written informed 
consent for TAVI and the use of anonymous clinical, procedural and follow-up data for 
research in accordance with Institutional Review Board approval.
Procedure.
Planning and execution of TAVI have been described before13
In each hospital, blood samples for hematology and chemistry were taken before and
at fixed intervals up to 72 hrs after TAVI and included the nadir Hb concentration, maximum 
. All procedures were 
performed under local or general anesthesia using the MCS (valve sizes 23, 26, 29, 31 mm), 
ESV (valve size 23, 26, 29 mm) or DFV (valve size 24, 25 mm). After TAVI, antiplatelet 
therapy consisted of clopidogrel 75 mg for 6 months and aspirin 80-100 mg indefinitely.
Patients on oral anticoagulant therapy before TAVI received peri-procedural therapeutic 
anticoagulation with unfractionated heparin or low molecular weight heparin in combination 
with either clopidogrel or aspirin. Oral anticoagulation was resumed shortly after TAVI.
Definitions And Data Collection.
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serum creatinine (SCr) and maximum leucocyte count. Pre-operative anemia was defined 
according to the American College of Physicians and World Health Organization criteria as a
preoperative Hb level <12.0 g/dl in women and <13.0 g/dl in men14. Patients were also 
divided into categories of 1.0-g/dL Hb increments from <10.0 to JG/ to assess the dose-
dependent effects of decreased versus normal pre-operative Hb level on mortality.
Pre-operative SCr values were used to calculate the baseline SCr clearance using the 
Cockcroft and Gault equation15. In accordance with the K/DOQI guidelines, pre-operative 
kidney function was classified as stage I (>90 ml/min/1.73 m2), stage II (60-89 ml/min/1.73 
m2), stage III (30-59 ml/min/1.73 m2), stage IV (15-29 ml/min/1.73 m2) and stage V (<15 
ml/min/1.73 m2), with stage ,,indicating chronic kidney disease (CKD)16.
After TAVI, the nadir Hb concentration was determined  24 and 72 hrs after TAVI 
and used to define the Hb decline relative to the patient’s pre-operative Hb value. The number 
of units of blood transfusions was determined at 3 time intervals:  >24 to 72 hrs, and 
>72 hrs of TAVI. All endpoints were defined according to the Valve Academic Research 
Consortium (VARC) recommendations17.
Follow-Up.
Follow-up data on patient mortality were collected from the civil registries or the 
referring physician or general practitioner and was complete for all of the patients at 30 days 
and for 99.2% at follow-up (median of 356 (IQR: 89-662) days). Of all 398 patients who died
during follow-up, the cause of death was confirmed in 88.9%, unknown in 6.5% and 
missing/not assessed in 4.5%. The cause of death grouped according to the presence of pre-
operative anemia are listed in Supplement A and classified as cardiovascular or non-
cardiovascular in accordance with the VARC criteria17.
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Statistical Analysis.
Details of data completeness and management are summarized in Supplement B.
Categorical variables are summarized as frequencies and percentages and were compared with 
the Chi square test or Fisher’s exact test. The Shapiro-Wilk test was used to test for a normal 
distribution of continuous variables and comparison of continuous variables was done by 
using the Student’s t tests or Wilcoxon’s rank-sum test when appropriate. The independent 
determinants of pre-operative anemia were assessed using forward stepwise logistic 
regression analyses including all variables from Table 1 with p<0.10 in the univariable 
analysis. Independent determinants of 30-day and cumulative late mortality were assessed by,
respectively, forward stepwise logistic and Cox regression analyses including all variables
from Table 1 and 2 with p<0.10 in the univariable analyses. Exception was made for aortic 
regurgitation post TAVI which was forced into the multivariable model independent of the p-
value (which proved to be 0.12) given its established predictive effect on late mortality18-23.
The impact of low pre-operative Hb level on outcome was assessed by forcing this variable 
into the model of 30-day and late mortality both as a continuous and a dichotomous variable 
(anemia). This was also done for Hb coded as a multi-category predictor in 1-g/dL 
increments, with the Hb category exhibiting the lowest event rate used as the reference 
group5. Interaction terms were tested to evaluate the potential additive and/or synergistic 
harmful effects of baseline anemia and Hb decline at 24 and 72 hr after TAVI. Variables 
included in the multivariable model of determinants of pre-operative anemia, 30-day mortality 
and late mortality are listed in Supplement C. Results are reported as adjusted odds ratio 
(OR) or hazard ratio (HR) with a 95% confidence interval (CI). Kaplan-Meier methods were 
used to illustrate the timing of events during follow-up; statistical assessment was performed 
by the log-rank test. Patients lost to follow-up (0.8%) were considered at risk until the date of 
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last contact at which point they were censored. A two-sided p<0.05 was considered to indicate 
significance and all statistical analyses were performed with SPSS software version 20.0.
Table 1. Baseline characteristics of patients undergoing transcatheter aortic valve implantation grouped according to the 
presence of pre-operative anemia
Entire cohort No anemia Anemia p-value
n = 1599 n = 693 n = 906
Age (yrs), mean ± SD 81 ± 9 80 ± 7 81 ± 7 <0.001
Male, n (%) 830 (52) 330 (48) 500 (55) 0.003
Height (cm), mean ± SD 165 ± 9 166 ± 9 164 ± 10 0.026
Weight (kg), mean ± SD 72 ± 15 74 ± 15 71 ± 14 0.001
Body mass index (kg/m2), mean ± SD 26.5 ± 4.8 26.9 ± 5.0 26.4 ± 4.7 0.033
Body surface area (m2), mean ± SD 1.81 ± 0.21 1.83 ± 0.22 1.80 ± 0.20 0.001
New York Heart Association class ,,,Q 1338 (84) 559 (81) 779 (86) 0.004
Previous cerebrovascular event, n (%) 294 (18) 116 (17) 178 (20) 0.14
Previous myocardial infarction, n (%) 414 (26) 166 (24) 248 (28) 0.12
Previous coronary artery bypass graft surgery, n (%) 396 (25) 180 (26) 216 (24) 0.33
Previous percutaneous coronary intervention, n (%) 507 (32) 202 (29) 305 (34) 0.057
History of heart failure, n (%) 909 (57) 325 (47) 584 (65) <0.001
Diabetes mellitus, n (%) 451 (28) 178 (26) 273 (30) 0.050
Hypertension, n (%) 1234 (77) 534 (77) 700 (77) 0.92
Peripheral vascular disease, n (%) 437 (27) 157 (23) 280 (31) <0.001
Chronic obstructive pulmonary disease, n (%) 453 (28) 193 (28) 260 (29) 0.71
Creatinine (umol/L), median (IQR) 98 (79-123) 93 (77-114) 103 (82-132) <0.001
Creatinine clearance (ml/min), mean ± SD 51 ± 22 55 ± 21 48 ± 21 <0.001
Creatinine clearance (ml/min/1.73 m2), n (%)
stage I (>90) 78 (5) 43 (6) 35 (4)
<0.001
stage II (60-89) 361 (23) 194 (28) 167 (19)
stage III (30-59) 940 (59) 390 (56) 550 (61)
stage IV (15-29) 198 (12) 59 (9) 139 (15)
stage V (<15) 16 (1) 5 (1) 11 (1)
Hemoglobin (g/dl), mean ± SD 12.1 ± 1.7 13.6 ± 1.0 11.0 ± 1.1 <0.001
Leucocyte count (x 10^9/l), mean ± SD 7.3 ± 2.2 7.4 ± 2.0 7.2 ± 2.3 0.037
Atrial fibrillation, n (%) 453 (28) 178 (26) 275 (30) 0.040
Permanent pacemaker, n (%) 204 (13) 78 (11) 126 (14) 0.12
Left ventricular ejection fraction, mean ± SD 52 ± 15 53 ± 14 52 ± 15 0.13
Aortic valve area (cm2), mean ± SD 0.68 ± 0.19 0.68 ± 0.19 0.68 ± 0.19 0.44
Peak gradient, mean ± SD 72 ± 25 72 ± 23 72 ± 25 0.80
Mitral regurgitation grade ,,,Q 203 (13) 61 (9) 142 (16) <0.001
Aortic regurgitation grade ,,,Q 120 (8) 46 (7) 74 (8) 0.25
Logistic Euroscore, median (IQR) 19.3 (11.6-30.7 17.4 (10.3-26.4) 20.9 (12.7-33.0) <0.001
Results
Baseline patient characteristics and operative details of the 1599 patients are 
summarized in Table 1 and 2. Patients with anemia were older (81 vs. 80 years, p<0.001), 
more frequently male (55 vs. 48%, p=0.003), and had a lower body mass index (26.4 vs. 26.9 
kg/m2, p=0.033) and body surface area (1.80 vs. 1.83 m2, p=0.001). They were also more 
symptomatic (NYHA class ,,,  YV  S  04), had more often a history of  heart 
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failure (65 vs. 47%, p<0.001) and had a higher prevalence of peripheral vascular disease (31 
vs. 23%, p<0.001), CKD (77 vs. 66%, p<0.001), atrial fibrillation (30 vs. 26%, p=0.040) and 
mitral regurgitation grade ,,,  YV  S , but showed a lower pre-operative
leucocyte count (7.2 vs. 7.4 x 109
Table 2. Peri-operative results of patients undergoing transcatheter aortic valve implantation grouped according to the presence of pre-operative 
anemia 
cells/L, p=0.037). They, therefore, had a higher estimated 
operative risk (Logistic EuroSCORE: 21 vs. 17%, p<0.001) as compared to patients without 
anemia. The baseline patient characteristics independently associated with pre-operative 
anemia are shown in Table 3.
No anemia Anemia p-value
n = 693 n = 906
Intra-operative or KU
Early experience, n (%) * 133 (19) 184 (20) 0.58
Device, n (%)
Medtronic CoreValve 419 (61) 527 (58) 0.37
Edwards Sapien 266 (39) 373 (41) 0.25
Direct Flow Medical 6 (1) 2 (0.2) 0.084
Access strategy, n (%)
Trans-femoral 539 (78) 673 (74)
0.25Trans-apical 134 (19) 192 (21)
Trans-subclavian 12 (2) 26 (3)
Trans-aortic 8 (1) 15 (2)
Circulatory support, n (%) 21 (3) 25 (3) 0.75
Prosthesis size, n (%) †
20, 23, 25-mm 147 (21) 196 (22) 0.84
26, 29, 31-mm 544 (79) 707 (78) 0.84
Post implantation balloon dilation, n (%) 94 (14) 162 (18) 0.020
Duration of procedure (min), mean ± SD 118 ± 74 111 ± 64 0.032
Hemoglobin (g/dl), mean ± SD
Preprocedural 13.6 ± 1.0 11.0 ± 1.1 <0.001
Postprocedural 10.9 ± 1.7 9.5 ± 1.3 <0.001
Decline 2.7 ± 1.4 1.5 ± 1.4 <0.001
Blood transfusion, n (%)
none 594 (86) 646 (71)
<0.0011-2 units 67 (10) 205 (23)3-4 units 13 (2) 41 (5)
XQLWV 19 (3) 14 (2)
Post-operative KU
6HUXPFUHDWLQLQHȝPROOPHGLDQ,45
Preprocedural 93 (77-114) 103 (82-132) <0.001
Postprocedural 89 (73-117) 98 (74-136) 0.003
Creatinine clearance (ml/min), mean ± SD
Preprocedural 55 ± 21 48 ± 21 <0.001
Postprocedural 58 ± 30 54 ± 37 0.056
Leucocyte count (x 10^9/l), mean ± SD
Preprocedural 7.4 ± 2.0 7.2 ± 2.3 0.037
Postprocedural 11.9 ± 4.2 11.7 ± 5.8 0.52
Hemoglobin (g/dl), mean ± SD
Postprocedural 10.3 ± 1.6 9.0 ± 1.3 <0.001
Decline 3.3 ± 1.5 2.0 ± 1.3 <0.001
Blood transfusion, n (%)
none 544 (79) 489 (54) <0.001
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1-2 units 95 (14) 286 (32)
3-4 units 26 (4) 95 (11)
XQLWV 28 (4) 36 (4)
In-hospital results
Echocardiography
Peak gradient, mean ± SD 19 ± 8 18 ± 10 0.22
Mitral regurgitation grade ,,,Q 43 (7) 100 (12) <0.001
Aortic regurgitation grade ,,,Q 35 (5) 47 (6) 0.83
Length of stay (days), median (IQR) 8 (6-14) 10 (6-15) <0.001
In-hospital complications 
Mortality (GD\VÁ
all-cause 34 (5) 84 (9) 0.001
cardiovascular 27 (4) 64 (7) 0.007
non-cardiovascular 7 (1) 19 (2) 0.089
Myocardial infarction (peri-procedural, KU 15 (2) 10 (1) 0.090
Cerebrovascular complications
major stroke 13 (2) 27 (3) 0.16
minor stroke 12 (2) 5 (1) 0.023
TIA 8 (1) 5 (1) 0.18
Vascular complication, n (%)
major 57 (8) 85 (9) 0.42
minor 69 (10) 80 (9) 0.44
Bleeding complication, n (%)
life-threatening or disabling 31 (5) 36 (4) 0.62
major 45 (7) 78 (9) 0.12
minor 51 (7) 84 (9) 0.17
Acute kidney injury, n (%)
stage 1 86 (12) 117 (13) 0.76
stage 2 10 (1) 18 (2) 0.41
stage 3 22 (3) 41 (5) 0.17
Combined 30-day safety endpoint 120 (17) 207 (23) 0.007
* Early experience represents the first 33 patients in each center who underwent transcatheter aortic valve implantation (29)
† Six patients did not receive a valve because of death before valve insertion
‡ The cause of death was missing in one patient who died GD\V
The overall prevalence of preoperative anemia was 57% and varied between 42% and 
67% in the participating hospitals. The mean pre-operative Hb concentration was 12.1 ± 1.7
g/dL (range: 7.2 - 17.5 g/dL). The distribution of pre-operative Hb concentration (including
the patients excluded from analysis) is presented in Figure 1.
Figure 1. Distribution Of Pre-
Operative Hemoglobin 
Concentration In Patients 
Undergoing Transcatheter 
Aortic Valve Implantation. 
Fourty-three patients on chronic 
hemodialysis were excluded 
from analyses because anemia 
in these patients is most likely a 
marker of the severity of illness 
(9).
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30-day mortality.
Thirty-day all-cause mortality was 5% in patients without and 9% in patients with 
anemia (p=0.001). Independent predictors of 30-day all-cause mortality are shown in Table 4.
With respect to the dichotomous variables, postoperative aortic regurgitation grade ,,, (OR: 
4.64; 95% CI: 1.89-11.43) was the most powerful predictor followed by – in descending order 
of odds – AKI (OR: 3.03; 95% CI: 1.73-5.31), male gender (OR: 2.03; 95% CI: 1.13-3.65)
and pre-operative atrial fibrillation (OR: 1.94; 95% CI: 1.11-3.38) while preoperative anemia 
was the weakest predictor of mortality (OR: 1.89; 95% CI: 1.04-3.46). With respect to the 
continuous variables, the administration of every unit of blood transfusion was associated 
with a 20% higher risk of 30-day mortality whereas every 1 percent increase in Logistic 
EuroSCORE increased the risk of death by 3%. The peak aortic valve gradient before TAVI 
proved to be protective.
Table 3. Multivariable logistic regression analysis for determinants of pre-operative anemia in patients undergoing transcatheter aortic 
valve implantation
Odds ratio
Determinant (95% CI) p-value
Pre-operative mitral regurgitation grade ,,, 1.80 (1.28-2.52) 0.001
History of heart failure 1.74 (1.41-2.16) <0.001
Diabetes mellitus 1.47 (1.14-1.88) 0.003
Male gender 1.46 (1.16-1.85) 0.001
Peripheral vascular disease 1.36 (1.07-1.73) 0.013
Body surface area (per 1 m2 increase) 0.29 (0.16-0.51) <0.001
Pre-operative creatinine (per 10 umol/L increase) 1.06 (1.04-1.09) <0.001
Pre-operative leucocyte count (per 1 x 10^9 cells/L increase) 0.95 (0.91-1.00) 0.039
Age (per 1 year increase) 1.02 (1.01-1.04) 0.004
Late mortality.
At 1 year, all-cause mortality was 20% in patients without and 29% in patients with 
anemia (p<0.001); patients with anemia more frequently had a non-cardiovascular cause of 
death (p=0.048, Supplement C). The predictors of all-cause mortality during follow-up are 
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shown in Table 5. With respect to the dichotomous variables, a significant and inverse 
relationship was found between the severity of preoperative Hb level and mortality during 
follow-up. In particular patients with a preoperative Hb level <10 g/dL had a 2.92 fold higher 
risk of dying during the follow-up period whereas patients with a preoperative Hb level 
between 10-11 g/dL and 11-12 g/dL had a 2.38 and 1.88 fold high risk, respectively.
Postoperative AKI (HR: 2.08; 95% CI: 1.61-2.68) and aortic regurgitation grade ,,, (HR: 
1.87; 95% CI: 1.22-2.87) in addition to preoperative atrial fibrillation (HR: 1.80; 95% CI: 
1.41-2.29), male gender (HR: 1.60; 95% CI: 1.26-2.04) and history of peripheral vascular 
disease (HR: 1.31; 95% CI: 1.01-1.69) also predicted late mortality. Similar to 30-day 
mortality, the administration of blood transfusions predicted mortality during follow-up; every 
unit of transfusion was associated with a 13% increase in risk of late death. This also
accounted for leucocyte count post TAVI and Logistic EuroSCORE (i.e. 5% increase in risk 
of late death for every 1 percent increase in Logistic EuroSCORE) while left ventricular 
ejection fraction and peak gradient proved to be protective. Kaplan-Meier estimates of 
survival of patients without and with preoperative anemia are shown in Figure 2.
Table 4. Multivariable logistic regression analysis for determinants of 30-day mortality after transcatheter aortic valve implantation
Odds ratio
Determinant (95% CI) p-value
Pre-operative anemia 1.89 (1.04-3.46) 0.038
Pre-operative hemoglobin (per 1 g/dL increase) 0.88 (0.75-1.03) 0.12
Post-operative aortic regurgitation grade ,,, 4.64 (1.89-11.43) 0.001
Acute kidney injury, stage I-III 3.03 (1.73-5.31) <0.001
Male gender 2.03 (1.13-3.65) 0.018
Pre-operative atrial fibrillation 1.94 (1.11-3.38) 0.019
Blood transfusion KUSHUXQLWLQFUHDVH 1.20 (1.04-1.39) 0.014
Maximum leucocyte count KUSHU[AFHOOV/LQFUHDVH 1.11 (1.06-1.17) <0.001
Logistic EuroSCORE (per 1% increase) 1.03 (1.02-1.05) <0.001
Pre-operative peak gradient (per 10 mmHg increase) 0.84 (0.74-0.96) 0.009
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Table 5. Multivariable Cox regression analysis for determinants of cumulative late mortality after transcatheter aortic valve implantation
Hazard ratio
Determinant (95% CI) p-value
Pre-operative anemia 1.49 (1.17-1.90) 0.001
Pre-operative hemoglobin (per g/dL increase) 0.85 (0.80-0.92) <0.001
Pre-operative hemoglobin category, g/dL *
ш15 vs. 14 to 15 (n=65) 1.33 (0.63-2.79) 0.45
14 to 15  (n=123) reference 0.001
13 to 14 vs. 14 to 15  (n=289) 1.66 (0.96-2.88) 0.070
12 to 13 vs. 14 to 15  (n=350) 1.48 (0.85-2.58) 0.17
11 to 12 vs. 14 to 15  (n=350) 1.88 (1.09-3.25) 0.024
10 to 11 vs. 14 to 15 (n=257) 2.38 (1.37-4.13) 0.002
<10 vs. 14 to 15 (n=165) 2.92 (1.66-5.13) <0.001
Acute kidney injury, stage I-III 2.08 (1.61-2.68) <0.001
Post-operative aortic regurgitation grade ,,, 1.87 (1.22-2.87) 0.004
Pre-operative atrial fibrillation 1.80 (1.41-2.29) <0.001
Male gender 1.60 (1.26-2.04) <0.001
Peripheral vascular disease 1.31 (1.01-1.69) 0.041
Blood transfusion KUSHUXQLWLQFUHDVH 1.13 (1.06-1.20) <0.001
Pre-operative left ventricular ejection fraction (per 10% increase) 0.91 (0.83-0.99) 0.034
Pre-operative peak gradient (per 10 mmHg increase) 0.94 (0.90-0.99) 0.025
Maximum leucocyte count KUSHU[AFHOOV/LQFUHDVH 1.05 (1.03-1.08) <0.001
Logistic EuroSCORE (per 1% increase) 1.01 (1.00-1.02) 0.002
* To establish the dose-dependent effect of decreased vs. normal preoperative hemoglobin values (= 14 to 15 g/dL) on cumulative late mortality, 
hazard ratio values of decreased hemoglobin levels are shown in steps of 1 g/dL, and each was compared with patients with hemoglobin values 
between 14 and 15 g/dL. 
Discussion
In this multicenter study encompassing 1599 patients who underwent TAVI, we found 
that pre-operative anemia was present in 57% of the patients with an equal distribution of its 
prevalence in the participating institutions (range: 42-67%). Despite differences in baseline 
characteristics between patients with and without preoperative anemia, preoperative anemia 
was an independent predictor of 30-day and 1-year mortality (9 and 29%, respectively). 
Moreover, a significant inverse relationship was found between the severity of preoperative 
anemia (i.e. serum Hb level) and mortality during follow-up. This was in particular the case 
for patients with an Hb <12.0 g/dL. We also found that patients with preoperative anemia 
received more units of blood transfusions at 24 and 72 hrs after TAVI and that the 
administration of blood transfusion was an independent predictor of late mortality in a dose 
dependent fashion.
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The herein reported prevalence of anemia of 57% is higher than demonstrated in 
patients with acute coronary syndrome and patients undergoing percutaneous coronary 
intervention or cardiac surgery (up to 36%)5, 7-8. This is most likely explained by differences 
in patient characteristics. Patients who are referred for TAVI are older and, therefore, more 
often have associated cardiac and non-cardiac chronic disease or comorbid conditions, which 
both may explain a higher prevalence of anemia in these patients4, 24-25
The main objective of the present study was to assess whether preoperative anemia 
was an independent predictor of (short- and long-term) mortality rather than being a marker of 
disease. For that purpose multivariable analyses were performed. With respect to 30-day 
mortality, preoperative anemia was an independent predictor 30-day mortality albeit with 
moderate strength considering its odds ratio and 95% CI. A number of postoperative
complications - in particular valve dysfunction (i.e. aortic regurgitation) and renal failure –
and a few baseline variables such as male gender and preoperative atrial fibrillation were 
more powerful independent predictors. We could not study the relationship between the 
severity of preoperative anemia (i.e Hb levels) and 30-day mortality due to a low absolute
number of deaths in some of the Hb categories. Yet, what we perceive as an even more 
important clinical observation, is that patients with preoperative anemia receive more units of 
blood transfusion during the perioperative period and that every unit of transfusion is 
associated with a 20% increase in risk of 30-day mortality, which was also found in the 
assessment of long-term mortality albeit that the association was less pronounced (increase in 
risk of 13% per transfusion). In this study, the possibility of heterogeneity in timing of the 
collection of data in each institution precluded an accurate estimation of the total blood loss 
calculated by the Landefeld equation (which assumes that the net Hb decline corresponds to 
.
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the addition of the number of blood transfusion to the baseline-minus-measured post-
operative nadir Hb)26. Yet, in accordance with our previous findings27
Figure 2. Kaplan-Meier 
Survival Estimates.
, the current results 
show that patients with anemia had a smaller post-operative Hb drop but received significant 
more frequent and also more units of blood transfusions as compared to patients without 
anemia. This suggests an uncontrolled or subjective use of blood products during TAVI. 
Given the significant and inverse relationship between blood transfusion and mortality, these 
data at least indicate that improved perioperative care (awareness) may improve outcome in
addition to the need of uniform criteria for the use of blood products.
In essence, the same observations were made when studying the independent 
predictors of mortality during follow-up. The difference, however, was the significant inverse 
relationship between the severity of preoperative anemia (i.e. Hb level) and late death, in 
particular when the Hb level was < 12 g/dl.  Preoperative anemia defined by the World Health 
Organization criteria was a weak independent predictor while - in descending order of hazard
– AKI, postoperative aortic regurgitation, and a few baseline patient-related variables such as 
preoperative atrial fibrillation, male gender and peripheral vascular disease were more 
strongly associated with late death.
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The clinical translation of the findings above is two-fold. On one hand, it is 
conceivable that the correction of preoperative anemia and/or treatment of its cause may 
beneficially affect outcome. On the other, the data of this study indicate the need of a more 
thoughtful use of blood transfusion during and immediately after TAVI. With respect to the 
former, data from surgical series indicate that common causes of anemia are chronic disease 
and iron deficiency anemia in addition to hospital acquired anemia6, 12. The first two offer a 
simple and logic basis for proposals of management that may improve outcome in TAVI and, 
potentially, other cardiac and non-cardiac interventions in patients with preoperative anemia.
Its effects obviously need to be studied in appropriately designed trials. It is also clear that all 
efforts should be made to avoid AKI which predicted both short- and long-term mortality and 
aortic regurgitation which was a strong independent predictor of 30-day mortality. The latter 
has stimulated the design of novel frames that facilitates centring and seating of the valve 
within the annulus28,29.
Limitations 
Despite the fact that pre-operative anemia was an independent predictor of short- and 
long-term mortality by multivariable analysis, it cannot be excluded that anemia still is a
marker of disease since we could not assess the cause of anemia itself. For instance, in case 
anemia is caused by on-going malignancy, frailty and/or malnutrition or any other treatable 
cause, it is conceivable that the undetermined cause of anemia is the determinant of outcome 
and not anemia. A similar thought also applies to blood transfusion since we did not assess the 
triggers why blood transfusion was administered despite the correction in the multivariable
analysis for – among others - bleeding- and vascular complications. This information is 
needed to better understand the herein reported relation between transfusion and mortality, 
and to make propositions for improved peri-operative management and care.
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Colombian Experience 
with Transcatheter Aortic 
Valve Implantation of 
Medtronic CoreValve
At our institutions, increasing numbers of aortic stenosis patients were not candidates for 
surgical aortic valve replacement. Accordingly, we initiated the Cali Colombian Transcathe-
ter Aortic Valve Implantation (TAVI) program. From March 2008 through January 2011, 53 
consecutive patients (mean age, 79 r 6 yr; men, 58%) underwent TAVI with the Medtron-
ic CoreValve System, and data were prospectively collected. Our study’s endpoints con-
formed with Valve Academic Research Consortium recommendations. We report our 
clinical results.
Predicted mortality rates were 25% (interquartile range, 17%–34%) according to logis-
tic EuroSCORE and 6% (interquartile range, 3%–8%) according to the Society of Thoracic 
Surgeons score. The 30-day mortality rate was 9% (3 intraprocedural deaths, 5 total). The 
combined 30-day safety endpoint was 30% (major vascular sequelae, 23%; life-threaten-
ing bleeding, 12%; myocardial infarction, 4%; major stroke, 4%; and acute kidney injury 
[stage 3], 2%). Eight patients (15%) required post-implantation balloon dilation and 2 (4%) 
required valve-in-valve implantation, for a technical device success rate of 77%. Mean 
peak transvalvular gradient decreased from 74 r 29 to 17 r 8 mmHg and mean transvalvu-
lar gradient from 40 r 17 to 8 r 4 mmHg (both P=0.001). Moderate or severe aortic regur-
gitation decreased from 32% to 18% (P=0.12) and mitral regurgitation from 32% to 13% 
(P=0.002). The 1-year survival rate was 81%.
We found that TAVI with the CoreValve prosthesis was safe and feasible, with sus-
tained long-term results, for treating aortic stenosis in patients at excessive surgical risk; 
nonetheless, serious adverse events occurred in 30% of the patients. (Tex Heart Inst J 
2012;39(3):351-8)
T ranscatheter aortic valve implantation (TAVI) is a relatively new catheter-based, minimally invasive procedure performed on a beating heart to treat patients with aortic stenosis (AS) who are considered to be at too high a risk 
for surgical aortic valve replacement. The procedure has proved to be superior to med-
ical therapy (including aortic balloon valvuloplasty) for such patients.1 Since the first 
use of TAVI in 2002,2 the number of patients thus treated has increased exponen-
tially: an estimated 30,000 procedures had been performed by 2011, mostly in Eu-
rope and Canada.
 Transcatheter aortic valve implantation is still evolving from an initially experimen-
tal therapy into an established treatment for high-risk patients with AS, and very lit-
tle experience with TAVI has been reported in Latin America. At our institutions, 
increasing numbers of AS patients were at high surgical risk because of age or comor-
bidities. Therefore, we initiated the Cali Colombian TAVI program in 2007. After a 
nearly 3-year experience in performing TAVI with use of the Medtronic CoreValve® 
System (Medtronic CV Luxembourg S.a.r.l.; Luxembourg), we report our clinical re-
sults in 53 patients.
Patients and Methods
When our TAVI program was formed in November 2007, our multidisciplinary team 
consisted of 2 interventional cardiologists, a cardiothoracic surgeon, a vascular sur-
geon, an anesthetist, an imaging specialist, and 2 research nurses. The team took the-
oretical courses, paid multiple visits to different experienced centers in Europe, and 
performed 21 TAVI procedures in the presence of a proctor.
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Inclusion and Exclusion Criteria
Eligibility criteria for treatment with the CoreValve have 
been published.3,4 Our study’s inclusion criteria were as 
follows: aortic valve area, d1 cm2 or 0.6 cm2/m2; native 
aortic valve annular sizes, d20 mm or t27 mm; fem-
oral artery diameter, t6 mm; severe symptoms (New 
York Heart Association [NYHA] functional class III 
or IV); and age t75 years plus a logistic EuroSCORE 
t20% or age t65 years with one of the following major 
complicating factors: liver cirrhosis, severe pulmonary 
disease (forced expiratory volume in 1 s, <1 L), severe 
pulmonary hypertension (>60 mmHg), previous car-
diac surgery, porcelain aorta, recurrent pulmonary em-
boli, right ventricular dysfunction, contraindication to 
open-heart surgery (previous chest radiation), or ca-
chexia (body mass index, <18 kg/m2).
 Major exclusion criteria were life expectancy of less 
than 12 months because of comorbid conditions; an 
existing bioprosthesis; myocardial infarction within the 
preceding 14 days; unprotected left main coronary ar-
tery stenosis >70%; hemodynamic instability or cardio-
genic shock; history of, or active, endocarditis; active 
peptic ulcer or upper gastrointestinal bleeding within 
the prior 6 months; active infections requiring current 
antibiotic therapy, or clinical suspicion of active infec-
tion; contraindication to antiplatelet or anticoagulative 
therapy or contrast media; and hypersensitivity to niti-
nol.
 All patients underwent a structured evaluation consist-
ing of a formal interview, physical examination, labora-
tory tests, 12-lead electrocardiography, transesophageal 
echocardiography, and angiographic evaluation of the 
coronary and peripheral arteries. Thirty-three of the pa-
tients also underwent this arterial study by means of 
multislice computed tomography.
 From March 2008 through January 2011, we screened 
91 consecutive patients with suspected severe AS for po-
tential TAVI with the CoreValve. Three were referred 
for surgical aortic valve replacement. Fourteen contin-
ued a medical regimen without cardiac intervention: 4 
by choice, 4 whose annular dimensions did not match 
the CoreValve criteria, 3 with nonsevere AS, 1 with un-
protected left main coronary artery stenosis >70%, and 
2 for unknown reasons. Of 74 patients in whom TAVI 
was indicated, 14 were hemodynamically unstable and 
needed aortic balloon valvuloplasty before TAVI. Of 
these 14 patients, 7 died after valvuloplasty and before 
TAVI could be performed, and 7 were bridged to TAVI 
at a median of 38 days after valvuloplasty (interquartile 
range [IQR], 2–57 d). In total, 21 of the 74 patients died 
while on the waiting list, so our study population com-
prised 53 patients.
Interventional Procedure
Details of the device and the procedure have been pub-
lished.4,5 In brief, the CoreValve is a trileaf let porcine 
pericardial tissue valve mounted on a self-expanding ni-
tinol frame and currently available in sizes with 26- and 
29-mm inflow diameters. All 53 of our patients were 
treated with the 3rd-generation CoreValve, which we 
implanted with use of an 18F disposable delivery cath-
eter inserted into the common femoral artery or sub-
clavian artery via a pigtail approach. We performed 
closure through a preclose technique with use of a Pro-
star® XL 10F Percutaneous Vascular Surgical System6 
(Abbott Vascular, part of Abbott Laboratories; Abbott 
Park, Ill), or we used surgical closure in the presence 
of severe circumferential femoral vascular calcification. 
Valve implantation was performed under f luoroscop-
ic and angiographic guidance. We placed most patients 
under local anesthesia with sedation but without me-
chanical ventilation. Patients with a suspected increased 
risk of developing complications during or immediately 
after the procedure were placed under general anesthe-
sia with mechanical ventilation.
Data Collection
All endpoints were selected and defined according to 
the Valve Academic Research Consortium (VARC) 
recommendations, available in 2010 and published in 
2011.7 For patients treated before 2011, we applied the 
VARC definitions, as other investigators have done. The 
VARC—consisting of representatives of academic re-
search organizations in Europe and the United States 
and representatives of the European and American so-
cieties of Cardiology and Cardiothoracic Surgery—was 
formed in 2009. The VARC established standardized 
endpoint definitions for TAVI clinical trials, in order 
to increase comparability between studies.
 Transesophageal echocardiography, including con-
tinuous pulsed-wave Doppler study, was performed at 
a median of 43 days before TAVI (IQR, 32–91 d) and 
within 7 days after TAVI, to calculate aortic valve area 
and mean transvalvular gradient in conformity with 
recommendations from the American Society of Echo-
cardiography.8 Paraprosthetic aortic regurgitation was 
determined in accordance with the following VARC-
proposed criteria: jet width in central jets (percentage 
of left ventricular diameter), jet density, jet deceleration 
rate (pressure half time, ms), diastolic f low reversal in 
the descending aorta, and the circumferential extent of 
paraprosthetic aortic regurgitation.
 Endpoint data collected during or immediately after 
the procedure included death; myocardial infarction; 
cerebrovascular, vascular, and bleeding sequelae; and 
acute kidney injury. All cerebrovascular sequelae were 
diagnosed by a neurologist, with evaluation of such pa-
tients daily and then at least once during a later out-
patient clinical visit. Full hematologic and chemistry 
blood samples were collected daily from all patients dur-
ing the first 3 days, to determine the severity of vascu-
lar, bleeding, and renal sequelae. The use of red blood 
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cell transfusions was documented by our institution’s 
blood-bank laboratory. The occurrence of new-onset 
3rd-degree atrioventricular (AV) block and the timing 
of permanent pacemaker implantation were recorded 
during the patients’ hospital stays.
 In conformity with VARC recommendations, tech-
nical (device success) and hierarchical composite end-
points (combined safety endpoint) were collected. 
Device success was achieved through 1) successful vas-
cular access, successful delivery and deployment of the 
device, and successful retrieval of the delivery system; 
2) correct positioning of the device in the proper ana-
tomic location with the prosthetic heart valve perform-
ing as intended (aortic valve area >1.2 cm2 and mean 
aortic valve gradient <20 mmHg or peak velocity <3 
m/s, without moderate or severe paraprosthetic aor-
tic regurgitation); and 3) the need to implant only one 
valve in the proper anatomic location. The combined 
safety endpoint was defined as a composite of all-cause 
death, major stroke, major vascular sequelae, life-threat-
ening or disabling bleeding, acute kidney injury (stage 
3), periprocedural myocardial infarction, and repeat 
surgical or interventional procedures for valve-related 
dysfunction. Structured follow-up involved the confir-
mation of vital status by contacting referring hospitals 
or each patient’s family.
Statistical Analysis
Statistical analysis was performed with use of SPSS 
software version 17.0 (IBM Corporation; Somers, NY). 
Categorical variables were compared by means of the 
F2 or Fisher exact test and are presented as numbers 
and percentages. Normality of distribution for contin-
uous variables, determined by means of the Shapiro-
Wilk test, is presented as mean r SD or as median and 
IQR. Continuous variables were compared by using 
the Student t or Wilcoxon rank sum test. The Wilcox-
on signed rank test (for continuous variables) and the 
McNemar test conducted by exact methods (for bi-
nomial variables) were used to perform paired com-
parisons between pre-treatment and post-treatment 
echocardiographic results. A Kaplan-Meier survival 
curve was constructed. Two-sided P values <0.05 in-
dicated statistical significance.
Results
Table I shows the baseline characteristics of the 53 pa-
tients who underwent TAVI. Their mean age was 79 r 
6 years, 40 were in NYHA class III or IV (75%), and 31 
were men (58%). The predicted surgical risk was 25% 
according to logistic EuroSCORE and 6% according to 
the Society of Thoracic Surgeons score. Left ventricular 
ejection fraction was <0.35 in 9 of the patients (17%), 
and mean aortic valve area was 0.69 r 0.19 cm2 with a 
mean transvalvular gradient of 40 r 17 mmHg. Aortic 
TABLE I. Baseline Clinical and Echocardiographic 
Characteristics of the 53 Patients Who Underwent TAVI
 Variable Value
Age, yr 79 r 6
Male sex 31 (58)
Height, cm 164 r 8
Weight, kg 67 r 10
Body mass index, kg/m2 24.8 r 3.5
Body surface area, m2 1.75 r 0.15
NYHA functional class III–IV 40 (75)
Previous myocardial infarction 2 (4)
Previous CABG 8 (15)
Previous PCI 11 (21)
Diabetes mellitus 14 (26)
Hypertension 50 (94)
Creatinine level, μmol/L 148 r 220
Chronic hemodialysis 3 (6)
COPD 28 (53)
Permanent pacemaker 9 (17)
Atrial fibrillation 4 (8)
Logistic EuroSCORE, % 24.6 (17.4–34.4)
STS score, % 5.9 (3.2–8.3)
Left ventricular hypertrophy 
   Mild 23 (43) 
   Moderate 17 (32) 
   Severe 2 (4)
Left ventricular dilation 
   Mildly dilated 7 (13) 
   Dilated 11 (21)
LVEF d0.35 9 (17)
Aortic valve area, cm2 0.69 r 0.19 
Aortic valve annulus, mm 20 r 1.4
Peak velocity, m/s 4.23 r 0.8 
Transvalvular gradient, mmHg 40 r 17
Aortic regurgitation 
   Mild 28 (53) 
   Moderate 16 (30) 
   Severe 1 (2)
Mitral regurgitation 
   Mild 30 (57) 
   Moderate 16 (30) 
   Severe 1 (2)
 
CABG = coronary artery bypass grafting; COPD = chronic  
obstructive pulmonary disease; LVEF = left ventricular ejection 
fraction; NYHA = New York Heart Association; PCI = percutane-
ous coronary intervention; STS = Society of Thoracic Surgeons; 
TAVI = transcatheter aortic valve implantation 
 
Data are presented as mean r SD, median and interquartile 
range, or number and percentage.
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regurgitation and mitral regurgitation were each mod-
erate in 16 patients (30%) and severe in 1 patient (2%).
Thirty-Day Clinical Outcomes
Transcatheter aortic valve implantation was performed 
through the femoral artery in 50 patients, and through 
the left subclavian artery in 3 who had severe periph-
eral vascular disease. Table II summarizes the clinical 
outcomes. Five patients died. The 30-day mortality rate 
was 9% for all-cause death and 6% for cardiovascular 
death (3 patients). Of note, 4 of the 5 deaths occurred 
either during the original procedure (n=3) or during car-
diac re-intervention (n=1). The intraprocedural deaths 
were due to coronary obstruction, retroperitoneal hem-
orrhage, and electromechanical complications, respec-
tively. All deaths occurred in the earlier half of the cohort 
(March 2008 through November 2009). The technical 
composite endpoint (device success rate) was 77%. This 
is explained by paraprosthetic aortic regurgitation in 8 
patients, valve-in-valve implantation in 2 patients, and 
failed vascular closure associated with fatal bleeding in 2 
patients. The device success rate in the earlier half of the 
cohort was 74%, compared with 81% in the later half.
 Cerebrovascular sequelae were diagnosed in 3 pa-
tients: major stroke in 2 (on day 1 and day 2, respec-
tively) and a transient ischemic attack in one (on day 
30). Vascular sequelae in 13 patients were associated 
with problematic functioning of the Prostar device in 
10 patients, retroperitoneal hemorrhage in 2, and an ac-
cess-site hematoma leading to a significant drop in he-
moglobin in one. All these sequelae were associated with 
overt bleeding events. In total, there were 4 life-threat-
ening or disabling, 7 major, and 4 minor overt bleeding 
events within the first 24 hours. Another 2 severe bleed-
ing events occurred more than 24 hours after TAVI: one 
caused by cardiac tamponade, and one by a fatal retro-
peritoneal hemorrhage during re-intervention that in-
volved balloon dilation of an underexpanded CoreValve 
prosthesis.
 In 16 patients, a new permanent pacemaker was im-
planted because of 3rd-degree AV block (15 patients) 
and 2nd-degree AV block (1 patient). The indication 
for pacemaker implantation occurred during the pro-
cedure in 6 patients, after the procedure in 8, and after 
discharge from the hospital in 2 (day 10 and day 24).
 The combined 30-day safety endpoint of 30% did 
not change between the 2 halves of the cohort.
 Figure 1 shows the periprocedural echocardiographic 
results. CoreValve implantation resulted in a significant 
increase in aortic valve area from 0.7 r 0.2 to 2.5 r 0.6 
cm2 (P <0.001). This in turn reduced the peak trans-
valvular velocity from 4.2 r 0.8 to 2 r 0.5 m/s and the 
peak gradient from 74 r 29 to 17 r 8 mmHg (both P 
<0.001). After TAVI, fewer patients had moderate or 
severe mitral regurgitation (13% vs 32% at baseline, 
P=0.002).
TABLE II. Thirty-Day Cardiovascular and Noncardiovas-
cular Sequelae, Prosthetic Valve-Associated Endpoints, 
and Therapy-Specific Endpoints in the 53 Patients Who 
Underwent TAVI*
 Variable No. (%)
Cardiovascular Complications
30-day death 
   All-cause 5   (9)** 
   Cardiovascular cause 3   (6)
Myocardial infarction 
   Periprocedural 2   (4) 
   Spontaneous  0
Stroke 
   Major 2   (4) 
   Minor  0 
   Transient ischemic attack 1   (2)
Vascular 
   Major 12 (23) 
   Minor 1   (2)
Bleeding, <24 hr 
   Life-threatening or disabling 4   (8) 
   Major 7 (13) 
   Minor 4   (8)
Bleeding, >24 hr 
   Life-threatening or disabling 2   (4) 
   Major  0 
   Minor  0
Noncardiovascular Complications
Acute kidney injury 
   Stage 1 7 (13) 
   Stage 2 1   (2) 
   Stage 3 1   (2)
Combined safety endpoint (at 30 d)*** 16 (30)
Prosthetic Valve-Associated Endpoints****
New PPI 16 (30)
New PPI for 3rd-degree atrioventricular block 15 (28)
Therapy-Specific Endpoints
Post-implantation balloon dilation 8 (15)
Valve-in-valve implantation 2   (4)
Unplanned cardiopulmonary bypass use 1   (2)
In-hospital re-intervention 1   (2)
 
PPI = permanent pacemaker implantation; TAVI = transcatheter 
aortic valve implantation 
 
* Mutually nonexclusive analysis (t1 event/patient possible) 
except for combined safety endpoint
**Includes 3 intraprocedural deaths 
 
*** Composite of all-cause death, major stroke, major vascular 
complication, life-threatening bleeding, acute stage 3 
kidney injury, myocardial infarction, and repeat procedures 
for valve-related dysfunction
**** There were no prosthetic valve-related occurrences of 
worsening mitral regurgitation or mitral valve stenosis, left 
ventricular outflow tract rupture, or new ventricular septal 
defect.
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Clinical Follow-Up
Clinical follow-up was available for all patients and 
ranged from 0 to 16 months (median, 9 mo). During 
follow-up, 10 patients died at a median of 87 days after 
TAVI (IQR, 1–358 d). Of these, 5 died after discharge 
from the hospital at a median of 324 days after TAVI 
(IQR, 166–414 d). Three in-hospital deaths (60%) and 
1 death after hospital discharge (20%) were cardiac- 
related. At 1 year, the survival rate was 81% (Fig. 2).
Discussion
In our early experience with CoreValve TAVI in a Latin 
American population, the short-term mortality rate was 
9%—comparable to that in previous studies.1,4,9-11 The 
Fig. 1  Comparisons before and after transcatheter aortic valve  
implantation in A) aortic valve area, B) peak transvalvular velocity, 
C) peak transvalvular gradient, D) mean transvalvular gradient, 
and E) aortic and mitral regurgitation.
A B
C D
E
Fig. 2  Kaplan-Meier survival curve after transcatheter aortic 
valve implantation.
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fact that most of our patients’ deaths occurred during the 
procedure itself is most likely associated with a learn-
ing curve; our device success rates improved over time 
in parallel with lower mortality rates in the second half 
of the cohort.
 Upon enrollment, our high-risk study population 
faced the poor prognosis associated with standard medi-
cal therapy alone. The patients presented with a median 
EuroSCORE of 25% and poor left ventricular function 
in 17% of cases. The 9% short-term mortality rate after 
TAVI (with a decrease to 4% in the second half of the 
cohort) seems to confirm the safety of this treatment 
in very high-risk patients. Nonetheless, 30% of the pa-
tients experienced a severe adverse event. The frequency 
of adverse events (the combined 30-day safety endpoint) 
did not decrease over time and was most often driven by 
problems at the access site during vascular closure. The 
importance of a learning curve has been described in 
previous studies, in which procedural success rates im-
proved as a function of time and were subsequently as-
sociated with improved early survival rates.12,13
 Vascular sequelae reportedly occur in 4% to 32% of 
patients and are associated with a 2- or 3-fold higher 
mortality rate.14-16 In our study, all vascular sequelae 
were associated with a bleeding component (fatal in 2 
patients) and were most often due to problematic func-
tioning of the Prostar device. For these reasons, we cur-
rently prefer a more controlled and limited surgical 
cutdown to the femoral artery, with exposure of its sur-
rounding tissues when peripheral calcification is pres-
ent at the site of access. Also, the Prostar device was 
originally designed for puncture holes up to 10F in 
size.17 Therefore, it seems reasonable to perform a lim-
ited surgical cutdown, because “off-label” application 
of the Prostar for the CoreValve requires the insertion 
of a large 18F sheath in the femoral artery.18 If we are at 
all uncertain about hemostasis, we will routinely per-
form follow-up angiography to pinpoint contrast-medi-
um leakage that might not be clinically visible at the end 
of the procedure. Given the importance of adequately 
preventing and managing vascular and bleeding sequel-
ae during TAVI, it is prudent to visit institutions that 
have expertise in percutaneous femoral closure tech-
niques before embarking upon a percutaneous trans-
femoral TAVI program.
 In our study, a mean of 1.6 r 2.3 units of red blood 
cells per patient were transfused, and 28 of the patients 
required 1 or more units while hospitalized; this is in 
accordance with previous reports.19,20 Red blood cell 
transfusion is a predictor of acute kidney injury after 
TAVI, along with baseline renal dysfunction and con-
trast-medium administration during the procedure.19-23 
Stage 1, 2, or 3 acute kidney injury occurred in 17% of 
our patients, similar to findings of 12% to 28% in pre-
vious studies.19-23 Measures to reduce the risk of acute 
kidney injury include strict application of a pre-hydra-
tion protocol preprocedurally when contrast-enhanced 
multislice computed tomography and left-sided heart 
catheterization are performed, and maintaining suffi-
cient time between these imaging procedures and TAVI 
itself. Renal damage can be avoided by reducing con-
trast-medium administration and red blood cell trans-
fusions, and by controlling hemodynamic status during 
and after the procedure. Finally, patients with acute kid-
ney injury require close periprocedural monitoring of 
renal function and vital signs (heart rate, blood pres-
sure, and urinary production), given their 2- to 3-fold 
higher risk of short- and long-term death.19-21
 Although TAVI can be safe in very high-risk patients 
with AS, there may be an increased risk of perioper-
ative stroke and encephalopathy during the immedi-
ate postprocedural period. The reported prevalence of 
stroke after TAVI ranges between 1% and 10%; how-
ever, the frequency of encephalopathy has rarely been 
documented.10,24 Two of our patients had major isch-
emic strokes within 2 days postprocedurally, immedi-
ately after recovery from general anesthesia. Another 
patient had a transient ischemic attack on day 30, after 
hospital discharge. Encephalopathy, defined as deliri-
um, coma, or seizures at any time during the postpro-
cedural period, occurred in 4 patients (8%). Stroke and 
encephalopathy reportedly share similar pathophysio-
logic mechanisms, including microembolic formation 
or hypoperfusion induced by the procedure itself or oc-
curring secondary to persistent atrial fibrillation. Well-
established predictive factors after open-heart surgery 
include advanced age, hypertension, diabetes mellitus, 
and peripheral vascular disease25—all common comor-
bid conditions in our cohort. Existing patient-related 
predictive factors (such as septal wall thickness, noncor-
onary cusp thickness, and existing right bundle branch 
block) can be distinguished from procedure-related fac-
tors (including depth of valve implantation within the 
left ventricular outflow tract, prosthesis expansion after 
implantation, and type of prosthesis).
 Conduction abnormalities frequently occur during 
TAVI, and with use of the CoreValve in particular. 
After CoreValve implantation, the prevalence of new 
left bundle branch block has ranged from 29% to 65%, 
3rd-degree AV block from 15% to 44%, and perma-
nent pacemaker implantation from 9% to 49%.4,26-29 In 
comparison, after implantation of the SAPIEN valve 
(Edwards Lifesciences LLC; Irvine, Calif ), the corre-
sponding ranges in prevalence have been 6% to 18%, 
0 to 27%, and 0 to 27%.1,30-32 A new permanent pace-
maker was implanted in 16 of our patients (30%) dur-
ing hospitalization or within 30 days after TAVI. The 
new conduction abnormality for which a new perma-
nent pacemaker was implanted occurred during TAVI 
in 6 of these patients and after TAVI in the others. In 
view of the large number of patients who developed 
3rd-degree AV block after the procedure, we have sub-
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stantially lowered our threshold for implanting a pace-
maker.
 From a technical standpoint, TAVI significantly in-
creased aortic valve area and reduced the transvalvular 
gradient. The subsequent reduction in afterload may ex-
plain our observed reduction in severe mitral regurgita-
tion, from 32% at baseline to 13% after TAVI. These 
f indings suggest that coexisting severe mitral regur-
gitation—currently a contraindication for CoreValve 
implantation, according to the manufacturer’s guide-
lines—might not always preclude TAVI in high-risk 
AS patients. Dedicated prospective echocardiographic 
studies are warranted to determine which patients with 
combined AS and severe mitral regurgitation might 
benefit from TAVI.
 In our study, actuarial survival at 1 year was 81% (10 
deaths), similar to that in the most recent registries.1,10,33 
Five of the deaths can be attributed to the procedure it-
self, whereas the other 5 patients died approximately 1 
year after TAVI and predominantly of noncardiovas-
cular causes. This suggests that short-term survivors of 
TAVI have a more favorable prognosis than do patients 
remaining on medical therapy, with its annual mortal-
ity rates of 25%. We are disappointed that many of our 
patients could not be offered TAVI, chiefly because of 
limited patient accessibility to the treatment. In ad-
dition, aortic balloon valvuloplasty does not seem to 
meet the clinical needs of high-risk AS patients. In our 
patients, the mortality rate after balloon valvuloplasty 
was 50%.
Limitations
The data used for this study were prospectively collect-
ed, but the analyses were performed on a relatively small 
sample of 53 patients. Therefore, this study does not 
permit firm conclusions, despite the fact that the direc-
tion of outcomes is in accordance with those of previ-
ous reports.
Conclusion
Transcatheter aortic valve implantation with the Med-
tronic CoreValve System in this Latin American popula-
tion was associated with promising results, as evidenced 
by a short-term mortality rate of 9% and sustained 
1-year results. Nevertheless, 30% of the patients expe-
rienced a severe adverse event, which is most likely ex-
plained by the nature of TAVI, the baseline risk of the 
patients under treatment, and the learning curve of the 
medical personnel.
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Valve-in-Valve-in-Valve 
Transcatheter Aortic  
Valve Implantation
to Treat a Degenerated Surgical  
Bioprosthesis in a Subaortic Position
Transcatheter aortic valve implantation for aortic stenosis has evolved as an alternative 
treatment for patients who are at high or excessive surgical risk. We report the case of an 
84-year-old man with a degenerated surgically implanted valve in a subaortic position (9 
mm below the native annulus) who underwent “valve-in-valve” transcatheter aortic valve 
implantation with use of a Medtronic CoreValve system. We planned to deploy the Core-
Valve at a conventional depth in the left ventricular outflow tract; we realized that this might 
result in paravalvular regurgitation, but it would also afford a “deep” landing site for a sec-
ond valve, if necessary. Ultimately, we implanted a second CoreValve deep in the left ven-
tricular outflow tract to seal a paravalvular leak. The frame of the first valve—positioned at 
the conventional depth—enabled secure anchoring of the second valve in a deeper posi-
tion, which in turn effected successful treatment of the failing subaortic surgical prosthesis 
without paravalvular regurgitation. (Tex Heart Inst J 2013;40(3):323-9)
T ranscatheter aortic valve implantation (TAVI) has emerged as an alternative to surgical aortic valve replacement for the treatment of aortic stenosis in patients who are at high or excessive operative risk.1 It has been shown that implanting 
a transcatheter valve within a failing surgical valve (“valve-in-valve”) is safe and effec-
tive.2 However, the feasibility of this intervention for failing valves in subaortic posi-
tion has not been reported. The implantation of a self-expandable transcatheter valve 
at a deep level in the left ventricular outflow tract (LVOT) (with inflow portion >8 
mm below the noncoronary cusp) could expectedly be associated with an increased 
risk of paravalvular regurgitation, valve dislodgment, or both, because of insecure an-
choring of the prosthesis in the lower anatomic structures of the LVOT.3 We report the 
case of a patient in whom we implanted 2 CoreValve® devices (Medtronic, Inc.; Min-
neapolis, Minn), to safely replace a failing surgical bioprosthesis in a subaortic position.
Case Report
In December 2011, an 84-year-old man presented with increasing dyspnea, New York 
Heart Association (NYHA) functional class III, and a history of congestive heart fail-
ure, coronary artery disease, and aortic stenosis. At the age of 74 years, he had un-
dergone coronary artery bypass grafting that had involved a left internal mammary 
artery anastomosis to the left anterior descending coronary artery and saphenous vein 
grafts to the right coronary artery and obtuse marginal branch. Concomitantly, sur-
gical aortic valve replacement was performed with implantation of a 21-mm stentless 
bioprosthesis (Labcor Laboratorios Ltda.; Belo Horizonte, Brazil). Postoperatively, the 
patient developed symptoms associated with patient–prosthesis mismatch and a mean 
transvalvular gradient of 40 mmHg. Therapy with E-blockers yielded symptom-free 
survival for 10 years, whereupon sudden deterioration occurred and the patient pre-
sented with heart-failure symptoms. Echocardiography showed a left ventricular (LV) 
ejection fraction of 0.55 with mild LV dilation, a mean transvalvular gradient of 15 
mmHg, an LV pseudoaneurysm, and a failing, subaortic-positioned bioprosthesis that 
was causing severe central and paravalvular regurgitation.
 Screening for valve-in-valve TAVI was performed. Multislice computed tomogra-
phy (MSCT) and cardiac and peripheral angiography showed patent grafts, grade 3 
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aortic regurgitation, and a peripheral vascular tree of 
more than 7 mm in luminal diameter. In view of the 
patient’s age and the high risk of repeat open surgery, it 
was decided to perform transfemoral TAVI with use of 
a 26-mm CoreValve. However, MSCT revealed that the 
surgically implanted bioprosthesis was in a subaortic po-
sition, approximately 9 mm below the native annulus. 
This prompted debate regarding how deeply the Core-
Valve should be implanted within the LVOT to achieve 
successful bioprosthetic replacement without valve dis-
lodgment, paravalvular regurgitation, or both, because 
of insecure anchoring of the CoreValve so deeply in the 
LVOT.2
 We planned to insert a second CoreValve if the first—
positioned conventionally with its inf low portion 6 
to 8 mm from the noncoronary cusp—failed to con-
trol the paravalvular leak. If leakage persisted, it was 
thought that the frame of the f irst valve would facili-
tate secure anchoring of the second valve deeper in the 
LVOT, thereby replacing the failing subaortic biopros-
thesis with minimal risk of valve dislodgment.
 The patient was given local anesthesia with mild se-
dation. The procedure was performed with use of cine 
and fluoroscopic guidance and monitoring with trans-
esophageal echocardiography (TEE). After the failing 
bioprosthesis was crossed with a straight wire that was 
exchanged for a stiff support wire, the CoreValve de-
livery catheter was positioned in the LVOT with the 
ventricular edge 10 mm from the noncoronary cusp. 
However, the final valve landing was only 4 mm from 
the cusp, because of upward migration during frame ex-
pansion of the CoreValve. Immediately thereafter, he-
modynamic tracings and f luoroscopy showed severe 
aortic regurgitation and a blood pressure of 160/40 
mmHg (Fig. 1).
 According to TEE, the CoreValve was 4 mm from the 
noncoronary cusp. The failing bioprosthesis remained 
visible, with active leaf let movement just below the 
Core Valve (Fig. 2). At this stage, preparations were 
made to implant the second valve deep within the 
LVOT, to safely replace the failing, subaortic-positioned 
surgical valve.
 The second CoreValve was positioned with its inflow 
portion 9 mm lower than that of the first CoreValve, 13 
mm below the noncoronary cusp and 4 mm superior 
to the hinge point of the anterior mitral leaflet. Aortog-
raphy and fluoroscopy revealed an excellent technical 
result, without aortic regurgitation (Fig. 1C) or mitral 
dysfunction, and with improved hemodynamics: the 
patient’s blood pressure was 140/70 mmHg. Follow-up 
MSCT confirmed that the second CoreValve had cov-
ered both the bioprosthesis and the first CoreValve (Fig. 
3). The patient was discharged from the hospital after 
4 days, asymptomatic and in NYHA functional class I; 
he remained in that functional class as of May 2013.
Fig. 1  Fluoroscopy A) shows severe aortic regurgitation before implantation of the first valve; B) after implantation, the inflow portion of 
the valve is 4 mm from the noncoronary cusp. Despite complete expansion of the CoreValve frame, grade 3 aortic regurgitation persist-
ed. C) After implantation of the second CoreValve, the inflow portion is 13 mm from the noncoronary cusp, and no aortic regurgitation is 
observed.
Fig. 2  Transesophageal echocardiogram shows the first Core-
Valve with the inflow portion 4 mm below the native annulus, 
and the failing bioprosthesis just inferior to the CoreValve. 
 
A = hinge point of anterior mitral leaflet; B = ring of degenerated 
bioprosthesis; C = leaflet of degenerated bioprosthesis;  
D = inflow portion of the CoreValve; LA = left atrium; LV = left 
ventricle; LVPA = left ventricular pseudoaneurysm
A B C
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Discussion
Consequent to greater use of TAVI in clinical practice, 
interest has increased in treating degenerated surgical 
bioprostheses with valve-in-valve procedures.2 The sub-
aortic position of the failing bioprosthesis in our patient 
necessitated an exceptionally deep CoreValve landing 
in the LVOT—13 mm below the noncoronary cusp—
instead of the usual 6 to 8 mm for which the device 
is designed. Such a deep landing increases the risk of 
paravalvular leak, valve dislodgment, or both, because 
of insecure anchoring of the prosthesis in the deep ana-
tomic structures of the LVOT.2,3 Accordingly, we chose 
to implant 2 CoreValve devices, with one of them posi-
tioned deeply and anchored securely in the LVOT. The 
second successfully replaced the failing subaortic bio-
prosthesis (Fig. 3).
 An important factor associated with this deep implant 
location relates to mitral valve function: the ventricular 
end of the valve-support frame might interfere with the 
mobility of the anterior mitral leaflet and alter the ge-
ometry of the mitral annulus, leading to (new) mitral 
valve dysfunction. De Chiara and colleagues4 showed 
that the implantation depth of a CoreValve prosthesis 
was an independent predictor of worsening mitral re-
gurgitation. In our case, the distance between the fail-
ing bioprosthesis and the hinge point of the anterior 
mitral leaflet was 11.7 mm, which enabled deep posi-
tioning of the CoreValve in the LVOT without causing 
new mitral dysfunction (Fig. 2).
 Similar to low implant locations, a “high” implanta-
tion can also occur as a result of valve dislocation from 
insecure anchoring during or immediately after valve 
positioning. This could lead to coronary artery obstruc-
tion because of impingement of the coronary ostia by 
the valve-support structure. Although this sequela is 
encountered in less than 1% of cases, it frequently ne-
cessitates emergency revascularization by means of per-
cutaneous coronary intervention or open-heart surgery.5
 For these reasons, correct positioning of the biopros-
thesis in the aortic annulus is crucial during TAVI. Al-
though the ideal location of the inflow portion of the 
CoreValve is 6 to 8 mm from the noncoronary cusp, 
our patient’s case shows that a very low implant loca-
tion might be necessary in patients who present with a 
degenerated valve in a subaortic position. Careful pre-
procedural planning (in deciding upon the use of 1 or 2 
CoreValve devices) and a pre- and periprocedural team 
approach between cardiologists and imaging specialists 
(in deciding upon the correct implant location) can en-
able safe TAVI in a patient with a failing subaortic bio-
prosthesis.
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SUMMARYANDGENERALDISCUSSION

Transcatheteraorticvalve implantation (TAVI) is increasinglyused to treatpatients
with aortic stenosis who are considered at high or excessive risk for surgical valve
replacement(AVR)1Ͳ4.Theaimofthisthesiswastoprovideinsightsintothepotentialcurrent
and future roleofTAVI in the treatmentofpatientswithaortic stenosiswho are athigh
(currently) and eventually lower risk (future) for AVR by addressing the frequency,
pathophysiology andprognosticeffectsof various complications that are characteristic to
TAVI.

PartI.ClinicaldecisionͲmaking,complicationsandeffectofexperience
In Chapter 2, we found that approximately two thirds of the patients who are
referredforTAVIreceiveTAVI,7%undergoesAVRand28%receivesmedicaltreatment(i.e.
novalvereplacement).ReasonstodeclineTAVIinfavourofAVRormedicaltherapyinclude
patient’spreference(29%),peripheralvasculardisease(15%)andnonͲsevereaorticstenosis
(11%). Although direct comparisons cannot bemade due to the absence of randomized
treatment allocation,mortality is lower after TAVI compared tomedical treatment at 6
months, 1 year and 2 years. These data, nevertheless, confirm the dismal prognosis in
patientswith aortic stenosiswho are referred for further treatment but do not undergo
valvereplacementorimplantation.
Chapter 3 provides an overview of the complications that occur during and after
TAVI.TAVI isassociatedwith ш1cardiovascularand/ornonͲcardiovascularevent in51%of
thepatients;permanentpacemakerimplantationisneededinanother8%,andTAVIistruly
uncomplicatedin41%.Patientswhosufferacomplicationorundergoadditionalpacemaker
implantationhaveahospitalstayof14dayswhichis2timeslongerthanpatientswhohave
anuncomplicatedperiͲoperativecourse.
BecauseTAVIconcernsanewtreatmentforpatientsathighorevenextremeriskfor
AVR,outcomeafterTAVIparticularlydependsonthepatientbaselineriskprofile,operator
experience, and progress in technology and technique. In Chapter 4, we compared the
resultsofTAVIduring the initiationphaseandaftercertification toperformTAVIwith the
MedtronicCoreValveSystemwithout thepresenceofaproctor.The increasing familiarity
with the procedure allowed the proposals of simplification of the procedure that were
subsequently applied in practice, which transformed the complexity of the procedure
graduallywith a better outcome albeit that therewas still a significant number of periͲ
operative(majorcardiovascular)complications.

PartII.Frequency,pathophysiologyandpersistenceofnewconductionabnormalities
NewͲonset leftbundlebranchblockandcompleteatrioventricularblock frequently
occurduringandafterTAVIandoftenleadtotheimplantationofapermanentpacemaker5.
Theseconductionabnormalities (CAs)aremorecommon followingthe implantationofthe
selfͲexpandable Medtronic CoreValve as compared to the balloonͲexpandable Edwards
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Sapien valve implantation (up to 65 and 27%, respectively)6, 7. In Chapter 5, we used
continuous12ͲleadECGanalysesduringTAVIandfoundthat>80%ofthepatientsdeveloped
anewCAduringorafterCoreValve implantationandthat75%oftheseCAspersisteduntil
hospitaldischarge.WealsofoundthatmorethanhalfoftheseCAsoccurredduringballoon
preͲdilation (i.e.before theactualvalve implantation)and thatpatientswhodevelopeda
newCAduringballoon valvuloplastyhad a significantlyhigherballoon/annulus ratio than
thosewhodidnot.GiventhepreponderanceofnewCAsduringballoonvalvuloplastyandits
relationship with the balloon/annulus ratio, the findings indicate that new CAs (and
potentiallynewPPI)cansubstantiallybereducedbyusingaballoon/annulusratiocloseto
1.0.We also found that newCAs following the implantation of theMedtronicCoreValve
Systempersistuntil6monthsafterTAVI.

PARTIII.Frequencyandpathophysiologyofcerebrovascularcomplications
Wefoundthatstroke/TIAoccurredin9%ofthepatientsandthatmorethanhalfof
theseeventsoccurred>24hoursaftertheprocedure.Braincomputedtomographyshowed
a cortical infarct inmost patients (42%) and a lacunar infarct in 26%.  NewͲonset atrial
fibrillationwasassociatedwitha4Ͳfoldhigherriskofstrokeandallpatientswhosuffereda
strokebeyond24hoursafterTAVIalsohad(anepisodeof)newatrialfibrillationafterTAVI.
Ofnotenoneofthesepatientshadreceivedanticoagulanttherapyatthetimeoftheevent.
In linewiththesefindings,wefound inamulticenterstudythatstrokeoccurred in5.1%of
the patients of which approximately half of the events occurred >24 hours after the
procedure (Chapter 9).Determinants of stroke that occurswithin 24 hourswere balloon
dilationofthevalveimmediatelyafterimplantationandvalvedislodgmentorembolization.
NewͲonset atrial fibrillationwas found to be associatedwith stroke that occurs after 24
hours followingtheprocedure.Strokeoccurringafterhospitaldischarge isseen inanother
3.3%ofthepatientsandisassociatedwithpreͲexistentchronicatrialfibrillation,peripheral
vasculardiseaseandpriorcerebrovasculardisease.Inadditiontothedevastatingeffectson
qualityoflife,strokewasalsofoundtobeanindependentpredictorofboth30ͲdayandlateͲ
mortality.
The fact thatapproximatelyhalfof the strokesoccurafterTAVI,whichare in turn
associatedwiththedevelopmentofpostoperativenewonsetatrialfibrillationindicatesthat
ͲinanumberofpatientsͲthereisnodirectrelationshipbetweentheinterventionitselfand
thedevelopmentofa stroke,and that clinical rather than technicalorprocedural factors
play a more important role in the occurrence of perioperative stroke. It is, therefore,
conceivable that preventive measures should above all be directed at improved
postoperativemanagementand,thatendovascularembolicprotectiondevicesusedduring
theprocedure–asincreasinglyadvocated–mayreducestrokeonlyinacertainproportion
ofpatientsifproventobesafeandeffective8.Thisisfurthersupportedbythefactthat26%
ofthestrokeswerelacunar,whichiswidelyregardedascausedbycerebralhypoͲperfusion
in thepresenceof localatherosclerosis.Thisalsosuggests thatalleffortsshouldbemade
duringTAVItomaintainadequatebloodpressureand,thus,brainperfusion.
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PARTIV.Frequencyandpathophysiologyofacutekidneyinjury
InChapter10,wefoundthatacutekidneyinjury(AKI)occurredin19%ofthepatients
followingTAVIofwhom2%neededtemporaryhemodialysis.Bloodtransfusionwasfoundto
bean independentpredictorofAKI,which inturnwas independentlyassociatedwithboth
30Ͳday and 1Ͳyearmortality. In Chapter 11, we sought to elucidate inmore detail the
relationbetweenblood transfusionandAKI inaddition to theeffectson shortͲand longͲ
termmortality inamuch larger cohortofpatients.We foundAKI tooccur in21%of the
patients.Thenumberofunitsofbloodtransfusionч24hrwasthestrongestpredictorofAKI.
Factorsthatmaytriggertheadministrationoftransfusionsuchasbaselineanemia,bleedingͲ
vascularcomplicationsandperiͲoperativeblood losswerenotfoundtopredictAKI.Also, it
was found that patientswith severe baseline anemia had 2.4 times less blood loss but
received2.3foldmoreunitsofbloodincomparisontopatientswithoutanemiabeforeTAVI.
ThissuggestseitheranunconsciousorbettercontrolofhemostasisduringTAVI inpatients
withseverebaselineanemiaand/ora lowerthresholdforadministeringtransfusionduring
TAVI in such patients. With respect to the prognostic effects, AKI and lifeͲthreatening
bleedingwere independentpredictorsof30Ͳdaymortality (OR:3.04 [1.52Ͳ6.07],OR:5.39
[2.14Ͳ13.57], respectively) while blood transfusion (ш3 units), baseline anaemia and AKI
predictedmortalitybeyond30days.TheclinicaltranslationisthatoutcomeofTAVImaybe
improvedbyamore restrictiveuseof transfusions that shouldbedirectedbymore strict
guidelinesforbloodtransfusiontherapy.

PARTV.EffectsofpreͲoperativeanemiaandbloodtransfusions
In Chapter 12,we found that the prevalence of preͲoperative anemia in patients
undergoing TAVIwas 57%,which is higher than reported in elderly patients undergoing
cardiac (surgical) interventions (up to 36%). Independent determinants of preͲoperative
anemiawere Ͳ indescendingorderofodds ͲpreͲoperativemitral regurgitationgrade шIII,
historyofheart failure,diabetes,malegender,peripheralvasculardiseaseandbodymass
index.Althoughanemiaasabinaryvariablewasaweakindependentdeterminantof30Ͳday
mortality, the severity of anemia (preoperative Hb level)was the strongest predictor of
mortalityat1yearwithahazardratioof2.92 (95%CI:1.66Ͳ5.13) inpatientswithHb<10
g/dl.Moreover,patientswithanemiareceived2timesmoreoftenш1bloodtransfusion in
comparison to patients without anemia and, more importantly, blood transfusion
independently predicted mortality at 30 days and during followͲup. It remains to be
elucidatedwhether the correction of anemia and/or its treatmentwill beneficially affect
outcomebutthedataofthepresentstudyindicatethatbloodtransfusiontherapyshouldbe
usedcautiously.

FUTURECHALLENGES

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The clinicalapplicationof catheterͲbasedaorticvalve implantationviaaperipheral
bloodvesselwasfirstperformedbyAlainCribieretalin2002inFrance9.Itistheresultofan
intrinsic featureofmankind,namely thedrive to innovate andof a remarkably shortbut
intenseperiodofiterationandstructuralandfunctionaltestingofframesandleafletsinthe
preclinicalsettingthathasleadtothedevelopmentofaprosthesissuitableforuseinclinical
practice.
Hard tograsphow suchaconceptwouldprove tobeapplicableandbeneficial for
patients,itwasembracedbysomeandreceivedwithsuspicionbyothers.Nevertheless,the
shear increase in thenumberofproceduresand institutionsperforming thisprocedureby
itselfpreceding the resultsof randomized comparisons (TAVIvs.AVR) simply forecasts its
future.At the timeof thiswriting (March2013), it isestimated thatapproximately75.000
patients have undergone TAVI in 500 centers around theworld. The number of patients
treatedsofarcontrastswiththenumberofpatientsenrolledin2pivotalrandomizedstudies
(PARTNERA&B, in total1057patients)ofwhich thedatahavebeenpublished inapear
reviewedmedical journal1Ͳ4.Therefore, it is fair toconclude thatTAVIwillenjoy thesame
fateaspercutaneouscoronaryinterventionaspredictedbyM.Mack10.
ThedataofthePARTNERstudieshaveshownthatselectedpatientswhoreceiveTAVI
indeedbenefitfromtheprocedure intermsofsurvivalandqualityof life1Ͳ4.Ofnote,these
studiesusedaprosthesis thatbycurrentstandardsmaybeconsideredobsoletegiven the
large sizeof thedelivery cathetersused in these studies.With the clinicaluseof smaller
cathetersandforecastedadventofevensmallerones,itisnotdifficulttoforeseeitsfuture
intermsofapplicationandexpansion.
Yet,TAVIremainsaninvasiveprocedureusedinpatientswithdegenerativecalcified
aorticstenosis. It is, thus,notsurprising thatTAVI is invariablyassociatedwithsubstantial
risksthatareofamoregeneral(i.e.seenininvasiveprocedures)andmorespecifictoTAVI.
The data of this thesis indicate that the underlying risk is multiͲfactorial. As shown,
distinction can bemade between patientͲ, procedure/physician/institutionͲ, and deviceͲ
relatedfactorsexplainingtheoccurrenceofcomplications.Itshould,however,benotedthat
whilewehaveshownthatthesefactorsmaypredicttheoccurrenceofacomplication,the
statisticalmethodused (i.e.multivariableanalysis)doesnotallow todrawconclusionson
thenatureoftheassociation(e.g.causal).
Irrespectiveofthenatureoftheassociationbetweenavariableandoutcomefound
inthisthesis,itisclearthatoutcomewillimprovebyfurtherreducingthesizeofthedelivery
catheter11.WhileatthebeginningofTAVIdeliverycathetersof24/25Fr(transfemoral)and
33Fr (transapical)wereused, theyarecurrently16and24Fr,respectively12.Cathetersof
14e Fr will be soon available. The downͲsizing of these catheters will further reduce
bleedingͲandvascularcomplicationsasaresultofwhichonemayexpectafurtherdecrease
ofmortalityandalsocomplicationssuchasacutekidneyinjury.
Thedevastatingcomplicationofstrokemaybe reducedby improvedpostoperative
care(e.g.byamorestrictandadequateresponseincaseapatientdevelopsnewonsetatrial
fibrillation) and, eventually the use of filters placed in the cerebral arteries that capture
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embolic debris that is liberated during the procedure. It remains, however, to be seen
whethertheuseofsucha filterswillreducestroke.Forthatpurpose,arandomizedstudy
hasbeeninitiatedandstartedinRotterdam(CLARET).
Conductionabnormalitiesmaybereducedbyimprovedcontrolofthereleaseofthe
prosthesis. Experiencewith TAVI plays aminor role as demonstrated in this thesis, but
improvedergonomicsofthedeliverycatheterandoftechniqueofrelease(e.g.motorized)is
expected to help. The question is whether novel software that helps the physician to
continuously define the base of the aortic root during the procedure will improve the
correctness of positioning. Perhaps, all factors combined will ultimately prove to be
beneficialwithanaddedvalueofeach individualcomponentof improvement.Yet,mostof
the improvement is tobeexpected fromadvancements in thedesignand functionof the
frameofthebioprosthesis.Atpresenta lotofeffort is invested intothepossibilitytofully
retrieve thevalve incaseofan inadequateposition.Onesuchvalves (i.e.Portico,St Jude,
Minneapolis,USA)hasalreadyenteredtheclinicalarenaandhasreceivedCEapproval13.
The sameholds for addressingparavalvar aortic regurgitation14. In addition to the
correctness of positioning, an extra skirt at the inflow region of the prosthesis has been
added to theballoonexpandablebioprosthesis (Edwards Life Sciences). Such a change in
designmayprooftobeessentialsince–atvariancewithAVR–thecalciumisnotremoved
duringTAVI.This calciummayprevent completeor adequate frameexpansion leading to
paravalvar aortic regurgitation15, 16. Also, the use and understanding of 3Ͳdimensional
imagingwillhelptoimproveoutcomebyimprovedpatientplanningandevaluation17,18.
Thecycleof iterations indesign, increase inclinicalexperienceandongoingclinical
research assessing the role of TAVI relative to AVR but also, and perhaps in particular,
observationalcohortresearchinlargeseriesofpatientswhoaremoreclosetomostpatients
seeninclinicalpracticewillleadtoongoingimprovementsinoutcome.Thiscyclealsoallows
new proposals of improvement in terms of patient selection, procedure planning and
execution and, postoperative care in addition to insights how to improve the next
generationofprostheses.Criticalassessmentinaccordancewithclinicalscientificandethical
principalswillboostthefutureofTAVItothebenefitofcareofpatientswithvalvularheart
disease.Itwillnotberestrictedtotheaorticvalve.

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SAMENVATTINGENCONCLUSIES

Transcatheter aortaklep implantatie (TAVI) betreft een nieuwe minimaal invasieve
behandeling waarbij de aortaklep wordt vervangen zonder dat een openͲhart operatie,
gebruikvaneenhartͲlongmachineenstilleggenvanhethartnodigis.Deingreepisminder
ingrijpendvoordepatiëntenwordt inhetbijzonderuitgevoerdbijouderepatiëntenmet
een verhoogd risico voor een openͲhart operatie. Dit proefschrift draagt bij aan nieuwe
inzichten in de huidige en toekomstige rol van TAVI voor de behandeling van aortaklep
stenose inoudere,hoogrisicopatiëntenaandehandvaneenevaluatievandefrequentie,
pathofysiologieenprognostischeeffectenvancomplicatiesdiekarakteristiekzijnvoorTAVI.

DEELI.Behandelingskeuze,complicatiesenheteffectvanervaring.
Inhoofdstuk2bleekdatongeveertweederdevandepatiëntendatwerdverwezenvooreen
eventueleTAVIdaadwerkelijkdezebehandelingondergingendatbij7%een chirurgische
klepvervangingwerd verricht terwijl 28%werd behandeldmetmedicamenteuze therapie
zonder klepvervanging. Redenen om af te zien van TAVI en te kiezen voor ofwel een
chirurgische klepvervanging ofwel medicamenteuze therapie waren de voorkeur van de
patiënt (29%), perifeer arterieel vaatlijden (15%) en nietͲsignificante aortaklep stenose
(11%). Ondanks dat een directe vergelijking tussen de effecten van bovengenoemde
behandelingsoptiesnietmogelijk isgezienheteennietͲgerandomiseerdonderzoekbetreft,
ondersteunen de resultaten dat TAVI gepaard gaat met een betere overleving dan
medicamenteuzetherapieop6maanden,1jaaren2jaar.Daarnaastbevestigtditonderzoek
deslechteprognosevanpatiëntendiemedicamenteuzebehandelingzonderklepvervanging
ondergaan(TAVIofchirurgischeklepvervanging).
Hoofdstuk3bestaatuiteen gedetailleerdoverzicht vande verschillende complicatiesdie
kunnenoptreden tijdensennaTAVI. Inditonderzoekbleekdat ш1cardiovasculaireen/of
nietͲcardiovasculairecomplicatievoorkwambij51%vandepatiëntenendatdaarnaasteen
permanentepacemakernodigwasbij8%terwijlTAVIongecompliceerdwas in41%vande
patiënten. Patiëntenmet een complicatie en/of een pacemaker implantatie hadden een
medianehospitalisatieduurvan14dagen.Ditwaseentweekeerzo langdurigeopnametijd
alsbijpatiëntendieeenongecompliceerdbeloophadden.
GezienhetkortebestaanvanTAVI(sinds2002)endetoepassingervaninouderehoogͲrisico
patiënten die ongeschiktworden bevonden voor een chirurgische klepvervanging zal de
veiligheid en effectiviteit van TAVImet nameworden bepaald door patiëntͲgerelateerde
factoren, de TAVI ervaring van de clinicus, en de ontwikkelingen in de technologie en
techniek.Inhoofdstuk4wordenderesultatenvanTAVIvergelekenvóórennacertificering
om TAVI in het ErasmusMC uit te voeren (zonder de aanwezigheid van een proctor).
AanvankelijkwerdTAVIuitgevoerdineenexperimentelesituatiewaarbijdeprocedurewerd
gekenmerktdoorcomplexehandelingenentechnieken.Dooreentoenemendeervaringen
bekendheidmetdeprocedure isdetechniekmettertijd inbelangrijkematevereenvoudigd
watheeft geleid tot een afname inde frequentie endeernst van complicaties.Ondanks
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deze positieve ontwikkeling zal TAVI net als elke andere interventie/operatie bij een
belangrijkdeelvandepatiëntengepaardblijvengaanmetcomplicaties.

DEELII.Frequentie,pathofysiologieenpersistentievannieuwegeleidingsvertraging.
Het optreden van een nieuw linker bundeltak blok en/of compleet atrioventriculair blok
vormteenfrequentecomplicatietijdensennaTAVIenleidtvaaktotdeimplantatievaneen
permanentepacemaker.Hetoptredenvandezetypengeleidingsvertragingkomtvakervoor
na de implantatie van de zelfͲexpandeerbareMedtronic CoreValve klep dan de ballonͲ
expandeerbareEdwards Sapienklep (tot, respectievelijk,65en27%).Hoofdstuk5betreft
eenartikelwaarbijmetbehulpvaneencontinue12ͲafleidingenECGanalysewerdgevonden
datmeerdan80%vandepatiënteneennieuwegeleidingsvertragingontwikkelttijdensofna
TAVIwaarvan75%persisteerttotaanhetontslagvandepatiënt.Tevensbleekdatmeerdan
dehelft vandenieuwe geleidingsvertragingenoptreedt tijdensdeballondilatatie vande
natieve aortaklep (vóór klepimplantatie) en dat patiënten met een nieuwe
geleidingsvertraging tijdens deze fase van de procedure een grotere ballonͲannulus ratio
hadden dan patiënten die op dat moment geen nieuwe geleidingsvertragingen
ontwikkelden. De associatie tussen, enerzijds, het optreden van een nieuwe
geleidingsvertragingtijdensdeballondilatatieen,anderzijds,hetoptredenvaneennieuwe
geleidingsvertraging bij patiënten met een grotere ballonͲannulus ratio, suggereert dat
geleidingsvertragingenvoorkomenkunnenwordendooreenballonͲannulusratiotekiezen
van ч1.0. Hoofdstuk 6 toont aan dat nieuwe periͲoperatieve geleidingstoornissen die
persisterentotaanhetontslagvandepatiëntookpersisterentot6maandennaTAVIenom
dieredenbeschouwdkunnenwordenalseennieuwepermanentegeleidingsvertraging.

DEELIII.Frequentieenpathofysiologievancerebrovasculairecomplicaties.
InHoofdstuk8vondenwijdateencerebrovasculairecomplicatie(CVA/TIA)voorkomtbij9%
vandepatiëntenendatmeerdandehelftvandezecomplicatiesш24uurnadeprocedure
optreedt.DeCTresultatenvanhetbreintoondendatdecerebrovasculairecomplicatiewerd
veroorzaaktdooreencorticaal infarct indemeestepatiënten(42%)eneen lacunair infarct
in26%.HetpostͲoperatiefoptredenvan(nieuw)atriumfibrillerenwasgeassocieerdmeteen
4Ͳvoudigverhoogdrisicoopeencerebrovasculairecomplicatie.Allepatiëntendieш24uurna
TAVI een cerebrovasculaire complicatie ontwikkelden hadden ш1 episode van atrium
fibrillerendoorgemaaktvóóroftijdenshetoptredenvandecerebrovasculairecomplicatie.
Echter,geenvandezepatiëntenhadanticoagulantiatoegediendgekregen.In lijnmetdeze
resultaten vondenwij in een soortgelijk artikel Ͳ gebaseerd op data van 5 ziekenhuizen
(Hoofdstuk9)Ͳdateencerebrovasculairecomplicatievoorkomtbij5.1%vandepatiëntenen
dat ongeveer de helft van deze complicaties ш24 uur na de procedure optreedt.
Onafhankelijkedeterminantenvaneenacute(<24uur)cerebrovasculairecomplicatiewaren
ballon dilatatie van de klepprothese direct na implantatie en klepprothese
embolisatie/migratie.Nieuw atrium fibrillerenwaseen voorspeller voor cerebrovasculaire
complicatiesdieш24uurnaTAVIontstaan.Daarnaastwerdbij3.1%vandepatiëntentijdens
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defollowͲupperiode(>30dagennadeTAVI)een“laat”cerebrovasculaireventvastgesteld.
Onafhankelijk voorspellers van late events waren chronisch atrium fibrilleren, perifeer
arterieel vaatlijden en een voorgeschiedenis van cerebrovasculaire infarcten. Naast de
invaliderendeeffectenvancerebrovasculairecomplicatiesopdekwaliteitvan levenvande
patiënt, bleek er een belangrijke associatie te zijnmetmortaliteit op de korte en lange
termijnnaTAVI.
Het feit dat ongeveer de helft van de cerebrovasculaire complicaties ш24 uur na de
procedureoptreedtendatereenassociatiebestaatmetnieuwatriumfibrillerensuggereert
dat– inbepaaldepatiënten–ergeendirecterelatiebestaattussendeTAVIprocedurezelf
enhetontstaanvaneencerebrovasculairecomplicatie,endatklinischemeerdantechnische
ofprocedureͲgerelateerde factoreneenbelangrijkere rol spelenbijhetontstaanvanperiͲ
operatieve cerebrovasculaire complicaties. Het is om die redenmogelijk dat preventieve
maatregelenmetnamegericht zoudenmoetenwordenophetpostͲoperatieve trajecten
datendovasculairebeschermingsmiddelendiegebruiktworden tijdensdeTAVIprocedure
nietallecerebrovasculairecomplicatieskunnenvoorkomen.Daarnaastmoetnogblijkenof
endovasculairebeschermingsmiddelendiegepositioneerdworden indegrotehalsvatenop
eenveiligeeneffectievewijzekalkentromboͲembolischedeeltjeskunnenopvangenenhet
aantalcerebrovasculaireeventskunnenverminderen.Ditistemeerdevraagaangezieneen
kwart van de cerebrovasculaire complicatieswordt veroorzaakt door een lacunair infarct
waarvan bekend is dat deze ontstaan door cerebrale hypoperfusie bij preͲexistent lokale
atheroscleroseennietdoor tromboͲembolischeocclusie vande cerebralebloedvaten.Dit
suggereert dat de hemodynamische circulatie tijdens TAVI procedures optimaal
gehandhaafdmoetblijvenomcerebralehypoperfusietevoorkomen.

DEELIV.Frequentieenpathofysiologievanacuutnierfalen.
InHoofdstuk10vondenwijdat19%vandepatiëntenacuutnierfalenontwikkeltnaTAVIen
dat 2% tijdelijk nierdialyse behoeftig wordt. Het gebruik van periͲoperatieve
bloedtransfusiesbleekeenbelangrijke voorspeller voorhetoptreden vanacuutnierfalen,
terwijlacuutnierfalenophaarbeurtonafhankelijkwasgeassocieerdmetmortaliteitopde
korte en lange termijn. De relatie tussen bloedtransfusie en het optreden van acuut
nierfalen is inmeer detail onderzocht in een grotere populatie in Hoofdstuk 11. In dit
onderzoek vondenwij dat acuut nierfalen voorkwam bij 21% van de patiënten.Opnieuw
bleek dat bloedtransfusie de belangrijkste voorspellerwas voor het optreden van acuut
nierfalen. Potentieel uitlokkende factoren die de kans op een bloedtransfusie vergroten
zoals preͲoperatieve anemie, bloedingsͲ en vasculaire complicaties en periͲoperatief
bloedverlieswerdennietgeassocieerdmethetoptredenvanacuutnierfalen.Welbleekdat
patiëntenmeteenernstigepreͲoperatieveanemie2.4keerminderbloedverliesen2.3keer
meer bloedtransfusies hadden dan patiënten zonder anemie.Deze resultaten suggereren
dat er (mogelijk onbewust) een betere controle bestaat met minder bloedverlies bij
patiëntenmet(ernstige)preͲoperatieveanemieen/ofdatereenlageredrempelbestaatom
transfusies toe te dienen bij deze patiëntengroep. Ten aanzien van de prognostische
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effecten bleek dat zowel acuut nierfalen als ernstige bloedingen belangrijke voorspellers
waren voor vroege mortaliteit terwijl bloedtransfusie, preͲoperatieve anemie en acuut
nierfalenbelangrijke voorspellerswaren voormortaliteit tijdensde followͲupperiode.De
klinische boodschap van dit onderzoek vertaalt zich in het mogelijk verbeteren van de
uitkomstennaTAVIdooreen(meer)terughoudendbeleidtehanterentenaanzienvanhet
gebruikvanbloedtransfusietherapie.

DeelV.EffectenvanpreͲoperatieveanemieenbloedtransfusietherapie.
InHoofdstuk12bleekdatdeprevalentievanpreͲoperatieveanemieinTAVIpatiënten57%
is en dat dit hoger is dan bij andere patiëntgroepen die op hogere leeftijd een cardioͲ
chirurgische interventie ondergaan (tot 36%). Onafhankelijke determinanten van preͲ
operatieve anemie waren – in volgorde van odds ratio Ͳ preͲoperatieve mitralisklep
insufficiëntie, een voorgeschiedenis van hartfalen, diabetes,mannelijk geslacht, perifeer
arterieelvaatlijdenenbodymassindex.Terwijlanemiealseenbinairevariabeleeenzwakke
associatiehadmet vroegemortaliteit,bleekdatdeernst vande anemiedebelangrijkste
voorspellerwas voormortaliteitopde lange termijnmeteenhazard ratio van2.92 (95%
betrouwbaarheidsinterval:1.66Ͳ5.13)op1jaarnaTAVI.Bovendienbleekdatpatiëntenmet
anemie ongeveer twee keer vaker ш1 bloedtransfusie ondergingen in vergelijking met
patiëntendiegeenanemiehaddenendatbloedtransfusieeenvoorspellerwasvoorzowel
vroegealslatemortaliteit.OfpreͲoperatievecorrectievananemieen/ofeenterughoudend
beleid ten aanzien van bloedtransfusie therapie een positief effect zal hebben op de
uitkomstennaTAVIdientonderzochttewordenineengerandomiseerdonderzoek.

Toekomstuitdagingen
Deklinische toepassingvaneenkathetergebondenaortaklep implantatieviaeenperifeer
bloedvat werd voor het eerst uitgevoerd door Alain Cribier in 2002 in Frankrijk. Deze
gebeurtenistypeerthetinnovatievevermogenvandemensheidombinneneenuitzonderlijk
kortemaar intensieve periode tot de ontwikkeling te komen van een katheter gebonden
hartklepprothesedietoepasbaarisindeklinischepraktijk.
Datdit concept klinisch toepasbaar zouwordenen voordelen zoubieden voorpatiënten,
werdaanvankelijkdoordeeenbetwijfeldendoordeandermetenthousiasmeontvangen.
Uiteindelijkheeftdewereldwijdeexponentiele toename inhetaantalproceduresenTAVI
instituten reeds vóór de publicatie van gerandomiseerde onderzoeken (TAVI versus
chirurgischeklepvervangingversusconservatieve therapie)de toekomstvanTAVIbepaald.
Geschatwordtdatvandaagdedagongeveer75.000patiëntenin500 institutenwereldwijd
een TAVI hebben ondergaan.Dit aantal patiënten staat in schril contrastmet het aantal
patiënten dat is geïncludeerd binnen gerandomiseerd onderzoek waarvan de resultaten
gepubliceerd zijn in een peerͲreviewmedisch tijdschrift (PARTNER A& B, in totaal 1057
patiënten).Het isomdie redengerechtvaardigdom te stellendatTAVIeen vergelijkbare
toekomst zal hebben als percutane coronaire interventie zoals eerder voorspeld doorM.
Mack.
197Samenvatting en conclusies
De data van de PARTNER onderzoeken hebben aangetoond dat patiënten die TAVI
ondergaan inderdaad voordeel hebben van de procedure ten aanzien van overleving en
kwaliteit van leven. Deze onderzoeken maakten gebruik van een TAVI technologie die
volgens huidige maatstaven als “verouderd” kan worden beschouwd gezien de grote
dimensiesvandetoengebruiktekatheters.Metdehuidigeklinischeapplicatievanverfijnde
kathetersenhet toekomstiggebruikvanverdergeavanceerdesystemenenklepprothesen
lijkt de toekomst van TAVImet betrekking tot de klinisch toepasbaarheid eenvoudig te
voorspellen. Echter, TAVI blijft een invasieve procedure diewordt toegepast in patiënten
meteenverkalkteaortaklepstenoseenderhalvegepaardgaatmetbelangrijke risico’s.Dit
proefschrift beschrijft dat de onderliggende risico’s van TAVImultifactorieel zijn. Er kan
onderscheid gemaaktworden tussen patiëntͲ, procedure/clinicus/instituutͲ, enmateriaalͲ
gerelateerde factorenalsoorzaakvandecomplicaties.Hoeweldeze factorenhetontstaan
vaneencomplicatiekunnenvoorspellenopbasisvanstatistischemethodenzoalstoegepast
in dit proefschrift (multivariabele analyses), kunnen conclusies met betrekking tot het
onderliggendoorzakelijkverbandnietwordengevormd.
Ongeachtderedenvandeassociatietusseneenvariabeleeneenuitkomstzoalsvastgesteld
inditproefschrift,ishetduidelijkdatdeuitkomstennaTAVIzullenverbeterenmetverdere
verfijning van katheters. Aanvankelijkwerd TAVI uitgevoerdmet katheters van 24/25 Fr
(transfemoraal)en33Fr (transapicaal), terwijldehuidigediameters, respectievelijk,16en
24Frzijn.Kathetersvan14Frzullenbinnenkortbeschikbaarzijn.Aangeziendereductievan
de diameter van de katheter zal bijdragen aan een afname van de ernst en het aantal
bloedingsͲ en vasculaire complicaties zal – indirect Ͳ een afname te verwachten zijn in
mortaliteitenanderecomplicatieszoalsacuutnierfalen.
DereductievanhetaantalcerebrovasculairecomplicatiesnaTAVIkanwordenbereiktdoor
adequate behandeling van (nieuw) atrium fibrilleren en eventueel het gebruik van
endovasculaire beschermingsmiddelen waarmee tromboͲembolische deeltjes worden
opgevangen tijdensdeprocedure.Hetmoetnogblijkenofdergelijke filterswerkelijkhet
aantalcerebrovasculairecomplicatieskanverminderen.Omdiereden is inRotterdameen
gerandomiseerdonderzoekopgezet(CLARET).
Het ontstaan van nieuwe intraventriculaire geleidingsvertraging kanworden tegengegaan
aan de hand van geoptimaliseerde controle van katheters en klepprothesen tijdens de
positionering en ontplooiing. De TAVI ervaring van de clinicus lijkt een beperkte rol te
spelen, maar verbeteringen in de ergonomie van de katheters en het gemotoriseerd
ontplooien van de klepprothese zalmogelijk bijdragen. De vraag is of nieuwe software
applicatieskunnenbijdragenaanhetbeterpositionerenvandeklepprothesedoordebasis
vandelinkerventrikeluitstroomzoneopcontinuewijzetedefiniërenopeenangiogram.Zo
mogelijk hebben de bovengenoemde factoren tezamen een positieve invloed op het
optredenvandegeleidingsvertragingentijdensennaTAVI.Demeestewinstvaltechterte
verwachtenbij verdergaandeontwikkelingen inhetontwerpende functie vande frames
vandeklepprothesen.Deontwikkelingvaneenvolledigherpositioneerbareenuitneembare
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prothese is momenteel gaande en het prototype van een dergelijke klep is inmiddels
beschikbaar(Portico,STJude,Minneapolis,USA).
Verbeteringen in het ontwerp van de klepprothesen zijn daarnaast van belang voor het
tegengaanvanparavalvulaireaortakleplekkage.Naasteenoptimalepositieiseenextrarok
rond de instroomregio van de prothese aangebracht bij de ballonͲexpandeerbare klep
(EdwardsLifeSciences).Eendergelijkewijziging inhetontwerpkaneenessentieelverschil
maken aangezien de kalk van de natieve aortaklep niet wordt verwijderd tijdens TAVI
waardoor een complete ontplooiing van het frame van de klepprothese kan worden
verhinderd.Hierdoorkanlekkageoptredenlangsderandenvandeprothese.Daarnaastzal
deontwikkelingvan3Ͳdimensionalebeeldvormingbruikbaarzijnvoordeoptimalisatievan
patiëntenselectieenpreͲoperatieveplanning/voorbereiding.
De cyclus vanmodificaties inhetontwerp,de toenemendeervaring,het continueren van
klinisch onderzoek waarbij de rol van TAVI wordt geobjectiveerd ten op zichte van
chirurgische klep vervanging en – in het bijzonder – het continueren van observationeel
onderzoekaandehandvangrotepatiëntcohortenwaarbijde“werkelijkTAVIpatiënt”het
onderwerpvanonderzoekbetreft,zalbijdragenaaneengecontinueerdeverbetering inde
uitkomstenvanTAVI.Dezecyclusbiedtdaarbijruimtevoornieuwevoorstellentenaanzien
vanverbeteringvanpatiëntenselectie,deprocedurezelf,hetpostͲoperatievetrajectenhet
ontwerpvanaankomendegeneratieskathetersenklepprothesen.Kritischeevaluatieaande
hand van klinischwetenschappelijk onderzoek zal de toekomst van TAVI stimuleren ten
behoeve van patiëntenmet hartklepziekten. De techniek zal niet beperkt blijven tot de
aortaklep.

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Rotterdam, Netherlands, with summer sessions at the Johns Hopkins University School of 
Public Health, Baltimore, USA. He obtained the MSc degree in 2010. 
In 2009 he graduated from the preclinical years of Medical School and started a 1-
year research period in the transcatheter valve program at the Cardiology Department of the 
Erasmus Thoraxcenter under supervision of Prof.dr. P.P.T. de Jaegere. In 2010, he postponed 
his clinical years of Medical School by 6 months to conduct clinical research in the Colombian 
TAVI program. He started his medical internships in 2011 and obtained the MD degree in 
2013. By that time, he obtained a PhD degree in Interventional Cardiology with the thesis 
entitled: “Transcatheter aortic valve implantation: current results, insights & future 
challenges”, under supervision of Prof.dr. P.P.T. de Jaegere and Prof.dr. F Zijlstra. During the 
same period he spent a 3 month clinical rotational at the Emergency Department of the 
Jewish General Hospital at McGill University, Montreal, Canada, and passed step 1 of the 
United States Medical Licensing Examination (USMLE).  
In September 2013 he will start his residency at the Department of Cardiology in the 
Erasmus Thoraxcenter, Rotterdam, The Netherlands. 
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2009-2010 Erasmus Academic Research Project (EARP) - teaching fellow 
medical students in human anatomy and dissection skills  
Erasmus Medical Center, Rotterdam, The Netherlands 
2007-2009 Skills lab – assisting during surgical courses.  
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MSC CLINICAL RESEARCH COURSE DATE ECTS 
COURSE TYPES       
        
Erasmus Summer Principles of Research in Med. and Epid. Aug-07 0,7 
Programme Introduction to Data-analysis Sep-08 1 
  Regression Analysis Sep-08 1,9 
  Methods of Clinical Research Aug-07 0,7 
  Clinical Trials Aug-07 0,7 
  Topics in Meta-analysis Feb-08 0,7 
  Pharmaco-epidemiology Aug-07 0,7 
  Survival Analysis Sep-08 1,9 
  Case-control Studies Aug-07 0,7 
  Introduct.to Decision-making in Medicine Aug-07 0,7 
        
Core courses Study Design Jan-08 4,3 
        
Programme specific Broad orientation - 2nd year elective Feb-10 5 
Courses Modern Statistical Methods Dec-08 4,3 
        
Advanced courses Introduction to Clinical Research Feb-08 0,9 
  Adv.Topics in Decision-making in Med. Feb-08 1,9 
  Pharmaco-epidemiology and Drug Safety Apr-10 1,9 
  Intervention Research and Clinical Trial Feb-08 0,9 
  Diagnostic Research (EWP05) Feb-08 0,9 
  Advanced Topics in Clinical Trials Feb-10 1,9 
  Advanced Analysis of Prognosis Studies Feb-10 0,9 
  Prognosis Research (EWP16) Feb-08 0,9 
  Princ.of Epidemiologic Data-analysis Feb-10 0,7 
  Ethnicity, Health and Health Care Mrch-08 1,1 
  Research Themes and Methodologies A Feb-08 1 
  Research Seminars 1 Jun-10 3 
  Research Seminars 2 Jun-10 3 
  Harvard or Johns Hopkins Jul-09 4 
  Vascular Clinical Epidemiology Mrch-10 1,5 
  Cardiovascular Imaging and Diagnostics Apr-10 1,5 
        
Skills courses Working with SPSS for Windows Feb-08 0,15 
  A First Glance at SPSS for Windows Feb-08 0,15 
  Scientific Writing in Eng. for Publ. Dec-09 2 
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Research Research Period Mey-10 60,7 
  Research Period 2 Jan-11 25 
        
Extra-curricular Development Research Proposal Jan-09 11 
        
TOTAL ECTS     148,3 
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6. Gerrit Jan Mulder Award 2011 – Best research thesis Erasmus University Medical Center. 
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“Zorg dat je snel weet welke kant je op wil en ga zo snel mogelijk onderzoek doen”. Dit was 
het advies van Vincent Nieuwenhuijs, een Nederlandse chirurg die ik in 2004 in Australië heb 
leren kennen en die een belangrijke rol heeft gespeeld bij mijn decentrale toelating tot de 
studie geneeskunde in Rotterdam. Halverwege het eerste jaar viel mijn keus op de 
cardiologie en een jaar later was ik betrokken bij cardiovasculair onderzoek. De afgelopen 
jaren heb ik met veel plezier gewerkt aan dit onderzoek en kijk ik terug op een leerzame 
periode waarvan ik in het begin niet had verwacht dat het zou resulteren in een promotie.  
 
Onderzoek doen tijdens de studie geneeskunde en promoveren tijdens de coschappen is erg 
leuk en uitdagend, maar had nooit volbracht kunnen worden zonder de bijdrage en steun 
van collega’s, vrienden en familie. Het verschijnen van dit proefschrift biedt mij de 
gelegenheid om allen te bedanken en enkele personen in het bijzonder te noemen. 
 
Allereerst mijn eerste promotor, Prof.dr. P.P.T. de Jaegere. Beste Peter, graag wil ik jou 
bedanken voor de plezierige periode waarin je mijn onderzoek hebt begeleid en mij de weg 
hebt gewezen naar de totstandkoming van dit proefschrift. Grote bewondering heb ik voor 
jouw manier van werken en hoe jij het TAVI programma in 2005 in het Erasmus MC hebt 
opgestart en uitgebreid. Sinds die tijd hebben jouw drive, passie en visie ertoe geleid dat het 
TAVI programma een belangrijke bijdrage heeft geleverd ten aanzien van de ontwikkelingen 
van deze nieuwe behandelingstechniek. Dit heeft mogen resulteren in jouw benoeming tot 
hoogleraar en was (voor mij) zonder meer een hoogtepunt. Mijn samenwerking met jou 
heeft mij op wetenschappelijk, klinisch en persoonlijk vlak gevormd voornamelijk tijdens de 
vele schrijfsessies waar ik heb geleerd om te denken, schrijven, herdenken en herschrijven. 
Met regelmaat wilde ik volgens jou “te veel” en riep je mij terug om allereerst één project 
tegelijk te doen en dat eerst af te ronden om vervolgens zorgvuldig na te denken over een 
eventueel vervolgonderzoek. We hebben op elk denkbare locatie samengewerkt: op jouw 
kamer op de 5e verdieping, in het kathlab, in Colombia, op Miami Beach etc. Naast mijn 
waardering voor jouw manier van werken heb ik bewondering voor jou en Sophie als mens 
buiten de wereld van het ziekenhuis/onderzoek. Peter, ik ben vereerd om jouw eerste 
promovendus te mogen zijn en ik kijk uit naar het vervolg van onze samenwerking. 
 
Mijn eerste (email)contact met de cardiologie verliep via Ron van Domburg in het tweede 
jaar van mijn studie. Ik vroeg hem of ik eens kon komen praten over de mogelijkheden om te 
helpen bij wetenschappelijk onderzoek: nog geen 2 weken later was ik aan het werk gezet. 
Beste Ron, mijn copromotor en de statistische “backbone” van dit proefschrift, net als alle 
andere studenten kon ik de afgelopen jaren bij jou terecht met mijn vragen en – zeer 
belangrijk – kon ik erop rekenen dat ik binnen 1 dag een bruikbaar antwoord had. Vrijwel 
altijd sta je positief en enthousiast tegenover nieuwe onderzoeksvoorstellen. Ik heb je laten 
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weten dat ik interesse had voor de interventiecardiologie waarna je mij bij het TAVI 
programma hebt geïntroduceerd. Onze samenwerking vond ik altijd prettig en gemakkelijk; 
ik hoop dat dit in de toekomst voortgezet mag worden. Veel dank. 
 
Prof.dr. F. Zijlstra, graag wil ik u bedanken voor uw optreden als tweede promotor. Prof.dr. 
H. Boersma, Prof.dr. A.P. Kappetein, Prof.dr. A. Bogers en Prof.dr. H. Suryapranata wil ik 
graag bedanken voor hun bereidheid zitting te nemen in de kleine promotie commissie en 
het beoordelen van mijn proefschrift. Dr. A. Balk en Prof.dr. J Bosmans wil ik hartelijk danken 
voor het zitting nemen in de grote commissie en jullie bereidheid om van gedachten te 
wisselen over de inhoud van het proefschrift.  
 
Nicolas van Mieghem, wat is het super om samen te werken met jouw eindeloze 
enthousiasme, je “Ferrari” mentaliteit en je onuitputtelijke ideeënstroom. We kwamen 
ongeveer tegelijk aan in Rotterdam: ik als student, jij als cardioloog en allebei relatief 
onwetend en onbekend binnen de onderzoekswereld. Al snel zaten we met Nicolo aan tafel 
en hadden we een eerste artikel geschreven, wat een snelle en energetische tijd was dat. Ik 
kijk uit naar de klinische periode die nu voor mij ligt waarin ik veel van jou zal leren.  
 
Robert van der Boon, mijn opvolger met betrekking tot data management; jouw 
enthousiasme en snelle zelfstandigheid hebben ertoe geleid dat je in korte tijd veel hebt 
bereikt. Ik kijk met een heel goed gevoel terug op onze samenwerking. Soms moesten we 
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